<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<!-- Created by: EDGAR Online, Inc. EDGAR Filing HTML Converter, Version: 4.61, http://www.edgar-online.com -->
<TITLE> VERMILLION, INC. (Form: 10-K, Received: 03/01/2013 16:04:31) </TITLE>
<META NAME="TABLES" CONTENT="FIS_FORM **FIS_PART_I **FIS_BUSINESS **FIS_RISK_FACTORS **FIS_UNRESOLVED_STAFF_COMMENTS **FIS_PROPERTIES **FIS_LEGAL_PROCEEDINGS **FIS_MINE_SAFETY_DISCLOSURE **FIS_PART_II **FIS_MARKET **FIS_FINANCIAL_DATA **FIS_MANAGEMENTS_DISCUSSION **FIS_LIQUIDITY_CAPITAL **FIS_MARKET_RISK **FIS_FINANCIAL_STATEMENTS **FIS_ACCOUNTING_CHANGES **FIS_CONTROL_AND_PROCEDURES **FIS_OTHER_INFORMATION **FIS_PART_III **FIS_DIRECTORS_AND_OFFICERS **FIS_NAME_AND_TITLE **FIS_COMPENSATION **FIS_NAME_AND_TITLE_2 **FIS_COMPENSATION_TABLE **FIS_SECURITY_OWNERS **FIS_BENEFICIAL_OWNERS **FIS_OFFICER_TRANSACTIONS **FIS_ACCOUNTANT_FEES **FIS_PART_IV **FIS_EXHIBITS **FIS_AUDITORS_OPINION **FIS_AUDITORS_OPINION_2 **FIS_BALANCE_SHEET **FIS_INCOME_STATEMENT **FIS_STOCKHOLDERS_EQUITY **FIS_CASH_FLOW **FIS_NOTES_TO_FINANCIAL_STATEMENT **FIS_SIGNATURES **FIS_EXHIBIT_INDEX FIS_EXHIBIT_3 **FIS_BY-LAWS FIS_EXHIBIT_21 **FIS_SUBSIDIARIES FIS_EXHIBIT_23 **FIS_EXPERTS_CONSENT FIS_EXHIBIT_23_2 **FIS_EXPERTS_CONSENT_2 FIS_EXHIBIT_31 **FIS_CERTIFICATION FIS_EXHIBIT_31_2 **FIS_CERTIFICATION_2 FIS_EXHIBIT_32 **FIS_CERTIFICATION_3 ">
<META NAME="DETECTED PAGES" CONTENT="142">
<STYLE TYPE="text/css">
<!--
	body          { background-color: white; color: black }
	.eolNewPage   { page-break-after: always; line-height: 0; height: 0; margin: 0; padding: 0 }
	.eolLeftAlign { text-align: left; margin-left: auto; margin-right: auto }
	.eolCenter    { text-align: center }
	a:link        { color: blue }
	a:active      { color: red }
	a:visited     { color: purple }
	
	@media print
	{
		@page           { margin: 0.25in }
		body            { font-size: 10pt }
		a               { text-decoration: none }
		thead           { display: table-header-group }
		tfoot           { display: table-footer-group }
		hr.eolPageBreak { display: none }
		.eolPrint50pt   { font-size: 5pt }
		.eolPrint55pt   { font-size: 5.5pt }
		.eolPrint60pt   { font-size: 6pt }
		.eolPrint65pt   { font-size: 6.5pt }
		.eolPrint70pt   { font-size: 7pt }
		.eolPrint75pt   { font-size: 7.5pt }
		.eolPrint80pt   { font-size: 8pt }
		.eolPrint85pt   { font-size: 8.5pt }
		.eolPrint90pt   { font-size: 9pt }
		.eolPrint95pt   { font-size: 9.5pt }
	}
-->
</STYLE>
</HEAD>
<BODY>
<A NAME="eolPage1"></A>
<A NAME="FIS_TOP_OF_DOCUMENT"></A>

<A NAME="D453081D10K_HTM"></A>
<EFX_FORM>
<A NAME="FIS_FORM"></A>
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="LINE-HEIGHT:0PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX;BORDER-BOTTOM:0.5PT SOLID #000000">
	&nbsp;
</P>
<P STYLE="LINE-HEIGHT:3PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:2PX;BORDER-BOTTOM:0.5PT SOLID #000000">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:4PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="5">
<B>
	UNITED STATES
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="5">
<B>
	SECURITIES AND EXCHANGE COMMISSION
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="3">
<B>
	Washington, D. C. 20549
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE:3PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<CENTER>
<P STYLE="LINE-HEIGHT:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:2PX;BORDER-BOTTOM:1PT SOLID #000000;WIDTH:21%">
	&nbsp;
</P>
</CENTER>
<P STYLE="MARGIN-TOP:3PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="5">
<B>
	FORM 10-K
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="3">
<B>
</B>
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#120;
</FONT>
<B>
</B>
<B>
</B>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="3">
<B>
	ANNUAL REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="3">
<B>
	For the Fiscal Year Ended December&nbsp;31, 2012.
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="3">
<B>
</B>
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#168;
</FONT>
<B>
</B>
<B>
</B>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="3">
<B>
	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="3">
<B>
	For the transition period from &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="3">
<B>
	Commission File Number: 001-34810
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE:3PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<CENTER>
<P STYLE="LINE-HEIGHT:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:2PX;BORDER-BOTTOM:1PT SOLID #000000;WIDTH:21%">
	&nbsp;
</P>
</CENTER>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE"></A>
<P STYLE="MARGIN-TOP:3PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="6">
<B>
	Vermillion, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	(Exact name of registrant as specified in its charter)
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="50%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="48%">
</TD>
</TR>
<TR>
<TD VALIGN="TOP" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Delaware
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	33-0595156
</B>
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	(State or other jurisdiction of
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	incorporation or organization)
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	(I.R.S. Employer
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Identification No.)
</B>
</FONT>
</P>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD VALIGN="TOP" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	12117 Bee Caves Road, Building Three,
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Suite 100, Austin, Texas
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	78738
</B>
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	(Address of principal executive offices)
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	(Zip Code)
</B>
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Registrant&#146;s telephone number, including area code: (512)&nbsp;519-0400
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<CENTER>
<P STYLE="LINE-HEIGHT:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:2PX;BORDER-BOTTOM:1PT SOLID #000000;WIDTH:21%">
	&nbsp;
</P>
</CENTER>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Securities registered pursuant to Section&nbsp;12(b) of the Act:
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="50%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="48%">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:124PT" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Title of each class to be so registered
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:148PT" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Name of each exchange on which registered
</B>
</FONT>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP" ALIGN="CENTER">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Common Stock, par value $0.001 per share
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The NASDAQ Stock Market, LLC
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Securities registered pursuant to Section&nbsp;12(g) of the Act:
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	None
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE:3PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<CENTER>
<P STYLE="LINE-HEIGHT:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:2PX;BORDER-BOTTOM:1PT SOLID #000000;WIDTH:21%">
	&nbsp;
</P>
</CENTER>
<P STYLE="MARGIN-TOP:3PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Indicate by check mark if the
	registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
	&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#168;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#120;
</FONT>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Indicate by check mark if the registrant is not required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Act. &nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#168;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#120;
</FONT>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Indicate by
	check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to
	file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#120;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#168;
</FONT>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Indicate by check mark whether the registrant has submitted electronically and posted on its
	corporate Web site, if any, every Interactive Date File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such
	files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#120;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#168;
</FONT>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Indicate by check mark if disclosure of delinquent filers pursuant to Item&nbsp;405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant&#146;s knowledge, in
	definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#120;
</FONT>
	.
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.
	See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange Act. (Check one):
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="17%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="58%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="21%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="1%">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Large&nbsp;accelerated&nbsp;filer
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#168;
</FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Accelerated&nbsp;filer
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#168;
</FONT>
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Non-Accelerated filer
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#168;
</FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Smaller&nbsp;reporting&nbsp;company
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#120;
</FONT>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the
	Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#168;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#120;
</FONT>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Section&nbsp;12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution
	of securities under a plan confirmed by a court.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#120;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#168;
</FONT>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The aggregate market value of voting common stock held by non-affiliates of the Registrant is $30,444,327 and is based upon the last sales price as quoted
	on The NASDAQ Global Market as of June&nbsp;30, 2012.
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	As of February&nbsp;28, 2013, the Registrant had 15,200,079 shares of common stock, par
	value $0.001 per share, outstanding.
</FONT>
</P>
<P STYLE="FONT-SIZE:3PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<CENTER>
<P STYLE="LINE-HEIGHT:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:2PX;BORDER-BOTTOM:1PT SOLID #000000;WIDTH:21%">
	&nbsp;
</P>
</CENTER>
<P STYLE="MARGIN-TOP:3PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	DOCUMENTS INCORPORATED BY REFERENCE
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE:8PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<P STYLE="LINE-HEIGHT:0PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX;BORDER-BOTTOM:0.5PT SOLID #000000">
	&nbsp;
</P>
<P STYLE="LINE-HEIGHT:3PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:2PX;BORDER-BOTTOM:0.5PT SOLID #000000">
	&nbsp;
</P>
<A NAME="eolPage2"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_TOC">
</A>
	VERMILLION, INC.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	FORM 10-K
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	For the Fiscal Year Ended December&nbsp;31, 2012
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Table of Contents
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="15%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD WIDTH="75%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Page&nbsp;No.
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="TOP" COLSPAN="3">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081D10K_HTM_TOC453081_1">
	PART I
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ITEM 1.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081D10K_HTM_TOC453081_2">
	Business
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ITEM 1A.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081D10K_HTM_TOC453081_3">
	Risk Factors
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	21
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ITEM 1B.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081D10K_HTM_TOC453081_4">
	Unresolved Staff Comments
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	30
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ITEM 2.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081D10K_HTM_TOC453081_5">
	Properties
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	31
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ITEM 3.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081D10K_HTM_TOC453081_6">
	Legal Proceedings
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	31
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ITEM 4.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081D10K_HTM_TOC453081_7">
	Mine Safety Disclosures
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	32
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="TOP" COLSPAN="3">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081D10K_HTM_TOC453081_8">
	PART II
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	33
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ITEM 5.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081D10K_HTM_TOC453081_9">
	Market For Registrant&#146;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	33
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ITEM 6.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081D10K_HTM_TOC453081_10">
	Selected Financial Data
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	36
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ITEM 7.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081D10K_HTM_TOC453081_11">
	Management&#146;s Discussion and Analysis of Financial Condition and Results of
	Operations
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	37
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ITEM 7A.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081D10K_HTM_TOC453081_12">
	Quantitative and Qualitative Disclosures about Market Risk
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	49
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ITEM 8.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081D10K_HTM_TOC453081_13">
	Financial Statements and Supplementary Data
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	49
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ITEM 9.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081D10K_HTM_TOC453081_14">
	Changes in and Disagreements With Accountants on Accounting and Financial
	Disclosure
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	49
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ITEM 9A.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081D10K_HTM_TOC453081_15">
	Controls and Procedures
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	50
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ITEM 9B.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081D10K_HTM_TOC453081_16">
	Other Information
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	51
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="TOP" COLSPAN="3">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081D10K_HTM_TOC453081_17">
	PART III
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	52
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ITEM 10.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081D10K_HTM_TOC453081_18">
	Directors, Executive Officers and Corporate Governance
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	52
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ITEM 11.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081D10K_HTM_TOC453081_19">
	Executive Compensation
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	58
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ITEM 12.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081D10K_HTM_TOC453081_20">
	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder
	Matters
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	72
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ITEM 13.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081D10K_HTM_TOC453081_21">
	Certain Relationships and Related Transactions, and Director Independence
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	73
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ITEM 14.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081D10K_HTM_TOC453081_22">
	Principal Accountant Fees and Services
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	75
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="TOP" COLSPAN="3">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081D10K_HTM_TOC453081_23">
	PART IV
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	76
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ITEM 15.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081D10K_HTM_TOC453081_24">
	Exhibits and Financial Statement Schedules
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	76
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="TOP" COLSPAN="3">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081D10K_HTM_TOC453081_25">
	SIGNATURES
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="TOP" COLSPAN="3">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081D10K_HTM_TOC453081_26">
	INDEX TO EXHIBITS
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Vermillion, OVA1, VASCLIR and OvaCalc
</I>
	are registered trademarks of Vermillion, Inc.
<I>
	ProteinChip
	is
</I>
	a registered trademark of Bio-Rad Laboratories, Inc.
<I>
	BioSepra
</I>
	is a registered trademark of Pall Corporation.
</FONT>
</P>
<A NAME="eolPage3"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_PART_I>
<A NAME="FIS_PART_I"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_TOC453081_1">
</A>
	PART I
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	FORWARD-LOOKING STATEMENTS
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Vermillion, Inc. (&#147;Vermillion&#148;) and its subsidiaries (collectively, the &#147;Company&#148;) has made statements in Part I Item&nbsp;1, &#147;Business&#148;; Part II Item&nbsp;7,
	&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148;; and other sections of this Annual Report on Form 10-K that are deemed forward-looking statements for purposes of the safe harbor provisions under
	the Private Securities Litigation Reform Act of 1995. We claim the protection of such safe harbor, and disclaim any intent or obligation to update any forward-looking statement. You can identify these statements by forward-looking words such as
	&#147;may,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;plan,&#148; &#147;could,&#148; &#147;should&#148; and &#147;continue&#148; or similar words. These forward-looking
	statements may also use different phrases. We have based these forward-looking statements on management&#146;s (&#147;we,&#148; &#147;us&#148; or &#147;our&#148;) current expectations and projections about future events. Examples of language found
	in forward-looking statements include the following:
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	projections of our future revenue, results of operations and financial condition;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	anticipated efficacy of our products, product development activities and product innovations;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	competition and consolidation in the markets in which we compete;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	existing and future collaborations and partnerships;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the utility of biomarker discoveries;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	our belief that particular biomarker discoveries may have diagnostic and/or therapeutic utility;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	achieving milestones in product development, future regulatory or scientific submissions and presentations;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	our plans to develop and commercialize diagnostic tests through our strategic alliance with Quest Diagnostics, Incorporated (&#147;Quest
	Diagnostics&#148;) or elsewhere;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	our ability to expand and protect our intellectual property portfolio;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	anticipated future losses;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	expected levels of expenditures;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	expected market adoption of our diagnostic tests, including OVA1;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	results of clinical trials, post-market studies required by FDA, and publications on OVA1;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	our ability to obtain reimbursement from third-party payers for our diagnostic tests, including OVA1;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	recognition of revenue under our agreement with Quest Diagnostics;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the period of time for which our financial resources will be sufficient to enable us to maintain current and planned operations; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	expected reimbursement for our products from third party payers such as private insurance companies and government insurance plans.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Such statements are subject to significant risks and uncertainties, including those identified in Part I
	Item&nbsp;1A, &#147;Risk Factors&#148;, that could cause actual results to differ materially from those projected in such forward-looking statements due to various factors, including our ability to generate sales after completing development of
	diagnostic products; our ability to manage our operating expenses and cash resources consistently with our plans; our ability to secure adequate funds on acceptable terms to execute our business plan; our ability to develop and commercialize
	diagnostic products using both our internal and external research and development resources; our ability to obtain market acceptance of OVA1 or future diagnostic products, including the risk that our products
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1
</FONT>
</P>
<A NAME="eolPage4"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for our products from third party payers such as private
	insurance companies and government insurance plans; our ability to successfully license or otherwise successfully partner with third parties to commercialize our products; our ability to obtain any regulatory approval for our future diagnostic
	products; our success in achieving development milestones, achieving desired results in clinical trials or FDA-mandated studies; and our ability to protect and promote our proprietary technologies. We believe it is important to communicate our
	expectations to our investors. However, there may be events in the future that we are not able to accurately predict or that we do not fully control that could cause actual results to differ materially from those expressed or implied in our
	forward-looking statements.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2
</FONT>
</P>
<A NAME="eolPage5"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_BUSINESS>
<A NAME="FIS_BUSINESS"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_TOC453081_2">
</A>
	ITEM&nbsp;1.
</B>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	BUSINESS
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Company Overview
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Corporate Vision:
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	To become a
	recognized leader in the advancement of women&#146;s health by providing innovative methods to detect, monitor and manage the treatment of gynecologic cancers and other related diseases
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Corporate Mission:
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We will develop and commercialize high-value multi-marker diagnostic tests
	which address unmet needs in gynecologic oncology and women&#146;s health.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We will accomplish our mission through internal development,
	targeted acquisitions, and collaborations with leading scientific and clinical institutions.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our commercial efforts will include direct
	marketing and sales activities as well as partnerships with leading companies in women&#146;s health.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Mission Statement:
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We are dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose,
	treat and improve outcomes for patients. Our tests are intended to detect, diagnose and stage disease, and to help guide decisions regarding patient prognosis and treatment. These may include decisions to refer patients to specialists, to perform
	additional testing, or to assist in the selection or monitoring of therapy and disease progression. A distinctive feature of our approach is to combine multiple biomarkers into a single, reportable index score that has higher diagnostic
	effectiveness than its constituents. We concentrate our development of novel diagnostic tests in the fields of gynecologic oncology and women&#146;s health, with the initial focus on ovarian cancer. We also intend to address clinical unmet needs
	related to early disease detection, treatment response, monitoring of disease progression, prognosis and others through collaborations with leading academic and clinical research institutions.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our lead product, OVA1, an ovarian cancer blood test was cleared by the United States Food and Drug Administration (&#147;FDA&#148;) on
	September&nbsp;11, 2009. OVA1 addresses a clear unmet clinical need, namely the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. Numerous studies have documented the benefit of referral of these women to
	gynecologic oncologists for their initial surgery. Prior to the clearance of OVA1, no blood test had been cleared by the FDA for physicians to use in the pre-surgical management of ovarian adnexal masses. OVA1 is a qualitative serum test that
	utilizes five well-established biomarkers and proprietary FDA-cleared software to determine the likelihood of malignancy in women over age 18, with a pelvic mass for whom surgery is planned. OVA1 was developed through large clinical studies in
	collaboration with numerous academic medical centers encompassing over 2,500 clinical samples. OVA1 was fully validated in a prospective multi-center clinical trial encompassing 27 sites reflective of the diverse nature of the clinical centers at
	which ovarian adnexal masses are evaluated. The results of the clinical trial demonstrated that in a clinical cohort of 516 patients, OVA1, in conjunction with clinical evaluation, was able to identify 95.7% (154/161)&nbsp;of the malignant ovarian
	tumors overall, and to rule out malignancy with a negative predictive value (&#147;NPV&#148;) of 94.6% (123/130). At the 2010 International Gynecologic Cancer Society Meeting, data were presented demonstrating the high sensitivity of OVA1 for
	epithelial ovarian cancers; OVA1 detected 95/96 epithelial ovarian cancer cases for a sensitivity of 99.0%, including 40/41 stage I and stage II epithelial ovarian cancers, for an overall sensitivity of 97.6% for early stage epithelial ovarian
	cancers, as compared to 65.9% for CA125 using the American College of Obstetricians and Gynecologists (&#147;ACOG&#148;) cutoffs. The improvement in sensitivity was even greater among premenopausal women; for OVA1, sensitivity for early stage
	epithelial ovarian cancer was 92.9% and for CA125, sensitivity was 35.7%. Overall, OVA1 detected 76% of malignancies missed by CA125, including all advanced stage malignancies. OVA1 is not indicated for use as a screening or stand-alone diagnostic
	assay.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3
</FONT>
</P>
<A NAME="eolPage6"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In 2012, we completed a second pivotal clinical study of OVA1, called the &#147;OVA500
	study&#148; and led by Dr.&nbsp;Robert E. Bristow, Director of Gynecologic Oncology Services with UC Irvine Healthcare. The study evaluated OVA1 performance in a population of 494 patients who underwent surgery for an adnexal mass after enrollment
	by a non-gynecologic oncologist, the intended use population for routine OVA1 testing. In the new study, of the 27 sites used in each study, only 10 were common to both. Collectively, the two studies evaluated 1,110 eligible subjects at a total of
	44 sites. Despite the difference in population between the two studies, and the large number of differing sites, the sensitivity of OVA1 added to clinical impression (also called OVA1 dual assessment) was identical, at 95.7% (88/92). In addition,
	overall NPV of OVA1 dual assessment was 98.1% (204/208), higher than the 94.6% NPV found in the earlier validation study. In premenopausal surgery patients, OVA1 dual assessment sensitivity was 93.5% (29/31), NPV was 98.6% (145/147) and specificity
	was 58.9% (145/246) when combined with clinical assessment. OVA1 also showed strong performance in detecting early stage malignancies. OVA1 correctly stratified 91.4% (32/35) of early stage cancers and 89.3% (25/28) of stage I cancers as high risk,
	respectively. In comparison, CA125-II sensitivity was 65.7% (23/35) for early stage and 64.3% (18/28) for stage I malignancies. Overall, the results strongly and independently confirmed the clinical performance of OVA1 in presurgical triage of
	adnexal mass patients, including premenopausal and early stage cancers.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The OVA500 study was recently published in the
	peer-reviewed journal
<I>
	Gynecologic Oncology
</I>
	, which enjoys the highest impact factor rating of any journal worldwide focused on gynecologic oncology. The results have also been incorporated into an updated Medical Education presentation, as
	well as our Marketing and Reimbursement collateral. Since many professional medical societies stress the importance of multiple independent clinical trials as so-called &#147;evidence levels&#148;, we also believe that OVA500 contributes to a higher
	evidence level relative to OVA1&#146;s utility in the medical management of adnexal masses.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In addition to OVA1, we have
	development programs in other clinical aspects of ovarian cancer as well as in peripheral arterial disease. In the field of peripheral arterial disease, we have identified candidate biomarkers that may help to identify individuals at high risk for a
	decreased ankle-brachial index score, which is indicative of the likely presence of peripheral arterial disease. We have completed an intended-use study, published in the December 2012 edition of
<I>
	Vascular Medicine
</I>
	, to develop and validate a
	multi-marker algorithm for the assessment of individuals at risk for peripheral arterial disease. This algorithm will be specifically directed at a primary care population in which the peripheral arterial disease blood test is expected to be used.
	With our recent decision to focus on gynecologic oncology and related diseases, we now plan to seek a Development/Commercial Partner for this program who will work with us to complete the product development, conduct the required clinical validation
	studies, and eventually commercialize this product on a global basis. In another program, we have also initiated pilot experiments intended to identify markers with high clinical specificity that may complement OVA1. These experiments are early
	stage and may take different directions depending on the results. We have yet to select one or more intended uses, and establish a regulatory pathway for this potential next generation OVA product.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Current and former academic and research institutions that we have or have had collaborations with include the Johns Hopkins University
	School of Medicine (&#147;JHU&#148;); the University of Texas M.D. Anderson Cancer Center (&#147;M.D. Anderson&#148;); University College London (&#147;UCL&#148;); the University of Texas Medical Branch (&#147;UTMB&#148;); the Katholieke
	Universiteit Leuven; Clinic of Gynecology and Clinic of Oncology, Rigshospitalet, Copenhagen University Hospital (&#147;Rigshospitalet&#148;); the Ohio State University Research Foundation (&#147;OSU&#148;); Stanford University
	(&#147;Stanford&#148;); and the University of Kentucky (&#147;UK&#148;).
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4
</FONT>
</P>
<A NAME="eolPage7"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have a strategic alliance agreement (the &#147;Strategic Alliance Agreement&#148;) with
	Quest Diagnostics to develop and commercialize up to three diagnostic tests from our product pipeline (the &#147;Strategic Alliance&#148;). Quest Diagnostics has the exclusive right to commercialize OVA1 in the clinical laboratory market until
	September 2014, with an option to extend such exclusive period in its sole discretion for one additional year. Prior to the expiration of the strategic alliance in October 2012, Quest Diagnostics selected two diagnostic tests to commercialize, a
	peripheral arterial disease blood test and OVA1.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We were originally incorporated in California on December&nbsp;9, 1993,
	under the name Abiotic Systems. In March 1995, we changed our corporate name to Ciphergen Biosystems, Inc. and in May 2000, we reincorporated in Delaware. We had our initial public offering in September 2000. On November&nbsp;13, 2006, we sold
	assets and liabilities of our protein research tools and collaborative services business (the &#147;Instrument Business Sale&#148;), to Bio-Rad Laboratories, Inc. (&#147;Bio-Rad&#148;), in order to concentrate our resources on developing clinical
	protein biomarker diagnostic products and services. On August&nbsp;21, 2007, we changed our corporate name to Vermillion, Inc. On March&nbsp;30, 2009, we filed a voluntary petition for relief under Chapter 11 of Title 11 of the United States Code
	(the &#147;Bankruptcy Code&#148;) in the United States Bankruptcy Court for the District of Delaware (the &#147;Bankruptcy Court&#148;). Subsequently, on January&nbsp;22, 2010, the confirmation order issued by the Bankruptcy Court approving our
	Second Amended Plan of Reorganization under Chapter 11 dated January&nbsp;5, 2010 became final and all conditions precedent to January&nbsp;22, 2010 were satisfied or waived. Accordingly, we emerged from bankruptcy protection under Chapter 11 on
	January&nbsp;22, 2010. Our Bankruptcy case was formally closed on January&nbsp;19, 2012.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	OVA1 was launched on March&nbsp;9,
	2010 by Quest Diagnostics under the terms of the Strategic Alliance Agreement. On March&nbsp;11, 2010, the Medicare contractor Highmark Medicare Services announced that it would cover OVA1 in its reimbursement program. On September&nbsp;20, 2010, we
	announced that OVA1 was CE marked, a requirement for marketing the test in the European Union. OVA1 has satisfied all certification requirements to complete its declaration of conformity.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In November 2011, we entered into an asset purchase agreement with Correlogic Systems, Inc. (&#147;Correlogic&#148;), pursuant to which
	we paid to Correlogic $435,000 and purchased from Correlogic substantially all of its assets, including certain documents, diagnostic samples and intellectual property owned by Correlogic in connection with Correlogic&#146;s ovarian cancer
	diagnostics business, including a diagnostic test under the name &#147;OvaCheck2&#153;&#148; for the detection of ovarian cancer (the &#147;Acquisition&#148;). Correlogic was in Chapter 11 proceedings in the United States Bankruptcy Court for the
	District of Maryland (the &#147;Court&#148;) at the time the asset purchase agreement was entered into and the Acquisition was subject to Court approval. Court approval was received and the Acquisition completed in December 2011. We plan to use the
	Correlogic assets purchased from the Acquisition to advance the goals of our ovarian cancer franchise, including the development of the next generation OVA product.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	The Diagnostic Market
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The economics of healthcare demand improved
	allocation of resources which can be derived through disease prevention, early detection of disease leading to early intervention, and diagnostic tools that can triage patients to more appropriate therapy and intervention. According to the May 2009
	In Vitro Diagnostics Market Analysis 2009-2024 report, the worldwide market for in vitro diagnostics (&#147;IVDs&#148;) in 2008 was approximately $40.0 billion. Visiongain, an independent business information provider, predicts that the market will
	generate nearly $60.0 billion in 2014. We have chosen to concentrate primarily in the areas of oncology and women&#146;s health. Demographic trends suggest that, as the population ages, the burden from these diseases will increase and the demand for
	quality diagnostic, prognostic and predictive tests will increase. In addition, these areas generally lack quality diagnostic tests and, therefore, we believe patient outcomes can be significantly improved by the development of novel diagnostic
	tests.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our focus on translational biomarkers enables us to address the market for novel diagnostic tests that simultaneously
	measure multiple biomarkers. A biomarker is a biomolecule or variant biomolecule that is present
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5
</FONT>
</P>
<A NAME="eolPage8"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	at measurably greater or lesser concentrations in a disease state versus a normal condition. Conventional protein tests measure a single protein biomarker whereas most diseases are complex. We
	believe that efforts to diagnose cancer and other complex diseases have failed in large part because the disease is heterogeneous at the causative level (i.e., most diseases can be traced to multiple potential etiologies) and at the human response
	level (i.e., each individual afflicted with a given disease can respond to that ailment in a specific manner).
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Consequently,
	measuring a single biomarker when multiple biomarkers may be altered in a complex disease is unlikely to provide meaningful information about the disease state. We believe that our approach of monitoring and combining multiple protein biomarkers
	using a variety of analytical techniques will allow us to create diagnostic tests with sufficient sensitivity and specificity about the disease state to aid the physician considering treatment options for patients with complex diseases. Such assays
	are commonly referred to as IVDMIA (In Vitro Diagnostic Multivariate Index Assays), and often utilize advanced algorithms based on logistic regression, pattern recognition and the like. Often, IVDMIA algorithms are non-intuitive, and therefore
	require rigorous clinical validation and error modeling. Vermillion and its collaborators are expert in these areas, and in the case of OVA1, presented both the clinical validation and error modeling in order to gain 510(k) clearance of OVA1, as an
	IVD software device.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Ovarian Cancer
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Background.
</I>
</B>
	Commonly known as the &#147;silent killer,&#148; ovarian cancer leads to approximately 15,000 deaths each year in the United States. The American Cancer Society (ACS) estimates
	that over 22,000 new ovarian cancer cases will be diagnosed in 2013, with the majority of the patients in the late stages of the disease in which the cancer has spread beyond the ovary. Unfortunately, ovarian cancer patients in the late stages of
	the disease have a poor prognosis, which leads to the high mortality rates. According to the ACS, when ovarian cancer is diagnosed at its earliest stage, the patient has a 5-year survival rate of 93%. Ovarian cancer patients have up to a 90% cure
	rate following surgery and/or chemotherapy if detected in stage 1. However, only 19% of ovarian cancer patients are diagnosed before the tumor has spread outside the ovary. For ovarian cancer patients diagnosed in the late-stages of the disease, the
	5-year survival rate falls to as low as 18%.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	While the diagnosis of ovarian cancer in its earliest stages greatly increases
	the likelihood of survival from the disease, another factor that predicts survival from ovarian cancer is the specialized training of the surgeon who operates on the ovarian cancer patient. Numerous studies have demonstrated that treatment of
	malignant ovarian tumors by specialists such as gynecologic oncologists or at specialist medical centers improves outcomes for women with these tumors. Published guidelines from the Society of Gynecologic Oncologists (the &#147;SGO&#148;) and the
	ACOG recommend referral of women with malignant ovarian tumors to specialists. Unfortunately, today, only about one third of women with these types of tumors are operated on by specialists, in part because of inadequate tests and procedures that can
	identify such malignancies with high sensitivity. Accordingly, an unmet clinical need is a diagnostic test that can provide adequate predictive value to stratify patients with a pelvic mass into those with a high risk of invasive ovarian cancer
	versus those with a low risk of ovarian cancer, which is essential for improving overall survival in patients with ovarian cancer.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Although adnexal masses are relatively common, malignant tumors are less so. Screening studies have indicated that the prevalence of adnexal masses in postmenopausal women can be as high as 5 percent.
	Adnexal masses are thought to be even more common in premenopausal women, but there are more non-persistent, physiologic ovarian masses in this demographic. In the Prostate Lung Colorectal and Ovarian Cancer study, 28,519 post-menopausal women were
	screened for ovarian malignancy and 4.7% received an abnormal ultrasound.&nbsp;Using the US census of 53&nbsp;million women over the age of 50, this suggests there are more than 2.4&nbsp;million adnexal masses in this segment alone. Although many of
	these do not present to the physician or are not concerning enough to warrant surgery, those that do require evaluation for the likelihood for malignancy could potentially benefit from the use of OVA1.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The ACOG and the SGO have issued guidelines to help physicians evaluate adnexal masses for malignancy. These guidelines take into account
	menopausal status, CA125 levels, and physical and imaging findings.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	6
</FONT>
</P>
<A NAME="eolPage9"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	However, these guidelines have notable shortcomings because of their reliance on tools with certain weaknesses. Most notably, the CA125 blood test, which is cleared by the FDA only for monitoring
	for recurrence of ovarian cancer, is negative in up to 50% of early stage ovarian cancer cases. Moreover, CA125 can be elevated in numerous conditions and diseases other than ovarian cancer, including benign ovarian masses and endometriosis. These
	shortcomings limit the CA125 blood test&#146;s utility in distinguishing benign from malignant ovarian tumors or for use in detection of early stage ovarian cancer. Transvaginal ultrasound is another diagnostic modality used with patients with
	ovarian masses. Attempts at defining specific morphological criteria that can aid in a benign versus malignant diagnosis have led to the morphology index and the risk of malignancy index, with reports of 40-70% predictive value. However, ultrasound
	interpretation can be variable and dependent on the experience of the operator. Accordingly, the ACOG and SGO guidelines perform only modestly in identifying early stage ovarian cancer and malignancy in pre-menopausal women. Efforts to improve
	detection of cancer by lowering the cutoff for CA125 (the &#147;Modified ACOG/SGO Guidelines&#148;) provide only a modest benefit, since CA125 is absent in about 20% of epithelial ovarian cancer cases and is poorly detected in early stage ovarian
	cancer.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Clinical Development
</I>
</B>
<B>
	.
</B>
	To address this documented unmet clinical need, we initiated an ovarian
	cancer biomarker discovery program. In August 2004, we, along with collaborators at JHU, UCL and M.D. Anderson, reported in a
<I>
	Cancer Research
</I>
	paper the discovery of three biomarkers that, when combined with CA125, provided higher diagnostic
	accuracy for early stage ovarian cancer than other biomarkers, including CA125 alone. The three biomarkers that we reported in the August 2004
<I>
	Cancer Research
</I>
	paper formed the basis of an expanded panel of biomarkers that together have
	demonstrated risk stratification value in a series of studies involving over 2,500 clinical samples from more than five clinical sites. Data presented at the June 2006 Annual Meeting of the American Society of Clinical Oncology demonstrated the
	portability of this biomarker panel among different clinical groups, indicating its potential validity across various testing populations. Data presented at the March 2007 Annual Meeting of the SGO described results from a cohort study. We were able
	to demonstrate in 525 consecutively sampled women, a significant increase in the positive predictive value using its biomarker panel over the baseline level. This translates into the potential to enrich the concentration of ovarian cancer cases
	referred to the gynecologic oncologist by more than twofold.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%;PADDING-BOTTOM:0PX; ">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	OVA1
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	&reg;
</SUP>
</FONT>
	Ovarian Tumor Triage Test
</I>
</B>
<B>
	.
</B>
	In January, 2007, we commenced our multi-center prospective clinical trial
	to demonstrate the clinical performance and utility of OVA1, which was developed based on the studies described above. The clinical study population came from institutions with primary care physicians, gynecologists (&#147;non-GO&#148;), and/or
	gynecologic oncologists (&#147;GO&#148;). The clinical study subject enrollment centers were representative of institutions where ovarian tumor subjects potentially undergo a gynecologic examination. The specimens were collected at 27
	demographically mixed sites that included large and small medical centers (universities/community hospitals), clinics that specialize in women&#146;s health, small gynecology/obstetrics groups, gynecology/oncology practices, and HMO groups. The
	performance of OVA1 was determined based on 516 evaluable subjects who underwent surgery to remove a documented ovarian tumor and for whom a pathology result was available. Physicians were asked, based on the information they had, which included
	physical, radiologic, and laboratory results, whether they believed the patient had cancer (&#147;Clinical Assessment&#148;). Physicians were not provided with OVA1 score in making this determination. After surgery, the specimen was examined by a
	surgical pathologist per routine clinical practice. The ability of physicians to predict malignancy without OVA1 was compared to the ability of physicians or OVA1 (&#147;Dual Assessment&#148;) to predict malignancy. With Dual Assessment, which
	included OVA1, 80.0% of cancers missed by clinician impression alone were detected. Dual Assessment, which included OVA1, had greater sensitivity and negative predictive value than Clinical Assessment alone and the metrics of clinical performance
	were 91.7% and 93.2%, respectively. We obtained FDA clearance of OVA1 on September&nbsp;11, 2009. OVA1 is the first FDA-cleared test to be used in the pre-surgical evaluation of ovarian adnexal masses.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Results from the clinical trial were presented at the 2010 Annual Meeting of the SGO. A presentation by Rachel Ware Miller, M.D.,
	Associate Professor of Gynecologic Oncology at the University of Kentucky&#146;s Markey Cancer Center, demonstrated that the ACOG/SGO guidelines detected only 77% of ovarian malignancies and that the Modified ACOG/SGO Guidelines improved detection
	to only 80%. Moreover, detection of early
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	7
</FONT>
</P>
<A NAME="eolPage10"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	stage ovarian cancer was only 47%. A second presentation by Fred Ueland, M.D., Associate Professor of Gynecologic Oncology, demonstrated that among non-gynecologic oncologists, OVA1, in
	conjunction with clinical impression, improved detection of malignancy to 92% from 72% using clinical impression alone among patients evaluated by non-gynecologic oncologists. Among these patients, detection of stage I ovarian cancer was 79%.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Additional results from the clinical trial were presented at the 2010 International Gynecologic Cancer Society (IGCS)
	meeting. This presentation reported that OVA1 had overall sensitivity for ovarian cancer of 92.5%, as compared to 68.9% for CA125 using cutoffs established in the ACOG criteria for adnexal mass evaluation and 77.0% for CA125 using cutoffs in the
	modified ACOG criteria. Additionally, data were presented demonstrating the high sensitivity of OVA1 for epithelial ovarian cancers; OVA1 detected 95/96 epithelial ovarian cancer cases for a sensitivity of 99.0%, including 40/41 stage I and stage II
	epithelial ovarian cancers, for an overall sensitivity of 97.6% for early stage epithelial ovarian cancers, as compared to 65.9% for CA125 using the ACOG cutoffs. The improvement in sensitivity was even greater among premenopausal women; for OVA1,
	sensitivity for early stage epithelial ovarian cancer was 92.9% and for CA125, sensitivity was 35.7%. Overall, OVA1 detected 76% of malignancies missed by CA125, including all advanced stage malignancies. OVA1 is not indicated for use as a screening
	or stand-alone diagnostic assay.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In 2012, we completed a second pivotal clinical study of OVA1, called the &#147;OVA500
	study&#148; and led by Dr.&nbsp;Robert E. Bristow, Director of Gynecologic Oncology Services with UC Irvine Healthcare. The study evaluated OVA1 diagnostic performance in a population of 494 evaluable patients who underwent surgery for an adnexal
	mass after enrollment by a non-gynecologic oncologist. Like the earlier OVA1 validation study, this was a prospective, multi-center study of consecutively enrolled, eligible subjects coordinated through 27 sites across the U.S.A. In the OVA500
	study, adnexal surgery patients were only enrolled from non-gynecologic oncology caregivers. As a result, the patient population in this study more closely resembled the intended use population for routine OVA1 testing; women aged 18 years or older,
	with an adnexal mass requiring surgery but not yet referred to gynecologic oncologist, and in which the mass was determined to be benign or malignant after enrollment. Moreover, of the 27 sites used in each study, only 10 were common to both. So
	collectively, the two studies evaluated 1,024 eligible subjects at a total of 44 sites. Despite the difference in population between the two studies, and the large number of differing sites, the sensitivity of OVA1 added to clinical impression (also
	called OVA1 dual assessment) was identical, at 95.7% (88/92). Interestingly, the overall prevalence of malignancy was lower in the OVA500 study than the 31.2% (161/516) previously found in the earlier OVA1 validation study. Cancer prevalence in
	OVA500 was 18.6% overall (92/494) and just 11.2% (31/277) in premenopausal surgery patients. This difference may be explained by the exclusion of subjects enrolled by gynecologic oncologist, a potentially malignancy-enriched subset of all adnexal
	mass surgeries. Even so, OVA1 sensitivity was 93.5% (29/31) in premenopausal subjects, with or without clinical assessment. NPV is another critical element of OVA1 performance in the context of a referral or triage test. In OVA500, overall NPV of
	OVA1 dual assessment was 98.1% (204/208), higher than the 94.6% NPV found in the earlier validation study. In premenopausal subjects, where functional ovarian cysts are more common and gynecologists may elect to operate more frequently, the NPV of
	OVA1 with or without clinical assessment was 98.6%. In contrast, clinical assessment predicted just 73.9% of malignancies overall, and only 64.5% of premenopausal malignancies. Together, the differential sensitivity and high NPV of OVA1 strongly
	confirmed previous findings, supporting the evidence of clinical utility in the presurgical triage of patients undergoing adnexal mass surgery. One additional finding related to medical necessity was the detection of early stage malignancies, since
	stage I cancers are 90-95% curable if appropriately operated and treated. Of the 92 malignancies in OVA500, 35 were early stage and 28 were stage I: 38.0% and 30.4% of all malignancies, respectively. OVA1 standalone sensitivity in stratifying
	patients as high-risk was 91.4% (32/35) for all early stage and 89.3% (25/28) for stage I malignancies, respectively. Comparatively, CA125-II sensitivity was 65.7% (23/35) for all early stage and 64.3% (18/28) for stage I malignancies. The success
	rate of OVA1 classifying a benign mass as low risk, although of secondary importance (considering surgery will be performed regardless), was also measured in the OVA500 study. This statistic (specificity) was 53.5% (215/402) overall, and in
	premenopausal patients was 61.4% (151/246). Overall, the results strongly and independently confirmed the value of OVA1 in presurgical triage of adnexal mass patients, and sensitive identification of premenopausal and early stage malignancies.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8
</FONT>
</P>
<A NAME="eolPage11"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The OVA500 study was recently published in the peer-reviewed journal
<I>
	Gynecologic
	Oncology
</I>
	, which enjoys the highest impact factor rating of any journal worldwide focused on gynecologic oncology. The results have also been incorporated into an updated Medical Education presentation, as well as our Marketing and Reimbursement
	collateral. Since many professional medical societies stress the importance of multiple independent clinical trials as so-called &#147;evidence levels&#148;, we also believe that OVA500 contributes to a higher evidence level relative to OVA1&#146;s
	utility in the medical management of adnexal masses. Health economic analysis indicates that anticipated benefits of OVA1 include i) more appropriate referrals of women with high risk of malignancy to a gynecologic oncologist and fewer referrals of
	women at low risk of malignancy; ii) fewer second surgeries as a result of an initial surgery by a generalist on a woman with a malignant tumor; iii) reduced need for a backup surgeon (i.e. specialist) during a surgery by a generalist; iv) more
	appropriate and efficient administration of intraperitoneal chemotherapy; v) longer survival, associated with better quality of life.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Peripheral Arterial Disease
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Peripheral arterial disease
	(&#147;PAD&#148;) represents atherosclerosis of the lower extremities and is generally reflective of systemic atherosclerotic disease and is therefore a risk factor for adverse cardiac events such as myocardial infarction and stroke. This disease
	affects between 8-12&nbsp;million Americans, and the number of people diagnosed with PAD is expected to increase concurrently with the rising number of people diagnosed with diabetes. The American Heart Association and the American College of
	Cardiology have identified three demographics at risk for PAD: smokers 50 years of age or older; diabetics 50 years of age or older; and the elderly 65 years of age or older. Collectively, this represents tens of millions of Americans.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%;PADDING-BOTTOM:0PX; ">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	PAD is most commonly diagnosed using the ankle-brachial index (&#147;ABI&#148;), which is performed using a handheld
	Doppler. Blood pressures are measured in the arm and at the ankles and the ratio (ankle/arm) is calculated. Non-affected individuals should have a ratio of 0.9 or greater, while individuals with a ratio of less than 0.9 are defined as having PAD.
	Although the ABI has good sensitivity and specificity for PAD, its implementation into routine clinical practice has been hampered by poor physician adoption, generally because of the need to utilize special equipment by a specially trained
	technician and the need to have the patient lie supine in an examination room for 10 to 30 minutes prior to the administration of this test. Additionally, studies have shown that the ABI is often performed incorrectly. Recently, a bedside instrument
	has been introduced to simplify PAD testing, in which blood pressure measurement and user operation have been greatly simplified. The system, called Unetixs REVO
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	&#153;
</SUP>
</FONT>
	, eliminates pre-test resting and takes less than 10 minutes to produce a result. However, the instrument retails for over $12,000 and uses Pulse Volume waveforms,
	rather than Doppler waveforms, and requires technician training and accurate placement of pressure cuffs. Our PAD experts advise us that this method has had little uptake and does not produce a validated ABI score. Therefore, a blood test that can
	be more routinely implemented and reliably drawn by primary care providers has potential in identifying at increased risk of PAD, for referral to vascular medicine specialists.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In collaboration with John P. Cooke, M.D., Ph.D., a Professor and Associate Director of the Stanford Cardiovascular Institute at Stanford
	University School of Medicine, we have performed both an initial discovery study and a first validation study that has resulted in the identification of blood markers that could assist in the diagnosis of PAD. These findings form the basis of a
	novel blood test for identification and specialist referral of patients at higher risk for PAD, similar to the use of OVA1 to detect and refer patients at higher risk of ovarian malignancy.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The results of these early studies, including the publication of two blood markers for PAD, were published in the August 2007 on-line
	issue of the peer-reviewed journal Circulation, which is published by the American Heart Association (the &#147;AHA&#148;). Independent validation of these initial findings was subsequently published in the peer-reviewed journal Vascular Medicine in
	2008. This study, which encompassed 540 individuals, confirmed the elevation of the two biomarkers in subjects with PAD. Moreover, the study showed that a panel of markers improved the identification of subjects with PAD and was complementary to
	available data, including the AHA risk score. In this study, subjects with a moderate AHA risk score but elevated PAD biomarker score had almost a 7 times increased likelihood of having PAD than if they had a normal PAD biomarker score.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	9
</FONT>
</P>
<A NAME="eolPage12"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The PAD intended use study, titled &#147;A validated biomarker panel to identify peripheral
	artery disease,&#148; and published in the December 2012 edition of Vascular Medicine, was authored by Dr.&nbsp;William Hiatt, Novartis Foundation endowed professor for cardiovascular research at the University of Colorado School of Medicine,
	Division of Cardiology. The article reported the results of a multi-center, prospective clinical study of 1,025 subjects, consecutively enrolled from the PAD at-risk population of those aged 70 or older, and diabetics and smokers 50 or older.
	Several different multi-marker algorithms were evaluated in at-risk patients with or without PAD, and compared to conventional cardiovascular risk assessment by the Framingham Risk Score (FRS). The best model demonstrated a c-statistic of 0.73 and
	more important, identified 17 of 20 (85%)&nbsp;of patients with PAD who were missed by the FRS high-risk cutoff. Similar results were seen in asymptomatic PAD subjects, where the algorithm correctly classified 84% (48/57). In a statement, the
	study&#146;s co-author Dr.&nbsp;Cooke commented, &#147;Since one in every 20 Americans over the age of 50 has PAD, this study suggests the possibility for a simple and practical way to screen at-risk patients. By detecting undiagnosed or
	asymptomatic PAD, primary care physicians can intervene earlier and improve the health and prognosis for their patients. We are truly excited at the confirmation our biomarker research achieved in this large group of at-risk subjects, and look
	forward to advancing our program.&#148;
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Commercialization
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We expect to commercialize and sell diagnostic tests (which may consist of reagents and/or proprietary software) in one or both of two phases. One phase, referred to as the laboratory developed test
	(&#147;LDT&#148;) phase, will involve the sale of certain reagents (which may be in the form of proprietary software) to certain customers coupled with the grant to such customer of a sublicense to utilize the reagent in a laboratory-developed test
	using the methodology covered by the relevant license(s) obtained from our collaborators. An LDT would comprise multiple reagents (such as assay test kits, software, or other reagents), some of which would be supplied by us, and would be utilized by
	clinical laboratories to develop and perform &#147;home brew&#148; laboratory tests in laboratories federally regulated under the Clinical Laboratory Improvement Amendments of 1988 (&#147;CLIA&#148;). In the other phase, referred to as the IVD
	phase, we plan to sell FDA-cleared devices (which may comprise multiple reagents such as assay test kits, software, or other reagents).
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Under the terms of the Amended Strategic Alliance Agreement, Quest Diagnostics had the right to commercialize up to three diagnostic tests from our product pipeline. Prior to the expiration of the
	strategic alliance, Quest Diagnostics selected two tests, peripheral arterial disease blood test and OVA1. We believe Quest Diagnostics no longer has the right to select the final diagnostic test. Pursuant to the Amended Strategic Alliance
	Agreement, Quest Diagnostics will have the non-exclusive right to commercialize each of the tests other than OVA1 in the clinical reference laboratory marketplace on a worldwide basis, with exclusive commercialization rights in each exclusive
	territory, as this term is defined in the Amended Strategic Alliance Agreement, beginning on the date each test is first commercialized and ending on the third anniversary of the date that such test is cleared or approved by the FDA. Quest has
	exclusive commercialization rights to commercialize OVA1 in the clinical reference laboratory marketplace in each exclusive territory through September 2014 and the right to extend the exclusivity period for one additional year. These exclusive
	territories consist of the United States, India, Mexico, and the United Kingdom. Quest Diagnostics has the non-exclusive right to commercialize OVA1 on a worldwide basis outside of these exclusive territories.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Customers
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%;PADDING-BOTTOM:0PX; ">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In the United States, the IVD market can be segmented into three major groups: clinical reference laboratories, the largest of which are Quest Diagnostics and Laboratory Corporation of America; hospital
	laboratories; and physician offices. Initially, substantially all of our revenue in the United States will be generated through clinical reference laboratories, and Quest Diagnostics will be the major customer. In 2013, we plan to begin a direct
	selling effort to hospitals which have the required instrumentation and testing capabilities to perform the 5 markers that are in the OVA1 product and utilize the OvaCalc
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	&reg;
</SUP>
</FONT>
	algorithm. Outside the United
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10
</FONT>
</P>
<A NAME="eolPage13"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	States, laboratories may become customers, either directly with us or via distribution relationships established between us and authorized distributors. In 2013 we plan to begin to actively seek
	out distributors/partners for the European marketplace.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Research and Development
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our research and development efforts center on the discovery and validation of biomarkers and combinations of biomarkers that can be
	developed into diagnostic assays. We do this predominantly through collaborations we have established with academic institutions such as JHU, Rigshospitalet, and Stanford as well as through contract research organizations (&#147;CRO&#146;s&#148;)
	such as PrecisionMed and the Colorado Prevention Center. In addition, we actively seek collaborations and initiate dialog with clinical academics, in order to generate publications, intellectual property or test development in broader areas of
	gynecologic oncology.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Scientific Background
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Genes are the hereditary coding system of living organisms. Genes encode proteins that are responsible for cellular functions. The study of genes and their functions has led to the discovery of new
	targets for drug development. Industry sources estimate that, within the human genome, there are approximately 30,000 genes. Although the primary structure of a protein is determined by a gene, the active structure of a protein is frequently altered
	by interactions with additional genes or proteins. These subsequent modifications result in hundreds of thousands of different proteins. In addition, proteins may interact with one another to form complex structures that are ultimately responsible
	for cellular functions.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Genomics allows researchers to establish the relationship between gene activity and disease. However,
	many diseases are manifested not at the genetic level, but at the protein level. The complete structure of modified proteins cannot be determined by reference to the encoding gene alone. Thus, while genomics provides some information about diseases,
	it does not provide a full understanding of disease processes. We are focused on converting recent advances in proteomics into clinically useful diagnostic tests.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Relationship Between Proteins and Diseases
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The entire genetic
	content of any organism, known as its genome, is encoded in strands of deoxyribonucleic acid (&#147;DNA&#148;). Cells perform their normal biological functions through the genetic instructions encoded in their DNA, which results in the production of
	proteins. The process of producing proteins from DNA is known as gene expression or protein expression. Differences in living organisms result from variability in their genomes, which can affect the types of genes expressed and the levels of gene
	expression. Each cell of an organism expresses only approximately 10% to 20% of the genome. The type of cell determines which genes are expressed and the amount of a particular protein produced. For example, liver cells produce different proteins
	from those produced by cells found in the heart, lungs, skin, etc. Proteins play a crucial role in virtually all biological processes, including transportation and storage of energy, immune protection, generation and transmission of nerve impulses
	and control of growth. Diseases may be caused by a mutation of a gene that alters a protein directly or indirectly, or alters the level of protein expression. These alterations interrupt the normal balance of proteins and create disease symptoms. A
	protein biomarker is a protein or protein variant that is present in a greater or lesser amount in a disease state versus a normal condition. By studying changes in protein biomarkers, researchers may identify diseases prior to the appearance of
	physical symptoms. Historically, researchers discovered protein biomarkers as a byproduct of basic biological disease research, which resulted in the validation by researchers of approximately 200 protein biomarkers that are being used in
	commercially available clinical diagnostic products.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Limitations of Existing Diagnostic Approaches
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The IVD industry manufactures and distributes products that are used to detect thousands of individual components present in human derived
	specimens. However, the vast majority of these assays are used specifically to identify single protein biomarkers. The development of new diagnostic products has been limited
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11
</FONT>
</P>
<A NAME="eolPage14"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	by the complexity of disease states, which may be caused or characterized by several or many proteins or post-translationally modified protein variants. Diagnostic assays that are limited to the
	detection of a single protein often have limitations in clinical specificity (true negatives) and sensitivity (true positives) due to the complex nature of many diseases and the inherent biological diversity among populations of people. Diagnostic
	products that are limited to the detection of a single protein may lack the ability to detect more complex diseases, and thus produce results that are unacceptable for practical use. The heterogeneity of disease and of the human response to disease
	often underlies the shortcoming of single biomarkers to diagnose and predict many diseases accurately.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Our Solution
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our studies, particularly in ovarian cancer, have given us a better understanding of both the disease pathophysiology
	and the host response. By using multiple biomarkers, we are able to better characterize the disease and host response heterogeneity. In addition, by examining specific biomarkers and their variants, for example, post-translational modifications, we
	believe we can improve sensitivity and specificity over traditional diagnostic biomarkers because these biomarker combinations reflect both the pathophysiology and host response. This is accomplished using novel biomarker panels coupled with
	multivariate pattern recognition software to identify IVDMIA algorithms which can be commercialized as disease-specific assays.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We are applying translational biomarker research, algorithm development tools, and statistical error modeling methods to discover robust
	associations between biomarker panels and clinically relevant disease endpoints. We plan to develop new IVDMIA algorithms and molecular diagnostic tests based on known and newly identified protein markers to help physicians better predict and manage
	disease and treatment, and thereby improve patient outcomes and overall health economic resource utilization. Examples of diagnostic applications include, but are not limited to: asymptomatic population screening, early detection, triage to
	specialists, aid in diagnosis, prognosis or disease sub-classification, prediction or selection of therapy, monitoring of therapeutic response or residual disease, monitoring for recurrence or identification of appropriate fallback therapy or
	clinical trial eligibility.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We therefore anticipate ongoing and new partnerships with leading scientific and clinical
	institutions who have active proteomic or genomic programs in the area of gynecologic cancers, or with relevant clinical trial interests, with the goal of expanding our product portfolio with relevant solutions to unmet medical needs in women&#146;s
	health.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Addressing the Heterogeneity of Disease
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our strategy is to create a diagnostics paradigm that is based on risk estimation, multiple-biomarker testing and information integration.
	This strategy is based on the belief that cancer and other gynecologic diseases are heterogeneous and, therefore, that relying on a single disease biomarker to provide a simple &#147;yes-no&#148; answer is likely to fail. We believe that efforts to
	diagnose cancer and other complex diseases have failed in large part because the disease is heterogeneous at the causative level, meaning that most diseases can be traced to multiple potential etiologies, and at the individual response level,
	meaning that each individual afflicted with a given disease can respond to that ailment in a specific manner. Consequently, diagnosis, disease monitoring and treatment decisions can be challenging. This heterogeneity of disease and difference in
	human response to disease and/or treatment underlies the shortcomings of single biomarkers to predict and identify many diseases. A better understanding of heterogeneity of disease and human response is necessary for improved diagnosis and treatment
	of many diseases.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Validation of Biomarkers Through Proper Study Design
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Analysis of peer-reviewed publications reveals almost daily reports of novel biomarkers or biomarker combinations associated with specific
	diseases. Few of these are used clinically. As with drug discovery, preliminary research results fail to canvass sufficient variation in study populations or laboratory practices and,
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12
</FONT>
</P>
<A NAME="eolPage15"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	therefore, the vast majority of candidate biomarkers fail to be substantiated in subsequent studies. Recognizing that validation is the point at which most biomarkers fail, our strategy is to
	reduce the attrition rate between discovery and clinical implementation by building validation into the discovery process. Biomarkers fail to validate for a number of reasons, which can be broadly classified into pre-analytical and analytical
	factors. Pre-analytical factors include study design that does not mimic actual clinical practice, inclusion of the wrong types of control individuals and demographic bias (usually seen in studies in which samples are collected from a single
	institution). Analytical factors include poor control over laboratory protocols, inadequate randomization of study samples and instrumentation biases (for example, higher signal early in the experimental run compared to later in the experimental
	run). Finally, the manner in which the data are analyzed can have a profound impact on the reliability of the statistical conclusions.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	When designing clinical studies, we begin with the clinical question, since this drives the downstream clinical utility of the biomarkers. With the starting point of building validation into the discovery
	process, we design our studies to include the appropriate cases and control groups. We further incorporate an initial validation component even within the discovery component. We place an emphasis on multi-institutional studies, inclusion of
	clinically relevant controls, using qualified and trained operators to run assays and collect data. For example, in an August 2004 cancer research paper, which describes the first three biomarkers in the ovarian cancer panel, there were more than
	600 specimen samples taken from five hospitals that were analyzed. In the development of OVA1, we analyzed more than 2,500 samples from five additional medical centers prior to initiating the prospective ovarian clinical study for submission to the
	FDA. Additionally to date, we have examined over 600 samples in our PAD program. In analyzing the complex proteomics data, we take a skeptical view of statistical methodologies, choosing to use a variety of approaches and looking for concordance
	between approaches, taking the view that biomarkers deemed significant by multiple statistical algorithms are more likely to reflect biological conditions than mathematical artifacts.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Through biomarker discovery efforts conducted predominantly from 2000 through 2007, we have amassed a portfolio of candidate biomarkers
	identified in retrospective sample sets. Our research and development efforts are now mostly focused on validating these biomarkers in prospective studies. During the period from 2007 through 2008, we conducted a multi-center prospective clinical
	trial to determine the clinical performance of OVA1, which was submitted to the FDA on June&nbsp;19, 2008, and cleared by the FDA on September&nbsp;11, 2009. We have additional markers for ovarian cancer that we plan to evaluate and validate.
	Additionally, we completed a prospective intended use study for PAD in 2011. These activities are outlined below.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	R&amp;D-sponsored initiatives to support market development of OVA1
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have two ongoing R&amp;D-sponsored initiatives to support OVA1 market development and adoption as an improved standard of care in the
	pre-surgical triage and evaluation of adnexal masses. The first is a major new clinical study of OVA1, focused on its performance in the predominantly pre-menopausal non-gynecologic oncologist patient population. The study, called OVA500, has
	resulted in first publication in the February 2013 edition of
<I>
	Gynecologic Oncology
</I>
	, a peer-reviewed journal with the highest impact factor rating of any journal worldwide focused on gynecologic oncology. OVA500 was conducted to confirm and
	extend the landmark findings of Ueland and Miller, published in
<I>
	Obstetrics&nbsp;&amp; Gynecology
</I>
	in the June 2011 edition, with a completely new, prospectively enrolled patient cohort. The findings of OVA500, reported in
<I>
	Gynecologic
	Oncology
</I>
	, are summarized in a preceding section of this document. Additional manuscripts are in preparation to follow up on the initial study report, and will be submitted in the first or second quarter of 2013. The second R&amp;D initiative
	supporting OVA1 is a series of Vermillion-assisted, independent clinical research studies of OVA1. Through this new program, Vermillion offers limited support for well-qualified Principal Investigators in the form of materials, testing services, and
	scientific consulting. As a result, we are currently in discussion with a number of potential investigators, to support new research publications on OVA1&#146;s clinical utility, cost-effectiveness, and potential line extensions. While agreements
	are still pending, at least one study has begun enrolling patients under a clinical institution IRB approval.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	13
</FONT>
</P>
<A NAME="eolPage16"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	New ovarian cancer indications
</I>
</B>
<B>
	.
</B>
	While our focus on supporting the
	commercialization of OVA1 is our primary priority, we also may extend our ovarian cancer franchise beyond OVA1, enabled by three key initiatives. First, we have just signed a 3-year extension of a research and license agreement with JHU to evaluate
	markers that provide improved specificity in the detection of ovarian cancer. Candidate markers are currently being assessed in small, pilot sample sets. Markers demonstrating high specificity may then be assessed in larger, clinical samples sets.
	Pilot results of these studies were reported in early 2011 at the Society of Gynecologic Oncologists. Second, our research and license agreement with Rigshospitalet (Copenhagen) generated data showing that a certain combination of markers can
	separate ovarian cancer patients into those with good prognosis from those with poor prognosis. These results were published in 2010 and we filed a patent application. Third, the acquisition of Correlogic assets in 2011 brings with it highly curated
	clinical samples, intellectual property and promising biomarker leads. These have the potential to further amplify our ovarian cancer diagnostic efforts in the future.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Prospective intended-use clinical study for Peripheral Arterial Disease (PAD)
</I>
</B>
<B>
	.
</B>
	In 2011, we completed an intended-use study to validate a multi-marker algorithm for the assessment of
	individuals at risk for PAD. The PAD intended use study, titled &#147;A validated biomarker panel to identify peripheral artery disease,&#148; and published in the December 2012 edition of Vascular Medicine, was authored by Dr.&nbsp;William Hiatt,
	Novartis Foundation endowed professor for cardiovascular research at the University of Colorado School of Medicine, Division of Cardiology. The article reported the results of a multi-center, prospective clinical study of 1,025 subjects,
	consecutively enrolled from the PAD at-risk population of those aged 70 or older, and diabetics and smokers 50 or older. Several different multi-marker algorithms were evaluated in at-risk patients with or without PAD, and compared to conventional
	cardiovascular risk assessment by the Framingham Risk Score (FRS). The best model demonstrated a c-statistic of 0.73 and more important, identified 17 of 20 (85%)&nbsp;of patients with PAD who were missed by the FRS high-risk cutoff. Similar results
	were seen in asymptomatic PAD subjects, where the algorithm correctly classified 84% (48/57). In a statement, the study&#146;s co-author Dr.&nbsp;Cooke commented, &#147;Since one in every 20 Americans over the age of 50 has PAD, this study suggests
	the possibility for a simple and practical way to screen at-risk patients. By detecting undiagnosed or asymptomatic PAD, primary care physicians can intervene earlier and improve the health and prognosis for their patients. We are truly excited at
	the confirmation our biomarker research achieved in this large group of at-risk subjects, and look forward to advancing our program.&#148;
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our PAD achievements, intellectual property and publications will support future discussions with potential development/ commercial partners and help to define the appropriate validation pathway, which
	may be as an FDA-approved or cleared test, or as a Laboratory Developed Test validated under the auspices of a CLIA-regulated clinical laboratory. Our path forward is to evaluate partnering options for the PAD program with third parties who have
	substantial presence in the cardiovascular market, as well as the funding and development capabilities to take this important blood test to market.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our research and development expenses were $2,216,000 and $5,387,000 for the years ended December&nbsp;31, 2012 and 2011, respectively. The decrease from the prior year was due primarily to a decrease in
	clinical trial costs for the ongoing development of our ovarian cancer franchise and our PAD program as our PAD intended use study was completed in 2011. The clinical trial cost decrease was net of ongoing expenses for our OVA1 FDA post-marketing
	study that commenced during 2012.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Commercial Operations
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have a commercial infrastructure, including sales and marketing and reimbursement expertise. Our sales representatives work with Quest Diagnostics to identify opportunities for communicating the
	benefits of OVA1 to general gynecologists and gynecologic oncologists alike. Our success will also depend on our ability to penetrate markets outside of the United States. OVA1 is CE marked, a requirement for marketing the test in the European
	Union. OVA1 has satisfied all certification requirements to complete its declaration of conformity.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	14
</FONT>
</P>
<A NAME="eolPage17"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	At the end of 2012, approximately 16,460 OVA1 tests had been performed in the calendar year,
	an increase of 8% over 2011. Additionally, we estimate over 275 gynecologic oncologists are supportive or advocating the use of OVA1 for the triage of women with adnexal masses. This broad number of specialists supporting the test indicates an
	understanding of the unmet clinical need and the ability of OVA1 to serve a significant market to assist physicians to triage women who need a specialist for surgery from those who can be treated by the primary physician. As of December 2012, over
	5,300 doctors had ordered the test, an increase of 43% over 2011.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We continue to develop the market through experienced
	Territory Development Managers and have expanded their scope of responsibility. As market awareness continues to build, these managers are focused on efforts that will have a positive impact on regional payers and create positive coverage decisions.
	They are working with local key opinion leaders and meeting with medical directors to discuss the unmet clinical need, our technology assessment package and increasing experience and cases studies showing the positive outcomes utilizing OVA1.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In 2013, our Territory Development Managers will also be targeting key hospital accounts that are interested in providing
	OVA1 results to their OB/GYN and GYN/ONC physicians. These hospitals must have the required instrumentation as required in our product requirements insert to be eligible to perform the OVA1 risk algorithm.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	There are still obstacles to overcome and significant milestones to attain to insure ongoing success. First, although the test volume and
	the number of doctors continue to increase, the average Gynecologist will only see about 2 to 4 appropriate patients per month and additional effort will be required to establish a consistent ordering pattern. Second, insurance coverage and patient
	bills are a concern to the physician and can disrupt the ordering pattern of a generalist who is supportive of OVA1.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Reimbursement
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In the United States, revenue for diagnostic tests comes from several sources, including third-party payers such as
	insurance companies and government healthcare programs, such as Medicare and Medicaid. In 2010, we announced that Highmark Medicare Services, the Medicare contractor that has jurisdiction over claims submitted by Quest Diagnostics for OVA1, will
	cover OVA1. This local coverage determination from Highmark Medicare Services essentially provides national coverage for patients enrolled in Medicare as well as Medicare Advantage health plans. We have worked together with Quest Diagnostics to
	obtain coverage and reimbursement from private payers across the country. As of January&nbsp;1, 2013, twenty-seven independent BlueCross BlueShield plans, representing more than 46.8&nbsp;million lives, provide coverage for OVA1. In total, including
	Medicare and other private payers, approximately 93.3&nbsp;million patients have access and coverage for OVA1. The Company and Quest Diagnostics continue to pursue coverage from additional payers.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%;PADDING-BOTTOM:0PX; ">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On March&nbsp;6, 2012, the American Medical Association (AMA) Current Procedural Terminology (CPT
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	&reg;
</SUP>
</FONT>
	) Panel voted to approve an application for a Category I CPT code for OVA1, which became effective January&nbsp;1,
	2013. The new CPT code is a positive step forward in advancing the commercialization of OVA1, as we believe it will help streamline claims processing and accelerate further coverage and adoption by private payers.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	New and innovative diagnostic tests often face reimbursement challenges that can affect adoption; the three key focus areas are coding,
	claims, and coverage or payer adoption. In conjunction with Quest Diagnostics, we are consistently addressing these three areas.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Coding
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	OVA1 is a new class of diagnostics and therefore no specific code existed at the time of its launch. This is often the case with new diagnostic tests
	and companies will bill using a miscellaneous code which is the path we and Quest Diagnostics implemented. Now, after establishing OVA1 in the market, creating demand, demonstrating the utility of the test, obtaining coverage and reimbursement, we
	filed for a CPT code specific for OVA1 in 2011, which was effective beginning January&nbsp;1, 2013. Achieving the unique Category I CPT code # 81503 was a critical step our commercialization process.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	15
</FONT>
</P>
<A NAME="eolPage18"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The test is priced in 2013 by the Centers for Medicare and Medicaid Services (CMS) using their gap-fill process. CMS uses this process when no
	comparable test exists. Medicare currently reimburses OVA1 at $516 per test and our test list price is $650.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Claims Process
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In the early launch of a product, claims can be rejected due to lack of medical necessity, lack of payer understanding, or even billing process errors.
	To address these items, our Territory Development Managers are engaging with physicians&#146; offices to assist in the appeals process and are using these claims to educate payers and create awareness about the medical necessity of our test.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Payer Coverage
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We continue to focus on&#150;going efforts toward obtaining national coverage decisions. However, these decisions typically have a much longer lead
	time due to industry established processes and time frames. In most cases, these entail clinical and technical reviews that are performed on an annual basis.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have assembled a Technology Assessment Package that will provide a nucleus of materials tailored to each National Plan.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have launched a program to aid local key opinion leaders to work with health plans to support coverage for OVA1. These strategic actions are
	necessary steps to convert those plans representing numerous regional payers and late adopters.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Competition
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The diagnostics industry in which we operate is competitive and evolving. There is intense competition among healthcare,
	biotechnology and diagnostics companies attempting to discover candidates for potential new diagnostic products. These companies may:
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	develop new diagnostic products in advance of us or our collaborators;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	develop diagnostic products that are more effective or cost-effective than those developed by us or our collaborators;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	obtain regulatory clearance or approval of their diagnostic products more rapidly than us or our collaborators; or
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	obtain patent protection or other intellectual property rights that would limit the ability to develop and commercialize, or a customers&#146; ability
	to use our or our collaborators&#146; diagnostic products.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We compete with companies in the United States
	and abroad that are engaged in the development and commercialization of novel biomarkers that may form the basis of novel diagnostic tests. These companies may develop products that are competitive with and/or perform the same or similar to the
	products offered by us or our collaborators, such as biomarker specific reagents or diagnostic test kits. Also, clinical laboratories may offer testing services that are competitive with the products sold by us or our collaborators. For example, a
	clinical laboratory can either use reagents purchased from manufacturers other than us or use its own internally developed reagents to make diagnostic tests. If clinical laboratories make tests in this manner for a particular disease, they could
	offer testing services for that disease as an alternative to products sold by us used to test for the same disease. The testing services offered by clinical laboratories may be easier to develop and market than test kits developed by us or our
	collaborators because the testing services are not subject to the same clinical validation requirements that are applicable to FDA-cleared or approved diagnostic test kits.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In September 2011, Fujirebio Diagnostics received FDA clearance for Risk of Ovarian Malignancy Algorithm. This test combines two tumor markers and menopausal status into a numerical score using a publicly
	available algorithm. This test has the same intended use and precautions as OVA1. The Risk of Ovarian
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	16
</FONT>
</P>
<A NAME="eolPage19"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Malignancy Algorithm is currently marketed as having utility limited to epithelial ovarian cancers, which accounts for 80% of ovarian malignancies. The two tests have not been compared in a side
	by side cohort evaluation to date, so no direct performance comparisons can be made.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Intellectual Property Protection
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our intellectual property includes a portfolio of owned, co-owned or licensed patents and patent applications. As of December&nbsp;31,
	2012, our clinical diagnostics patent portfolio included 24 issued United States patents, 14 pending United States patent applications, and numerous pending patent applications and issued patents outside the United States. These patents and patent
	applications fall into 32 patent families and are directed to several areas of technology important to our business, including ovarian cancer, breast cancer, PAD, Alzheimer&#146;s and other clinical diagnostic technologies. The clinical diagnostics
	market includes laboratories engaged in the research and development and/or manufacture of diagnostic tests using biomarkers, commercial clinical laboratories, hospitals and medical clinics that perform diagnostic tests.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	For intellectual property derived from Surface-Enhanced Laser Desorption/Ionization (&#147;SELDI&#148;) technology, we now share
	exclusive rights with Bio-Rad. The Company and Bio-Rad each have the right to engage in negotiations with the other party for a license to any improvements in the proprietary rights created by the other party.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The patent portfolio enumerated above also includes intellectual property which was acquired, together with other clinical diagnostics
	assets from Correlogic, Inc.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%;PADDING-BOTTOM:0PX; ">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On May&nbsp;8, 2012 the United States Patent and Trademark Office
	(&#147;USPTO&#148;) granted patent number 8,173,433, titled &#147;Platelet biomarkers for cancer.&#148; The patent resulted from a collaboration with the late Dr.&nbsp;Judah Folkman, a renowned cancer expert, and identifies three biomarkers that can
	be used to assess changes in endogenous angiogenesis in a subject. Angiogenesis is commonly associated with cancer, and novel therapeutics such as bevacizumab (Avastin
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	&reg;
</SUP>
</FONT>
	) target angiogenesis to limit tumor recruitment of blood vessels. The patented biomarkers, which are associated with platelets, can be used to measure ongoing
	angiogenic activity. The patent covers the measurement of these biomarkers over time and correlating changes in expression with the changing level of endogenous angiogenic activity. Consequently, this patent also enables the use of these biomarkers
	to monitor efficacy of therapy directed at angiogenic pathways.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On June&nbsp;26, 2012, the USPTO granted patent number
	8,206,934, titled &#147;Methods for diagnosing ovarian cancer.&#148; This patent further expands the list of biomarkers Vermillion has employed in the diagnosis or status determination of ovarian cancer. In this patent, the granted claims cover the
	use of Protein C Inhibitor (PCI) in ovarian cancer tests using blood and several other sample types.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On July&nbsp;17, 2012,
	the USPTO granted patent number 8,221,984, titled &#147;Biomarkers for ovarian cancer.&#148; The patent makes claims in the uses of a urinary Small MBL-associated protein C-terminal fragment (sMAP) in the diagnosis of ovarian cancer, ovarian cancer
	monitoring, and patient management.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On July&nbsp;24, 2012, the USPTO granted patent number 8,227,201, titled
	&#147;Beta2-microglobulin and C reactive protein (CRP) as biomarkers for peripheral artery disease.&#148; The patent contains claims to the use of beta2-microglobulin (B2M) and CRP to diagnose PAD in patients with risk factors of symptoms of
	cardiovascular disease, as well as a software classification algorithm, test reports or computer displays, and managing the treatment of such a patient. This work was done in coordination with Dr.&nbsp;John Cooke at Stanford University.
	Dr.&nbsp;Cooke is Professor and Associate Director of the Stanford Cardiovascular Institute at Stanford University School of Medicine.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Under the terms of an amended research collaboration agreement with the Johns Hopkins University School of Medicine, we are required to pay JHU $400,000 for 2013 and $100,000 for 2014. Collaboration costs
	under the JHU collaboration were $251,000 and $235,000 for the years ended December&nbsp;31, 2012 and 2011,
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	17
</FONT>
</P>
<A NAME="eolPage20"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	respectively. In addition, under the terms of the amended research collaboration agreement, we are required to pay the greater of 4% royalties on net sales of diagnostic tests using the assigned
	patents or annual minimum royalties of $57,500. Other institutions and companies from which we hold options to license intellectual property related to biomarkers or are a co-inventor on applications include UCL, M.D. Anderson, UK, OSU, McGill
	University (Canada), Eastern Virginia Medical School, Aaron Diamond AIDS Research Center, UTMB, Goteborg University (Sweden), University of Kuopio (Finland), The Katholieke Universiteit Leuven (Belgium) and Rigshospitalet.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Manufacturing
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%;PADDING-BOTTOM:0PX; ">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We are the manufacturer of OVA1. Components of OVA1 include reagents for each of the component assays as well as the OvaCalc
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	&reg;
</SUP>
</FONT>
	software. Because we do not directly manufacture the component assays, we are required to maintain supply agreements with manufacturers of each of the assays. As part
	of our Quality Systems, reagent lots for these assays are tested to ensure they meet specifications required for inclusion in OVA1. Only reagent lots determined by us as having met these specifications are permitted for use in OVA1.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Environmental Matters
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Medical Waste
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have been subject to licensing and regulation under federal, state and local laws relating to the handling and disposal of medical specimens and hazardous waste as well as to the safety and health of
	laboratory employees. Our laboratories were operated in material compliance with applicable federal and state laws and regulations relating to disposal of all laboratory specimens. We utilized outside vendors for disposal of specimens. We cannot
	eliminate the risk of accidental contamination or discharge and any resultant injury from these materials. Federal, state and local laws and regulations govern the use, manufacture, storage, handling and disposal of these materials. We could be
	subject to damages in the event of an improper or unauthorized release of, or exposure of individuals to, hazardous materials. In addition, claimants may sue us for injury or contamination that results from our use, or the use by third parties, of
	these materials, and our liability may exceed our total assets. Compliance with environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development or production efforts.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Occupational Safety
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In addition to its comprehensive regulation of safety in the workplace, the Federal Occupational Safety and Health Administration has established extensive requirements relating to workplace safety for
	healthcare employers whose workers may be exposed to blood-borne pathogens such as HIV and the hepatitis virus. These regulations, among other things, require work practice controls, protective clothing and equipment, training, medical follow-up,
	vaccinations and other measures designed to minimize exposure to chemicals and transmission of the blood-borne and airborne pathogens. Although we believe that we are currently in compliance in all material respects with such federal, state and
	local laws, failure to comply could subject us to denial of the right to conduct business, fines, criminal penalties and other enforcement actions.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Specimen Transportation
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Regulations of the Department of
	Transportation, the International Air Transportation Agency, the Public Health Service and the Postal Service apply to the surface and air transportation of clinical laboratory specimens. Although we believe that we are currently in compliance in
	all material respects with such federal, state and local laws, failure to comply could subject us to denial of the right to conduct business, fines, criminal penalties and other enforcement actions.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Government Regulation
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	General.
</B>
	Our activities related to diagnostic products are, or have the potential to be, subject to regulatory oversight by the FDA
	under provisions of the Federal Food, Drug and Cosmetic Act and regulations thereunder, including regulations governing the development, marketing, labeling, promotion, manufacturing and export of
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	18
</FONT>
</P>
<A NAME="eolPage21"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	our products. The Food, Drug and Cosmetic Act requires that medical devices introduced to the United States market, unless exempted by regulation, be the subject of either a pre-market
	notification clearance, known as a 510(k) clearance or 510(k) de novo clearance, or a PMA. OVA1 was cleared by the FDA on September&nbsp;11, 2009 under the 510(k) de novo guidelines. OVA1 was the first FDA-cleared blood test for the pre-operative
	assessment of ovarian masses. We have not yet established a regulatory pathway for our future potential products such as our PAD test and our next generation ovarian cancer test. Clinical studies to support either a 510(k) submission or a PMA
	application would need to be conducted in accordance with FDA requirements. If the FDA indicates that a PMA is required for any of our potential future clinical products, the application will require extensive clinical studies, manufacturing
	information and likely review by a panel of experts outside the FDA. Additionally, the FDA will generally conduct a pre-approval inspection for PMA devices.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Even in the case of devices like analyte specific reagents (&#147;ASRs&#148;), which may be exempt from 510(k) clearance or PMA approval requirements, the FDA may impose restrictions on marketing. Our
	potential future ASR products may be sold only to clinical laboratories certified under the CLIA to perform high complexity testing. In addition to requiring approval or clearance for new products, the FDA may require approval or clearance prior to
	marketing products that are modifications of existing products or the intended uses of these products. Additionally, the FDA will generally conduct a pre-approval inspection for PMA devices. Our suppliers&#146; manufacturing facilities are, and, if
	and when we begin commercializing and manufacturing our products ourselves, our manufacturing facilities will be, subject to periodic and unannounced inspections by the FDA and state agencies for compliance with Quality System Regulations
	(&#147;QSRs&#148;). Additionally, the FDA will generally conduct a pre-approval inspection for PMA devices. Although we believe that we and our suppliers will be able to operate in compliance with the FDA&#146;s QSRs for ASRs, we cannot assure that
	we or our suppliers will be in or be able to maintain compliance in the future. We have never been subject to an FDA inspection and cannot assure that we will pass an inspection, if and when it occurs. If the FDA believes that we or our suppliers
	are not in compliance with applicable laws or regulations, the FDA can issue a Form 483 List of Observations, warning letter, detain or seize our products, issue a recall notice, enjoin future violations and assess civil and criminal penalties
	against us. In addition, approvals or clearances could be withdrawn under certain circumstances.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Any customers using our
	products for clinical use in the United States may be regulated under CLIA, which is intended to ensure the quality and reliability of clinical laboratories in the United States by mandating specific standards in the areas of personnel
	qualifications, administration, participation in proficiency testing, patient test management, quality control, quality assurance and inspections. The regulations promulgated under CLIA establish three levels of diagnostic tests&#151;namely, waived,
	moderately complex and highly complex&#151;and the standards applicable to a clinical laboratory depend on the level of the tests it performs. Medical device laws and regulations are also in effect in many of the countries in which we may do
	business outside the United States. These range from comprehensive device approval requirements for some or all of our potential future medical device products, to requests for product data or certifications. The number and scope of these
	requirements are increasing. In addition, products which have not yet been cleared or approved for domestic commercial distribution may be subject to the FDA Export Reform and Enhancement Act of 1996 (&#147;FDERA&#148;).
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	FDA Regulation of Cleared Tests
</B>
<B>
<I>
	.
</I>
</B>
	Once granted, a 510(k) clearance or PMA approval may place substantial restrictions
	on how our device is marketed or to whom it may be sold. All devices cleared by the FDA are subject to continuing regulation by the FDA and certain state agencies. As a medical device manufacturer, we are also required to register and list our
	products with the FDA. We are required to set forth and adhere to a Quality Policy and other regulations. In addition, we are required to comply with the FDA&#146;s QSRs, which require that our devices be manufactured and records be maintained in a
	prescribed manner with respect to manufacturing, testing and control activities. Additionally, we may be subject to inspection by federal and state regulatory agencies. Non-compliance with these standards can result in, among other things, fines,
	injunctions, civil penalties, recalls, total or partial suspension of production. Further, we are required to comply with FDA requirements for labeling and promotion. For example, the FDA prohibits cleared or approved devices from being promoted for
	uncleared or unapproved uses. Labeling and promotional activities are subject to scrutiny by
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	19
</FONT>
</P>
<A NAME="eolPage22"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the FDA, which prohibits the marketing of medical devices for unapproved uses. Additionally, the FDA requires us to perform certain post-marketing studies (&#147;Post-market Surveillance&#148;)
	to verify or validate the clinical performance of FDA-cleared tests, as is permitted by their statutory authority.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In
	addition, the medical device reporting regulation requires that we provide information to the FDA whenever evidence reasonably suggests that one of our devices may have caused or contributed to a death or serious injury, or where a malfunction has
	occurred that would be likely to cause or contribute to a death or serious injury if the malfunction were to recur.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Foreign Government Regulation of Our Products
</B>
<B>
<I>
	.
</I>
</B>
	We intend to obtain regulatory approval in other countries to market
	our tests. Each country maintains its own regulatory review process, tariff regulations, duties and tax requirements, product standards, and labeling requirements. In 2010, we retained the services of the Emergo Group and TUV SUD America Inc. to
	assist in our efforts to satisfy the regulatory requirements necessary for commercialization in Europe. In September 2010, OVA1 was CE marked, a requirement for marketing the test in the European Union.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Employees
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	As of
	December&nbsp;31, 2012, we had 20 full-time employees. We also engage independent contractors from time to time.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Code of Ethics for
	Executive Officers
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have adopted a Code of Ethics for Executive Officers. We publicize the Code of Ethics for Executive
	Officers by posting the policy on our website, www.vermillion.com. We will disclose on our website any waivers of, or amendments to, our Code of Ethics.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Information About Us
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We file annual reports, quarterly reports, special
	reports, proxy and information statements, and other information with the Securities and Exchange Commission (the &#147;SEC&#148;). You may read and copy any material we file with the SEC at the SEC&#146;s Public Reference Room located at the
	following address:
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	100 F Street, NE
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Washington, DC 20549
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	You may obtain information on the operation of the
	SEC&#146;s Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC also maintains an Internet website, www.sec.gov, that contains reports, proxy and information statements, and other information regarding issuers that file electronically
	with the SEC.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In addition, we make available free of charge under the Investors Relation section of our website,
	www.vermillion.com, the Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934, as
	amended (&#147;Exchange Act&#148;) as soon as reasonably practicable after we have electronically filed such material with or furnished it to the SEC. The information contained on our website is not incorporated by reference in this Annual Report on
	Form 10-K and should not be considered a part of this Annual Report on Form 10-K. You may also obtain these documents free of charge by submitting a written request for a paper copy to the following address:
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Investor Relations
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Vermillion, Inc.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12117 Bee Caves Road, Building Three, Suite 100
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Austin, TX 78738
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	20
</FONT>
</P>
<A NAME="eolPage23"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_BUSINESS>
<EFX_RISK_FACTORS>
<A NAME="FIS_RISK_FACTORS"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_TOC453081_3">
</A>
	ITEM&nbsp;1A.
</B>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	RISK FACTORS
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	You
	should carefully consider the following risk factors and uncertainties together with all of the other information contained in this Annual Report on Form 10-K, including our audited consolidated financial statements and the accompanying notes in
	Part II Item&nbsp;8, &#147;Financial Statements and Supplementary Data.&#148; The risks and uncertainties management describes below are the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem
	immaterial may also adversely affect our business.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Risks Related to Our Business
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	If we are unable to increase the volume of OVA1 sales, our revenues, results of operations and financial condition would be adversely affected.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have experienced significant operating losses each year since our inception and we expect to incur a net loss for
	fiscal year 2013 and the foreseeable future. Our losses have resulted principally from costs incurred in research and development, sales and marketing, litigation, and general and administrative costs.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	All of our revenues are currently generated from sales of OVA1 tests by Quest Diagnostics. If we are unable to increase the volume of
	OVA1 sales, our consolidated results of operations and financial condition would be adversely affected.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Our ability to commercialize OVA1
	is heavily dependent on our strategic alliance with Quest Diagnostics.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Quest Diagnostics has an exclusive license to
	offer OVA1 as a clinical laboratory test in the US, Mexico, Britain and India through September&nbsp;11, 2014, which may be extended for an additional year beyond September&nbsp;11, 2014. Consequently, our ability to generate revenue from OVA1 is
	heavily dependent on Quest Diagnostics and its ability to market and offer these tests in its clinical laboratories.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	We expect that for
	the foreseeable future nearly all of our revenue will be derived from Quest Diagnostics and will depend on the number of OVA1 tests performed by Quest Diagnostics and the reimbursement rate for performing those tests, which are outside of our
	control.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We expect that nearly all of our revenues for the foreseeable future will be derived through our strategic
	partnership with Quest Diagnostics and will be based on the number of OVA1 tests performed by Quest Diagnostics and the reimbursement rate received by Quest Diagnostics for those tests. Under the terms of our Strategic Alliance Agreement with Quest
	Diagnostics, we are to be paid $50 for each domestic OVA1 performed by Quest Diagnostics, as well as a 33% royalty of Quest Diagnostics&#146; gross margin from performing OVA1. The Agreement provides for a monthly payment by Quest Diagnostics to us
	based on Quest Diagnostics&#146; average reimbursement per OVA1 in the previous month, and the royalty portion of our revenue is subject to adjustment, either up or down, on an annual basis within 60 days of end of each calendar year based on Quest
	Diagnostics&#146; actual reimbursement history for that calendar year. To the extent Quest Diagnostics is not reimbursed, is reimbursed at a lower than expected rate, or has reimbursement claims rejected, the royalty amounts owed to us would be
	reduced. Any amounts owed by us to Quest Diagnostics will be deducted against payments owed to us in future periods. The number of tests performed by Quest Diagnostics and the amount of reimbursements received by Quest Diagnostics in any given
	period is largely outside of our control, and Quest Diagnostics has many other test products that it promotes in addition to OVA1, which could result in a reduced focus by Quest Diagnostics on promoting OVA1. If Quest Diagnostics does not experience
	growing OVA1 test volumes or receives less reimbursement per test than expected, it could have a material adverse effect on our revenue, results of operations and cash flows.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	21
</FONT>
</P>
<A NAME="eolPage24"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	How we will recognize future revenue under the Quest Diagnostics Strategic Alliance Agreement remains
	uncertain and is likely to change, which could affect our revenue in future periods.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Given our limited commercialization
	history with OVA1 and our inability to know or control Quest Diagnostics&#146; reimbursement rates for OVA1, it is difficult for us to estimate future royalties and the size of any year-end adjustment calculated by Quest Diagnostics within 60 days
	of every calendar year end as required by the Strategic Alliance Agreement with Quest Diagnostics. Therefore, it is difficult for us to recognize some or all of the revenue related to the royalty payments to be received from Quest Diagnostics during
	the calendar year until we are better able to estimate the final royalty payment amounts and the magnitude and effect of the annual recalculation and adjustment mechanism. Accordingly, the amount of revenue we will be able to recognize in any
	quarter could vary significantly, and the method used to calculate that revenue could be subject to change.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Failures by third party payers
	to reimburse OVA1 or changes or variances in reimbursement rates could materially and adversely affect our revenues and could result in significant fluctuations in our revenues.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Most of our revenue is dependent on the amount Quest Diagnostics receives from third party payers for performing OVA1 tests. Insurance
	coverage and reimbursement rates for diagnostic tests are uncertain, subject to change and particularly volatile during the early stages of commercialization. There remain questions as to what extent third party payers, like Medicare, Medicaid and
	private insurance companies will provide coverage for OVA1 and for which indications. The reimbursement rates for OVA1 are largely out of our control, as Quest Diagnostics handles all reimbursements of OVA1 performed. We have limited visibility into
	any specific payer-level reimbursement data for OVA1 as such data is provided to us by Quest once a year as part of the annual revenue true-up process. We endeavor to maintain a dialogue with Quest Diagnostics regarding reimbursement issues as they
	arise. Quest Diagnostics has advised us that it has experienced volatility in the coverage and reimbursement of OVA1 due to contract negotiation with third party payers and implementation requirements and that the reimbursement amounts it has
	received from third party payers varies from payer to payer, and, in some cases, the variation is material. Third party payers, including private insurance companies as well as government payers such as Medicare and Medicaid, have increased their
	efforts to control the cost, utilization and delivery of healthcare services. These measures have resulted in reduced payment rates and decreased utilization for the diagnostic test industry. From time to time, Congress has considered and
	implemented changes to the Medicare fee schedules in conjunction with budgetary legislation, and pricing for tests covered by Medicare is subject to change at any time. Reductions in the reimbursement rate of payers may occur in the future.
	Reductions in the price at which OVA1 is reimbursed could have a material adverse effect on our revenues. If we and Quest Diagnostics are unable to establish and maintain broad coverage and reimbursement for OVA1 or if third party payers change
	their coverage or reimbursement policies with respect to OVA1, our revenues could be materially and adversely affected.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	We will need to
	raise additional capital in the future and if we are unable to secure adequate funds on terms acceptable to us, we may be unable to execute our business plan.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In order to continue our operations through 2013 and beyond, we will need to raise additional capital. Our independent registered public accounting firm&#146;s report on our financial statements for the
	year ended December&nbsp;31, 2012 includes an explanatory paragraph expressing substantial doubt about our ability to continue as a going concern, given our recurring net losses and negative cash flows from operations. We may seek to raise
	additional capital through the issuance of equity or debt securities in the public or private markets, or through a collaborative arrangement or sale of assets. Additional financing opportunities may not be available to us, or if available, may not
	be on favorable terms. The availability of financing opportunities will depend, in part, on market conditions, and the outlook for our business. Any future issuance of equity securities or securities convertible into equity could result in
	substantial dilution to our stockholders, and the securities issued in such a financing may have rights, preferences or privileges senior to those of our common stock. If we raise additional funds by issuing debt, we may be subject to limitations on
	our operations, through debt covenants or other restrictions. If we obtain additional funds through arrangements with collaborators or strategic partners, we may
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	22
</FONT>
</P>
<A NAME="eolPage25"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	be required to relinquish rights to certain technologies or products that we might otherwise seek to retain. If adequate and acceptable financing is not available to us at the time that we seek
	to raise additional capital, our ability to execute our business plan successfully may be negatively impacted.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	We may not succeed in
	developing additional diagnostic products, and, even if we do succeed in developing additional diagnostic products, the diagnostic products may never achieve significant commercial market acceptance.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our success depends on our ability to continue to develop and commercialize diagnostic products. There is considerable risk in developing
	diagnostic products based on our biomarker discovery efforts, as candidate biomarkers may fail to validate results in larger clinical studies or may not achieve acceptable levels of clinical accuracy. For example, markers being evaluated for OVA2
	may not be validated in downstream pre-clinical or clinical studies, once we undertake and perform such studies. Although our PAD blood test in development achieved positive top-line results from an intended use clinical study, it is possible that
	these biomarkers, upon further analysis and clinical study, may not meet acceptance criteria for validation or regulatory clearance.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Clinical testing is expensive, takes many years to complete and can have an uncertain outcome. Clinical failure can occur at any stage of the testing. Clinical trials for our PAD, OVA2, and other future
	diagnostic tests may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical and/or non-clinical testing on these tests. In addition, the results of our clinical trials may identify
	unexpected risks relative to safety or efficacy, which could complicate, delay or halt clinical trials, or result in the denial of regulatory approval by the FDA and other regulatory authorities.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	If we do succeed in developing additional diagnostic tests with acceptable performance characteristics, we may not succeed in achieving
	commercial market acceptance for those tests. Our ability to successfully commercialize diagnostic products, including OVA1, will depend on many factors, including:
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	our ability to convince the medical community of the safety and clinical efficacy of our products and their advantages over existing diagnostic
	products;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	our success in establishing new clinical practices or changing previous ones, such that utilization of the tests fail to meet established standards of
	care, medical guidelines and the like;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	our ability to further establish business relationships with other diagnostic or laboratory companies that can assist in the commercialization of these
	products in the US and globally; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the scope and extent of the agreement by Medicare and third-party payers to provide full or partial reimbursement coverage for our products, which will
	affect patients&#146; willingness to pay for our products and will likely heavily influence physicians&#146; decisions to recommend or use our products.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	These factors present obstacles to commercial acceptance of our existing and potential diagnostic products, for which we will have to spend substantial time and financial resources to overcome, and there
	is no guarantee that we will be successful in doing so. Our inability to do so successfully would prevent us from generating revenue from future diagnostic products.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	The diagnostics market is competitive and we may not be able to compete successfully, which would adversely impact our ability to generate revenue.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our principal competition currently comes from the many clinical options available to medical personnel involved in clinical decision
	making. For example, rather than ordering an OVA1 for a woman with an adnexal mass, obstetricians, gynecologists, and gynecologic oncologists may choose a different clinical option or none at all. If we are not able to convince clinicians that OVA1
	provides significant improvement over current clinical practices, our ability to commercialize OVA1 would be adversely affected. Additionally, Fujirebio Diagnostics, Inc. announced in September 2011 that they have received clearance from the FDA to
	commercialize its Risk of Malignancy Algorithm (&#147;ROMA&#148;) test. The ROMA test may be in direct competition with OVA1 and our
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	23
</FONT>
</P>
<A NAME="eolPage26"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	revenues could be materially and adversely affected if and when the ROMA test is successfully commercialized. In addition, competitors, such as Becton Dickinson, ArrayIt Corporation, and Abbott
	Labs have publicly disclosed that they have been or are currently working on ovarian cancer diagnostic assays. Academic institutions periodically report new findings in ovarian cancer diagnostics that may have commercial value. Our failure to
	compete with any competitive diagnostic assay if and when commercialized could adversely affect our business.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have priced
	OVA1 at a point that recognizes the value-added by its increased sensitivity for ovarian malignancy. If others develop a test that is viewed to be similar to OVA1 in efficacy but is priced at a lower point, we and/or our strategic partners may have
	to lower the price of OVA1 in order to effectively compete, which would impact our margins and potential for profitability.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	The
	commercialization of our diagnostic tests may be affected adversely by changing FDA regulations, and any delay by or failure of the FDA to approve our diagnostic tests submitted to the FDA may adversely affect our consolidated revenues, results of
	operations and financial condition.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The FDA cleared OVA1 on September&nbsp;11, 2009. Our activities related to diagnostic
	products are, or have the potential to be, subject to regulatory oversight by the FDA under provisions of the Federal Food, Drug and Cosmetic Act and regulations thereunder, including regulations governing the development, marketing, labeling,
	promotion, manufacturing and export of our products. Failure to comply with applicable requirements can lead to sanctions, including withdrawal of products from the market, recalls, refusal to authorize government contracts, product seizures, civil
	money penalties, injunctions and criminal prosecution.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Food, Drug and Cosmetic Act requires that medical devices
	introduced to the United States market, unless exempted by regulation, be the subject of either a pre-market notification clearance, known as a 510(k) clearance or 510(k) de novo clearance, or a PMA. Some of our potential future clinical products
	may require a 510(k) or 510(k) de novo clearance, while others may require a PMA. With respect to devices reviewed through the 510(k) process, we may not market a device until an order is issued by the FDA finding our product to be substantially
	equivalent to a legally marketed device known as a predicate device. A 510(k) submission may involve the presentation of a substantial volume of data, including clinical data. The FDA may agree that the product is substantially equivalent to a
	predicate device and allow the product to be marketed in the United States. On the other hand, the FDA may determine that the device is not substantially equivalent and require a PMA, or require further information, such as additional test data,
	including data from clinical studies, before it is able to make a determination regarding substantial equivalence. By requesting additional information, the FDA can delay market introduction of our products. Delays in receipt of or failure to
	receive any necessary 510(k) clearance or PMA approval, or the imposition of stringent restrictions on the labeling and sales of our products, could have a material adverse effect on us. If the FDA indicates that a PMA is required for any of our
	potential future clinical products, the application will require extensive clinical studies, manufacturing information and likely review by a panel of experts outside the FDA. Clinical studies to support either a 510(k) submission or a PMA
	application would need to be conducted in accordance with FDA requirements. Failure to comply with FDA requirements could result in the FDA&#146;s refusal to accept the data or the imposition of regulatory sanctions. We cannot assure that any
	necessary 510(k) clearance or PMA approval will be granted on a timely basis, or at all. To the extent we seek FDA 510(k) clearance or FDA pre-market approval for other diagnostic tests, any delay by or failure of the FDA to clear or approve those
	diagnostic tests may adversely affect our consolidated revenues, results of operations and financial condition.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	If we or our suppliers
	fail to comply with FDA requirements for production, marketing and postmarket monitoring of our products, we may not be able to market our products and services and may be subject to stringent penalties, product restrictions or recall; further
	improvements to our manufacturing operations may be required that could entail additional costs.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The commercialization of
	our products could be delayed, halted or prevented by applicable FDA regulations. If the FDA were to view any of our actions as non-compliant, it could initiate enforcement actions,
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	24
</FONT>
</P>
<A NAME="eolPage27"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	such as a warning letter and possible imposition of penalties. In addition, analyte specific reagents (&#147;ASRs&#148;) that we may provide would be subject to a number of FDA requirements,
	including compliance with the FDA&#146;s Quality System Regulations (&#147;QSR&#148;), which establish extensive requirements for quality assurance and control as well as manufacturing procedures. Failure to comply with these regulations could
	result in enforcement actions for us or our potential suppliers. Adverse FDA actions in any of these areas could significantly increase our expenses and limit our revenue and profitability. We will need to undertake steps to maintain our operations
	in line with the FDA&#146;s QSR requirements. Some components of OVA1 are manufactured by other companies and we are required to maintain supply agreements with these companies. If these agreements are not satisfactory to the FDA, we will have to
	renegotiate these agreements. Any failure to do so would have an adverse effect on our ability to commercialize OVA1. Our suppliers&#146; manufacturing facilities will be subject to periodic regulatory inspections by the FDA and other federal and
	state regulatory agencies. If and when we begin commercializing and assembling our products by ourselves, our facilities will be subject to the same inspections. We or our suppliers may not satisfy such regulatory requirements, and any such failure
	to do so would have an adverse effect on our commercialization efforts.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	If our suppliers fail to produce acceptable or sufficient stock,
	make changes to the design or labeling of their biomarker kits or discontinue production of existing biomarker kits, we may be unable to meet market demand for OVA1.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The commercialization of our OVA1 test depends on the supply of five different immunoassay kits from third-party manufacturers. Failure by any of these manufacturers to produce kits that pass
	Vermillion&#146;s quality control measures might lead to back-order and/or loss of revenue due to missed sales and customer dissatisfaction. In addition, if the design or labeling of any kit were to change, continued OVA1 supply could be threatened
	since new validation and submission to the FDA for 510(k) clearance could be required as a condition of sale. Discontinuation of any of these kits would require identification, validation and 510(k) submission on a revised OVA1 design. While
	Vermillion has experienced no such issues to date, there can be no assurances that this will not occur in the future.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	If we fail to
	continue to develop our technologies, we may not be able to successfully foster adoption of our products and services or develop new product offerings.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our technologies are new and complex, and are subject to change as new discoveries are made. New discoveries and advancements in the diagnostic field are essential if we are to foster the adoption of our
	product offerings. Development of these technologies remains a substantial risk to us due to various factors, including the scientific challenges involved, our ability to find and collaborate successfully with others working in the diagnostic field,
	and competing technologies, which may prove more successful than our technologies.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	If we fail to maintain our rights to utilize
	intellectual property directed to diagnostic biomarkers, we may not be able to offer diagnostic tests using those biomarkers.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	One aspect of our business plan is to develop diagnostic tests based on certain biomarkers, which we have the right to utilize through licenses with our academic collaborators, such as the Johns Hopkins
	University School of Medicine, Stanford University, and the University of Texas M.D., Anderson Cancer Center. In some cases, our collaborators own the entire right to the biomarkers. In other cases, we co-own the biomarkers with our collaborators.
	If, for some reason, we lose our license to biomarkers owned entirely by our collaborators, we may not be able to use those biomarkers in diagnostic tests. If we lose our exclusive license to biomarkers co-owned by us and our collaborators, our
	collaborators may license their share of the intellectual property to a third party that may compete with us in offering diagnostic tests, which would materially adversely affect our consolidated revenues, results of operations and financial
	condition.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	25
</FONT>
</P>
<A NAME="eolPage28"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	If a competitor infringes on our proprietary rights, we may lose any competitive advantage we may have as
	a result of diversion of our time, enforcement costs and the loss of the exclusivity of our proprietary rights.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our
	success depends in part on our ability to maintain and enforce our proprietary rights. We rely on a combination of patents, trademarks, copyrights and trade secrets to protect our technology and brand. We have submitted a number of patent
	applications covering biomarkers that may have diagnostic or therapeutic utility. Our patent applications may or may not result in additional patents being issued.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	If competitors engage in activities that infringe on our proprietary rights, our focus will be diverted and we may incur significant costs in asserting our rights. We may not be successful in asserting
	our proprietary rights, which could result in our patents being held invalid or a court holding that the competitor is not infringing, either of which would harm our competitive position. We cannot be sure that competitors will not design around our
	patented technology.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We also rely upon the skills, knowledge and experience of our technical personnel. To help protect our
	rights, we require all employees and consultants to enter into confidentiality agreements that prohibit the disclosure of confidential information. These agreements may not provide adequate protection for our trade secrets, knowledge or other
	proprietary information in the event of any unauthorized use or disclosure. If any trade secret, knowledge or other technology not protected by a patent were to be disclosed to or independently developed by a competitor, it could have a material
	adverse effect on our business, consolidated results of operations and financial condition.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	If others successfully assert their
	proprietary rights against us, we may be precluded from making and selling our products or we may be required to obtain licenses to use their technology.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our success depends on avoiding infringing on the proprietary technologies of others. If a third party were to assert claims that we are violating their patents, we might incur substantial costs defending
	ourselves in lawsuits against charges of patent infringement or other unlawful use of another&#146;s proprietary technology. Any such lawsuit may not be decided in our favor, and if we are found liable, it may be subject to monetary damages or
	injunction against using the technology. We may also be required to obtain licenses under patents owned by third parties and such licenses may not be available to us on commercially reasonable terms, if at all.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Current and future litigation against us could be costly and time consuming to defend.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We are from time to time subject to legal proceedings and claims that arise in the ordinary course of business, such as claims brought by
	our clients in connection with commercial disputes, employment claims made by current or former employees, and claims brought by third parties alleging infringement on their intellectual property rights. In addition, we may bring claims against
	third parties for infringement on our intellectual property rights. Litigation may result in substantial costs and may divert our attention and resources, which may seriously harm our business, consolidated results of operations and financial
	condition.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	An unfavorable judgment against us in any legal proceeding or claim could require us to pay monetary damages. In
	addition, an unfavorable judgment in which the counterparty is awarded equitable relief, such as an injunction, could have an adverse impact on our licensing and sublicensing activities, which could harm our business, consolidated results of
	operations and consolidated financial condition.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Because our business is highly dependent on key executives and employees, our inability
	to recruit and retain these people could hinder our business plans.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We are highly dependent on our executive officers and
	certain key employees. Our executive officers and key employees are employed at will by us. Any inability to engage new executive officers or key employees could impact operations or delay or curtail our research, development and commercialization
	objectives. To continue our research and product development efforts, we need people skilled in areas such as clinical operations, regulatory affairs and clinical diagnostics. Competition for qualified employees is intense.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	26
</FONT>
</P>
<A NAME="eolPage29"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	If we lose the services of any senior executive officers or key employees, our ability to
	achieve our business objectives could be harmed, which in turn could adversely affect our business and operating results.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Our diagnostic
	efforts may cause us to have significant product liability exposure.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The testing, manufacturing and marketing of medical
	diagnostic tests entail an inherent risk of product liability claims. Potential product liability claims may exceed the amount of our insurance coverage or may be excluded from coverage under the terms of the policy. Our existing insurance will have
	to be increased in the future if we are successful at introducing new diagnostic products and this will increase our costs. In the event that we are held liable for a claim or for damages exceeding the limits of our insurance coverage, we may be
	required to make substantial payments. This may have an adverse effect on our consolidated results of operations, financial condition and cash flows, and may increase the volatility of our common stock price.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Business interruptions could limit our ability to operate our business.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our operations, as well as those of the collaborators on which we depend, are vulnerable to damage or interruption from fire; natural disasters, including earthquakes; computer viruses; human error; power
	shortages; telecommunication failures; international acts of terror; and similar events. Although we have certain business continuity plans in place, we have not established a formal comprehensive disaster recovery plan, and our back-up operations
	and business interruption insurance may not be adequate to compensate it for losses we may suffer. A significant business interruption could result in losses or damages incurred by us and require us to cease or curtail our operations.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	If we fail to maintain proper and effective internal controls, our ability to produce accurate and timely financial statements could be impaired,
	which could adversely affect our business, operating results, and financial condition.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We are required to comply with the
	management certification requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002. We are required to report, among other things, control deficiencies that constitute a &#147;material weakness&#148; or changes in internal controls that, or
	that are reasonably likely to, materially affect internal controls over financial reporting. A &#147;material weakness&#148; is a deficiency or combination of deficiencies that results in a reasonable possibility that a material misstatement of the
	annual or interim consolidated financial statements will not be prevented or detected. If we fail to continue to comply with the requirements of Section&nbsp;404, we might be subject to sanctions or investigation by regulatory authorities such as
	the SEC. If we fail to remedy any material weakness, our consolidated financial statements may be inaccurate, which could adversely affect our business, operating results, and financial condition.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Legislative actions resulting in higher compliance costs are likely to adversely affect our future consolidated results of operations, financial
	position and cash flows.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Compliance with laws, regulations and standards relating to corporate governance and public
	disclosure, including the Sarbanes-Oxley Act of 2002, and new regulations adopted by the SEC, are resulting in increased compliance costs. We, like all other public companies, are incurring expenses and diverting employees&#146; time in an effort to
	comply with Section&nbsp;404 of the Sarbanes-Oxley Act of 2002. The SEC and other regulators have continued to adopt new rules and regulations and make additional changes to existing regulations that require our compliance. In July 2010, the
	Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional
	rules and regulations in these areas. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations. Compliance
	with these evolving standards will result in increased general and administrative expenses and may cause a diversion of our time and attention from revenue-generating activities to compliance activities.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	27
</FONT>
</P>
<A NAME="eolPage30"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Changes in healthcare policy could increase our costs and impact sales of and reimbursement for our
	tests.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In March 2010, President Barack Obama signed the Patient Protection and Affordable Care Act, as amended by the
	Health Care and Education Affordability Reconciliation Act (collectively, the&nbsp;&#147;PPACA&#148;), which makes changes that are expected to significantly impact the pharmaceutical and medical device industries. Beginning in 2013, each medical
	device manufacturer will have to pay a sales tax in an amount equal to 2.3 percent of the price for which such manufacturer sells its medical devices. The PPACA also mandates a reduction in payments for clinical laboratory services paid under the
	Medicare Clinical Laboratory Fee Schedule of 1.75% for the years 2011 through 2015. This adjustment is in addition to a productivity adjustment to the Clinical Laboratory Fee Schedule. In addition to the PPACA, the impact of which cannot be
	predicted given its recent enactment and current lack of implementing regulations or interpretive guidance, a number of states are also contemplating significant reform of their healthcare policies. We cannot predict whether future healthcare
	initiatives will be implemented at the federal or state level, or the effect any future legislation or regulation will have on us. The taxes imposed by the new federal legislation may result in decreased profits to us, and lower reimbursements by
	payers for our tests, all of which may adversely affect our business.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	We are subject to environmental laws and potential exposure to
	environmental liabilities.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We are subject to various international, federal, state and local environmental laws and
	regulations that govern our operations, including the handling and disposal of non-hazardous and hazardous wastes, the recycling and treatment of electrical and electronic equipment, and emissions and discharges into the environment. Failure to
	comply with such laws and regulations could result in costs for corrective action, penalties or the imposition of other liabilities. We are also subject to laws and regulations that impose liability and clean-up responsibility for releases of
	hazardous substances into the environment. Under certain of these laws and regulations, a current or previous owner or operator of property may be liable for the costs to remediate hazardous substances or petroleum products on or from its property,
	without regard to whether the owner or operator knew of, or caused, the contamination, as well as incur liability to third parties affected by such contamination. The presence of, or failure to remediate properly, such substances could adversely
	affect the value and the ability to transfer or encumber such property. Based on currently available information, although there can be no assurance, we believe that such costs and liabilities have not had and will not have a material adverse impact
	on our consolidated results of operations.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Risks Related to Owning our Stock
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	The liquidity and trading volume of our common stock may be low.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The
	liquidity and trading volume of our common stock has at times been low in the past and may again be low in the future. If the liquidity and trading volume were to fall, this could impact the trading price of our shares and adversely affect our
	ability to issue stock and for holders to obtain liquidity in their shares should they desire to sell.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Our stock price has been, and may
	continue to be, highly volatile, and an investment in our stock could suffer a decline in value.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The trading price of our
	common stock has been highly volatile and could continue to be subject to wide fluctuations in price in response to various factors, many of which are beyond our control, including:
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	failure to significantly increase revenue and volumes of OVA1;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	actual or anticipated period-to-period fluctuations in financial results;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	failure to achieve, or changes in, financial estimates by securities analysts;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	announcements or introductions of new products or services or technological innovations by us or our competitors;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	28
</FONT>
</P>
<A NAME="eolPage31"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	publicity regarding actual or potential discoveries of biomarkers by others;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	comments or opinions by securities analysts or stockholders;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	conditions or trends in the pharmaceutical, biotechnology and life science industries;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	announcements by us of significant acquisitions and divestitures, strategic partnerships, joint ventures or capital commitments;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	developments regarding our patents or other intellectual property or that of our competitors;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	litigation or threat of litigation;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	additions or departures of key personnel;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	limited daily trading volume;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	economic and other external factors, disasters or crises; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	our announcement of additional fund raisings.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In addition, the stock market in general and the market for diagnostic technology companies, in particular, have experienced significant price and volume fluctuations that have often been unrelated or
	disproportionate to the operating performance of those companies. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance. In the past, following periods of volatility
	in the market price of a company&#146;s securities, securities class action litigation has often been instituted. A securities class action suit against us could result in substantial costs, potential liabilities and the diversion of our attention
	and our resources.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	If we fail to meet all applicable Nasdaq Capital Market requirements and Nasdaq determines to delist our common stock,
	the market liquidity and market price of our common stock could decline, and our ability to access the capital markets could be negatively affected.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In order to maintain the listing on the Nasdaq Capital Market, we must satisfy minimum financial and other requirements, including requirements that we maintain a minimum stockholders&#146; equity of $2.5
	million and a minimum bid price of $1 per share. If we fail to meet all applicable Nasdaq Capital Market requirements and Nasdaq determines to delist our common stock, the delisting could adversely affect the market liquidity of our common stock and
	adversely affect our ability to obtain financing for the continuation of our operations. This delisting could also impair the value of our investors&#146; investment.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Anti-takeover provisions in our charter, bylaws and under Delaware law could make a third party acquisition of the Company difficult.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our certificate of incorporation and bylaws contain provisions that could make it more difficult for a third party to acquire us, even if
	doing so might be deemed beneficial by our stockholders. These provisions could limit the price that investors might be willing to pay in the future for shares of our common stock. We are also subject to certain provisions of Delaware law that could
	delay, deter or prevent a change in control of the Company.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	We could face adverse consequences as a result of the actions of activist
	stockholders.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Certain of our stockholders may, from time to time, attempt to aggressively involve themselves in the
	governance and strategic direction of our Company above and apart from normal interactions between stockholders and management. Such activism, and any related negative publicity, could result in substantial costs that negatively impact our stock
	price and increase its volatility. In addition, such activism could cause a diversion of the attention of our management and Board of Directors and create perceived uncertainties with existing and potential strategic partners impacting our ability
	to consummate potential transactions,
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	29
</FONT>
</P>
<A NAME="eolPage32"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	collaborations or opportunities in furtherance of our strategic plan. In addition, such activism could make it more difficult to attract and retain qualified personnel, customers and business
	partners, which could disrupt the growth of the market for OVA1, delay the development and commercialization of new tests and further adversely affect the trading price of our common stock and increase its volatility. In addition, the activists may
	have little or no experience in the diagnostics industry or may seek to elect members to our Board of Directors with little or no experience in the diagnostics industry who may have a specific agenda different and apart from the majority of our
	stockholders.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Because we do not intend to pay dividends, our stockholders will benefit from an investment in our common stock only if it
	appreciates in value.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have never declared or paid any cash dividends on our common stock. We currently intend to
	retain our future earnings, if any, to finance the expansion of our business and do not expect to pay any cash dividends in the foreseeable future. As a result, the success of an investment in our common stock will depend entirely upon any future
	appreciation. There is no guarantee that our common stock will appreciate in value or even maintain the price at which our investors purchased their shares.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	We may need to sell additional shares of our common stock or other securities in the future to meet our capital requirements which could cause significant dilution.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	As of December&nbsp;31, 2012, we had 15,200,079 shares of our common stock outstanding and 22,471 shares of our common stock reserved for
	future issuance to employees, directors and consultants pursuant to our employee stock plans, which excludes 1,092,374 shares of our common stock that were subject to outstanding options. In addition, as of December&nbsp;31,&nbsp;2012, warrants to
	purchase 63,000 shares of our common stock were outstanding at an exercise price of $2.78 per share.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The exercise of all or a
	portion of our outstanding options and warrants, and the vesting of our restricted stock, will dilute the ownership interests of our stockholders. Furthermore, future sales of substantial amounts of our common stock in the public market, or the
	perception that such sales are likely to occur, could affect prevailing trading prices of our common stock and the value of the notes.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	If
	an increase to the 2010 Stock Incentive Plan is not approved by stockholders, the limited number of shares we could issue may impact our ability to attract, retain and motivate key personnel, including a permanent chief executive officer.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have a limited number of shares available under the 2010 Stock Incentive Plan (the &#147;2010 Plan&#148;). We are
	seeking stockholder approval of an increase in the number of shares available for issuance under the 2010 Plan, but there can be no assurances that such increase will be approved. We have historically used stock options as a significant component of
	our employee compensation program in order to align employees&#146; interests with the interests of our stockholders, encourage employee retention, and provide competitive compensation packages. We currently have an interim chief executive officer
	and are in the process of searching for a permanent chief executive officer. If we are unable to increase the number of shares available under the 2010 Plan, our ability to offer attractive equity incentive awards in the future may be limited or
	nonexistent and may make it more difficult for us to attract, retain and motivate key personnel, including a permanent chief executive officer.
</FONT>
</P>
</EFX_RISK_FACTORS>
<P STYLE="FONT-SIZE:18PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_UNRESOLVED_STAFF_COMMENTS>
<A NAME="FIS_UNRESOLVED_STAFF_COMMENTS"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_TOC453081_4">
</A>
	ITEM&nbsp;1B.
</B>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	UNRESOLVED STAFF COMMENTS
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	None.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	30
</FONT>
</P>
<A NAME="eolPage33"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_UNRESOLVED_STAFF_COMMENTS>
<EFX_PROPERTIES>
<A NAME="FIS_PROPERTIES"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_TOC453081_5">
</A>
	ITEM&nbsp;2.
</B>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	PROPERTIES
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our principal
	facility is located in Austin, Texas. The following chart indicates the facility that we lease, the location and size of the facility and its designated use.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_2"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="37%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD WIDTH="10%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD WIDTH="34%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:30PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Location
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Approximate
<BR>
	Square Feet
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Primary Functions
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Lease&nbsp;Expiration&nbsp;Date
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Austin, Texas
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4,218&nbsp;sq.&nbsp;ft.
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Research and development, clinical and regulatory, marketing, sales and administrative offices
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2014
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
</EFX_PROPERTIES>
<P STYLE="FONT-SIZE:18PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_LEGAL_PROCEEDINGS>
<A NAME="FIS_LEGAL_PROCEEDINGS"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_TOC453081_6">
</A>
	ITEM&nbsp;3.
</B>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	LEGAL PROCEEDINGS
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Robert Goggin
	and Gy&ouml;rgy Bessenyei Litigation
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On May&nbsp;25, 2012, Gy&ouml;rgy B. Bessenyei and Robert S. Goggin, III, both
	stockholders of Vermillion, filed a verified complaint in the Delaware Court of Chancery (the &#147;Court&#148;) against Vermillion, each current member of our Board of Directors, and Gail S. Page. On June&nbsp;1, 2012, Mr.&nbsp;Bessenyei and
	Mr.&nbsp;Goggin filed an amended verified complaint that was substantially similar to the verified complaint. The amended verified complaint contains the following causes of action: breach of fiduciary duty under two standards, declaratory relief,
	preliminary injunctive relief, and permanent injunctive relief. The allegations in the amended verified complaint challenge the recent adoption by the Board of Directors of an amendment to our bylaws eliminating the board seat formerly held by
	Ms.&nbsp;Page. As previously disclosed by Vermillion, on May&nbsp;15, 2012, Ms.&nbsp;Page was terminated without cause as Vermillion&#146;s President and Chief Executive Officer (&#147;CEO&#148;), and, upon her termination, Ms.&nbsp;Page resigned
	her seat on the Board of Directors. For a variety of reasons, including an effort to streamline Vermillion&#146;s organization and extend its cash runway, the Board of Directors amended our bylaws to eliminate the vacant board seat, thereby reducing
	the size of the Board of Directors from seven to six members. This effort to streamline Vermillion&#146;s organization had begun in January 2012, when the Board of Directors amended the bylaws to eliminate an additional (eighth) seat on the Board of
	Directors. Mr.&nbsp;Bessenyei and Mr.&nbsp;Goggin claim that the Board of Directors&#146; decision to eliminate the seat on May&nbsp;15, 2012 was a breach of its fiduciary duties, alleging that the Board of Directors&#146; actions were intended to
	prevent Mr.&nbsp;Bessenyei&#146;s and Mr.&nbsp;Goggin&#146;s nominees from both being able to be elected to the Board of Directors, and to entrench the Board of Directors&#146; current members. Among other things, Mr.&nbsp;Bessenyei and
	Mr.&nbsp;Goggin sought to have the Court declare null and void the May&nbsp;15, 2012 amendment to the bylaws, and award to Mr.&nbsp;Bessenyei and Mr.&nbsp;Goggin the costs and fees incurred by them in the action.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The parties negotiated a scheduling order, which was approved on June&nbsp;6, 2012, setting trial in this expedited action to start on
	July&nbsp;31, 2012. On June&nbsp;13, 2012, Vermillion and the other defendants filed an answer. The parties then engaged in extensive discovery, including document production, service of interrogatory responses, and the taking of depositions. On
	July&nbsp;26, 2012, Vermillion and the other defendants filed a motion to dismiss the case arguing that plaintiffs and their counsel improperly notarized documents verifying the complaint, amended complaint and discovery responses. On
	November&nbsp;16, 2012, the Court dismissed the lawsuit with prejudice. The plaintiffs filed a notice of appeal of that dismissal order on December&nbsp;10, 2012, and filed their opening appellate brief on February&nbsp;1, 2013. On February&nbsp;12,
	2013, the Delaware Supreme Court denied Vermillion and the other defendants&#146; motion to summarily affirm. Vermillion and the other defendants are in the process of preparing an appellate answering brief which will be filed by March&nbsp;4, 2013.
	No hearing date on the appeal has been set by the Delaware Supreme Court.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Gy&ouml;rgy Bessenyei Annual Shareholder Meeting Litigation
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On January&nbsp;9, 2013, Gy&ouml;rgy B. Bessenyei, a stockholder of Vermillion, filed a verified complaint in the
	Delaware Court of Chancery (the &#147;Court&#148;) against Vermillion, and each current member of our Board of Directors. The complaint contains a cause of action for violation of Section&nbsp;211 of the General Corporation Law
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	31
</FONT>
</P>
<A NAME="eolPage34"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	of Delaware. The allegations in the complaint relate to the 2012 annual shareholder meeting which had not yet been held due to a scheduling order entered in the Goggin and Bessenyei litigation
	discussed above. The complaint seeks to have the Court compel Vermillion to hold its annual shareholder meeting and to award to Mr.&nbsp;Bessenyei the costs and fees incurred by him in the action. On January&nbsp;16, 2013, the parties held a
	scheduling conference with the Court. On January&nbsp;18, 2013, Vermillion filed its preliminary proxy setting the annual meeting date for March&nbsp;21, 2013. Thereafter, both parties submitted competing proposed orders related to the upcoming
	annual shareholder meeting. The Court has not yet signed either order.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In addition, from time to time, we are involved in
	legal proceedings and regulatory proceedings arising out of our operations. We established reserves for specific liabilities in connection with legal actions that are deemed to be probable and estimable. Other than as disclosed above, we are not
	currently a party to any proceeding, the adverse outcome of which would have a material adverse effect on our financial position or results of operations.
</FONT>
</P>
</EFX_LEGAL_PROCEEDINGS>
<P STYLE="FONT-SIZE:18PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_MINE_SAFETY_DISCLOSURE>
<A NAME="FIS_MINE_SAFETY_DISCLOSURE"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_TOC453081_7">
</A>
	ITEM&nbsp;4.
</B>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	MINE SAFETY DISCLOSURES
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Not applicable.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	32
</FONT>
</P>
<A NAME="eolPage35"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_MINE_SAFETY_DISCLOSURE>
</EFX_PART_I>
<EFX_PART_II>
<A NAME="FIS_PART_II"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_TOC453081_8">
</A>
	PART II
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_MARKET>
<A NAME="FIS_MARKET"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_TOC453081_9">
</A>
	ITEM&nbsp;5.
</B>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	MARKET FOR REGISTRANT&#146;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our common stock was traded on the Nasdaq Global Market under the symbol &#147;VRML.&#148; Effective February&nbsp;15, 2012, we
	transferred our listing from the NASDAQ Global Market to the NASDAQ Capital Market.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On January&nbsp;24,&nbsp;2013, there were
	68 registered holders of record of our common stock, including multiple beneficial holders and depositories, banks and brokers listed as a single holder in the street name of each respective depository, bank or broker. The closing price of our
	common stock on February&nbsp;20, 2013 was $1.38.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The following sets forth the quarterly high and low trading prices as
	reported by The Nasdaq Global Market and NASDAQ Capital Market for the periods indicated.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_3"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="68%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2012
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2011
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	High
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Low
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	High
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Low
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	First Quarter
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3.02
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.19
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	9.25
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3.75
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Second Quarter
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2.79
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.62
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	7.60
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3.33
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Third Quarter
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2.36
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.56
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4.36
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2.14
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Fourth Quarter
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.88
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.13
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2.89
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0.97
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Dividends
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have never paid or declared any dividend on our common stock and we do not anticipate paying cash dividends on our common stock in the foreseeable future. If we pay a cash dividend on our common stock,
	we also may be required to pay the same dividend on an as-converted basis on any outstanding preferred stock, warrants, convertible notes or other securities. Moreover, any preferred stock or other senior debt or equity securities to be issued and
	any future credit facilities might contain restrictions on our ability to declare and pay dividends on our common stock. We intend to retain all available funds and any future earnings to fund the development and expansion of our business.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Unregistered Sales of Equity Securities
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	None.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Equity Compensation Plan Information
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We currently maintain two equity-based compensation plans that were approved by our stockholders. The plans are the Amended and Restated
	2000 Stock Plan (the &#147;2000 Plan&#148;), and the 2010 Stock Incentive Plan (the &#147;2010 Plan&#148;).
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	2000
	Plan.
</I>
</B>
	The authority of our Board of Directors to grant new stock options and awards under the 2000 Plan terminated in 2010. The Board of Directors continues to administer the 2000 Plan with respect to the stock options that remain
	outstanding to our officers, employees, directors and a consultant. At December&nbsp;31, 2012, options to purchase 336,656 shares of common stock remained outstanding under the 2000 Plan.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	2010 Plan.
</I>
</B>
	The 2010 Plan is administered by the Compensation Committee of the Board. Our employees, directors, and
	consultants are eligible to receive awards under the 2010 Plan. The 2010 Plan permits the granting of a variety of awards, including stock options, share appreciation rights, restricted shares, restricted share units, and unrestricted shares,
	deferred share units, performance and cash-settled awards, and dividend equivalent rights. We are authorized to issue up to 1,322,983 shares of common stock, par value $0.001 per share under the 2010 Plan, subject to adjustment as provided in the
	2010 Plan. At December&nbsp;31, 2012, options to purchase 755,718 shares of common stock remained outstanding under the 2010 Plan.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	33
</FONT>
</P>
<A NAME="eolPage36"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The number of shares of our common stock to be issued upon exercise of outstanding stock
	options, the weighted-average exercise price of outstanding stock options and the number of shares available for future stock option grants and stock awards under equity compensation plans as of December&nbsp;31, 2012, were as follows:
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_4"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="65%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:49PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Plan Category
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Number of
<BR>
	Securities to
<BR>
	be&nbsp;Issued&nbsp;Upon
<BR>
	Exercise of
<BR>
	Outstanding
<BR>
	Options,
<BR>
	Warrants
	and
<BR>
	Rights
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Weighted-
<BR>
	Average
<BR>
	Exercise
<BR>
	Price of
<BR>
	Outstanding
<BR>
	Options,
<BR>
	Warrants
<BR>
	and
	Rights
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Number of
<BR>
	Securities
<BR>
	Remaining
<BR>
	Available for
<BR>
	Future
<BR>
	Issuance
<BR>
	Under
	Equity
<BR>
	Compensation
<BR>
	Plans
<BR>
	(Excluding
<BR>
	Shares
<BR>
	Reflected in
<BR>
	First Column)
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Equity compensation plans approved by security holders
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,092,374
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(1)
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;4.17
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(2)
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	22,471
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(3)
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Equity compensation plans not approved by security holders
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,092,374
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	22,471
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(1)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Includes outstanding stock options for 336,656 shares of our common stock under the 2000 Plan and 755,718 shares of our common stock under the 2010 Plan.
</FONT>
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(2)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Includes the weighted average stock price for outstanding stock options of $7.22 under the 2000 Plan and $2.82 for the 2010 Plan.
</FONT>
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(3)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Includes 22,471 shares of our common stock for the 2010 Plan. No future awards shall occur under the 2000 Plan.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	34
</FONT>
</P>
<A NAME="eolPage37"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Performance Graph
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Pursuant to Instructions to Item&nbsp;201(e)(6) of Regulation S-K, information is not required.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	35
</FONT>
</P>
<A NAME="eolPage38"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_MARKET>
<EFX_FINANCIAL_DATA>
<A NAME="FIS_FINANCIAL_DATA"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_TOC453081_10">
</A>
	ITEM&nbsp;6.
</B>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	SELECTED FINANCIAL DATA
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Per Item&nbsp;301(c) of Regulation S-K, information is not required.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	36
</FONT>
</P>
<A NAME="eolPage39"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_FINANCIAL_DATA>
<EFX_MANAGEMENTS_DISCUSSION>
<A NAME="FIS_MANAGEMENTS_DISCUSSION"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_TOC453081_11">
</A>
	ITEM&nbsp;7.
</B>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	You should read the following discussion and analysis in conjunction with our Consolidated Financial Statements and related Notes
	thereto, included on pages F-1 through F-31 of this Annual Report on Form 10-K, and &#147;Risk Factors&#148;, which are discussed in Item&nbsp;1A. The statements below contain forward-looking statements within the meaning of the Private Securities
	Litigation Reform Act. See &#147;Forward-Looking Statements&#148; on page i.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Overview
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Vermillion was originally incorporated in California on December&nbsp;9, 1993, under the name Abiotic Systems. In March 1995, Abiotic
	Systems changed its corporate name to Ciphergen Biosystems, Inc., and subsequently on June&nbsp;21, 2000, it reincorporated in Delaware. Under the name Ciphergen Biosystems, Inc., we had our initial public offering on September&nbsp;28, 2000. On
	August&nbsp;21, 2007, Ciphergen Biosystems, Inc. changed its corporate name to Vermillion, Inc.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We are dedicated to the discovery,
	development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Our tests are intended to help guide decisions regarding patient treatment, which may include decisions to
	refer patients to specialists, to perform additional testing, or to assist in the selection of therapy. A distinctive feature of our approach is to combine multiple markers into a single, reportable index score that has higher diagnostic accuracy
	than its constituents. Management (&#147;we&#148;, &#147;us&#148; or &#147;our&#148;) concentrate its development of novel diagnostic tests in the fields of oncology, cardiology and women&#146;s health, with our initial focus on ovarian cancer. We
	also intend to address clinical questions related to early disease detection, treatment response, monitoring of disease progression, prognosis and others through collaborations with leading academic and research institutions.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our lead product, OVA1, was cleared by the FDA on September&nbsp;11, 2009. OVA1 addresses a clear unmet clinical need, namely the
	pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. Numerous studies have documented the benefit of referral of these women to gynecologic oncologists for their initial surgery. Prior to the clearance of
	OVA1, no blood test had been cleared by the FDA for physicians to use in the pre-surgical management of ovarian adnexal masses. OVA1 is a qualitative serum test that utilizes five well-established biomarkers and proprietary FDA-cleared software to
	determine the likelihood of malignancy in women over age 18, with a pelvic mass for whom surgery is planned. OVA1 was developed through large pre-clinical studies in collaboration with numerous academic medical centers encompassing over 2,500
	clinical samples. OVA1 was fully validated in a prospective multi-center clinical trial encompassing 27 sites reflective of the diverse nature of the clinical centers at which ovarian adnexal masses are evaluated. The results of the clinical trial
	demonstrated that in a clinical cohort of 516 patients, OVA1, in conjunction with clinical evaluation, was able to identify 95.7% (154/161)&nbsp;of the malignant ovarian tumors overall, and to rule out malignancy with a negative predictive value
	(&#147;NPV&#148;) of 94.6% (123/130). Data were presented at the 2010 International Gynecologic Cancer Society Meeting demonstrating the high sensitivity of OVA1 for epithelial ovarian cancers; overall OVA1 detected 95/96 epithelial ovarian cancer
	cases for a sensitivity of 99.0%, including 40/41 stage I and stage II epithelial ovarian cancers, for an overall sensitivity of 97.6% for early stage epithelial ovarian cancers, as compared to 65.9% for CA125 using the ACOG cutoffs. The improvement
	in sensitivity was even greater among premenopausal women; for OVA1, sensitivity for early stage epithelial ovarian cancer was 92.9% and for CA125, sensitivity was 35.7%. Overall, OVA1 detected 76% of malignancies missed by CA125, including all
	advanced stage malignancies. OVA1 is not indicated for use as a screening or stand-alone diagnostic assay.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	OVA1 is currently
	being offered by Quest Diagnostics. Under the terms of our strategic alliance agreement with Quest Diagnostics, as amended, Quest Diagnostics is required to pay us a fixed payment of $50 per OVA1 performed, as well as 33% of its &#147;gross
	margin&#148; from revenue from performing OVA1, as that term is defined in
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	37
</FONT>
</P>
<A NAME="eolPage40"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the strategic alliance agreement as amended. Quest Diagnostics is the exclusive clinical laboratory provider of OVA1 in its exclusive territory, which consists of the US, Mexico, Britain and
	India, through September&nbsp;11, 2014. Quest has the right to extend the exclusivity period for one additional year on the same terms and conditions. OVA1 was CE marked in September 2010, a requirement for marketing the test in the European Union.
	Quest Diagnostics has the right to extend the exclusivity period for an additional year beyond September&nbsp;11, 2014 on the same terms and conditions. An estimated 37,840 OVA1s have been performed from the launch on March&nbsp;9, 2010 through
	December&nbsp;31, 2012.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In addition to OVA1, we have development programs in other clinical aspects of ovarian cancer as well as in
	peripheral arterial disease, or PAD. In the field of peripheral arterial disease, we have identified candidate biomarkers that may help to identify individuals at high risk for a decreased ankle-brachial index score, which is indicative of the
	likely presence of PAD. We have completed an intended-use study to develop and validate a multi-marker algorithm for the assessment of individuals at risk for peripheral arterial disease in 2011. This algorithm will be specifically directed at a
	primary care population in which the peripheral arterial disease blood test is expected to be used. We plan to seek a Development/Commercial Partner for this product opportunity who will work with us to complete the product development, complete the
	required FDA studies for approval, and eventually commercialize this product opportunity on a global basis. Current and former academic and research institutions that we have or have had collaborations with include the Johns Hopkins University
	School of Medicine; the University of Texas M.D. Anderson Cancer Center; University College London; the University of Texas Medical Branch; the Katholieke Universiteit Leuven; Clinic of Gynecology and Clinic of Oncology, Rigshospitalet, Copenhagen
	University Hospital; the Ohio State University Research Foundation; Stanford University; and the University of Kentucky.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On
	February&nbsp;9, 2012, we entered into a Settlement Agreement and Release (the &#147;Settlement Agreement&#148;) with Oppenheimer&nbsp;&amp; Co., Inc. (&#147;Oppenheimer&#148;) related to&nbsp;losses on our short and long-term&nbsp;investments in
	previous years. Under the terms of the Settlement Agreement, we received a total settlement of $1,000,000; $535,000 was paid in March 2012 and $465,000 was paid in August 2012. We received approximately $710,000 of the total settlement, net of legal
	and related costs.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%;PADDING-BOTTOM:0PX; ">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On March&nbsp;5, 2012 we announced the receipt of a notice of allowance from the
	USPTO for &#147;Platelet biomarkers for cancer.&#148; The patent resulted from a collaboration with the late Dr.&nbsp;Judah Folkman, a renowned cancer expert, and identifies three biomarkers that can be used to assess changes in endogenous
	angiogenesis in a subject. Angiogenesis is commonly associated with cancer, and novel therapeutics such as bevacizumab
	(Avastin
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	&reg;
</SUP>
</FONT>
	) target angiogenesis to limit tumor recruitment of blood vessels. The patented biomarkers, which are
	associated with platelets, can be used to measure ongoing angiogenic activity. The patent covers the measurement of these biomarkers over time and correlating changes in expression with the changing level of endogenous angiogenic activity.
	Consequently, this patent also enables the use of these biomarkers to monitor efficacy of therapy directed at angiogenic pathways.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%;PADDING-BOTTOM:0PX; ">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On March&nbsp;6, 2012, the American Medical Association (AMA) Current Procedural Terminology (CPT
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	&reg;
</SUP>
</FONT>
	) Panel voted to approve an application for a Category I CPT code for OVA1, which became effective January&nbsp;1, 2013.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On March&nbsp;28, 2012, we announced the receipt of a notice of allowance from the USPTO for a patent, &#147;Methods for Diagnosing
	Ovarian Cancer.&#148; This patent further expands the list of biomarkers we have employed in the diagnosis or status determination of ovarian cancer. In this case, the granted claims cover the use of Protein C Inhibitor (PCI) in ovarian cancer tests
	using blood and several other sample types.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On April&nbsp;16, 2012, we announced the receipt of a notice of allowance from
	the USPTO for a patent, &#147;Biomarkers for Ovarian Cancer.&#148; The patent makes claims in the uses of a urinary Small MBL-associated protein C-terminal fragment (sMAP) in the diagnosis of ovarian cancer, ovarian cancer monitoring, and patient
	management.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	38
</FONT>
</P>
<A NAME="eolPage41"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On April&nbsp;30, 2012, we announced the resolution of four non-contingent contract claims
	made by Bio-Rad arising from the Instrument Business Sale. In exchange for a final settlement of the non-contingent claims, Bio-Rad received $700,000 from an escrow account established by the Company for the sale transaction and the Company received
	approximately $1,080,000 from the escrow account.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On May&nbsp;15, 2012, we announced our CEO succession plan beginning the
	process of identifying a successor to Gail S. Page, president and CEO. Our Board of Directors formed a search committee as part of the leadership succession plan and Ms.&nbsp;Page resigned from the Board of Directors.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On June&nbsp;15, 2012, we announced that results of the recent PAD multi-marker intended use study were presented at the Society for
	Vascular Medicine&#146;s 23rd Annual Scientific Sessions, in Minneapolis, Minnesota. This meeting hosted the nation&#146;s leading vascular medicine specialists, and included sessions on PAD guidelines, policy trends, and advances in the diagnosis
	and treatment of vascular diseases.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The poster presented to the meeting was authored by Professor of Medicine and Associate
	Director of Stanford Cardiovascular Institute Dr.&nbsp;John Cooke, together with colleagues at the University of Colorado and is entitled &#147;Results of a Biomarker Screen to Identify Peripheral Artery Disease.&#148; It reported the results of a
	multi-center clinical study involving 1,025 subjects, prospectively enrolled from the PAD at-risk population of subjects aged 70 or older, and diabetics and smokers 50 or older.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Different multi-marker algorithms were evaluated in patients with or without PAD, in comparison with the Framingham Risk Score (FRS). The
	multi-marker models were also assessed for their ability to identify PAD in patients below the high-risk FRS cutoff. The best model demonstrated a c-statistic of 0.73 and more importantly, identified 17 of 20 (85%)&nbsp;of patients missed by the FRS
	high-risk cutoff.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%;PADDING-BOTTOM:0PX; ">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On July&nbsp;30, 2012, we announced positive results from a new prospective,
	multi-center clinical study of our ovarian cancer diagnostic OVA1
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	&reg;
</SUP>
</FONT>
	. The study, referred to as OVA500, was led by
	Dr.&nbsp;Robert&nbsp;E. Bristow, director of Gynecologic Oncology Services at University of California Irvine Healthcare in Orange, California, and deputy editor of the journal Gynecologic Oncology.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The OVA500 study confirms and extends the pioneering work of Dr.&nbsp;Fred Ueland published last year. It was a prospective,
	multi-institutional, blinded study with a new cohort of 494 patients representing the intended use population for OVA1: female patients who were scheduled to undergo surgery for an adnexal mass, enrolled from non-gynecologic oncology practices via
	27 study coordination centers.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	All adnexal tumor types were included in the statistical analysis of test performance. The
	primary objective was to assess the performance of OVA1 in the intended use population with a focus on two particularly challenging subgroups: women with early-stage ovarian cancer, where approximately half of patients have a normal CA125 level, and
	pre-menopausal women, where the incidence of ovarian cancer is low and incidence of benign cysts is high.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Top-line data from
	the study are as follows:
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Overall Performance of OVA1
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Negative predictive value was reported at 98%
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Sensitivity was reported at 96%
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Specificity was reported at 51%
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Performance in the Pre-menopausal Population
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Sensitivity was reported at 94%
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	39
</FONT>
</P>
<A NAME="eolPage42"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Performance for Early-Stage Ovarian Cancer (I and II)
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Sensitivity was reported at 91%
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	OVA1 as a Risk Stratification Test (OVA1 score versus cutoff, independent of physician assessment)
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Sensitivity was reported at 92% overall:
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	91% for early-stage disease
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	94% for pre-menopausal patients
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	91% for stage I and II in pre-menopausal women with a specificity of 61%
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The OVA500 results were subsequently published online by
<I>
	Gynecologic Oncology
</I>
	on November&nbsp;22, 2012 in the article,
	&#147;Ovarian Malignancy Risk Stratification of the Adnexal Mass Using a Multivariate Index Assay.&#148;
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On October&nbsp;12,
	2012, we announced the payment to Quest Diagnostics of approximately $5,901,000, which we believe represents payment in full of all outstanding principal and interest under the Secured Line of Credit Agreement dated as of July&nbsp;22, 2005 between
	the Company and Quest Diagnostics. The payoff incorporated $1,000,000 in additional principal forgiveness under the terms of the Strategic Alliance and $106,000 in previous principal curtailment payments. However, Quest Diagnostics has disputed that
	such milestone forgiveness was achieved or principal curtailment was made. This disputed amount of $1,106,000 is reported as short-term debt on our consolidated balance sheet at December&nbsp;31, 2012.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On November&nbsp;16, 2012, we announced that the Delaware Court of Chancery dismissed with prejudice a lawsuit brought against
	Vermillion, Inc. and its board of directors by dissident stockholders, Gyorgy B. Bessenyei and Robert S. Goggin, III.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Following the decision, a proxy filed with the Securities Exchange Commission (SEC) by an alleged stockholder group led by Bessenyei and
	Goggin describes Goggin as &#147;honest and trustworthy.&#148; However, the Delaware Court of Chancery court issued findings to the contrary. The court ruled that Goggin and Bessenyei had illegally falsified documents by improperly notarizing court
	filings in connection with the lawsuit and, moreover, that the conduct of Goggin appeared to be a violation of the Pennsylvania rules of professional conduct applicable to Pennsylvania lawyers.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	With the suit now dismissed with prejudice, which disallows its re-filing, we were able to move forward with our annual meeting. The
	meeting had been delayed due to the Bessenyei and Goggin lawsuit, which prohibited the company from holding a meeting until the matter was resolved.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On November&nbsp;27, 2012, we announced the appointment of director Bruce A. Huebner as Interim Chief Executive Officer. He succeeded Gail S. Page, who had assisted in the transition and served as a
	strategic advisor to the company as requested by its board of directors. Mr.&nbsp;Huebner continues to serve on our board of directors.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On January&nbsp;3, 2013, the Company received a letter (the &#147;Delisting Notice&#148;) from the NASDAQ Stock Market LLC (&#147;NASDAQ&#148;) notifying the Company that it is not in compliance with
	NASDAQ&#146;s Listing Rule 5620(a), which requires the Company to hold an annual meeting of shareholders no later than one year after the end of the Company&#146;s fiscal year-end, and Listing Rule 5620(b), which requires the Company to solicit
	proxies and provide proxy statements for such meeting and to provide copies of such proxy solicitation to NASDAQ. The Delisting Notice stated that unless the Company requested an appeal of this determination, trading of the Company&#146;s common
	stock would be suspended on January&nbsp;14, 2013, and a Form 25-NSE would be filed with the SEC, which would remove the Company&#146;s securities from listing and registration on NASDAQ. The Company filed an appeal which stayed the delisting action
	while the appeal is pending.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The annual meeting was delayed due to a lawsuit brought against the Company and its board of
	directors by dissident stockholders, Gyorgy B. Bessenyei and Robert S. Goggin, III, which prohibited the Company from
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	40
</FONT>
</P>
<A NAME="eolPage43"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	holding a meeting until the matter was resolved. As previously announced by the Company, the case was dismissed with prejudice on November&nbsp;16, 2012. The Company has scheduled the 2012 Annual
	Meeting for March&nbsp;21, 2013.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Critical Accounting Policies and Estimates
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The notes to the consolidated financial statements contain a summary of the Company&#146;s significant accounting policies that are
	presented in Part II Item&nbsp;8, &#147;Financial Statements and Supplementary Data&#148;, of this Annual Report on Form 10-K. We believe that it is important to have an understanding of certain policies, along with the related estimates that we are
	required to make in recording the financial transactions of the Company, in order to have a complete picture of the Company&#146;s financial condition. In addition, in arriving at these estimates, we are required to make complex and subjective
	judgments, many of which include a high degree of uncertainty. The following is a discussion of these critical accounting policies and significant estimates related to these policies.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Revenue Recognition
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
<U>
	Product Revenue.
</U>
</I>
	We derive our product
	revenues from sales of OVA1 through Quest Diagnostics. We recognize product revenues for tests performed when the following revenue recognition criteria are met: (1)&nbsp;persuasive evidence that an arrangement exists; (2)&nbsp;delivery has occurred
	or services have been rendered; (3)&nbsp;the fee is fixed or determinable; and (4)&nbsp;collectability is reasonably assured.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
<U>
	License Revenue.
</U>
</I>
	Under the terms of the secured line of credit with Quest Diagnostics, portions of the borrowed principal
	amounts may be forgiven upon our achievement of certain milestones relating to the development, regulatory approval and commercialization of certain diagnostic tests. We account for forgiveness of principal debt balances as license revenues over the
	term of the exclusive sales period that Quest Diagnostics receives upon commercialization of an approved diagnostic test as we do not have a sufficient history of product sales that provides a reasonable basis for estimating future product sales. We
	recognize license revenue on a straight-line basis over the remaining period of Quest Diagnostics&#146; sales exclusivity ending in September 2015.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Research and Development Costs
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Research and development costs are expensed
	as incurred. Research and development costs consist primarily of payroll and related costs, materials and supplies used in the development of new products, and fees paid to third parties that conduct certain research and development activities on
	behalf of the Company. In addition, acquisitions of assets to be consumed in research and development, with no alternative future use, are expensed as incurred as research and development costs. Software development costs incurred in the research
	and development of new products are expensed as incurred until technological feasibility is established.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Patent Costs
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Costs incurred in filing, prosecuting and maintaining patents (principally legal fees) are expensed as incurred and recorded within
	selling, general and administrative expenses on the consolidated statements of operations and comprehensive loss. Such costs aggregated approximately $312,000 and $363,000 for the years ended December&nbsp;31, 2012 and 2011, respectively.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Stock-Based Compensation
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We record the fair value of non-cash stock-based compensation costs for stock options and stock purchase rights related to our 2010 Stock Incentive Plan (the &#147;2010 Plan&#148;) and 2000 Stock Plan
	(the &#147;2000 Plan&#148;). We estimate the fair value of stock options using a Black-Scholes option valuation model. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated
	forfeitures
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	41
</FONT>
</P>
<A NAME="eolPage44"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	of each award. We use the straight-line method to amortize the fair value over the vesting period of the award. Due to the limited amount of historical data available to us, particularly with
	respect to stock-price volatility, option exercise patterns and forfeitures, the actual value of stock options and stock purchase rights could differ from our estimates.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We also record the fair value of non-cash stock-based compensation costs for equity instruments issued to non-employees. We recalculate costs for these options each reporting period using a Black-Scholes
	option valuation model. Because we recalculate these costs each reporting period, changes in assumptions used in our calculations, including changes in the fair value of our common stock, can result in significant changes in the amounts we record
	from one reporting period to another.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Contingencies
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We account for contingencies in accordance with ASC 450 Contingencies (&#147;ASC 450&#148;). ASC 450 requires that an estimated loss from a loss contingency shall be accrued when information available
	prior to issuance of the financial statements indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements and when the amount of the loss can be reasonably estimated.
	Accounting for contingencies such as legal and contract dispute matters requires us to use our judgment. We believe that our accruals for these matters are adequate. Nevertheless, the actual loss from a loss contingency might differ from our
	estimates.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Income Taxes
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our income tax policy records the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the accompanying balance sheets, as well as
	operating loss and tax credit carry forwards. We have recorded a full valuation allowance to reduce our deferred tax assets, as based on available objective evidence; it is more likely than not that the deferred tax assets will not be realized. In
	the event that we were to determine that we would be able to realize our deferred tax assets in the future, an adjustment to the deferred tax assets would increase net income in the period such determination was made.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Recently Adopted Accounting Pronouncements
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Comprehensive Income&#151;In June 2011, the FASB issued new guidance on the presentation of comprehensive income. Specifically, the new guidance allows an entity to present components of net income and
	other comprehensive income in one continuous statement, referred to as the statement of comprehensive income, or in two separate, but consecutive statements. The new guidance eliminates the current option to report other comprehensive income and its
	components in the statement of changes in equity. While the new guidance changes the presentation of comprehensive income, there are no changes to the components that are recognized in net income or other comprehensive income under current
	accounting guidance. We adopted this pronouncement in the first quarter of 2012, and it had no effect on our financial position, results of operations or cash flows but did impact the way we present comprehensive income.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	42
</FONT>
</P>
<A NAME="eolPage45"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Results of Operations&#151;Year Ended December&nbsp;31, 2012 as compared to Year Ended December&nbsp;31,
	2011
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The selected summary financial and operating data of Vermillion for the years ended December&nbsp;31, 2012 and 2011
	were as follows:
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_5"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="65%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Year&nbsp;Ended&nbsp;December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Increase&nbsp;(Decrease)
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:69PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(dollars in thousands)
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	&nbsp;&nbsp;&nbsp;&nbsp;2011&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	&nbsp;&nbsp;&nbsp;&nbsp;Amount&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	&nbsp;&nbsp;&nbsp;&nbsp;%&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Revenue:
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Product
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,640
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,469
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	171
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	License
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	454
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	454
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total revenue
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2,094
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,923
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	171
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	9
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Cost of revenue:
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Product
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	131
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	129
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total cost of revenue
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	131
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	129
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Gross profit
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,963
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,794
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	169
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	9
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Operating expenses:
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Research and development
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2,216
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5,387
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(3,171
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(59
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Sales and marketing
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4,653
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5,539
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(886
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(16
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	General and administrative
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4,508
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8,509
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(4,001
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(47
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total operating expenses
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11,377
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	19,435
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(8,058
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(41
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Loss from operations
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(9,414
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(17,641
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8,227
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(47
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Interest income
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	28
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	64
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(36
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(56
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Interest expense
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(206
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(396
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	190
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(48
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Gain on sale of instrument business
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,830
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,830
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Gain on litigation settlement, net
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	710
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	710
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Change in fair value of warrants
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	378
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(378
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Reorganization items
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	88
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(96
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	184
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(192
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Other expense, net
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(182
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(99
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(83
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	84
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Loss before income taxes
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(7,146
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(17,790
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10,644
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(60
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Income tax benefit (expense)
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net loss
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(7,146
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(17,790
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10,644
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(60
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Product Revenue
</I>
</B>
<B>
	.
</B>
	Product revenue was $1,640,000 for the year ended
	December&nbsp;31,&nbsp;2012 compared to $1,469,000 for the same period in 2011. We recognized product revenue for the year ended December&nbsp;31, 2012 for the sale of OVA1 through Quest Diagnostics. Quest Diagnostics performed approximately 16,460
	OVA1 tests during the year ended December&nbsp;31, 2012 compared to approximately 15,225 tests for the same period in 2011. Product revenue increased $171,000 for the year ended December&nbsp;31, 2012 compared to the same period in 2011 due to the
	increased volume of tests as well as the recognition of deferred revenue upon meeting the criteria for revenue recognition. We recognized $816,000 of deferred revenue in 2012 upon receipt of an annual royalty report from Quest Diagnostics. During
	2011, we recognized $549,000 of deferred revenue related to 2011 in addition to $160,000 of deferred revenue related to 2010 upon receipt of two annual royalty reports from Quest Diagnostics.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The 2012 annual royalty report of $816,000 was based upon 13,709 OVA1 tests reported by Quest Diagnostics as resolved in 2012, or an
	average of $60 per test resolved. The resolved volume includes both reimbursed and unreimbursed tests for which the payment status was considered final by Quest Diagnostics as of December&nbsp;31, 2012. Tests that do not yet have a final resolution
	for 2012 will be included in a future annual royalty report. By comparison, the 2011 annual royalty report of $549,000 was based upon 11,708 OVA1 tests reported by Quest Diagnostics as resolved in 2011, or an average of $47 per test resolved. The
	royalty report revenue is incremental to the fixed $50 per test recognized for each OVA1 performed during the year.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	43
</FONT>
</P>
<A NAME="eolPage46"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Research and Development Expenses
</I>
</B>
<B>
	.
</B>
	Research and development expenses
	represent costs incurred to develop our technology and carry out clinical studies, and include personnel-related expenses, regulatory costs, reagents and supplies used in research and development laboratory work, infrastructure expenses, contract
	services and other outside costs. Research and development expenses also include costs related to activities performed under contracts with our collaborators and strategic partners. Research and development expenses decreased by $3,171,000, or 59%,
	for the year ended December&nbsp;31,&nbsp;2012 compared to the same period in 2011. This decrease was due primarily to a $2,457,000 decrease in clinical trial costs for the ongoing development of our ovarian cancer franchise and our PAD program as
	our PAD intended use study was completed in 2011. The clinical trial cost decrease was net of ongoing expenses for our OVA1 FDA post-marketing study that commenced during 2012. In addition, stock compensation costs decreased $554,000 compared to the
	same period in 2011. We anticipate that research and development expenses will increase in future periods due to costs of the FDA post-marketing study.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Sales and Marketing Expenses
</I>
</B>
<B>
	.
</B>
	Our sales and marketing expenses consist primarily of personnel-related expenses, education and promotional expenses, and infrastructure expenses. These
	expenses include the costs of educating physicians, laboratory personnel and other healthcare professionals regarding OVA1. Sales and marketing expenses also include the costs of sponsoring continuing medical education, medical meeting participation
	and dissemination of scientific and health economic publications. Our personnel-related expenses include the cost of our Territory Development Managers, the subject matter experts responsible for market development and the coordination of
	interactions with the Quest Diagnostic&#146;s sales team. Sales and marketing expenses decreased by $886,000, or 16%, for the year ended December&nbsp;31,&nbsp;2012 compared to the same period in 2011. The decrease was due primarily to a $538,000
	reduction in personnel and personnel-related expenses related to lower headcount in 2012 compared to 2011. In addition, advertising, medical education and trade show expenses decreased $545,000 compared to the same period in 2011 due to decreased
	print advertising compared to 2011 and fewer events being sponsored in 2012.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	General and Administrative
	Expenses
</I>
</B>
<B>
	.
</B>
	General and administrative expenses consist primarily of personnel-related expenses, professional fees and other costs, including legal, finance and accounting expenses, and other infrastructure expenses. General and
	administrative expenses decreased by $4,001,000, or 47%, for the year ended December&nbsp;31,&nbsp;2012 compared to the same period in 2011. The decrease was due to $1,486,000 in lower stock compensation expenses as there were no bankruptcy-related
	stock compensation costs in 2012 (the Debtor&#146;s Incentive Plan was fully amortized at June&nbsp;30, 2011). Personnel and personnel-related expenses also decreased $749,000 due to the departure of both our Chief Financial Officer and Vice
	President of Corporate Strategy. In addition, 2012 included a one-time reversal of $375,000 of amounts previously accrued for the Bio-Rad claims and audit and legal fees decreased $1,593,000 compared to calendar 2011 due to a decrease in overall
	activity and as 2012 legal expenses were recorded net of expenses incurred which have been or are anticipated to be covered and paid directly by our insurance carrier. These decreases were partially offset by a one-time charge for CEO severance of
	approximately $400,000 in the year ended December&nbsp;31, 2012.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Interest Expense.
</I>
</B>
	Interest expense decreased
	by $190,000, or 48%, for the year ended December&nbsp;31,&nbsp;2012 compared to the same period in 2011 as we paid off $5,000,000 of our 7.00% Senior Convertible Notes upon maturity in September 2011 and $5,894,000 of short-term debt to Quest upon
	maturity in October 2012.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Gain on sale of instrument business.
</I>
</B>
	Gain on sale of instrument business was
	$1,830,000 for the year ended December&nbsp;31, 2012. This gain was derived from the return in 2012 of funds held in escrow from our 2006 sale of the instrument business to Bio-Rad.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
</I>
<B>
<I>
	Gain on litigation settlement, net.
</I>
</B>
<I>
</I>
	On February&nbsp;9, 2012, we entered into a Settlement Agreement with
	Oppenheimer related to&nbsp;losses on our short and long-term&nbsp;investments in previous years. Under the terms of the Settlement Agreement, the total settlement was $1,000,000; $535,000 ($379,000 net after legal fees and costs) was paid in March
	2012 and $465,000 ($331,000 net after legal fees and costs) was paid in August 2012. The gain on litigation settlement represents recognition of the net proceeds received.
<I>
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	44
</FONT>
</P>
<A NAME="eolPage47"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Change in fair value of warrants.
</I>
</B>
	There was no change in fair value of
	warrants for the year ended December&nbsp;31, 2012 compared to $378,000 for the same period in 2011. This decrease of $378,000 was due primarily to the relative decrease in the Company&#146;s stock price during 2011.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Reorganization items.
</I>
</B>
	Reorganization items were income of $88,000 for the year ended December&nbsp;31, 2012 compared to
	expense of $96,000 for the same period in 2011. The increase was due to the one-time recognition of $103,000 in claims adjustments upon the formal closure of our voluntary petition for relief (our&nbsp;&#147;Bankruptcy Filing&#148;) under Chapter 11
	of the United States Bankruptcy Code (&#147;Chapter&nbsp;11&#148;) in the United States Bankruptcy Court for the District of Delaware (the&nbsp;&#147;Bankruptcy Court&#148;) in January 2012 as well as minimal ongoing reorganization costs in 2012.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Results of Operations&#151;Year Ended December&nbsp;31, 2011 as compared to Year Ended December&nbsp;31, 2010
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The selected summary financial and operating data of Vermillion for the years ended December&nbsp;31, 2011 and 2010 were as follows:
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_6"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="65%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Year&nbsp;Ended&nbsp;December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Increase&nbsp;(Decrease)
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:69PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(dollars in thousands)
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2011&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2010&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	&nbsp;&nbsp;&nbsp;&nbsp;Amount&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	&nbsp;&nbsp;&nbsp;&nbsp;%&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Revenue:
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Product
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,469
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	308
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,161
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	377
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	License
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	454
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	867
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(413
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(48
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total revenue
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,923
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,175
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	748
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	64
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Cost of revenue:
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Product
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	129
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	88
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	41
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	47
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total cost of revenue
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	129
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	88
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	41
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	47
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Gross profit
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,794
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,087
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	707
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	65
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Operating expenses:
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Research and development
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5,387
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3,848
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,539
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	40
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Sales and marketing
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5,539
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2,857
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2,682
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	94
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	General and administrative
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8,509
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8,984
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(475
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(5
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total operating expenses
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	19,435
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	15,689
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3,746
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	24
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Loss from operations
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(17,641
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(14,602
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(3,039
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	21
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Interest income
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	64
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	40
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	24
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	60
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Interest expense
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(396
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(491
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	95
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(19
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Gain on investments in auction rate securities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	58
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(58
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Change in fair value and gain from warrant exercise, net
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	378
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4,353
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(3,975
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(91
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Debt conversion costs
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(141
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	141
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Reorganization items
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(96
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(1,677
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,581
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(94
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Reorganization items&#151;related party incentive plan
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(6,932
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	6,932
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Other income (expense), net
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(99
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	358
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(457
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(128
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Loss before income taxes
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(17,790
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(19,034
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,244
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(7
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Income tax benefit (expense)
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net loss
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(17,790
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(19,034
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,244
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(7
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Product Revenue
</I>
</B>
<B>
	.
</B>
	Product revenue was $1,469,000 for the year ended
	December&nbsp;31,&nbsp;2011 compared to $308,000 for the same period in 2010. We recognized product revenue for the year ended December&nbsp;31, 2011 for the sale of OVA1 through Quest Diagnostics. Quest Diagnostics performed approximately 15,225
	OVA1 tests during the year ended December&nbsp;31, 2011 compared to approximately 6,155 tests for the same period in 2010. We commercially launched OVA1 on March&nbsp;9, 2010. Product revenue increased $1,161,000 for the year ended December&nbsp;31,
	2011 compared to the same period in 2010 due to the increased volume of tests as well as the
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	45
</FONT>
</P>
<A NAME="eolPage48"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	recognition of deferred revenue upon meeting the criteria for revenue recognition. During the fourth quarter of 2011, we recognized $549,000 of deferred revenue related to 2011 upon receipt of an
	annual royalty report from Quest Diagnostics based on final resolution of 11,708 tests. During the first quarter of 2011, we recognized $160,000 of deferred revenue related to 2010 upon receipt of an annual royalty report from Quest Diagnostics
	based on final resolution of 2,814 tests. Tests which do not yet have final resolution will be included in a future royalty report. During 2010, we recognized only the $50 fixed fee per test in product revenue and recorded additional payments as
	deferred revenue.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	License Revenue
</I>
</B>
<B>
	.
</B>
	License revenue was $454,000 for the year ended
	December&nbsp;31,&nbsp;2011 compared to $867,000 for the same period in 2010. Under the terms of our secured line of credit with Quest Diagnostics, $3,000,000 principal was forgiven upon the achievement of FDA approval for OVA1. This amount is
	recognized as license revenue over the period of sales exclusivity Quest Diagnostics received beginning on the OVA1 commercialization date of March&nbsp;9, 2010. License revenue decreased $413,000, or 48%, for the year ended December&nbsp;31, 2011
	compared to the same period in 2010 due to the extension of the term of exclusivity for up to three additional years in Quest Amendment No.&nbsp;4. The balance of the $3,000,000 forgiven is being recognized over the revised period of exclusivity.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Cost of Product Revenue
</I>
</B>
<B>
	.
</B>
	Cost of product revenue includes royalties on net sales paid to JHU, as well as
	sample acquisition and lot qualification costs related to the testing of reagent lots for the assays included in OVA1 to ensure they meet the specifications required for inclusion. Product cost of revenue was $129,000 for the year ended
	December&nbsp;31, 2011 compared to $88,000 for the same period in 2010 due to increased sample acquisition and lot qualification costs as a result of the increased testing volume.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Research and Development Expenses
</I>
</B>
<B>
	.
</B>
	Research and development expenses represent costs incurred to develop our
	technology and carry out clinical studies, and include personnel-related expenses, regulatory costs, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and
	information technology costs, contract services and other outside costs. Research and development expenses also include costs related to activities performed under contracts with our collaborators and strategic partners. Research and development
	expenses increased by $1,539,000, or 40%, for the year ended December&nbsp;31,&nbsp;2011 compared to the same period in 2010. This increase was due primarily to a $1,919,000 increase in clinical trial and collaboration costs for the ongoing
	development of our ovarian cancer program and our PAD blood test as well as $435,000 for the Correlogic asset acquisition which was expensed as the assets acquired will be consumed in research and development activities, with no alternative future
	use. These increases were partially offset by decreases in stock-based compensation expense of $307,000 as well as decreases in depreciation expense and outside consulting services compared to the same period in 2010 as well as a loss on sale and
	disposal of property and equipment in 2010 which did not recur in 2011.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Sales and Marketing Expenses
</I>
</B>
<B>
	.
</B>
	Our sales and marketing expenses consist primarily of personnel-related expenses, education and promotional expenses, and infrastructure expenses, including allocated facility occupancy and information technology costs. These expenses include the
	costs of educating physicians, laboratory personnel and other healthcare professionals regarding OVA1. Sales and marketing expenses also include the costs of sponsoring continuing medical education, medical meeting participation and dissemination of
	scientific and health economic publications. Our personnel-related expenses include the cost of our Territory Development Managers, the subject matter experts responsible for market development and the coordination of interactions with the Quest
	Diagnostic&#146;s sales team. Sales and marketing expenses increased by $2,682,000, or 94%, for the year ended December&nbsp;31,&nbsp;2011 compared to the same period in 2010. The increase was primarily due to a $1,844,000 increase in personnel and
	personnel-related expenses, reflecting a full year with the sales and marketing team while the Territory Development Managers were added over the course of 2010, a $540,000 increase in marketing expenses related to the continued commercialization
	and promotion of OVA1 as well as $141,000 increase in outside consulting services.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	General and Administrative
	Expenses
</I>
</B>
<B>
	.
</B>
	General and administrative expenses consist primarily of personnel-related expenses, professional fees and other costs, including legal, finance and accounting expenses, and other
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	46
</FONT>
</P>
<A NAME="eolPage49"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	infrastructure expenses, including allocated facility occupancy and information technology costs. General and administrative expenses decreased by $475,000, or 5%, for the year ended
	December&nbsp;31,&nbsp;2011 compared to the same period in 2010. The decrease was primarily due to a $1,422,000 decrease in stock compensation expense as Incentive Plan costs were fully amortized in June 2011. In addition, audit and tax related
	service costs decreased $781,000 compared to the same period in 2010 due to the substantial effort in 2010 to bring current all periodic reports required by the Securities and Exchange Act of 1934 following emergence from bankruptcy. These decreases
	were partially offset by a $1,662,000 increase in legal costs due to the MAS litigation as well as Correlogic and shareholder activist litigation legal costs. General and administrative stock-based compensation expense was $2,446,000 and $3,868,000
	for the years ended December&nbsp;31, 2011 and 2010, respectively.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Interest Expense.
</I>
</B>
	Interest expense decreased
	by $95,000, or 19%, for the year ended December&nbsp;31,&nbsp;2011 compared to the same period in 2010 as we paid off $5,000,000 of our 7.00% Senior Convertible Notes upon maturity in September 2011.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
</I>
<B>
<I>
	Gain on Investment in Auction Rate Securities
</I>
</B>
<I>
</I>
<B>
	.
</B>
<I>
</I>
	There was no gain on investment in auction rate
	securities for the year ended December&nbsp;31, 2011 compared to $58,000 in the same period in 2010. The auction rate securities were sold in July 2010.
<I>
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Change in Fair Value and Gain from Warrant Exercise, Net.
</I>
</B>
	The change in fair value and gain from exercise of warrants was $378,000 for the year ended December&nbsp;31, 2011 compared to
	$4,353,000 for the same period in 2010. The decrease of $3,975,000, or 91%, was primarily due to the relative decrease in the Company&#146;s stock price during the respective annual periods.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Debt Conversion Costs
</I>
</B>
	. There were no debt conversion costs for the year ended December&nbsp;31, 2011 compared to $141,000
	for the same period in 2010 as there was no conversion of debt to equity in 2011.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
</I>
<B>
<I>
	Reorganization
	Items
</I>
</B>
<I>
</I>
<B>
	.
</B>
<I>
</I>
	Reorganization items for the year ended December&nbsp;31,&nbsp;2011 totaled $96,000 compared to $1,677,000 for the same period in 2010. Reorganization items include professional advisory fees and other costs
	directly associated with our Chapter 11 bankruptcy activities. The activities were largely completed during 2010 resulting in lower expenses during the year ended December&nbsp;31, 2011.
<I>
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
</I>
<I>
</I>
<B>
<I>
	Reorganization Items&#151;Related Party Incentive Plan
</I>
</B>
<I>
</I>
	. All Incentive Plan expenses during 2011 were
	included in general and administrative expense. Reorganization items for the year ended December&nbsp;31,&nbsp;2010 amounted to $6,932,000. We paid $5,000,000 in cash and accrued $1,932,000 for the value of the vested portions of restricted stock
	under the Incentive Plan prior to us emerging from bankruptcy under the Bankruptcy Code.
<I>
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Other Income (Expense),
	Net
</I>
</B>
<B>
	.
</B>
	Net other expense was $99,000 for the year ended December&nbsp;31, 2011 compared to other income of $358,000 for the same period in 2010. Other expense for 2011 was due primarily to Delaware franchise tax. Other income for the
	year ended December&nbsp;31, 2010 included an award of two grants for the aggregate sum of $489,000 under the Internal Revenue Service Qualifying Therapeutic Discovery Projects Grant Program for the OVA2 and PAD programs.
</FONT>
</P>
<EFX_LIQUIDITY_CAPITAL>
<A NAME="FIS_LIQUIDITY_CAPITAL"></A>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Liquidity and Capital Resources
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On March&nbsp;9, 2010, we launched OVA1 commercially. We will continue to expend resources in the selling and marketing of OVA1 and developing additional diagnostic tests.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On February&nbsp;18, 2011, we completed an underwritten follow-on public offering of our common stock for net proceeds of $20,206,000
	after deducting underwriting discounts and offering expenses. We paid $5,000,000 in September 2011 to repay the outstanding 7.00% Notes. We paid $5,894,000 in October 2012 to repay the Secured Line of Credit with Quest Diagnostics. As of
	December&nbsp;31, 2012, we have $1,106,000 reported as short-term debt on our consolidated balance sheet that is in dispute with Quest Diagnostics.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	47
</FONT>
</P>
<A NAME="eolPage50"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have incurred significant net losses and negative cash flows from operations since
	inception. At December&nbsp;31, 2012, we had an accumulated deficit of $323,445,000 and stockholders&#146; equity of $4,667,000. On December&nbsp;31, 2012, we had $8,007,000 of cash and cash equivalents and $3,197,000 of current liabilities.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We expect cash for OVA1 from Quest Diagnostics to be our only material, recurring source of cash in 2013. In order to
	continue our operations as currently planned through 2013 and beyond, we will need to raise additional capital. Given the above conditions, there is substantial doubt about the Company&#146;s ability to continue as a going concern. The consolidated
	financial statements have been prepared on a going concern basis and do not include any adjustments that might result from these uncertainties.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The successful achievement of our business objectives will require additional financing and therefore, we will need to raise additional capital or incur indebtedness to continue to fund our future
	operations. We may seek to raise capital through a variety of sources, including the public equity market, private equity financing, collaborative arrangements, licensing arrangements, and/or public or private debt.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Any additional equity financing may be dilutive to stockholders, and debt financing, if available, may involve restrictive covenants. If
	we obtain additional funds through arrangements with collaborators or strategic partners, we may be required to relinquish our rights to certain technologies or products that we might otherwise seek to retain. Additional funding may not be available
	when needed or on terms acceptable to us. If we are unable to obtain additional capital, we may be required to delay, reduce the scope of or eliminate our sales and marketing and/or research and development activities.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our future liquidity and capital requirements will depend upon many factors, including, among others:
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	resources devoted to establish sales, marketing and distribution capabilities;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the rate of product adoption by physicians and patients;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	our determination to acquire or invest in other products, technologies and businesses;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the market price of our common stock as it affects the exercise of stock options; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the insurance payer community&#146;s acceptance of and reimbursement for OVA1.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Cash and cash equivalents as of December&nbsp;31,&nbsp;2012 and December&nbsp;31, 2011 were $8,007,000 and $22,477,000, respectively. At
	December&nbsp;31,&nbsp;2012 and 2011, working capital was $5,295,000 and $11,417,000, respectively.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net cash used in
	operating activities was $10,398,000 for the year ended December&nbsp;31, 2012, resulting primarily from $7,146,000 net loss incurred as adjusted for completion of the 2006 gain on sale of instrument business to Bio-Rad of $1,830,000 and non-cash
	license revenues of $454,000, partially offset by $1,295,000 of stock-based compensation expense. Net cash used in operating activities also included $2,472,000 of cash used from changes in operating assets and liabilities mainly driven by the
	$2,292,000 decrease of accounts payable and accrued liabilities.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net cash used in operating activities was $15,581,000 for
	the year ended December&nbsp;31,&nbsp;2011, resulting primarily from operating losses incurred as adjusted for a change in fair value of warrants of $378,000 and non-cash license revenues of $454,000, partially offset by $3,286,000 of stock-based
	compensation expense.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net cash provided by investing activities for the year ended December&nbsp;31, 2012 was $1,816,000 due primarily to the
	receipt of escrow funds upon completion of the 2006 sale of instrument business to Bio-Rad. Net cash used in investing activities was $99,000 for the year ended December&nbsp;31,&nbsp;2011, due to the purchase of property and equipment.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net cash used in financing activities was $5,888,000 for the year ended December&nbsp;31, 2012, which resulted primarily from our
	$5,894,000 repayment of short-term debt with Quest Diagnostics in October 2012.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	48
</FONT>
</P>
<A NAME="eolPage51"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net cash provided by financing activities was $15,240,000 for the year ended
	December&nbsp;31,&nbsp;2011, which resulted primarily from net proceeds of $20,206,000 in connection with our February 2011 follow-on public offering partially offset by our $5,000,000 repayment of our 7.00% Senior Convertible Notes in September
	2011.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Off-Balance Sheet Arrangements
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	As of December&nbsp;31, 2012, we had no off-balance sheet arrangements that are reasonably likely to have a current or future material effect on our consolidated financial condition, results of
	operations, liquidity, capital expenditures or capital resources.
</FONT>
</P>
</EFX_LIQUIDITY_CAPITAL>
</EFX_MANAGEMENTS_DISCUSSION>
<P STYLE="FONT-SIZE:18PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_MARKET_RISK>
<A NAME="FIS_MARKET_RISK"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_TOC453081_12">
</A>
	ITEM&nbsp;7A.
</B>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Pursuant to Item&nbsp;305(e) of Regulation S-K, information is not required.
</FONT>
</P>
</EFX_MARKET_RISK>
<P STYLE="FONT-SIZE:18PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_TOC453081_13">
</A>
	ITEM&nbsp;8.
</B>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our consolidated financial statements, including consolidated balance sheets as of December&nbsp;31, 2012 and 2011, consolidated statements of operations and comprehensive loss for the years ended
	December&nbsp;31, 2012 and 2011, consolidated statements of changes in stockholders&#146; equity for the years ended December&nbsp;31, 2012 and 2011, consolidated statements of cash flows for the years ended December&nbsp;31, 2012 and 2011 and notes
	to our consolidated financial statements, together with reports thereon of our independent registered public accounting firms, dated March 1, 2013 and March&nbsp;26, 2012, are attached hereto as pages F-1 through F-27.
</FONT>
</P>
</EFX_FINANCIAL_STATEMENTS>
<P STYLE="FONT-SIZE:18PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_ACCOUNTING_CHANGES>
<A NAME="FIS_ACCOUNTING_CHANGES"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_TOC453081_14">
</A>
	ITEM&nbsp;9.
</B>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On April&nbsp;4, 2012, we dismissed PricewaterhouseCoopers LLP (&#147;PwC&#148;) as our independent registered public accounting firm,
	upon approval of the Audit Committee of the Board of Directors.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The audit reports issued by PwC for the years ended
	December&nbsp;31, 2010 and December&nbsp;31, 2011 did not contain any adverse opinion or disclaimer of opinion, nor were the reports qualified or modified as to uncertainty, audit scope or accounting principles, except that the audit reports on the
	Company&#146;s financial statements for the years ended December&nbsp;31, 2010 and December&nbsp;31, 2011 included an explanatory paragraph noting that the Company voluntarily filed for Chapter 11 bankruptcy protection on March&nbsp;30, 2009 and
	subsequently emerged from bankruptcy on January&nbsp;22, 2010, and the audit report on the Company&#146;s financial statements for the year ended December&nbsp;31, 2011 also included an explanatory paragraph noting that there was substantial doubt
	about the Company&#146;s ability to continue as a going concern.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	During the years ended December&nbsp;31, 2010 and
	December&nbsp;31, 2011 and through April&nbsp;4, 2012, the Company did not have any disagreements (as defined in Item&nbsp;304(a)(1)(iv) of Regulation S-K and the related instructions to Item&nbsp;304 of Regulation S-K) with PwC on any matter of
	accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of PwC, would have caused PwC to make reference thereto in its report on the Company&#146;s
	financial statements for such years. Also, during the years ended December&nbsp;31, 2010 and December&nbsp;31, 2011 and through April&nbsp;4, 2012, there have been no reportable events as that term is defined in Item&nbsp;304(a)(1)(v) of Regulation
	S-K, except that, as disclosed in Item&nbsp;4 of the Company&#146;s Quarterly Reports on Form 10-Q for the quarters ended March&nbsp;31, 2010,&nbsp;June&nbsp;30, 2010 and September&nbsp;30, 2010, management of the Company concluded that because the
	Company filed for Chapter 11 bankruptcy protection on March&nbsp;30, 2009, the Company did not maintain sufficient staff with the necessary experience in U.S. generally accepted accounting principles to timely perform its controls procedures
	relating to the accounting and reporting processes. Specifically, the Company did not have sufficient accounting and reporting expertise necessary to make estimates requiring significant judgment or
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	49
</FONT>
</P>
<A NAME="eolPage52"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	to record complex transactions in a manner necessary to facilitate the timely filing of all Forms required by the Exchange Act of 1934, as amended, and as a result, the Company was not able to
	timely file all Forms required by the Exchange Act. Therefore, management concluded that this control deficiency constituted a material weakness as of March&nbsp;31, 2010,&nbsp;June&nbsp;30, 2010 and September&nbsp;30, 2010.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On April&nbsp;4, 2012, the Audit Committee approved the engagement of BDO USA, LLP (&#147;BDO&#148;) as the Company&#146;s new
	independent registered public accounting firm to audit the Company&#146;s financial statements as of and for the year ending December&nbsp;31, 2012. The Company will ask stockholders at the 2012 annual meeting of stockholders to ratify the
	appointment of BDO as the Company&#146;s independent registered public accounting firm for the year ended December&nbsp;31, 2012.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	During the years ended December&nbsp;31, 2010 and December&nbsp;31, 2011, and through April&nbsp;4, 2012, the Company did not consult BDO with respect to either (i)&nbsp;the application of accounting
	principles to a specified transaction, either completed or proposed; or the type of audit opinion that might be rendered on the Company&#146;s financial statements, and no written report or oral advice was provided to the Company by BDO that was an
	important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii)&nbsp;any matter that was either the subject of a disagreement, as that term is defined in Item&nbsp;304(a)(1)(iv)
	of Regulation S-K and the related instructions to Item&nbsp;304 of Regulation S-K, or a reportable event, as that term is defined in Item&nbsp;304(a)(2)(ii) of Regulation S-K.
</FONT>
</P>
</EFX_ACCOUNTING_CHANGES>
<P STYLE="FONT-SIZE:18PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_CONTROL_AND_PROCEDURES>
<A NAME="FIS_CONTROL_AND_PROCEDURES"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_TOC453081_15">
</A>
	ITEM&nbsp;9A.
</B>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	CONTROLS AND PROCEDURES
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Evaluation
	of Disclosure Controls and Procedures
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We maintain disclosure controls and procedures that are designed to ensure that
	information required to be disclosed in the reports we file or submit under the Exchange Act of 1934, is recorded, processed, summarized and reported within the time periods specified in the SEC&#146;s rules&nbsp;and forms, and that such information
	is accumulated and communicated to our management, including our Chief Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required financial disclosure.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	An evaluation was performed under the supervision and with the participation of our management, including our Chief Executive Officer and
	Chief Accounting Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act, as of December&nbsp;31, 2012.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Based on that evaluation, our Chief Executive Officer and Chief Accounting Officer have concluded that as of December&nbsp;31, 2012 our
	disclosure controls and procedures, as defined in Rule 13a-15(e) and Rule 15(d)-15(e) under the Exchange Act, were effective.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Management Report on Internal Control over Financial Reporting
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We are responsible for establishing and maintaining adequate internal control over our financial reporting. We have assessed the effectiveness of internal control over financial reporting as of
	December&nbsp;31, 2012. Our assessment was based on criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO, in Internal Control-Integrated Framework.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of
	financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of America (&#147;U.S. GAAP&#148;). Our internal control over financial reporting
	includes those policies and procedures that:
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(i)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and dispositions of our assets;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	50
</FONT>
</P>
<A NAME="eolPage53"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(ii)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that our
	receipts and expenditures are being made only in accordance with authorizations of our management and board of directors; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(iii)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect
	on the financial statements.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Because of its inherent limitations, internal control over financial reporting may
	not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the
	policies or procedures may deteriorate.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Based on using the COSO criteria, management concluded our internal control over
	financial reporting as of December&nbsp;31, 2012 was effective.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	This Annual Report on Form 10-K does not include an attestation report of our
	independent registered public accounting firm regarding internal control over financial reporting. Management&#146;s assessment of the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2012, was not subject to
	attestation by our independent registered public accounting firm pursuant to rules of the United States Securities and Exchange Commission (&#147;SEC&#148;) that permit a smaller reporting company to provide only management&#146;s report in this
	Annual Report on Form 10-K.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Changes in internal control over financial reporting.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	There was no change in our internal control over financial reporting that occurred during the quarter ended December&nbsp;31, 2012 that
	has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
</FONT>
</P>
</EFX_CONTROL_AND_PROCEDURES>
<P STYLE="FONT-SIZE:18PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_OTHER_INFORMATION>
<A NAME="FIS_OTHER_INFORMATION"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_TOC453081_16">
</A>
	ITEM&nbsp;9B.
</B>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	OTHER INFORMATION
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	None.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	51
</FONT>
</P>
<A NAME="eolPage54"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_OTHER_INFORMATION>
</EFX_PART_II>
<EFX_PART_III>
<A NAME="FIS_PART_III"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_TOC453081_17">
</A>
	PART III
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_DIRECTORS_AND_OFFICERS>
<A NAME="FIS_DIRECTORS_AND_OFFICERS"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_TOC453081_18">
</A>
	ITEM&nbsp;10.
</B>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
</B>
<I>
</I>
<B>
	Information Regarding Directors
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our Board of Directors
	currently consists of six directors, following the reduction in size authorized by the Board of Directors to eliminate the vacancy due to the resignation of Ms. Page. The directors are divided into three classes having staggered three-year terms, so
	that the term of one class expires at each annual meeting of stockholders. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will
	consist of an equal number of directors. The classes are currently comprised as follows:
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Class I directors.
</I>
	Bruce A. Huebner and William C. Wallen, Ph.D. are Class I directors, whose terms will expire at the next annual meeting
	following this one;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Class II directors.
</I>
	James S. Burns, Peter S. Roddy and Carl Severinghaus are Class II directors, whose terms will expire at the 2014 annual
	meeting; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Class III director and nominee.
</I>
	John F. Hamilton is a Class III director, whose term will expire upon the election of a new Class III director
	at the 2012 annual meeting of stockholders (the &#147;2012 Annual Meeting&#148;). John F. Hamilton is not nominated for re-election at the 2012 Annual Meeting and the Board has nominated Roberta L. Della Vedova as the Class III director to fill the
	board seat currently held by John F. Hamilton.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Class III Director Nominated for Election to a Three-Year Term Expiring
	at the 2015 Annual Meeting
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Roberta L. Della Vedova
</I>
</B>
	, age 59, has served as Vice President of Human Resources
	and Head of Global Diagnostic Sales at eBioscience, Inc., a global life sciences provider of innovative cell analysis products and technologies, since April 2011. From December 2010 to April 2011, she served as eBioscience&#146;s Director of Human
	Resources and Director of Global Diagnostic Sales.&nbsp;Ms. Vedova co-founded AlliedPath, Inc., a CLIA certified laboratory providing molecular solid tumor testing, and served as its President from June 2008 to November 2010. From February 2006 to
	June 2008, Ms. Vedova served as Vice President of Human Resources at CovX Research, LLC, a pharmaceutical research and development organization focusing on cancer therapeutics. As the owner of Organization Solutions Group, Inc. from December 2004 to
	December 2008, she oversaw a training and development franchise that provided services to pharmaceutical, medical device and biotechnology organizations. At Gen-Probe Incorporated, a large medical device organization with products ranging from blood
	screening to infectious disease diagnostics, Ms. Vedova served as the Vice President of Administration from January 2002 to September 2004, and prior to that as Gen-Probe&#146;s Vice President of Human Resources. Ms. Vedova also previously served as
	Director of Human Resources at Becton Dickinson &amp; Company, a Fortune 500 manufacturer of medical diagnostic equipment and supplies for hospital and laboratories. Ms. Vedova received her B.A. in Business Management from the University of Phoenix
	and her M.S. in Executive Leadership from the University of San Diego. She also has a lifetime certification as a Senior Professional in Human Resources and is a certified instructor of Zenger-Miller Frontline Leadership.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Board of Directors believes that Ms. Vedova is qualified to serve as our director as an independent investor representative because
	she brings a broad range of relevant industry experience to the Board, having previously provided direction and oversight to companies engaged in the development, manufacture, and marketing of bioreagents and instruments, as well as in the delivery
	of laboratory services for cancer diagnostics.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Class I Directors Continuing Office until the Next Annual Meeting Following the 2012 Annual
	Meeting
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Bruce A Huebner
</I>
</B>
	, age 62, has been our director since May 2011 and serves as the Company&#146;s
	Interim President and Chief Executive Officer on November 26, 2012. Mr. Huebner served as a managing director for LynxCom Partners, LLC, a healthcare consulting firm, from July 2010 through November 2012 and from July
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	52
</FONT>
</P>
<A NAME="eolPage55"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2008 through September 2009. From October 2009 to June 2010, Mr. Huebner served as President and Chief Executive Officer of TrovaGene, Inc., a developer of molecular diagnostics products based on
	the detection of transrenal genetic markers. From May 2005 to July 2008, Mr. Huebner served as President of Osmetech Molecular Diagnostics, where he successfully established Osmetech as a fully integrated business, obtaining FDA clearance for four
	molecular diagnostic microarray products and introducing them to the marketplace. From 2002 to 2004, Mr. Huebner was President and Chief Operating Officer of Nanogen, Inc., a publicly held nanotechnology/microarray company. From 1996 to 2002, Mr.
	Huebner was Executive Vice President and Chief Operating Officer of Gen-Probe, Inc. which today is one of the world leaders in the development of nucleic acid tests, including a focus on diagnostic tests for infectious disease that affect
	women&#146;s health. Mr. Huebner&#146;s other experience includes Vice President of Marketing and Sales at Quidel, Director of Marketing for the U.S. and Director of Marketing and Market Development in Europe for Hybritech, Inc., and various sales
	and marketing positions at Roche Diagnostics. He currently serves as a director on the board of directors of Pasadena Bioscience Collaborative and Corgenix Medical Corporation. Mr. Huebner received his Bachelor of Science degree in Chemistry from
	the University of Wisconsin-La Crosse and completed a graduate school senior executive program at Columbia University.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Mr.
	Huebner&#146;s broad experience with various diagnostic companies allows him to assist our Board in evaluating and refining our business strategies and commercial objectives.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	William C. Wallen
</I>
</B>
	,
<B>
<I>
	Ph.D.
</I>
</B>
	, age 69, has been our director since February 2010 and serves as Chairman of our Nominating and Governance Committee. Additionally, he is a member of
	our Audit Committee and Compensation Committee, and served on our Scientific Advisory Board from April 2006 until February 2010, when he joined the Board of Directors. Dr. Wallen served as the Senior Vice President and Chief Scientific Officer of
	IDEXX Laboratories, Inc. (&#147;IDEXX&#148;) beginning September 2003, and retired from IDEXX on March&nbsp;3, 2010. Commencing in December 2008, Dr. Wallen took on the position of leading its infectious disease product manufacturing operations. Dr.
	Wallen led IDEXX&#146;s pharmaceutical products business from September 2003 until IDEXX sold certain product lines and restructured that business in 2008. Prior to joining IDEXX, Dr.&nbsp;Wallen held various positions with Bayer Corporation, most
	recently as Senior Vice President, Research and Development, and Head, Office of Technology for the Diagnostics Division of Bayer Healthcare. From 2001 to 2003, Dr. Wallen served as Senior Vice President and Head of Research, Nucleic Acid
	Diagnostics Segment; from 1999 to 2001, as Senior Vice President of Research and Development Laboratory Testing Segment; and from 1993 to 1999, as Vice President of Research and Development, Immunodiagnostic and Clinical Chemistry Business Units.
	Before joining Bayer Corporation, from 1990 to 1993, Dr. Wallen was Vice President, Research and Development at Becton Dickinson Advanced Diagnostics. Dr. Wallen is a member of the American Association of Clinical Chemistry, the American Society for
	Microbiology, American Association for Cancer Research, The Leukemia Society of America, and the New York Academy of Science. Dr. Wallen has authored or co-authored 55 scientific papers and articles covering topics in immunology, virology, oncology
	and detection methodologies. Dr. Wallen received his B.S. in Zoology and M.S. in Microbiology from Michigan State University, and Ph.D. in Molecular Biology from University of Arizona College of Medicine.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Board of Directors has determined that based upon Dr. Wallen&#146;s extensive experience in research and development and corporate
	governance matters in the diagnostics industry, he has the qualifications and skills to serve as a member of our Board of Directors. Dr. Wallen also brings to the Board a background in managing public companies, which gives him the qualification and
	skills to serve as a key member of the Board&#146;s Audit, Compensation, and Nominating and Governance Committees.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Class II Directors
	Continuing Office until the 2014 Annual Meeting
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	James S. Burns
</I>
</B>
	, age 66, has been our director since June
	2005 and has served as Chairman of the Board since September 29, 2011. Mr. Burns is currently President, Chief Executive Officer and director of AssureRx, Health, Inc., a personalized medicine company which specializes in pharmacogenetics for
	neuropsychiatric disorders. Prior to joining AssureRx, Health, Inc., Mr. Burns was the President and Chief Executive Officer of
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	53
</FONT>
</P>
<A NAME="eolPage56"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	EntreMed, Inc. from June 2004 to December 2008, and a director from September 2004 to December 2008. Mr.&nbsp;Burns was a co-founder and, from 2001 to 2003, served as President and as Executive
	Vice President of MedPointe, Inc., a specialty pharmaceutical company that develops, markets and sells branded prescription pharmaceuticals. From 2000 to 2001, Mr. Burns served as a founder and Managing Director of MedPointe Capital Partners, a
	private equity firm that led a leveraged buyout to form MedPointe Pharmaceuticals. Previously, Mr. Burns was a founder, Chairman, President and Chief Executive Officer of Osiris Therapeutics, Inc., a biotech company developing therapeutic stem cell
	products for the regeneration of damaged or diseased tissue. Mr. Burns has also been Vice Chairman of HealthCare Investment Corporation and a founding General Partner of Healthcare Ventures L.P., a venture capital partnership specializing in forming
	companies building around new pharmaceutical and biotechnology products; Group President at Becton Dickinson and Company, a multidivisional biomedical products company; and Vice President and Partner at Booz &amp; Company, Inc., a multinational
	consulting firm. Mr. Burns is a director of Symmetry Medical Inc. (NYSE: SMA), a supplier of products and services to orthopedic and other medical device companies. Mr. Burns received his B.S. and M.S. in Biological Sciences from the University of
	Illinois, and M.B.A. from DePaul University. He is a 2012 Board Leadership Fellow of the National Association of Corporate Directors.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our Board of Directors has determined that based upon Mr. Burns&#146; extensive experience in the diagnostics industry, and current and prior directing and management experience, he has the qualifications
	and skills to serve as a member of our Board of Directors.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Peter S. Roddy
</I>
</B>
	, age 53, was appointed to our Board
	of Directors and Audit Committee on February 18, 2010. Mr. Roddy has served as Vice President and Chief Financial Officer of Pain Therapeutics, Inc. since July 2004, and as its Chief Financial Officer since November 2002. From 1990 to 2002, Mr.
	Roddy held a variety of senior management positions at COR Therapeutics, Inc. (now part of Takeda Pharmaceutical Company Limited), a biopharmaceutical company, including Senior Vice President, Finance and Chief Financial Officer between 2000 and
	2002. Prior to 1990, Mr. Roddy held a variety of positions at Price Waterhouse &amp; Company, Hewlett Packard Company and MCM Laboratories, Inc. Mr. Roddy received his B.S. in Business Administration from the University of California, Berkeley.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our Board of Directors has determined that based upon Mr. Roddy&#146;s extensive experience in the life science industry,
	including relevant experience as an executive officer and chief financial officer, as well as experience at a major accounting firm, he has the qualifications and skills to serve as a member of our Board of Directors and Chairman of the Audit
	Committee.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On December 2, 2011, a class action complaint claiming violations of certain securities laws was filed against
	Pain Therapeutics, Inc. and its executive officers, including Mr. Roddy, in the U.S. District Court for the Western District of Texas by a holder of its securities and its executive officers. This complaint alleged, among other things, violations of
	Section 10(b), Rule 10b-5, and Section 20(a) of the Exchange Act arising out of allegedly untrue or misleading statements of material facts made by Pain Therapeutics regarding REMOXY during the purported class period from February 3, 2011 to June
	23, 2011.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Carl Severinghaus
</I>
</B>
	, age 60, was appointed to our Board of Directors on March 3, 2010 and serves as our
	Compensation Committee Chairman. In addition, he is a member of our Audit Committee and also our Nominating and Governance Committee. Since January 1, 2011, Mr. Severinghaus is Vice President, Head Global Sales OEM Components of the Tecan Group.
	Previously from 2009 until 2011 he was President of Tecan Americas, responsible for Sales and Commercial Operations for the Americas Region, including US, Canada, Central and South America. From 2007 until 2009, he lived in Zurich and was Senior
	Vice President for International Sales, responsible for Worldwide Sales and Operations. From 1999 to 2007, Mr. Severinghaus was President and General Manager of Tecan US. Prior to becoming President and General Manager, he was Vice President of
	Sales from 1991 to 1998. Before he joined Tecan he was National Sales Manager for American Monitor Corporation.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	54
</FONT>
</P>
<A NAME="eolPage57"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Mr. Severinghaus received his Bachelor of Fine Arts Degree from Drake University in 1974.
	Mr.&nbsp;Severinghaus is or has been a member of the Analytical &amp; Life Science System Association, Society for Laboratory Automation and Screening (SLAS) and also the American Association of Clinical Chemistry (AACC).
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Board of Directors has determined that based upon Mr. Severinghaus&#146; demonstrated executive level management and commercial
	operations skills, both domestically and internationally, he has the qualifications and skills to serve as a member of our Board of Directors and a key member of the Board&#146;s Audit, Compensation, and Nominating and Governance Committees.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Class III Director Whose Term Will Expire at the Upcoming Annual Meeting of Stockholders
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	John F. Hamilton
</I>
</B>
	, age 68, has been our director since April 2008. From 1997 until his retirement in 2007, Mr. Hamilton
	served as Vice President and Chief Financial Officer of Depomed, Inc., a specialty pharmaceutical company focused on enhancing pharmaceutical products. Mr. Hamilton began his career in international banking with The Philadelphia National Bank and
	Crocker National Bank, and went on to hold senior financial positions at several bio-pharmaceutical companies including Glyko, Inc., which is now BioMarin Pharmaceuticals, and Chiron Corporation. Mr. Hamilton sits on the regional Board of Directors
	of the Association of Bioscience Financial Officers, and is past-president of the Treasurers Club of San Francisco. Mr. Hamilton received his M.B.A. from the University of Chicago and B.A. in International Relations from the University of
	Pennsylvania.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our Board of Directors has determined that based upon Mr. Hamilton&#146;s extensive experience in finance and
	capital markets gained through his education and his senior financial positions at various biopharmaceutical companies, he has the qualifications and skills to serve as a member of our Board of Directors. Mr. Hamilton also brings to the Board
	significant strategic and financial expertise and leadership experience.
</FONT>
</P>
<EFX_NAME_AND_TITLE>
<A NAME="FIS_NAME_AND_TITLE"></A>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Information Regarding Executive Officers
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Set forth below is the information about our executive officers in 2012:
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="47%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD WIDTH="45%">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Name
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Age
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Positions
</B>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Gail S. Page
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	57
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	President and Chief Executive Officer (former)
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Bruce A. Huebner
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	62
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Interim President and Chief Executive Officer
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Eric J. Schoen
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	44
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Chief Accounting Officer
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Donald G. Munroe, Ph.D.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	56
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Chief Scientific Officer and Vice President of Research and Development (through February 28, 2013); Senior Vice President of Business Development and Chief Scientific Officer
	(effective March 1, 2013)
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	William Creech
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	60
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Vice President of Sales and Marketing
</FONT>
</TD>
</TR>
</TABLE>
</EFX_NAME_AND_TITLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Gail S. Page
</I>
	joined us in January 2004 as President of our Diagnostics Division and an Executive
	Vice President, and was promoted to President and Chief Operating Officer of Vermillion in August 2005. Subsequently, Ms. Page became our President and Chief Executive Officer and was named a director in December 2005 and served as President and
	Chief Executive Officer until her resignation on March 27, 2009 due to our bankruptcy proceeding in 2009. In connection with our emergence from bankruptcy in 2010, Ms. Page was reappointed as our Chief Executive Officer on February 1, 2010. From
	October 2000 to January 2003, Ms.&nbsp;Page
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	55
</FONT>
</P>
<A NAME="eolPage58"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	was Executive Vice President and Chief Operating Officer of Luminex Corporation. From 1988 to 2000, Ms.&nbsp;Page held various senior level management positions with Laboratory Corporation of
	America (&#147;LabCorp&#148;). In 1993, Ms. Page was named Senior Vice President, Office of Science and Technology at LabCorp, responsible for the management of scientific affairs in addition to the diagnostics business segment. Additionally, from
	1995 to 1997, Ms. Page headed the Cytology and Pathology Services business unit for LabCorp. From 1988 to 2000, Ms. Page was a member of the Scientific Advisory Board at LabCorp and chaired the committee from 1993 to 1997. Prior to her years at
	LabCorp and its predecessor, Roche Biomedical, Ms.&nbsp;Page worked in various functions in the academic field and the diagnostics industry. Ms. Page received her A.S. in Medical Technology in combination with a Cardiopulmonary Technology Diploma
	from the University of Florida. Ms. Page also completed an executive management course at the Kellogg School of Management at Northwestern University. On May 15, 2012, we announced Ms.&nbsp;Page&#146;s immediate resignation as director, and the
	mutually agreed termination without cause of Ms.&nbsp;Page as our President and Chief Executive Officer, which was effective December 2, 2012. Ms. Page became a consultant for the Company effective December 3, 2012.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Bruce A. Huebner
</I>
	was appointed as the Company&#146;s Interim President and Chief Executive Officer on November 26, 2012. Mr.
	Huebner has been a director of the Company since May 2011 and will continue to serve on the Board. Mr. Huebner most recently served as a managing director for LynxCom Partners, LLC, a healthcare consulting firm. From October 2009 to June 2010, Mr.
	Huebner served as President and Chief Executive Officer of TrovaGene, Inc., a developer of molecular diagnostics products based on the detection of transrenal genetic markers. From May 2005 to July 2008, Mr. Huebner served as President of Osmetech
	Molecular Diagnostics, where he successfully established Osmetech as a fully integrated business, obtaining FDA clearance for four molecular diagnostic microarray products and introducing them to the marketplace. From 2002 to 2004, Mr. Huebner was
	President and Chief Operating Officer of Nanogen, Inc., a publicly held nanotechnology/microarray company. From 1996 to 2002, Mr. Huebner was Executive Vice President and Chief Operating Officer of Gen-Probe, Inc. which today is one of the world
	leaders in the development of nucleic acid tests, including a focus on diagnostic tests for infectious disease that affect women&#146;s health. Mr. Huebner&#146;s other experience includes Vice President of Marketing and Sales at Gen-Probe, Vice
	President of Marketing and Sales at Quidel, Director of Marketing for the U.S. and Director of Marketing and Market Development in Europe for Hybritech, Inc., and various sales and marketing positions at Roche Diagnostics. He currently serves as a
	director on the board of directors of Pasadena Bioscience Collaborative and Corgenix Medical Corporation. Mr. Huebner received his Bachelor of Science degree in Chemistry from the University of Wisconsin-La Crosse and completed a graduate school
	senior executive program at Columbia University.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Eric J. Schoen
</I>
	joined us in July 2010 as our Corporate Controller. He
	has been our Chief Accounting Officer since October 2011. Prior to joining us, Mr. Schoen served as Revenue Controller for Borland Software from 2007 to 2010. From 2000 to 2007, he served in Corporate Controller and Director of Finance roles for
	Trilogy Enterprises, Momentum Software and Alticast, Inc. Mr. Schoen also spent nine years with PricewaterhouseCoopers, most recently as a Manager in the audit and assurance, transaction services and global capital markets practices. Mr. Schoen
	received his Bachelor of Science in Finance from Santa Clara University.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%;PADDING-BOTTOM:0PX; ">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Donald G. Munroe
</I>
	,
<I>
	Ph.D.
</I>
	, joined us in October 2011 as our Chief Scientific Officer and Vice President of Research and Development. Effective March 1, 2013, Dr. Munroe was named our Senior Vice President of Business Development and Chief Scientific Officer. Dr.
	Munroe has extensive experience in the diagnostic industry, and has been a key member of upper management in a number of prominent diagnostic and life science companies. He served as Vice President, Immunoassay Research and Development from 2009 to
	2011 at Beckman Coulter, a preeminent manufacturer of automated diagnostic tests and biomedical instruments. In this role, Dr. Munroe was responsible for launching key Immunoassay menu additions and re-standardizing existing assays. He also
	initiated manufacturing science investigations and product improvement projects. Previously, Dr.&nbsp;Munroe worked at Invitrogen Corporation in several roles including Vice President, Research and Development (Transplant Diagnostics) from 2006 to
	2008, Vice President, Global Program and Portfolio Management (Corporate) from 2004 to 2005, and Director, Research and Development (GIBCO
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	&#153;
</SUP>
</FONT>
	) from 2002 to 2003. Dr. Munroe was Director of Technology Commercialization with Corning (Microarray Technologies) from
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	56
</FONT>
</P>
<A NAME="eolPage59"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2000 to 2002, and has 10 years of pharmaceutical discovery research experience at R.W. Johnson Pharmaceutical Research Institute (1990 to 1995) and Allelix Biopharmaceuticals (1996 to 2000). Dr.
	Munroe received his Bachelor of Science in Biology from the University of Guelph, Master of Science in Medical Sciences at McMaster University and Ph.D. in Medical Biophysics at University of Toronto. Dr. Munroe has served as a member of the
	Scientific Advisory Board of Minneapolis Community &amp; Technical College and is a member of the American Association for Clinical Chemistry and the American Association for the Advancement of Science. Dr. Munroe is an inventor in seven granted
	U.S. patents, and has authored peer-reviewed publications on the molecular basis of cancer, gastrointestinal disorders, inflammation and other topics.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%;PADDING-BOTTOM:0PX; ">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	William Creech
</I>
	joined us in March 2010 as Vice President of Sales and Marketing. Prior to joining us, Mr.&nbsp;Creech served as Principal of WBC Consulting, where he provided strategic and tactical
	consulting services to clients in the medical devices and diagnostics industry from 2008 until March 2010. Mr. Creech has over 30 years of experience in the diagnostics industry, serving as Vice President of Sales and Marketing at Capitol Vial, Inc.
	from 2005-2008 where he was responsible for creating a sales organization and initiating a scalable pricing program that increased gross margin 500 basis points. He also launched a key new product, &#147;Snappies&#148;
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	&#153;
</SUP>
</FONT>
	, increasing volume 400% year over year while increasing pricing by 30%. Mr. Creech was Vice President of Corporate
	Accounts at Apogent Technologies from 1998-2005 where he negotiated multi subsidiary contracts with key customers such as Quest Diagnostics and IDEXX. Prior to that, Mr. Creech was Director of Corporate Accounts at Ciba Corning/Chiron Diagnostics
	from 1995 to 1998. At Abbott Diagnostics, he served in various sales, sales training and sales management and corporate roles for 14 years from 1981 to 1995, receiving awards such as Presidents Club for 4 straight years and was sales rep of the year
	for the Diagnostics Division. Mr.&nbsp;Creech served as an Armor officer in the United States Army from 1975 to 1981 and graduated with a B.S. from Florida Southern College.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Section 16(a) Beneficial Ownership Reporting Compliance
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Section 16(a) of
	the Exchange Act requires our executive officers and directors, and persons who own more than 10% of a registered class of our equity securities, to file reports of ownership and changes in ownership with the SEC and with any national securities
	exchange on which such securities are traded or quoted. Executive officers, directors and such stockholders are required by SEC regulations to furnish us with copies of all Section 16(a) forms they file. As a practical matter, we assist our
	directors and officers by completing and filing Section 16 reports on their behalf. Based solely on a review of the copies of such reports furnished to us, and the written representations of our directors and executive officers, we believe that our
	directors and executive officers, and persons who own more than 10% of a registered class of our equity securities, complied with all applicable filing requirements for the year ended December 31, 2012.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Code of Ethics
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have
	adopted the Vermillion, Inc. Code of Ethics that applies to all our officers, directors and employees. The Code of Ethics is available under the Investor Relations section of our website at http://www.vermillion.com. We will disclose on our website
	any waiver of, or amendment to, the Code of Ethics.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	No Change in Director Nomination Process
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	As of the date of the filing of this Form 10-K, there have been no material changes to the procedures by which security holders may
	recommend nominees to our Board of Directors since we previously provided the disclosures required by Item 407(c)(2)(iv) or Item 407 (c)(3) of Regulation S-K.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Audit Committee
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Board of Directors has established an Audit Committee
	in accordance with section 3(a)(58)(A) of the Exchange Act. The Audit Committee is currently composed of three directors: Mr. Roddy, Chairperson,
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	57
</FONT>
</P>
<A NAME="eolPage60"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Dr.&nbsp;Wallen and Mr. Severinghaus. The Board has determined that all members of our Audit Committee are independent, as the term is currently defined in NASDAQ Listing Rules 5605(a)(2). The
	Board has determined that Mr. Roddy qualifies as an &#147;audit committee financial expert,&#148; as defined in applicable rules. The Board made a qualitative assessment of Mr. Roddy&#146;s level of knowledge and experience based on a number of
	factors, including his experience as the chief financial officer of other companies.
</FONT>
</P>
</EFX_DIRECTORS_AND_OFFICERS>
<P STYLE="FONT-SIZE:18PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_COMPENSATION>
<A NAME="FIS_COMPENSATION"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_TOC453081_19">
</A>
	ITEM&nbsp;11.
</B>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	EXECUTIVE COMPENSATION
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Director
	Compensation
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Outside directors
<I>
	(i.e.
</I>
	, non-employee directors) are compensated for their service as (1) a member of
	the Board of Directors, (2) a member of any committee of the Board of Directors, and (3) a chair of any committee of the Board of Directors. For 2012, we adopted a compensation program granting restricted stock units (&#147;RSUs&#148;) to outside
	directors with a targeted value on the grant date. The number of RSUs granted is determined by dividing the targeted value by a trailing average price of our common stock on the date of grant of the RSUs. 50% of the RSUs granted to directors vested
	on June 1, 2012 and 25% of the RSUs vested on each of September&nbsp;1, 2012 and December 1, 2012, except that 50% of the RSUs granted to John F. Hamilton vested May&nbsp;15, 2012 and 50% vested on December 13, 2012 due to the fact that Mr. Hamilton
	was not nominated for re-election at the delayed 2012 Annual Meeting. Outside directors did not receive any cash compensation in connection with their services as directors, nor did they sell any RSUs, except that historically certain RSUs were sold
	by certain directors only for the purpose of covering their tax liability incurred in connection with the distribution of the RSUs. Periodically, the Compensation Committee reviews and determines the adequacy of the compensation program for outside
	directors, and based upon the results of their analysis, the Compensation Committee will make recommendations in regards to the compensation program for outside directors to the Board of Directors. During fiscal year 2012, the outside directors were
	compensated as follows, with the RSU awards being made as of May 15, 2012 based on a grant date value of $1.99 per RSU:
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The chairman of the Board received a total of 35,000 RSU&#146;s;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	each other outside director received 30,000 RSUs;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the chairperson of the Audit Committee received an additional 6,000 RSUs;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the chairperson of the Compensation Committee received an additional 4,500 RSUs;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the chairperson of the Nominating and Governance Committee received an additional 3,000 RSUs;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the other members of the Compensation Committee each received an additional 2,000 RSUs;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the other members of the Nominating and Governance Committee received an additional 2,000 RSUs; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the other members of the Audit Committee each received an additional 3,000 RSUs.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	58
</FONT>
</P>
<A NAME="eolPage61"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The compensation earned by our outside directors for the year ended December 31, 2012 was as
	follows:
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="34%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR>
<TD VALIGN="BOTTOM" NOWRAP>
<A NAME="FIS_UNIDENTIFIED_TABLE_7"></A>
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:20PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Name
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Fees
<BR>
	Earned
<BR>
	or Paid
<BR>
	in&nbsp;Cash
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Stock
<BR>
	Awards
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(1)
</SUP>
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Option
<BR>
	Awards
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Non-Equity
<BR>
	Incentive Plan
<BR>
	Compensation
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Nonqualified
<BR>
	Deferred
<BR>
	Compensation
<BR>
	Earnings
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	All Other
<BR>
	Compensation
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Total
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	James S. Burns
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	69,650
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	69,650
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	John F. Hamilton
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	51,300
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	51,300
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Peter S. Roddy
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	71,640
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	71,640
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Carl Severinghaus
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	78,605
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	78,605
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	William C. Wallen, Ph.D.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	75,620
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	75,620
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	346,815
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	346,815
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="LINE-HEIGHT:8PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:2PX;BORDER-BOTTOM:0.5PT SOLID #000000;WIDTH:10%">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(1)
</SUP>
	&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	All outside directors received RSUs in lieu of any cash compensation.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	59
</FONT>
</P>
<A NAME="eolPage62"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	COMPENSATION COMMITTEE REPORT
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	1
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our executive compensation program for our Named Executive Officers is administered by the Compensation Committee of the Board of Directors. The Compensation Committee has reviewed the Compensation
	Discussion and Analysis and discussed that analysis with management. Based on its review and discussions with management, the Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in
	this proxy statement.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	This report is provided by the following independent directors of the Compensation Committee:
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Carl Severinghaus, Chairman
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	William C. Wallen
</FONT>
</P>
<P STYLE="LINE-HEIGHT:8PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:2PX;BORDER-BOTTOM:0.5PT SOLID #000000;WIDTH:10%">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	1
</SUP>
	&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The information provided under the heading &#147;Compensation Committee Report&#148; shall not be deemed to be &#147;soliciting material&#148; or &#147;filed&#148; or
	incorporated by reference in future filings with the SEC, or subject to the liabilities of Section 18 of the Exchange Act, except to the extent that it is specifically incorporated by reference into a document filed under the Securities Act of 1933,
	as amended (the &#147;Securities Act&#148;) or the Exchange Act.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	60
</FONT>
</P>
<A NAME="eolPage63"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	COMPENSATION DISCUSSION AND ANALYSIS
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	This section describes the compensation program for our Named Executive Officers. In particular, this section focuses on our 2012
	compensation program and related decisions. The Compensation Committee annually reviews our executive compensation program to ensure that it appropriately rewards performance that is tied to sound decision-making and creating stockholder value, and
	is designed to achieve our goals of promoting financial and operational success by attracting, motivating and facilitating the retention of key employees with outstanding talent and ability.
</FONT>
</P>
<EFX_NAME_AND_TITLE>
<A NAME="FIS_NAME_AND_TITLE_2"></A>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Named Executive Officers During 2012
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The following executive officers were our Named Executive Officers during 2012.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="51%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD WIDTH="46%">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Name
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Positions
</B>
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Gail S. Page
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	President and Chief Executive Officer (former)
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Bruce A. Huebner
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Interim Chief Executive Officer
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Donald G. Munroe, Ph.D.
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Chief Scientific Officer and Vice President of Research and Development (through February 28, 2013); Senior Vice President of Business Development and Chief Scientific Officer
	(effective March 1, 2013)
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	William Creech
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Vice President of Sales and Marketing
</FONT>
</TD>
</TR>
</TABLE>
</EFX_NAME_AND_TITLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On May 15, 2012, we announced the mutually agreed termination without cause of Gail S. Page as our
	President and Chief Executive Officer, which was effective December 2, 2012, after the Company entered into an employment agreement with a successor Chief Executive Officer. Ms. Page became a consultant for the Company effective December 3, 2012.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Compensation Philosophy and Objectives
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The goal of our compensation program for our Named Executive Officers is the same as for the overall Company, which is to foster compensation policies and practices that attract, engage and motivate high
	caliber talent by offering compensation in a competitive range. We are committed to a total compensation philosophy and structure that provides flexibility in responding to market factors; rewards and recognizes superior performance; attracts highly
	skilled, experienced and capable employees; and is fair and fiscally responsible.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Compensation Committee has designed and
	implemented compensation programs for Named Executive Officers to reward them for sustaining our financial and operating performance and leadership excellence, to align their interests with those of our stockholders and to encourage them to remain
	with us for long and productive careers. Because bonus and equity compensation play a key role in aligning our executives&#146; interests with our stockholders&#146; interests, annual incentives and equity incentives constitute an essential portion
	of the Named Executive Officer compensation. However, most of our compensation elements simultaneously fulfill one or more performance, alignment and/or retention objectives.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Base salary and annual bonus are designed to reward annual achievements and be commensurate with the executive&#146;s scope of responsibilities, demonstrated leadership abilities, and management
	experience and effectiveness. Our other elements of compensation focus on motivating and challenging the executive to achieve superior, longer-term, sustained results.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	61
</FONT>
</P>
<A NAME="eolPage64"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In establishing compensation for the Named Executive Officers, the following are the
	Compensation Committee&#146;s objectives:
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Attract, retain, reward and motivate high performing executive talent;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Ensure senior officer compensation is aligned with our corporate strategies, business objectives and the long-term interests of our stockholders;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Increase the incentive to achieve key strategic, financial and operational performance measures by linking incentive award opportunities to the
	achievement of performance goals in these areas;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Ensure that the elements of compensation, individually and in the aggregate, do not encourage excessive risk-taking; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Enhance the officers&#146; incentive to increase the Company&#146;s long term value, as well as promote retention of key people, by providing a portion
	of total compensation opportunities for senior management in the form of direct ownership in the Company through stock ownership.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Compensation Committee reviews all components of the Named Executive Officers&#146; compensation, including annual base salary, bonuses based on corporate and individual performance, and equity
	compensation, perquisites and termination-based compensation. For equity incentive compensation, which includes grants of RSUs and stock options, the Compensation Committee reviews accumulated realized and unrealized stock options and RSU gains. The
	Compensation Committee also reviews the dollar value to the executive and cost to the Company of all perquisites, as well as the actual and projected payout obligations under several potential severance and change in control scenarios. In addition,
	from time to time, the Compensation Committee may hire compensation and benefits consultants to assist in developing and reviewing overall executive compensation strategies. The Compensation Committee also receives input from the Chief Executive
	Officer regarding the compensation of all executives other than the Chief Executive Officer.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On June 6, 2011, we held a
	stockholder advisory vote on the compensation of our named executive officers, commonly referred to as a say-on-pay vote. Our stockholders approved the compensation of our named executive officers. As we evaluated our compensation practices and
	talent needs, we were mindful of the strong support our stockholders expressed for our philosophy of linking compensation to our operating objectives and the enhancement of stockholder value. As a result, our compensation committee decided to retain
	our general approach to executive compensation.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Compensation Components
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our executive compensation program is designed to attract executives with the requisite skills necessary to support our strategic
	objectives, to reward executives for the achievement of near-term and long-term objectives, and to retain executives by aligning compensation with the longer-term creation of stockholder value, by developing a sustainable business with consistent
	performance.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our compensation program is comprised of the following components for the Named Executive Officers:
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Base Salaries;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Annual Incentive Bonus;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Equity Incentives;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Employment Agreements providing for severance and change in control benefits; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Certain perquisites as well as 401(k) plan, health and welfare plan benefits.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Compensation Committee believes that these elements of compensation, when combined, are effective, and will continue to be effective,
	in achieving the overall objectives of our compensation program.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	62
</FONT>
</P>
<A NAME="eolPage65"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Base Salaries.
</I>
	Executive salaries are determined based on the data from our
	comparator group, on evaluation of each officer&#146;s individual performance throughout the year, level of responsibility, overall salary structure, budget guidelines and assessment of our financial condition. This approach ensures that our cost
	structure will allow us to remain competitive in the markets. Salaries paid to the Named Executive Officers in fiscal 2012 were within the targeted range. The Compensation Committee normally reviews and adjusts as appropriate the base salaries for
	the Named Executive Officers in the first half of each calendar year. For fiscal year 2012,
<B>
	no adjustment of base salary
</B>
	was made to our existing Named Executive Officers.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Annual Bonuses.
</I>
	Consistent with our objectives to tie a significant portion of the Named Executive Officers&#146; total
	compensation to our performance, all Named Executive Officers have a target bonus of a fixed percentage of their salary. At the beginning of each fiscal year, the Compensation Committee establishes performance measures and goals, which typically
	include milestones and targets. The Compensation Committee typically assigns a weight value based upon the overall goals in order to ensure a balanced approach to the various factors applied to determining bonus amounts. For fiscal year 2012, these
	goals, milestones and targets focused primarily on the following:
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Continued commercialization of OVA1 and increasing test volume;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Advancing our pipeline;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Broadening reimbursement coverage for OVA1; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Cash usage and maintaining a strong cash position;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Also, at the beginning of each fiscal year, the Compensation Committee establishes bonus payout targets for each Named Executive Officer. The Compensation Committee generally establishes the individual
	payout targets for each Named Executive Officer based on the executive&#146;s position, level of responsibility and a review of the compensation information of other companies. For 2012, the payout targets for each Named Executive Officer were as
	follows:
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_8"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="40%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD WIDTH="57%">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Gail S. Page
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	50% of annual base salary
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Bruce A. Huebner
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$50,000 annually
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Donald G. Munroe, Ph.D.
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	40% of annual base salary
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	William Creech
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	40% of annual base salary
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	After the close of each fiscal year, or other such timeframe as determined by the Compensation Committee,
	the Compensation Committee assesses the performance of each Named Executive Officer against the pre-established metrics. Each Named Executive Officer receives a bonus based on his or her individual payout target and our performance relative to the
	specific performance goal.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In its evaluation of performance for fiscal year 2012, the Compensation Committee considered the
	following goals, milestones and targets:(i) Continued commercialization of OVA1 and increasing test volume; (ii) Advancing our pipeline; (iii) Broadening reimbursement coverage for OVA1; and (iv) Cash usage and maintaining a strong cash position. As
	a result of this evaluation, the Compensation Committee determined that the targets for the fiscal year 2012 had partially been met and further, as a cost saving measure and to preserve cash, the Compensation Committee decided that it was in the
	best interest of the Company to pay actual bonus payouts of approximately 53% of the aggregate bonus target amount for the Named Executive Officers listed below. This resulted in the following payouts to each Named Executive Officer employed by us
	during such period:
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="51%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD WIDTH="46%">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Donald G. Munroe, Ph.D.
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$65,760
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	William Creech
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$34,263
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	63
</FONT>
</P>
<A NAME="eolPage66"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Ms. Page was terminated in 2012 and as such was not entitled to any bonus payments for 2012.
	Mr.&nbsp;Huebner was named Interim Chief Executive Officer on November 26, 2012 with an annual bonus package of $50,000. Thus, he was not paid a bonus for 2012.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Equity Incentive Compensation.
</I>
	The equity component of our executive compensation program is designed to fulfill our performance alignment and retention objectives. We previously maintained the
	Vermillion, Inc. 2000 Stock Plan (the &#147;2000 Stock Plan&#148;), which expired in 2010. We will make future equity awards under the 2010 Plan, which was approved by the Board of Directors on February 8, 2010 and by the stockholders on December 3,
	2010. The 2010 Plan will be administered by the Compensation Committee of the Board. Our employees, directors, and consultants are eligible to receive awards under the 2010 Plan. The 2010 Plan permits the granting of a variety of awards, including
	stock options, share appreciation rights, restricted shares, restricted share units, unrestricted shares, deferred share units, performance and cash-settled awards, and dividend equivalent rights. The 2010 Plan provides for issuance of up to
	1,322,983 shares of common stock, subject to adjustment as provided in the 2010 Plan.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The 2010 Plan generally authorizes us
	to make awards reserving the following recourse against a participant who does not comply with certain employment-related covenants, either during employment or for certain periods after ceasing to be employed: we may terminate any outstanding,
	unexercised, unexpired, unpaid, or deferred awards; rescind any exercise, payment or delivery pursuant to the award; or recapture any shares (whether restricted or unrestricted) or proceeds from the participant&#146;s sale of shares issued pursuant
	to the award. These remedies are also generally available to us for awards that would have had a lower grant level, vesting, or payment if a participant&#146;s fraud or misconduct had not caused or partially caused the need for a material financial
	restatement by us or any affiliate. In addition, all awards or proceeds from the sale of awards made or earned pursuant to the 2010 Plan will be subject to the right of us to full recovery (with reasonable interest thereon) in the event that the
	Board of Directors determines reasonably and in good faith that any participant&#146;s fraud or misconduct has caused or partially caused the need for a material restatement of our financial statements for any fiscal year to which the award relates.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In general, the Named Executive Officers receive incentive stock option grants at the time of hire; annually thereafter, they
	receive additional stock option grants or RSUs, as recommended by the Compensation Committee. Stock option grants and RSUs are based on individual performance and contributions toward the achievement of our business objectives, as well as overall
	Company performance. The number of underlying shares that may be purchased pursuant to the stock options granted to each Named Executive Officer varies based on the executive&#146;s position and responsibilities. In addition, amounts are determined
	by comparing the level of equity-based compensation that is awarded to executives of competing companies.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The grants of
	stock-based awards to Named Executive Officers during the year ended December 31, 2012 were as follows:
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_9"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="40%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="23%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="22%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Name
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Restricted&nbsp;Stock&nbsp;Awards:
<BR>
	Number of Shares of
<BR>
	Stock&nbsp;or&nbsp;Units
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	All&nbsp;Other&nbsp;Option&nbsp;Awards:
<BR>
	Number&nbsp;of&nbsp;Securities
<BR>
	Underlying&nbsp;
	Options
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Gail S. Page
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	150,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Bruce A. Huebner
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	34,000
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(1)
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	100,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Donald G. Munroe, Ph.D.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	35,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	William Creech
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	75,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="LINE-HEIGHT:8PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:2PX;BORDER-BOTTOM:0.5PT SOLID #000000;WIDTH:10%">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(1)
</SUP>
	&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Mr. Huebner was a member of our Board of Directors during all of 2012 and was appointed our Interim Chief Executive Officer on November 26, 2012. The
	restricted stock grant represented Mr. Huebner&#146;s sole compensation as a Board member during 2012.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On
	March 22, 2012, the Compensation Committee granted stock options in lieu of RSUs to executive officers. Certain of such stock options granted to executive officers are subject to a vesting schedule of equal
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	64
</FONT>
</P>
<A NAME="eolPage67"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	vesting over the next 36 months, starting from March 22, 2012. The rest of such options granted to executive officers are subject to a vesting schedule of 100% vesting on March 31, 2013. In
	addition, the Compensation Committee granted stock options to the interim Chief Executive Officer on November 26, 2012 which are subject to monthly vesting over a one-year period. Such option awards were granted to executive officers as an incentive
	to create long-term stockholder value and as a retention tool.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Employee Benefits Programs.
</I>
	Our employee benefits
	program primarily consists of two components: (1) severance and change in control arrangements and (2) perquisites and other benefits.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	Severance and Change in Control Arrangements
</U>
	. The Compensation Committee believes that executive officers have a greater risk of job loss or modification as a result of a change in control
	transaction than other employees. Accordingly, our employment agreement with Ms. Page as Chief Executive Officer included change of control provisions, and we have also entered into change in control agreements with our Chief Accounting Officer,
	Senior Vice President of Business Development and Chief Scientific Officer and Vice President of Sales and Marketing under which they will receive certain payments and benefits upon qualifying terminations that follow a change in control. Our
	employment agreement with Mr. Huebner as Interim Chief Executive Officer does not contain change of control provisions other than the acceleration of vesting of his stock option grant. The principal purpose of the change in control agreements is to
	provide executive officers with appropriate incentives to remain with us before, during and after any change in control transaction by providing the executive officers with security in the event their employment is terminated or materially changed
	following a change in control. By providing this type of security, the change in control agreements help ensure that the executive officers support any potential change in control transaction that may be in the best interests of our stockholders,
	even while the transaction may create uncertainty in the executive officer&#146;s personal employment situation. The Compensation Committee believes that the payment of salary and benefits for one year for Ms. Page as Chief Executive Officer and
	nine months for the Chief Accounting Officer, Senior Vice President of Business Development and Chief Scientific Officer and Vice President of Sales and Marketing is reasonable and appropriate to achieve the desired objectives of the agreements.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	Perquisites and Other Benefits
</U>
	. Our Named Executive Officers participate in our standard employee benefits programs
	including medical, dental, life, short-term and long-term disability insurance, 401(k) Plan and flexible spending accounts.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Method for Determining Compensation Amounts
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In deciding on the type and amount of compensation for each executive, the Compensation Committee seeks to align the interests of the Named Executive Officers with those of our stockholders. In making
	compensation decisions, the Compensation Committee reviews the performance of the company and carefully evaluates an executive&#146;s performance during the year against established goals, leadership qualities, operational performance, business
	responsibilities, career with the company, current compensation arrangements and long-term potential to enhance shareowner value. The types and relative importance of specific financial and other business objectives vary among our Named Executive
	Officers depending on their positions and the particular operations or functions for which they are responsible. The Compensation Committee does not adhere to rigid formulas when determining the amount and mix of compensation elements. Compensation
	elements for each executive are reviewed in a manner that optimizes the executive&#146;s contribution to the Company, and reflects an evaluation of the compensation paid by our competitors.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Compensation Committee reviews both current pay and the opportunity for future compensation to achieve an appropriate mix between
	equity incentive awards and cash payments in order to meet our objectives. However, prior stock compensation gains are not considered in setting future compensation levels. The mix of compensation elements is designed to reward recent results and
	motivate long-term performance through a combination of cash and equity incentive awards.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	65
</FONT>
</P>
<A NAME="eolPage68"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Compensation Committee has primary responsibility for assisting the Board of Directors
	in developing and evaluating potential candidates for executive positions, including the Chief Executive Officer, or CEO. As part of this responsibility, the Committee oversees the design, development and implementation of the compensation program
	for the CEO and the other Named Executive Officers. The Compensation Committee evaluates the performance of the CEO and determines CEO compensation in light of the goals and objectives of the compensation program. The CEO and the Compensation
	Committee assess the performance of the other Named Executive Officers and determine their compensation, based on initial recommendations from the CEO.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Compensation Committee approves stock option grants for Named Executive Officers at the time of hire, and thereafter, the Compensation Committee annually reviews and approves stock option or RSU
	grants. Stock option and RSU grants are based on individual performance and contributions toward the achievement of our business objectives, as well as overall Company performance. Amounts are determined by comparing the level of equity-based
	compensation awarded to executives of competing companies, along with consideration for attracting, retaining and motivating the executive officers. The stock option and RSU grants made under the 2010 Plan have provisions allowing us to recoup
	awards if we are required to restate corporate financial statements.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Compensation Policies and Practices Regarding Risk
	Management
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In fulfilling its role in assisting the Board in its risk oversight responsibilities, the Compensation
	Committee believes that our compensation policies and practices do not motivate imprudent risk taking. Specifically, the Compensation Committee reviewed the following features of our compensation programs that guard against excessive risk-taking:
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	our annual incentive compensation is based on balanced performance metrics that promote disciplined progress towards longer-term Company goals;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	we do not offer significant short-term incentives that might drive high-risk investments at the expense of long-term Company value; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	our compensation awards are capped at reasonable and sustainable levels, as determined by a review of the economic position and prospects, as well as
	the compensation offered by comparable companies.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Tax and Accounting Considerations
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Section 162(m) of the Internal Revenue Code (the &#147;Code&#148;) disallows a tax deduction to publicly-held companies for certain
	compensation in excess of $1,000,000 paid to our chief executive officer and three other officers (other than the chief financial officer) whose compensation is required to be reported to our stockholders pursuant to the Exchange Act. Certain
	performance-based compensation approved by our stockholders, including option grants under the 2010 Plan, generally is not subject to the deduction limit. It is the Compensation Committee&#146;s policy to maximize the effectiveness of our executive
	compensation in this regard.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have granted stock options as incentive stock options in accordance with Section 422 of the
	Code subject to the volume limitations contained in the Code. Generally, the exercise of an incentive stock option does not trigger any recognition of income or gain to the holder. If the stock is held until at least one year after the date of
	exercise (or two years from the date the option is granted, whichever is later), all of the gain on the sale of the stock, when recognized for income tax purposes, will be capital gain, rather than ordinary income, to the recipient. Consequently, we
	do not receive a tax deduction. For stock options that do not qualify as incentive stock options, we are entitled to a tax deduction in the year in which the stock options are exercised equal to the spread between the exercise price and the fair
	market value of the stock for which the stock option was exercised. The holders of the non-qualified stock options are generally taxed on this same amount in the year of exercise.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	66
</FONT>
</P>
<A NAME="eolPage69"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Named Executive Officer Compensation
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	President and Chief Executive Officer
</I>
	. On December 31, 2005, we entered into an employment agreement with Ms. Page as our President
	and Chief Executive Officer. Under the terms of her original employment agreement, Ms. Page had an initial base salary of $350,000, as adjusted by the Board of Directors from time to time; was eligible for a bonus of up to 50% of her base salary
	that is based on the achievement of reasonable performance-related goals as determined by the Board of Directors; had an initial option grant to purchase 40,000 shares of our common stock at $9.00 per share; and had an annual car allowance of
	$10,000. On November 18, 2008, Ms. Page&#146;s employment agreement was amended and restated to reflect an annual base salary of $364,000 and to comply with (or be exempted from) the applicable requirements of Section 409A of the Code. Ms.
	Page&#146;s employment with us was for an unspecified duration and constituted &#147;at-will&#148; employment. At the option of either Ms. Page or us, with or without notice, the employment relationship may be terminated at any time, with or without
	cause (as defined in the employment agreement) or for any or no cause. If we terminate Ms. Page&#146;s employment for reasons other than for cause, or if Ms. Page terminates her employment for good reason (as defined in the employment agreement),
	Ms. Page, upon executing a release of claims in favor of us will be entitled to receive (i) continued payment of base salary for a period of 12 months, (ii) immediate vesting of 24-months of any options previously granted by us in addition to a
	24-month period after termination to exercise any or all of her vested options to purchase our common stock; and (iii) continued health and dental benefits paid by us until the earlier of 12 months after termination or the time that Ms. Page obtains
	employment with reasonably comparable or better health and dental benefits. Additionally, if Ms. Page&#146;s employment is terminated by us for reasons other than for cause or by her for good reason within the 12-month period following a change in
	control (as defined in the employment agreement), Ms. Page will receive (i) continued payment of base salary for a period of 12 months, (ii) immediate 100% vesting of any then unvested options previously granted by us in addition to a period after
	termination at the discretion of us to exercise any or all of her vested options to purchase our common stock; and (iii) continued health and dental benefits paid by us until the earlier of 12 months after termination or the time that Ms. Page
	obtains employment with reasonably comparable or better health and dental benefits. Ms. Page&#146;s employment agreement also contains a &#147;non-solicitation&#148; clause, which provides that, in the event that Ms. Page&#146;s employment is
	terminated, she is prohibited from directly or indirectly soliciting or encouraging any employee or contractor of us or our affiliates to terminate employment with or cease providing services to us or our affiliates; and prohibited from soliciting
	or interfering with any person engaged by us as a collaborator, partner, licensor, licensee, vendor, supplier, customer or client to our detriment. On September 28, 2010, Ms. Page&#146;s employment agreement was further amended and restated to
	increase her annual base salary from $364,000 to $385,000.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On May 15, 2012, we announced the mutually agreed termination
	without cause of Ms. Page as our President and Chief Executive Officer, which was effective as of December 2, 2012, after we entered into an employment agreement with a successor Chief Executive Officer. Due to her mutually agreed termination
	without cause, pursuant to the terms of her employment agreement and a separation agreement, Ms. Page received (i) a payment equivalent to 12 months of base salary, (ii) upon the effective date of termination, immediate vesting of 24-months of any
	options and RSUs previously granted by us in addition to a 24-month period after termination to exercise any or all of her vested options to purchase our common stock; and (iii) continued health and dental benefits paid by us until the earlier of 12
	months after the effective date of termination or the time that Ms. Page obtains employment with reasonably comparable or better health and dental benefits.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Interim President and Chief Executive Officer
</I>
	. On November 26, 2012, we entered into an employment agreement with Mr. Huebner as our Interim President and Chief Executive officer. Pursuant to the
	terms of the employment agreement, we will pay Mr. Huebner an annual base salary of $252,000. We will also pay Mr.&nbsp;Huebner a bonus of $50,000 upon completion of his employment term, which term shall be from November&nbsp;26, 2012 through the
	earlier of (i) November 26, 2013, (ii) the Company&#146;s hiring of a permanent Chief Executive Officer, or (iii) such other date as determined by the Board. On November 26, 2012, the Board granted Mr.&nbsp;Huebner an option to purchase 100,000
	shares of the Company&#146;s common stock. The shares subject to the
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	67
</FONT>
</P>
<A NAME="eolPage70"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	option will vest monthly over a twelve (12) month period, provided that 100% of the shares subject to the option will vest immediately upon a change in control of the Company or the
	Company&#146;s hiring of a permanent chief executive officer, subject in each case to his continuing employment with the Company. Mr. Huebner will also be eligible for performance-based stock option grants based on achieving milestones approved by
	the Board.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Chief Scientific Officer and Vice President of Research and Development (former); Senior Vice President of
	Business Development and Chief Scientific Officer (effective March 1, 2013).
</I>
	On September 23, 2011, we entered into an employment agreement with Donald G. Munroe, Ph.D., effective October 11, 2011. Pursuant to the terms of the employment
	agreement between the Company and Dr. Munroe, the Company will pay Dr. Munroe an annual base salary of $250,000. Dr. Munroe will be eligible for a bonus of up to 40% of his base salary for achievement of reasonable performance-related goals and
	milestones. In the event Dr. Munroe is terminated without cause or resigns for good reason (as these terms are defined in the employment agreement), he is entitled to receive: (i) continued payment of his base salary as then in effect for a period
	of nine months following the date of termination; and (ii) continued health and dental benefits paid by the Company until the earlier of nine months after termination or the time that Dr. Munroe obtains employment with reasonably comparable or
	better health and dental benefits. Additionally, if Dr. Munroe&#146;s employment is terminated without cause or if he resigns for good reason within the 12-month period following a change of control (as the term is defined in the employment
	agreement), then, in addition to the severance obligations due to Dr. Munroe as described above, 50% of any then-unvested options previously granted by the Company will vest upon the date of such termination.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Vice President of Sales and Marketing.
</I>
	On April 4, 2012, we entered into an employment agreement with William Creech, effective
	April 4, 2012. Pursuant to the terms of the employment agreement between the Company and Mr. Creech, the Company will pay Mr. Creech an annual base salary of $225,000. Mr. Creech will be eligible for a bonus of up to 40% of his base salary for
	achievement of reasonable performance-related goals and milestones. In the event Mr. Creech is terminated without cause or resigns for good reason (as these terms are defined in the employment agreement), he is entitled to receive: (i) continued
	payment of his base salary as then in effect for a period of nine months following the date of termination; (ii) immediate vesting of 50% of any unvested options previously granted by the Company to him, in addition to a 24-month period after
	termination to exercise any and all of his vested options to purchase the Company&#146;s common stock; and (iii) continued health and dental benefits paid by the Company until the earlier of nine months after termination or the time that
	Mr.&nbsp;Creech obtains employment with reasonably comparable or better health and dental benefits. Additionally, if Mr. Creech&#146;s employment is terminated without cause or if he resigns for good reason within the 12-month period following a
	change of control (as the term is defined in the employment agreement), then, in addition to the severance obligations due to Mr. Creech as described above, 50% of any then-unvested options previously granted by the Company will vest upon the date
	of such termination.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	68
</FONT>
</P>
<A NAME="eolPage71"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_COMPENSATION_TABLE>
<A NAME="FIS_COMPENSATION_TABLE"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Compensation for the Named Executive Officers in 2012 and 2011
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The compensation earned by the Named Executive Officers for the years ended December 31, 2012 and 2011 was as follows:
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="40%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Name and Principal Position
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Year
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Salary
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Bonus
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Stock
<BR>
	Award
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(1)
</SUP>
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Option
<BR>
	Awards
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Non-Equity
<BR>
	Incentive
<BR>
	Plan
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(2)
</SUP>
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Nonqualified
<BR>
	Deferred
<BR>
	Compensation
<BR>
	Earnings
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	All
	Other
<BR>
	Compensation
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(9)
</SUP>
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Total
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	Gail S. Page
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	2012
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	352,917
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	258,884
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	168,837
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	$
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	508,855
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(4)
</SUP>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	1,289,493
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	President and Chief Executive Officer (former)
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	2011
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	385,000
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	1,085,946
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(3)
</SUP>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	76,726
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	57,750
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	22,281
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(4)
</SUP>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	1,627,703
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	Bruce A. Huebner
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	2012
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	25,846
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	67,660
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(5)
</SUP>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	7,869
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	4,800
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(6)
</SUP>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	106,175
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	Director and Interim Chief Executive Officer
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	2011
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	26,491
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(5)
</SUP>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	9,200
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(6)
</SUP>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	35,691
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	Donald G. Munroe, Ph.D.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	2012
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	250,000
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	61,802
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	65,760
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	572
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	378,134
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	Chief Scientific Officer and VP of Research and Development&nbsp;
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(10)
</SUP>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	2011
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	55,929
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	7,426
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	6,740
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	30,095
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(7)
</SUP>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	100,190
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	William Creech
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	2012
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	225,000
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	27,533
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	80,981
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	34,263
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	7,127
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(8)
</SUP>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	374,904
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	Vice President of Sales and Marketing
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	2011
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	214,236
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	21,686
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	56,705
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	27,000
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	7,400
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(8)
</SUP>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	327,027
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_COMPENSATION_TABLE>
<P STYLE="LINE-HEIGHT:8PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:2PX;BORDER-BOTTOM:0.5PT SOLID #000000;WIDTH:10%">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(1)
</SUP>
	&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Represents non-cash, equity-related compensation. More information regarding these awards is included the Compensation Discussion and Analysis as well
	as in Note 8 to our Annual Report on Form 10-K for the year ended December 31, 2012.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(2)
</SUP>
	&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Amount represents performance bonus for fiscal year 2012 and 2011.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(3)
</SUP>
	&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Includes non-cash, equity-related compensation determined as of the date of grant for restricted stock awards pursuant to the Debtor&#146;s Incentive
	Plan and included in the Company&#146;s financial statements for 2011. In 2011, includes $993,780 from Debtor&#146;s Incentive Plan and $92,166 for 2011 Restricted Stock Awards.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(4)
</SUP>
	&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In 2012, represents $385,000 severance payment, $51,825 PTO payout, $18,000 consulting fees, $17,100 post-employment benefit payments, tax gross-up on
	stock awards of $36,406 and $524 for insurance premiums. In 2011, represents tax gross-up payments on stock awards of $21,709 and $572 for insurance premiums.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(5)
</SUP>
	&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Represents Mr. Huebner&#146;s compensation as a member of our Board of Directors for 2012 (prior to his appointment as Chief Executive Officer on
	November 26, 2012) and 2011.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(6)
</SUP>
	&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Represents Mr. Huebner&#146;s consulting income prior to his appointment as Chief Executive Officer on November 26, 2012.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(7)
</SUP>
	&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Includes one-time payment of relocation assistance of $30,000.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(8)
</SUP>
	&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Includes Mr. Creech&#146;s car allowance of $6,600 in 2012 and $6,900 in 2011.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(9)
</SUP>
	&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	All Other Compensation also includes Company paid insurance premiums of less than $1,000.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(10)
</SUP>
	&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Effective March 1, 2013, Dr. Munroe was named our Senior Vice President of Business Development and Chief Scientific Officer.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	69
</FONT>
</P>
<A NAME="eolPage72"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The outstanding equity awards held by the Named Executive Officers as of December 31, 2012,
	were as follows:
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_10"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="38%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="18" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Option Awards
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="14" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Stock Awards
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:20PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Name
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Number of
<BR>
	Securities
<BR>
	Underlying
<BR>
	Unexercised
<BR>
	Options &#150;
<BR>
	Exercisable
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Number of
<BR>
	Securities
<BR>
	Underlying
<BR>
	Unexercised
<BR>
	Options &#150;
<BR>
	Unexercisable
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Equity
<BR>
	Incentive
<BR>
	Plan
<BR>
	Awards:
<BR>
	Number
	of
<BR>
	Securities
<BR>
	Underlying
<BR>
	Unearned
<BR>
	Options
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Option
<BR>
	Exercise
<BR>
	Price
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Option
<BR>
	Expiration
<BR>
	Date
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(1)
</SUP>
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Number
<BR>
	of
<BR>
	Shares
<BR>
	or Units
<BR>
	of Stock
<BR>
	that
<BR>
	have
<BR>
	not
<BR>
	Vested
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Market
<BR>
	Value of
<BR>
	Shares
<BR>
	or Units
<BR>
	of Stock
<BR>
	that
<BR>
	have not
<BR>
	Vested
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(2)
</SUP>
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Equity
<BR>
	Incentive
<BR>
	Plan
<BR>
	Awards:
<BR>
	Number
<BR>
	of
<BR>
	Unearned
<BR>
	Shares,
<BR>
	Units
	or
<BR>
	Other
<BR>
	Rights
<BR>
	that have
<BR>
	not
<BR>
	Vested
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Equity
<BR>
	Incentive
<BR>
	Plan
<BR>
	Awards:
<BR>
	Market
<BR>
	or Payout
<BR>
	Value of
<BR>
	Unearned
<BR>
	Shares,
<BR>
	Units
	or
<BR>
	Other
<BR>
	Rights
<BR>
	that have
<BR>
	not
<BR>
	Vested
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Gail S. Page
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	138,888
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.62
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12/2/2014
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	125,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2.30
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12/2/2014
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	35,999
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	14.70
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12/2/2014
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	25,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12.00
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12/2/2014
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	39,999
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	9.00
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12/2/2014
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12,500
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	21.90
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12/2/2014
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	9,999
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	29.60
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12/2/2014
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Bruce A. Huebner
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8,333
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	91,667
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.19
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11/25/2022
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Donald G. Munroe, Ph.D.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2,500
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	32,500
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.62
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3/21/2022
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	36,458
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	88,542
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.96
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11/7/2021
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	William Creech
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12,500
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	62,500
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.62
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3/21/2022
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8,334
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11,001
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	6,873
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3,127
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	28.65
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3/18/2020
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="LINE-HEIGHT:8PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:2PX;BORDER-BOTTOM:0.5PT SOLID #000000;WIDTH:10%">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(1)
</SUP>
	&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Stock options vest ratably on a monthly basis either over 12 or 36 month period, commencing on the date of the grant, or over four years as follows:
	25% of the shares vest one year following the vesting commencement date, with the remaining 75% vesting in equal monthly installments over the next three years. In addition, certain option grants cliff vest after a one year period from grant date.
	Each option expires 10 years after the date of the grant or, in the case of an incentive stock option, such shorter term as may be provided in the applicable agreement.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(2)
</SUP>
	&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The fair value of our common stock as of December 31, 2012 was $1.32 per share.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	70
</FONT>
</P>
<A NAME="eolPage73"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_11"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Potential Payments Upon Termination
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	A severance payment of $385,000 and benefits totaling $17,100 became payable to Gail S. Page upon her termination in December 2012.The
	following table set forth amounts payable to the other Named Executive Officers should an officer be terminated as of December 31, 2012:
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="45%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD WIDTH="16%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:20PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Name
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Termination&nbsp;Scenario
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Continued
<BR>
	Payment
<BR>
	of Base
<BR>
	Salary
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Non-Equity
<BR>
	Incentive
<BR>
	Payout
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Immediate
<BR>
	Vesting of
<BR>
	Stock
<BR>
	Options
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(3)
</SUP>
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Health
<BR>
	and
<BR>
	Dental
<BR>
	Insurance
<BR>
	Benefits
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(4)
</SUP>
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Bruce A. Huebner
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(5)
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Termination
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(1)
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	50,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11,917
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Within 12 Months After Change-in
	Control
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(2)
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	50,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11,917
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	For cause
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Donald G. Munroe, Ph.D.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Termination
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(1)
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	187,500
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	20,005
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Within 12 Months After Change-in
	Control
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(2)
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	187,500
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	20,005
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	For cause
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	William Creech
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Termination
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(1)
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	168,750
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	13,905
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Within 12 Months After Change-in
	Control
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(2)
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	168,750
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	13,905
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	For cause
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="LINE-HEIGHT:8PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:2PX;BORDER-BOTTOM:0.5PT SOLID #000000;WIDTH:10%">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(1)
</SUP>
	&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Termination includes the following separation scenarios: involuntary termination not for cause or resignation for good reason (in all cases, assuming
	the executive is not entering into competitive or other activity detrimental to us).
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(2)
</SUP>
	&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Termination of employment by us for reasons other than for cause or by Named Executive Officers for good reason within the 12-month period following a
	change in control (as defined in the respective employment agreements).
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(3)
</SUP>
	&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Assumes each Named Executive Officer exercised all vested, in-the-money options at $1.32 (the December&nbsp;31, 2012 closing price of our common
	stock). These amounts are in addition to the existing value of options vested at December 31, 2012.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(4)
</SUP>
	&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Assumes each Named Executive Officer does not obtain employment with reasonably comparable or better health and dental benefits within the time period
	specified in the respective employment agreements.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	71
</FONT>
</P>
<A NAME="eolPage74"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_COMPENSATION>
<EFX_SECURITY_OWNERS>
<A NAME="FIS_SECURITY_OWNERS"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_TOC453081_20">
</A>
	ITEM&nbsp;12.
</B>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	See the description regarding our equity compensation plans contained in Item 5 of this Form 10-K and in the notes to our financial
	statements, attached hereto.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Security Ownership of Certain Beneficial Owners and Management
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The following table sets forth certain information known to us regarding beneficial ownership of our common stock as of December 31, 2012,
	by (1) each person known by us to be the beneficial owner of five percent or more of the outstanding shares of the common stock, (2) each director as of December 31, 2012, (3) each Named Executive Officer as of December 31, 2012, and (4) all
	directors and executive officers as of December 31, 2012 as a group. All shares are subject to the named person&#146;s sole voting and investment power except where otherwise indicated. Unless otherwise noted below, the address of each beneficial
	owner listed in the table is c/o Vermillion, Inc., 12117 Bee Caves Road, Building Three, Suite 100, Austin, TX 78738.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Beneficial ownership is determined in accordance with Rule 13d-3(d)(1) under the Exchange Act. Shares of common stock, which are issued
	and outstanding, are deemed to be beneficially owned by any person who has or shares voting or investment power with respect to such shares. Shares of common stock which are issuable upon exercise of options or warrants are deemed to be issued and
	outstanding and beneficially owned by any person who has or shares voting or investment power over such shares only if the options or warrants in question are exercisable within 60 days of December 31, 2012, and, in any event, solely for purposes of
	calculating that person&#146;s percentage ownership of the common stock (and not for purposes of calculating the percentage ownership of any other person).
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The number of shares of common stock deemed outstanding and used in the denominator for determining percentage ownership for each person equals (i) 15,200,079 shares of common stock outstanding as of
	December&nbsp;31, 2012, plus (ii) such number of shares of common stock as are issuable pursuant to RSUs, options, warrants or convertible securities held by that person (and excluding RSUs, options, warrants and convertible securities held by other
	persons) which may be exercised within 60 days of December 31, 2012.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_BENEFICIAL_OWNERS>
<A NAME="FIS_BENEFICIAL_OWNERS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="80%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:134PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Name and Address of Beneficial Owner
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Number of
<BR>
	Common
<BR>
	Stock
<BR>
	Shares
<BR>
	Beneficially
<BR>
	Owned
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Percentage
<BR>
	of
<BR>
	Outstanding
<BR>
	Shares
<BR>
	Beneficially
<BR>
	Owned
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Beneficial Owners more than 5%:
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Quest Diagnostics Incorporated
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(1)
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:4.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1290 Wall Street West
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	860,595
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5.66
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:4.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Lyndhurst, NJ 07071
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Directors and Named Executive Officers:
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	James S. Burns
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(2)
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	164,108
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.08
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	John F. Hamilton
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(3)
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	148,708
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	*
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Bruce A. Huebner
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(4)
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	99,426
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	*
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Peter S. Roddy
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	69,700
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	*
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Carl Severinghaus
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	67,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	*
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Roberta L. Della Vedova (Nominee)
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	*
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	William C. Wallen, Ph.D.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	79,200
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	*
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Gail S. Page
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(5)
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(Former President and Chief Executive Officer)
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	612,292
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3.93
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Donald G. Munroe, Ph.D.
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(6)
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	44,721
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	*
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	William Creech
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(7)
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	44,313
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	*
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	All Directors and Executive Officers as a Group
</B>
	(11 persons)
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(8)
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
</B>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
</B>
	1,378,401
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
</B>
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8.74
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_BENEFICIAL_OWNERS>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	72
</FONT>
</P>
<A NAME="eolPage75"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="LINE-HEIGHT:8PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:2PX;BORDER-BOTTOM:0.5PT SOLID #000000;WIDTH:10%">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;*
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Less than 1%.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(1)
</SUP>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Quest Diagnostics
	Incorporated is a publicly-held company. Quest Diagnostics Incorporated&#146;s executive officers are responsible for running the business of the company and thus, exercise voting and investment control over the shares owned by Quest Diagnostics
	Incorporated.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(2)
</SUP>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Includes 40,400
	shares issuable upon exercise of options exercisable within 60 days of December 31, 2012.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(3)
</SUP>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Includes 30,000
	shares issuable upon exercise of options exercisable within 60 days of December 31, 2012.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(4)
</SUP>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Includes 24,999
	shares issuable upon exercise of options exercisable within 60 days of December 31, 2012.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(5)
</SUP>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Includes 387,385
	shares issuable upon exercise of options exercisable within 60 days of December 31, 2012.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(6)
</SUP>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Dr. Munroe is our
	Chief Scientific Officer and Vice President of Research and Development. Effective March 1, 2013, Dr. Munroe was named our Senior Vice President of Business Development and Chief Scientific Officer. Amount represents shares issuable upon exercise of
	options exercisable within 60 days of December 31, 2012.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(7)
</SUP>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Includes 24,232
	shares issuable upon exercise of options exercisable within 60 days of December 31, 2012.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(8)
</SUP>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The group includes
	James S. Burns, John F. Hamilton, Bruce A. Huebner, Gail S. Page, Peter S. Roddy, Carl Severinghaus, Roberta L. Della Vedova, William C. Wallen, Ph.D., Eric J. Schoen, Donald G. Munroe and William Creech.
</FONT>
</P>
</TD>
</TR>
</TABLE>
</EFX_SECURITY_OWNERS>
<P STYLE="FONT-SIZE:18PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_OFFICER_TRANSACTIONS>
<A NAME="FIS_OFFICER_TRANSACTIONS"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_TOC453081_21">
</A>
	ITEM&nbsp;13.
</B>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Transactions with Related Persons
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	For the years ended December 31, 2012,
	we did not engage in nor are we currently proposed to engage in any transaction or series of similar transactions to which we were or are to be a party in which the amount involved exceeds $120,000 and in which any director, executive officer,
	holder of more than 5% of our common stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest other than (1) compensation agreements and other arrangements, which are
	described in &#147;Executive Compensation,&#148; and (2) the transactions described below.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Relationship with Quest Diagnostics
	Incorporated
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Quest Diagnostics Incorporated (&#147;Quest Diagnostics&#148;) is a significant stockholder of Vermillion. On
	July&nbsp;22, 2005, we entered into a strategic alliance agreement (the &#147;Strategic Alliance Agreement&#148;) with Quest Diagnostics to develop and commercialize up to three diagnostic tests from our product pipeline (the &#147;Strategic
	Alliance&#148;). The Strategic Alliance Agreement was amended to expire on the earlier of (i) October 7, 2012 and (ii) the date on which Quest Diagnostics made its third development election. Quest Diagnostics has selected two diagnostic tests to
	commercialize, a peripheral arterial disease blood test and OVA1, prior to the October 7, 2012 expiration of the Strategic Alliance. Pursuant to the Amended Strategic Alliance Agreement, Quest Diagnostics will have the non-exclusive right to
	commercialize each of these tests on a worldwide basis, with exclusive commercialization rights in the clinical reference lab marketplace in each restricted territory, as the term is defined in the Amended Strategic Alliance Agreement, beginning on
	the date each test is first commercialized and ending on the third anniversary of the date that such test is cleared or approved by the United States Food and Drug Administration (&#147;FDA&#148;). As part of the Strategic Alliance, there is a
	royalty arrangement under which Quest Diagnostics will pay royalties to us based on fees earned by Quest Diagnostics for applicable diagnostic services, and we will pay royalties to Quest Diagnostics based on our revenue from applicable diagnostic
	products. On November 10, 2010, we entered into Amendment No. 4 to the Strategic Alliance Agreement with Quest Diagnostics. Pursuant to this Amendment, Quest Diagnostics will have the exclusive right to commercialize OVA1 for up to three additional
	years from the period as specified in the Strategic Alliance
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	73
</FONT>
</P>
<A NAME="eolPage76"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Agreement. The Amendment also establishes royalties, fees, and other payments related to the performance of OVA1. Quest Diagnostics will pay us a fixed payment of $50 for each domestic OVA1
	performed, as well as 33% of its &#147;gross margin,&#148; as the term is defined in the Amendment.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Directors and Executive Officers
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On June 17, 2011, we entered into a consulting agreement with Bruce A. Huebner, a member of our Board of Directors.
	Pursuant to the terms of the consulting agreement, Mr. Huebner provided consulting services regarding sales, marketing, business development and corporate strategy and was paid $200 per hour. For the year ended December 31, 2012 and 2011, the total
	amount of consulting fee expense for Mr. Huebner was $5,000 and $9,000, respectively. On November 27, 2012, we announced the appointment of Mr. Huebner as Interim Chief Executive Officer. Mr. Huebner continues to serve on our Board of Directors.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On December 3, 2012, we entered into a consulting agreement with our former President and Chief Executive Officer and
	director, Gail S. Page. Pursuant to the terms of the consulting agreement, Ms. Page will assist the Company as needed, including providing advice and recommendations with respect to the development and commercialization of the Company&#146;s
	existing and future diagnostic tests, and managing and developing relationships with existing and future collaborators and partners. She will provide a minimum of 48 and a maximum of 96 hours of consulting services per month. In consideration for
	such services, we will pay Ms. Page a monthly fee of $18,000, plus $250 for each hour of services provided in excess of the 48 hour minimum. The Consulting Agreement has an initial term of six months, after which it may be renewed for an additional
	six month term by mutual agreement of the Company and Ms. Page. For the year ended December 31, 2012, the total amount of consulting fee expense to Ms. Page was $18,000. The consulting agreement has been terminated with an effective date of March
	15, 2013.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In November 2011, we entered into a consulting agreement with our former Senior Vice President and Chief Science
	Officer, Eric T. Fung, M.D., Ph.D.. Pursuant to the terms of the consulting agreement, Dr. Fung served as our Chief Medical Officer and a member of our Scientific Advisory Board. Dr. Fung&#146;s consulting agreement and Scientific Advisory Board
	services were terminated in June 2012. For the year ended December 31, 2012 and 2011, the total amount of consulting fee expense for Dr. Fung was $27,000 and $6,000, respectively. During 2012, Dr. Fung also continued to vest in restricted stock with
	a fair value of $11,000 until the termination of the consulting agreement.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On March 1, 2012, we entered into a consulting
	agreement with our former Vice President of Strategy, who resigned effective February 29, 2012. Pursuant to the terms of the consulting agreement, our former Vice President of Strategy provided consulting services. This consulting agreement was
	terminated in June 2012. For the year ended December 31, 2012, the total amount of consulting fee expense to our former Vice President of Strategy was $23,000 and the fair value of continued vesting in restricted stock was $1,000 until the
	termination of the consulting agreement.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have entered into indemnification agreements with each of our directors and
	executive officers, which require us to indemnify our directors and officers to the fullest extent permitted by law in the State of Delaware.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Review and Approval of Transactions with Related Persons
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our written corporate governance guidelines require all members of the Board of Directors to inform the Audit Committee of the Board of Directors of all types of transactions between themselves (directly
	or indirectly) and the Company, prior to their conclusion, even if such transactions are in the ordinary course of business. The Audit Committee reviews and approves all related party transactions for which Audit Committee approval is required by
	NASDAQ Listing Rules and other applicable laws. The guidelines also provide that the Board of Directors should ensure that there is no abuse of corporate assets or unlawful related party transactions. Our corporate governance guidelines are posted
	under the Investor Relations section of our website at
<U>
	http://www.vermillion.com
</U>
	.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	74
</FONT>
</P>
<A NAME="eolPage77"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Independence of the Board of Directors and Nominee
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	After a review of all relevant transactions or relationships between each director and our recommended nominee for election, or any of his
	family members, on the one hand, and the Company, our senior management and its independent registered public accounting firm, on the other hand, the Board has affirmatively determined that our recommended nominee for election, and all of our
	directors other than Mr. Huebner (by virtue of his recent appointment as our Interim Chief Executive Officer) are, or, in the case of our recommended nominee, would be if elected, independent directors, as the term is currently defined under NASDAQ
	Listing Rule 5605(a)(2).
</FONT>
</P>
</EFX_OFFICER_TRANSACTIONS>
<P STYLE="FONT-SIZE:18PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_ACCOUNTANT_FEES>
<A NAME="FIS_ACCOUNTANT_FEES"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_TOC453081_22">
</A>
	ITEM&nbsp;14.
</B>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	PRINCIPAL ACCOUNTANT FEES AND SERVICES
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Audit Fees and Non-Audit Fees
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On April 4, 2012, the Audit Committee of the Board selected BDO USA, LLP to serve as our independent registered public accounting firm. BDO USA, LLP has represented to us that it is independent with
	respect to the Company within the meaning of the published rules and regulations of the SEC. Prior to April 4, 2012, PricewaterhouseCoopers LLP served as our independent registered public accounting firm.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The following is a summary of the fees and services provided by BDO USA, LLP for fiscal year 2012 and PricewaterhouseCoopers LLP for
	fiscal year 2011.
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_12"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="75%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2012
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2011
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Audit fees
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	146,412
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	298,786
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Audit-related fees
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Tax fees
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	31,952
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(2)
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	All other fees
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(1) (3)
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	15,107
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	25,971
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	193,471
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	324,757
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="LINE-HEIGHT:8PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:2PX;BORDER-BOTTOM:0.5PT SOLID #000000;WIDTH:10%">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(1)
</SUP>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Includes $12,497
	of fees paid in 2012 for preparation of the 2011 income tax provision and services provided prior to BDO USA, LLP being named our independent registered public accounting firm.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(2)
</SUP>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Represents $23,012
	in fees for the preparation of our 2011 federal and state tax returns and $8,940 for a loss limitation study under IRC Section 382 as of December 31, 2011.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(3)
</SUP>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	All other fees in
	2012 included $2,610 for consulting services regarding the liquidation of our Japanese subsidiary. All other fees in 2011 related to the review of our secondary offering filing on Form S-1 and miscellaneous other expenses.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Audit Committee Pre-Approval of Policies and Procedures
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Audit Committee is responsible for appointing, compensating and overseeing the work of the independent registered public accounting
	firm. The Audit Committee has established a pre-approval procedure for all audit and permissible non-audit services to be performed by our independent registered public accounting firm. The pre-approval policy requires that requests for services by
	the independent registered public accounting firm be submitted to our Chief Accounting Officer for review and approval. Any requests that are approved by the Chief Accounting Officer are then aggregated and submitted to the Audit Committee for
	approval at a meeting of the Audit Committee. Requests may be made with respect to either specific services or a type of service for predictable or recurring services.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	All audit, audit-related, tax and other services, which include all permissible non-audit services, provided to us by BDO USA, LLP and PricewaterhouseCoopers LLP were pre-approved by the Audit Committee.
	Additionally, the Audit Committee concluded that the provision of those services by BDO USA, LLP and PricewaterhouseCoopers LLP was compatible with the maintenance of the independent registered public accounting firm&#146;s independence.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	75
</FONT>
</P>
<A NAME="eolPage78"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_ACCOUNTANT_FEES>
</EFX_PART_III>
<EFX_PART_IV>
<A NAME="FIS_PART_IV"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_TOC453081_23">
</A>
	PART IV
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_EXHIBITS>
<A NAME="FIS_EXHIBITS"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_TOC453081_24">
</A>
	ITEM&nbsp;15.
</B>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(a)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	LIST OF DOCUMENTS FILED AS PART OF THIS REPORT:
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Financial Statements
</I>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:8%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The
	financial statements and notes thereto, and the report of the independent registered public accounting firm thereon, are set forth on pages F-1 through F-27.
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2.
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Exhibits
</I>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:8%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The exhibits
	listed in the accompanying index to exhibits are filed or incorporated by reference as part of this Annual Report on Form 10-K.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	76
</FONT>
</P>
<A NAME="eolPage79"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	VERMILLION, INC.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_INDEX">
</A>
	INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="92%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Page&nbsp;No.
</B>
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081D10K_HTM_FINTOC453081_1">
	Reports of Independent Registered Public Accounting Firms
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-1
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081D10K_HTM_FINTOC453081_2">
	Consolidated Balance Sheets at December&nbsp;31, 2012 and 2011
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-3
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081D10K_HTM_FINTOC453081_3">
	Consolidated Statements of Operations and Comprehensive Loss for the years ended December&nbsp;
	31, 2012 and 2011
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-4
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081D10K_HTM_FINTOC453081_4">
	Consolidated Statements of Changes in Stockholders&#146; Equity for the years ended December&nbsp;
	31, 2012 and 2011
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-5
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081D10K_HTM_FINTOC453081_5">
	Consolidated Statements of Cash Flows for the years ended December&nbsp;31, 2012 and
	2011
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-6
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081D10K_HTM_FINTOC453081_6">
	Notes to Consolidated Financial Statements
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-7
</FONT>
</TD>
</TR>
</TABLE>
<A NAME="eolPage80"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_EXHIBITS>
</EFX_PART_IV>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_FINTOC453081_1">
</A>
	Report of Independent Registered Public Accounting Firm
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Board of Directors and Stockholders
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Vermillion, Inc.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Austin, Texas
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have audited the accompanying consolidated balance sheet of Vermillion, Inc. (&#147;Company&#148;) as of December&nbsp;31, 2012 and the related consolidated statement of operations and comprehensive
	loss, changes in stockholders&#146; equity, and cash flows for the year then ended. These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these financial statements based
	on our audit.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those
	standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its
	internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an
	opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the
	financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provide a reasonable basis for our opinion.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of
	Vermillion, Inc. at December&nbsp;31, 2012, and the results of its operations and its cash flows for the year ended December&nbsp;31, 2012
<B>
	,
</B>
	in conformity with accounting principles generally accepted in the United States of America.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As
	described in Note 1 to the consolidated financial statements, the Company has suffered recurring losses and negative cash flows from operations and has an accumulated deficit, all of which raise substantial doubt about its ability to continue as a
	going concern. Management&#146;s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/s/ BDO USA, LLP
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Austin, Texas
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	March 1, 2013
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-1
</FONT>
</P>
<A NAME="eolPage81"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_AUDITORS_OPINION>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION_2"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Report of Independent Registered Public Accounting Firm
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	To the Board of Directors and Stockholders of Vermillion, Inc.:
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In our opinion, the consolidated financial statements listed in the accompanying index present fairly, in all material respects, the financial position of Vermillion, Inc. and its subsidiarie
<B>
	s
</B>
	(the
	&#147;Company&#148;) at December&nbsp;31, 2011, and the results of their operations and their cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America. These financial statements
	are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit of these statements in accordance with the standards of the Public Company
	Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test
	basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that
	our audit provides a reasonable basis for our opinion.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The accompanying financial statements have been prepared assuming that the Company
	will continue as a going concern. As described in Note 1 to the consolidated financial statements, the Company has incurred recurring losses and negative cash flows from operations and has debt outstanding due and payable in October 2012, all of
	which raise substantial doubt about its ability to continue as a going concern. Management&#146;s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the
	outcome of this uncertainty.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/s/ PricewaterhouseCoopers LLP
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Austin, Texas
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	March&nbsp;26, 2012
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-2
</FONT>
</P>
<A NAME="eolPage82"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_AUDITORS_OPINION>
<EFX_BALANCE_SHEET>
<A NAME="FIS_BALANCE_SHEET"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Vermillion, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_FINTOC453081_2">
</A>
	Consolidated Balance Sheets
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(Amounts in Thousands, Except Share and Par Value Amounts)
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="79%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2012
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2011
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Assets
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Current assets:
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Cash and cash equivalents
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8,007
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	22,477
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Accounts receivable
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	137
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	99
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Prepaid expenses and other current assets
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	348
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	317
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total current assets
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8,492
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	22,893
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Property and equipment, net
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	142
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	216
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Other assets
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total assets
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8,634
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	23,111
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN="TOP" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Liabilities and Stockholders&#146; Equity
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Current liabilities:
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Accounts payable
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	525
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,331
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Accrued liabilities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,074
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2,592
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Short-term debt
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,106
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	7,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Deferred revenue
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	492
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	553
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total current liabilities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3,197
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11,476
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Non-current liabilities:
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Long-term deferred revenue
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	770
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,224
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Other liabilities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	52
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total liabilities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3,967
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12,752
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Commitments and contingencies (Note 7)
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Stockholders&#146; equity:
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding at December&nbsp;31, 2012 and
	2011
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Common stock, $0.001 par value, 150,000,000 shares authorized; 15,200,079 and 14,900,831 shares issued and outstanding at
	December&nbsp;31, 2012 and 2011, respectively
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	15
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	15
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Additional paid-in capital
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	328,097
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	326,796
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Accumulated deficit
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(323,445
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(316,299
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Accumulated other comprehensive loss
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(153
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total stockholders&#146; equity
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4,667
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10,359
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total liabilities and stockholders&#146; equity
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8,634
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	23,111
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_BALANCE_SHEET>
<P STYLE="FONT-SIZE:72PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:24PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	See accompanying Notes to Consolidated Financial
	Statements
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-3
</FONT>
</P>
<A NAME="eolPage83"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_INCOME_STATEMENT>
<A NAME="FIS_INCOME_STATEMENT"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Vermillion, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_FINTOC453081_3">
</A>
	Consolidated Statements of Operations and Comprehensive Loss
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(Amounts in Thousands, Except Share and Per Share Amounts)
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="75%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Year Ended December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2012
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2011
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Revenue:
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Product
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,640
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,469
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	License
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	454
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	454
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total revenue
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2,094
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,923
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Cost of revenue:
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Product
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	131
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	129
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total cost of revenue
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	131
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	129
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Gross profit
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,963
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,794
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Operating expenses:
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Research and development
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(1)
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2,216
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5,387
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Sales and marketing
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(2)
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4,653
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5,539
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	General and administrative
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	(3)
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4,508
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8,509
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total operating expenses
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11,377
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	19,435
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Loss from operations
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(9,414
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(17,641
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Interest income
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	28
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	64
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Interest expense
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(206
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(396
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Gain on sale of instrument business
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,830
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Gain on litigation settlement, net
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	710
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Change in fair value of warrants
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	378
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Reorganization items
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	88
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(96
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Other expense, net
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(182
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(99
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Loss before income taxes
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(7,146
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(17,790
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Income tax benefit (expense)
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net loss
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(7,146
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(17,790
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net loss per share&#151;basic and diluted
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(0.48
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(1.25
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Weighted average common shares used to compute basic and diluted net loss per common share
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	15,010,868
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	14,249,570
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net loss
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(7,146
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(17,790
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Foreign currency translation adjustment
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	153
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Comprehensive loss
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(6,993
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(17,787
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Non-cash stock-based compensation expense included in operating expenses:
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(1) Research and development
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	127
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	686
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(2) Sales and marketing
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	203
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	158
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(3) General and administrative
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	965
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2,446
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_INCOME_STATEMENT>
<P STYLE="FONT-SIZE:72PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:36PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	See accompanying Notes to Consolidated Financial
	Statements
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-4
</FONT>
</P>
<A NAME="eolPage84"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_STOCKHOLDERS_EQUITY>
<A NAME="FIS_STOCKHOLDERS_EQUITY"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Vermillion, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_FINTOC453081_4">
</A>
	Consolidated Statements of Changes in Stockholders&#146; Equity
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(Amounts in Thousands, Except Share Amounts)
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="44%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Common Stock
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ROWSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Additional
<BR>
	Paid-In
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Capital
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ROWSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Accumulated
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Deficit
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ROWSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Accumulated
<BR>
	Other
<BR>
	Comprehensive
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Loss
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ROWSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Total
<BR>
	Stockholders&#146;
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Equity
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Shares
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Amount
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Balance at December&nbsp;31, 2010
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	10,657,564
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	11
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	303,270
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(298,509
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(156
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	4,616
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	Net loss
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(17,790
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(17,790
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	Foreign currency translation adjustment
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	3
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	3
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	Common stock issued in conjunction with follow-on public offering, net of issuance costs
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	4,000,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	4
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	20,202
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	20,206
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	Common stock issued in conjuntion with exercise of stock options
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	21,833
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	34
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	34
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	Common stock issued for debtor&#146;s incentive plan
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	75,637
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	1,656
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	1,656
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	Common stock issued for restricted stock awards
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	145,797
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	587
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	587
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	Warrants issued for services
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	4
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	4
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	Stock compensation charge
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	1,043
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	1,043
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Balance at December&nbsp;31, 2011
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	14,900,831
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	15
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	326,796
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(316,299
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(153
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	10,359
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	Net loss
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(7,146
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(7,146
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	Foreign currency translation adjustment
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	153
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	153
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	Common stock issued in conjuntion with exercise of stock options
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	8,333
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	6
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	6
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	Common stock issued for restricted stock awards
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	290,915
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	715
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	715
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	Warrants issued for services
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	14
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	14
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	Stock compensation charge
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	566
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	566
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Balance at December&nbsp;31, 2012
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	15,200,079
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	15
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	328,097
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(323,445
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	4,667
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_STOCKHOLDERS_EQUITY>
<P STYLE="FONT-SIZE:120PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:120PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:10PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	See accompanying Notes to Consolidated Financial Statements
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-5
</FONT>
</P>
<A NAME="eolPage85"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Vermillion, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_FINTOC453081_5">
</A>
	Consolidated Statements of Cash Flows
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(Amounts in Thousands)
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="81%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Year Ended
<BR>
	December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2012
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2011
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Cash flows from operating activities:
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net loss
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(7,146
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(17,790
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Adjustments to reconcile net loss to net cash used in operating activities:
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Change in fair value of warrants
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(378
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Foreign currency loss on liquidation
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	153
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Non-cash license revenue
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(454
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(454
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Loss on sale and disposal of property and equipment
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Depreciation and amortization
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	86
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	77
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Stock-based compensation expense
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,281
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3,286
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Warrants issued for services
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	14
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Gain from sale of instrument business to Bio-Rad
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(1,830
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Changes in operating assets and liabilities:
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:7.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Decrease (increase) in accounts receivable
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(38
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	37
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:7.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Decrease (increase) in prepaid expenses and other current assets
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(31
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	462
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:7.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Decrease in other assets
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:7.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Increase (decrease) in accounts payable and accrued liabilities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(2,292
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	253
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:7.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Decrease in deferred revenue
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(61
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(497
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:7.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Decrease in other liabilities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(52
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(207
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:7.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Reorganization items
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(32
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(384
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:9.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net cash used in operating activities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(10,398
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(15,581
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Cash flows from investing activities:
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Proceeds from the sale of instrument business to Bio-Rad
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,830
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Purchase of property and equipment
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(14
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(99
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:9.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net cash provided by / (used in) investing activities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,816
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(99
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Cash flows from financing activities:
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Principal repayment of short-term debt
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(5,894
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Principal repayment of 7.00% convertible senior notes
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(5,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Proceeds from sale of common stock, net of issuance costs
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	20,206
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Proceeds from issuance of common stock from exercise of stock options
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	6
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	34
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:9.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net cash (used in) / provided by financing activities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(5,888
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	15,240
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Effect of exchange rate changes on cash and cash equivalents
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net decrease in cash and cash equivalents
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(14,470
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(437
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Cash and cash equivalents, beginning of year
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	22,477
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	22,914
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Cash and cash equivalents, end of year
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8,007
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	22,477
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Supplemental disclosure of cash flow information:
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Cash paid during the period for:
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Interest
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	227
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	462
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Income taxes
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_CASH_FLOW>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	See accompanying Notes to Consolidated Financial
	Statements
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-6
</FONT>
</P>
<A NAME="eolPage86"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Vermillion, Inc.
</B>
</FONT>
</P>
<EFX_NOTES_TO_FINANCIAL_STATEMENT>
<A NAME="FIS_NOTES_TO_FINANCIAL_STATEMENT"></A>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081D10K_HTM_FINTOC453081_6">
</A>
	Notes to Consolidated Financial Statements
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	NOTE 1: B
<SMALL>
	ASIS
</SMALL>
<SMALL>
	OF
</SMALL>
	P
<SMALL>
	RESENTATION
</SMALL>
<SMALL>
	AND
</SMALL>
	S
<SMALL>
	UMMARY
</SMALL>
<SMALL>
	OF
</SMALL>
	S
<SMALL>
	IGNIFICANT
</SMALL>
	A
<SMALL>
	CCOUNTING
</SMALL>
<SMALL>
	AND
</SMALL>
	R
<SMALL>
	EPORTING
</SMALL>
	P
<SMALL>
	OLICIES
</SMALL>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Organization
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Vermillion, Inc. (&#147;Vermillion&#148;; Vermillion and its wholly-owned subsidiaries are collectively referred to as &#147;we&#148; or the &#147;Company&#148;) is incorporated in the state of Delaware,
	and is engaged in the business of developing and commercializing diagnostic tests in the fields of oncology, cardiology and women&#146;s health. On March&nbsp;9, 2010, we commercially launched OVA1&#153; ovarian tumor triage test (&#147;OVA1&#148;).
	As discussed in Note 3, we distribute OVA1 through Quest Diagnostics, which has the non-exclusive right to commercialize OVA1 on a worldwide basis, with exclusive commercialization rights in the clinical reference lab marketplace in each exclusive
	territory, beginning on the date OVA1 was first commercialized and ending on the fifth anniversary of the date that OVA1 was cleared by the FDA, with the right to extend the exclusivity period for one additional year. These exclusive territories
	include the United States, India, Mexico, and the United Kingdom.
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On December&nbsp;19, 2011, we completed the purchase of
	substantially all of the assets of Correlogic Systems, Inc. (&#147;Correlogic&#148;) for $435,000. The purchase included certain documents, diagnostic samples and intellectual property owned by and licensed to Correlogic in connection with
	Correlogic&#146;s ovarian cancer diagnostics business, including a diagnostic test under the name &#147;OvaCheck2&#153;&#148; for the detection of ovarian cancer. The purchase was expensed during the year ended December&nbsp;31, 2011 as the assets
	acquired will be consumed in research and development activities, with no alternative future use.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Liquidity
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On March&nbsp;9, 2010, we commercially launched OVA1. We will continue to expend resources in the selling and marketing of OVA1 and
	developing additional diagnostic tests.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On February&nbsp;18, 2011, we completed an underwritten follow-on public offering of
	our common stock for net proceeds of $20,206,000 after deducting underwriting discounts and offering expenses. We paid $5,000,000 in September 2011 to repay the 7.00% Notes. We paid $5,894,000 in October 2012 to repay the Secured Line of Credit with
	Quest Diagnostics.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have incurred significant net losses and negative cash flows from operations since inception. At
	December&nbsp;31, 2012, we had an accumulated deficit of $323,445,000 and stockholders&#146; equity of $4,667,000. On December&nbsp;31, 2012, we had $8,007,000 of cash and cash equivalents and $3,197,000 of current liabilities.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We expect cash for OVA1 from Quest Diagnostics to be our only material, recurring source of cash in 2013. In order to continue our
	operations as currently planned through 2013 and beyond, we will need to raise additional capital. Given the above conditions, there is substantial doubt about the Company&#146;s ability to continue as a going concern.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The consolidated financial statements have been prepared on a going concern basis and do not include any adjustments that might result
	from these uncertainties.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The successful achievement of our business objectives will require additional financing and
	therefore, we will need to raise additional capital or incur indebtedness to continue to fund our future operations. We may seek to raise capital through a variety of sources, including the public equity market, private equity financing,
	collaborative arrangements, licensing arrangements, and/or public or private debt.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Any additional equity financing may be
	dilutive to stockholders, and debt financing, if available, may involve restrictive covenants. If we obtain additional funds through arrangements with collaborators or strategic partners, we may be required to relinquish our rights to certain
	technologies or products that we might otherwise
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-7
</FONT>
</P>
<A NAME="eolPage87"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	seek to retain. Additional funding may not be available when needed or on terms acceptable to us. If we are unable to obtain additional capital, we may be required to delay, reduce the scope of
	or eliminate our sales and marketing and/or research and development activities.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Principals of Consolidation
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions
	have been eliminated in consolidation.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Use of Estimates
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The preparation of consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions
	that affect the amounts reported in the consolidated financial statements and accompanying notes. The primary estimates underlying our consolidated financial statements include assumptions regarding variables used in calculating the fair value of
	our equity awards, income taxes and contingent liabilities. Actual results could differ from those estimates.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Cash and Cash Equivalents
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Cash and cash equivalents consist of cash and highly liquid investments with maturities of three months or less from
	the date of purchase, which are readily convertible into known amounts of cash and are so near to their maturity that they present an insignificant risk of changes in value because of interest rate changes. Highly liquid investments that are
	considered cash equivalents include money market funds, certificates of deposits, treasury bills and commercial paper. The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Fair Value Measurement
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ASC 820, &#147;Fair Value and Measurements&#148; defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most
	advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and
	minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Level 1&#151;Quoted prices in active markets for identical assets or liabilities.
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Level 2&#151;Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets
	that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Level 3&#151;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the
	lowest level of input that is significant to the fair value calculation.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Concentration of Credit Risk
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents and accounts
	receivable. We maintain our cash and cash equivalents in recognized financial institutions in the United States. We have not experienced any losses associated with our deposits of cash and cash equivalents. We do not invest in derivative instruments
	or engage in hedging activities.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-8
</FONT>
</P>
<A NAME="eolPage88"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our accounts receivable are derived from sales made to a customer located in North America.
	We perform ongoing credit evaluations of our customer&#146;s financial condition and generally do not require collateral. We maintain an allowance for doubtful accounts based upon the expected collectability of accounts receivable. Our accounts
	receivable at December&nbsp;31, 2012 and 2011 and revenues for the years then ended are from one customer.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Property and Equipment
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Property and equipment are carried at cost less accumulated depreciation and amortization. Property and equipment are
	depreciated using the straight-line method over the estimated useful lives, generally three to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the
	remaining term of the lease. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is
	reflected in operations.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Property and equipment are reviewed for impairment when events or changes in circumstances indicate
	the carrying amount of an asset may not be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Revenue Recognition
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
<U>
	Product Revenue.
</U>
</I>
	We derive our
	product revenues from sales of OVA1 through Quest Diagnostics. We recognize product revenues for tests performed when the following revenue recognition criteria are met: (1)&nbsp;persuasive evidence that an arrangement exists; (2)&nbsp;delivery has
	occurred or services have been rendered; (3)&nbsp;the fee is fixed or determinable; and (4)&nbsp;collectability is reasonably assured. Accounts receivable from Quest Diagnostics Incorporated (&#147;Quest Diagnostics&#148;) totaled $137,000 and
	$85,000 at December&nbsp;31, 2012 and 2011, respectively.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
<U>
	License Revenue.
</U>
</I>
	Under the terms of the secured line
	of credit with Quest Diagnostics, portions of the borrowed principal amounts may be forgiven upon our achievement of certain milestones relating to the development, regulatory approval and commercialization of certain diagnostic tests (see Note 3).
	We account for forgiveness of principal debt balances as license revenues over the term of the exclusive sales period that Quest Diagnostics receives upon commercialization of an approved diagnostic test as we do not have a sufficient history of
	product sales that provides a reasonable basis for estimating future product sales. We recognize license revenue on a straight-line basis over the remaining period of Quest Diagnostics&#146; sales exclusivity ending in September 2015. Through
	December&nbsp;31, 2012, a total of $3,000,000 has been forgiven by Quest Diagnostics based upon milestone achievement.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Research and
	Development Costs
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Research and development costs are expensed as incurred. Research and development costs consist
	primarily of payroll and related costs, materials and supplies used in the development of new products, and fees paid to third parties that conduct certain research and development activities on our behalf. In addition, acquisitions of assets to be
	consumed in research and development are expensed as incurred as research and development costs. Software development costs incurred in the research and development of new products are expensed as incurred until technological feasibility is
	established.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Patent Costs
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Costs incurred in filing, prosecuting and maintaining patents (principally legal fees) are expensed as incurred and recorded within selling, general and administrative expenses on the consolidated
	statements of operations and comprehensive loss. Such costs aggregated approximately $312,000 and $363,000 for the years ended December&nbsp;31, 2012 and 2011, respectively.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-9
</FONT>
</P>
<A NAME="eolPage89"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Stock-Based Compensation
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We record the fair value of non-cash stock-based compensation costs for stock options and stock purchase rights related to our 2010 Stock
	Incentive Plan (the &#147;2010 Plan&#148;) and 2000 Stock Plan (the &#147;2000 Plan&#148;). We estimate the fair value of stock options using a Black-Scholes option valuation model. This model requires the input of subjective assumptions including
	expected stock price volatility, expected life and estimated forfeitures of each award. We use the straight-line method to amortize the fair value over the vesting period of the award. These assumptions consist of estimates of future market
	conditions, which are inherently uncertain, and therefore are subject to management&#146;s judgment.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The expected life of
	options is based on historical data of our actual experience with the options we have granted and represents the period of time that the options granted are expected to be outstanding. This data includes employees&#146; expected exercise and
	post-vesting employment termination behaviors. The expected stock price volatility is estimated using a combination of historical and peer group volatility for a blended volatility in deriving the expected volatility assumption. We made an
	assessment that blended volatility is more representative of future stock price trends than just using historical or peer group volatility, which corresponds to the expected life of the options. The expected dividend yield is based on the estimated
	annual dividends that we expect to pay over the expected life of the options as a percentage of the market value of our common stock as of the grant date. The risk-free interest rate for the expected life of the options granted is based on the
	United States Treasury yield curve in effect as of the grant date.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We also record the fair value of non-cash stock-based
	compensation costs for equity instruments issued to non-employees. We recalculate costs for these options each reporting period using a Black-Scholes option valuation model. Because we recalculate these costs each reporting period, changes in
	assumptions used in our calculations, including changes in the fair value of our common stock, can result in significant changes in the amounts we record from one reporting period to another.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Contingencies
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We account for contingencies in accordance with ASC
	450 Contingencies (&#147;ASC 450&#148;). ASC 450 requires that an estimated loss from a loss contingency shall be accrued when information available prior to issuance of the financial statements indicates that it is probable that an asset has been
	impaired or a liability has been incurred at the date of the financial statements and when the amount of the loss can be reasonably estimated. Accounting for contingencies such as legal and contract dispute matters requires us to use our judgment.
	We believe that our accruals for these matters are adequate. Nevertheless, the actual loss from a loss contingency might differ from our estimates.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Income Taxes
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We account for income taxes using the liability
	method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and the tax bases of assets and liabilities using the current tax laws and rates. A valuation allowance is
	established when necessary to reduce deferred tax assets to the amounts more likely than not expected to be realized.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	FASB
	ASC Topic 740-10-50, &#147;Accounting for Uncertainty in Income Taxes&#148; clarifies the accounting for uncertainty in income taxes recognized in the financial statements in accordance with FASB ASC Topic 740, Income Taxes. ASC Topic 740-10-50
	provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the
	technical merits. This interpretation also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, and disclosure.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-10
</FONT>
</P>
<A NAME="eolPage90"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We recognize interest and penalties related to unrecognized tax benefits within the interest
	expense line and other expense line, respectively, in the consolidated statement of operations. Accrued interest and penalties are included within the related liability lines in the consolidated balance sheet.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Foreign Currency Translation
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The functional currency of Ciphergen Biosystems KK, a wholly owned subsidiary, is the Japanese yen. Accordingly, all balance sheet accounts of this operation are translated into United States dollars
	using the current exchange rate in effect at the balance sheet date. The expenses of Ciphergen Biosystems KK are translated using the average exchange rates in effect during the period, and the gains and losses from foreign currency translation are
	recorded in accumulated other comprehensive loss. Ciphergen Biosystems KK was liquidated during 2012 and, consequently, the accumulated other comprehensive loss totaling $153,000 was recognized in the consolidated statement of operations for 2012
	and included in Other Expense in the consolidated statements of operations and comprehensive loss.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Net Loss Per Share
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Basic net loss per share is computed by dividing the net loss by the weighted average number of common stock shares
	outstanding during the period. Diluted loss per share is computed by dividing the net loss by the weighted average number of common stock shares adjusted for the dilutive effect of common stock equivalent shares outstanding during the period. Common
	stock equivalents consist of stock options, restricted stock units and stock warrants. Common equivalent shares are excluded from the computation in periods in which they have an anti-dilutive effect on earnings per share.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Fair Value of Financial Instruments
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and short-term debt. The estimated fair value of financial instruments has been
	determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily
	indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts. The carrying
	amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and short-term debt are at cost, which approximates fair value due to the short maturity of those instruments.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Segment Reporting
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We operate one reportable segment, novel diagnostic tests.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	NOTE 2: R
<SMALL>
	ECENT
</SMALL>
	A
<SMALL>
	CCOUNTING
</SMALL>
	P
<SMALL>
	RONOUNCEMENTS
</SMALL>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Comprehensive Income&#151;In June 2011, the FASB issued new guidance on the presentation of comprehensive income.
	Specifically, the new guidance allows an entity to present components of net income and other comprehensive income in one continuous statement, referred to as the statement of comprehensive income, or in two separate, but consecutive statements. The
	new guidance eliminates the current option to report other comprehensive income and its components in the statement of changes in equity. While the new guidance changes the presentation of comprehensive income, there are no changes to the components
	that are recognized in net income or other comprehensive income under current accounting guidance. We adopted this pronouncement in the first quarter of 2012, and it had no effect on our financial position, results of operations or cash flows but
	did impact the way we present comprehensive income.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-11
</FONT>
</P>
<A NAME="eolPage91"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	NOTE 3: S
<SMALL>
	TRATEGIC
</SMALL>
	A
<SMALL>
	LLIANCE
</SMALL>
<SMALL>
	WITH
</SMALL>
	Q
<SMALL>
	UEST
</SMALL>
	D
<SMALL>
	IAGNOSTICS
</SMALL>
	I
<SMALL>
	NCORPORATED
</SMALL>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Quest Diagnostics is a significant holder of our common stock. On July&nbsp;22, 2005, we entered into a strategic
	alliance agreement (the &#147;Strategic Alliance Agreement&#148;) with Quest Diagnostics to develop and commercialize up to three diagnostic tests from our product pipeline (the &#147;Strategic Alliance&#148;). The Strategic Alliance Agreement was
	amended to expire on the earlier of (i)&nbsp;October&nbsp;7, 2012 and (ii)&nbsp;the date on which Quest Diagnostics makes its third development election. We further amended the Strategic Alliance Agreement to give Quest Diagnostics the exclusive
	right to commercialize OVA1 for two additional years to September 2014, with an option to extend such exclusive period in its sole discretion for one additional year, and to establish royalties, fees, and other payments related to the performance of
	OVA1. Quest Diagnostics has selected two diagnostic tests to commercialize, a peripheral arterial disease blood test and OVA1.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Secured
	Line of Credit with Quest Diagnostics Incorporated
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In connection with the Strategic Alliance Agreement, Quest
	Diagnostics provided us with a $10,000,000 secured line of credit, which is collateralized by certain of our intellectual property. Under the terms of this secured line of credit, the interest rate is at the prime rate plus 0.5% and is payable
	monthly. The effective interest rate was 3.75% at December&nbsp;31, 2012 and 2011. This secured line of credit also contains provisions for Quest Diagnostics to forgive portions of the amounts borrowed that correspond to our achievement of certain
	milestones related to development, regulatory approval and commercialization of certain diagnostic tests. The amounts to be forgiven and the corresponding milestones that we must achieve are:
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(i)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$1,000,000 for each application that allows a licensed laboratory test to be commercialized with a maximum of three applications for $3,000,000;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(ii)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$3,000,000 for the earlier of FDA clearance of the first diagnostic test kit or commercialization of the first diagnostic test kit; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(iii)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$2,000,000 upon each FDA clearance of up to two subsequent diagnostic test kits but no later than the first commercialization of each such diagnostic test kit, with a
	maximum forgiveness of $4,000,000 for two diagnostic test kits.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	If not otherwise forgiven, the principal amount
	outstanding and any unpaid interest of this secured line of credit became due and payable on October&nbsp;7, 2012.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The
	outstanding principal balance of this secured line of credit was $1,106,000 and $7,000,000 at December&nbsp;31, 2012 and 2011, respectively. Interest expense related to this secured line of credit was $206,000 and $263,000 for the years ended
	December&nbsp;31, 2012 and 2011, respectively. On September&nbsp;11, 2009, we achieved the FDA clearance of OVA1 milestone provision in the secured line of credit agreement providing for a reduction in the principal amount of the loan of $3,000,000
	but was only able to apply the milestone once we were no longer in default under the terms of the secured line of credit while under Chapter 11 bankruptcy protection. In January 2010, we cured the default and the principal balance was reduced to
	$7,000,000.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We also believe we achieved the milestone for an application that allows a licensed laboratory test to be
	commercialized when OVA1 was cleared by the FDA in September 2009 and the secured line of credit is expected to be reduced by an additional $1,000,000 resulting in outstanding principal of $6,000,000. However, Quest Diagnostics has disputed that the
	milestone has been met.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have made monthly payments to Quest Diagnostics on the secured line of credit based on a principal
	balance of $7,000,000, which is in excess of the interest due on the expected $6,000,000 principal balance, which we believe resulted in a curtailment of the principal balance of $106,000. However, Quest Diagnostics has disputed that such additional
	principal curtailment has been made.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-12
</FONT>
</P>
<A NAME="eolPage92"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On October&nbsp;12, 2012, we paid Quest Diagnostics approximately $5,894,000 of principal
	and $7,000 of accrued interest which we believe represents payment in full of all outstanding principal and interest under the secured line of credit. We continue to show the amount of the liability as $1,106,000 as of December&nbsp;31, 2012 given
	that Quest Diagnostics has disputed that the $1,000,000 milestone was met.
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_13"></A>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	NOTE 4: P
<SMALL>
	ROPERTY
</SMALL>
<SMALL>
	AND
</SMALL>
	E
<SMALL>
	QUIPMENT
</SMALL>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The components of property and equipment as of December&nbsp;31, 2012 and 2011 were as follows:
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="79%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:48PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	(in thousands)
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2012
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2011
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Machinery and equipment
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	193
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	184
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Demonstration equipment
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	33
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	30
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Computer equipment and software
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	114
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	251
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Furniture and fixtures
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	65
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	65
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Gross property and equipment
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	405
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	530
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Accumulated depreciation and amortization
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(263
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(314
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Property and equipment, net
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	142
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	216
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Depreciation expense for property and equipment was $86,000 and $77,000 for the years ended
	December&nbsp;31, 2012 and 2011, respectively.
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_14"></A>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	NOTE 5: A
<SMALL>
	CCRUED
</SMALL>
	L
<SMALL>
	IABILITIES
</SMALL>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The components of accrued liabilities as of December&nbsp;31, 2012 and 2011 were as follows:
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="76%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:48PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	(in thousands)
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2012
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2011
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Payroll and benefits related expenses
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	464
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	641
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Collaboration and research agreements expenses
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	133
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	303
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Professional services
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	236
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	279
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Contingencies (See Note 9)
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,025
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Tax-related liabilities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	17
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	76
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Other accrued liabilities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	224
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	268
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total accrued liabilities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,074
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2,592
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	NOTE 6: C
<SMALL>
	ONVERTIBLE
</SMALL>
	S
<SMALL>
	ENIOR
</SMALL>
	N
<SMALL>
	OTES
</SMALL>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	7.00% Convertible Senior Notes Due September&nbsp;1, 2011
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On November&nbsp;15, 2006, we closed the sale of $16,500,000 of convertible senior notes due September&nbsp;1, 2011. The 7.00% Notes were
	sold pursuant to separate exchange and redemption agreements between Vermillion and holders of the then existing 4.50% convertible senior notes due September&nbsp;1, 2008, pursuant to which holders of an aggregate of $27,500,000 of the 4.50% Notes
	agreed to exchange and redeem their 4.50% Notes for an aggregate of $16,500,000 in aggregate principal amount of the 7.00% Notes and $11,000,000 in cash, plus accrued and unpaid interest on the 4.50% Notes of $254,000. The 7.00% Notes were unsecured
	senior indebtedness of Vermillion initially bearing interest at the rate of 7.00%&nbsp;per annum. The 7.00% Notes were reduced to 4.00%&nbsp;per annum on September&nbsp;11, 2009 upon FDA clearance of OVA1.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The 7.00% Notes were convertible at the option of each holder prior to September&nbsp;1, 2011 into shares of our common stock at a
	conversion price of $20.00 per share, equivalent to a conversion rate equal to 50 shares of our common stock per $1,000 principal of the 7.00% Notes, subject to adjustment for standard anti-dilution
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-13
</FONT>
</P>
<A NAME="eolPage93"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	provisions including distributions to common stockholders and stock splits as well as occurrence of a change in control, in which case the conversion rate was to be adjusted for a make-whole
	premium. The conversion feature, including the make-whole premium, expired unexercised in September 2011.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Holders of the
	7.00% Notes had the option to require us to repurchase the 7.00% Notes under certain circumstances, including at any time after September&nbsp;1, 2009, if we did not receive approval or clearance for commercial sale of any of our ovarian cancer
	tests by the FDA. We could redeem the 7.00% Notes at our option, in whole or in part, after September&nbsp;1, 2009, at specified redemption prices plus accrued and unpaid interest if the closing price of the stock equaled or exceeded 200.0% of the
	conversion price then in effect for at least 20 trading days within a period of 30 consecutive trading days ending on the trading day before the date of the notice of the optional redemption. Upon a change of control, each holder of the 7.00% Notes
	could have required us to repurchase some or all of the 7.00% Notes at specified redemption prices, plus accrued and unpaid interest. The 7.00% Notes contained a put option that entitles the holder to require us to redeem the 7.00% Notes at a price
	equal to 105.0% of the principal balance upon a change in control of the Company. These provisions expired with the repayment of the 7.00% Notes in September 2011.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	From October through November 2009, we exchanged a total of 220,000 shares of common stock for $4,400,000 in principal under the terms of the original 7.00% Notes. In November through December 2009, we
	exchanged a total of 421,667 shares of common stock for $7,100,000 in principal and $589,000 in unpaid interest. The conversion rate for the November and December 2009 redemption was approximately 55 shares per $1,000 principal amount. We recorded
	an additional debt conversion expense of $819,000 relating to the more favorable exchange rate during the year ended December&nbsp;31, 2009.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We were in default of the 7.00% Notes as of December&nbsp;31, 2009. However, we cured the default upon payment of accrued interest totaling approximately $362,000 upon emergence from bankruptcy under
	Chapter 11 in January 2010. In September 2011, $5,000,000 in aggregate principal amount of the 7.00% Notes remained outstanding and was repaid in full.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	4.50% Convertible Senior Notes Due September&nbsp;1, 2009
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On
	August&nbsp;22, 2003, we closed the sale of $30,000,000 of the 4.50% Notes with an original maturity date in September 2008. Offering costs were $1,866,000. Interest on the notes is 4.50%&nbsp;per annum on the principal amount. The effective
	interest rate was 6.28%&nbsp;per annum. The 4.50% Notes were convertible, at the option of the holder into shares of our common stock initially at a conversion rate of 10.88 shares per $1,000 principal amount of the 4.50% Notes, which is equal to a
	conversion price of $91.88 per share. The conversion price, and hence the conversion rate, was subject to adjustment upon the occurrence of certain events.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Following the closing of the November&nbsp;15, 2006 sale of $16,500,000 of the 7.00% Notes due September&nbsp;1, 2011, holders of an aggregate of $27,500,000 of the 4.50% Notes agreed to exchange and
	redeem their 4.50% Notes for an aggregate of $16,500,000 in aggregate principal amount of the 7.00% Notes and $11,000,000 in cash, plus accrued and unpaid interest on the 4.50% Notes of $254,000. As a result of negotiations between us and the
	holders of the 4.50% Notes, the $2,500,000 outstanding principal balance related to the 4.50% Notes was not redeemed by us on the original maturity date in September 2008. Interest of $56,000 related to the 4.50% Notes was paid in September 2008.
	Subsequently in December 2008, the holders of the $2,500,000 outstanding principal balance related to the 4.50% Notes agreed to extend the maturity date of the 4.50% Notes to September&nbsp;1, 2009, and to waive any past default by us of our
	obligation to make payment on the principal of and interest on the 4.50% Notes. We agreed to extend each holder&#146;s rights to require us to repurchase the 4.50% Notes at 105% of such holder&#146;s outstanding principal amount upon a change in
	control, as defined in the indenture governing the 4.50% Notes, and to convert the 4.50% Notes into common stock accordingly. In addition, the holders of the 4.50% Notes agreed to permit the full redemption of the outstanding principal related to
	the 4.50% Notes at a redemption price of 100% on or before August&nbsp;31, 2009, and we agreed to adjust the conversion rate for the 4.50% Notes to 20 shares per $1,000 principal amount of the 4.50% Notes, which is equal to a conversion price of
	$50.00 per share. The impact from adjusting the conversion rate was de minimis.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-14
</FONT>
</P>
<A NAME="eolPage94"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In November 2009, we exchanged a total of 6,750 shares of common stock for $135,000 in
	principal and $8,000 in unpaid interest. The conversion rate for redemption was approximately 47 shares per $1,000 principal amount. We recorded an additional debt conversion expense of $69,000 relating to the more favorable exchange rate.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We were in default of the 4.50% Notes as of December&nbsp;31, 2009. However, upon the emergence from bankruptcy under Chapter
	11 in 2010, we cured the default with a payment of $2,365,000 of principal and $140,000 of unpaid interest with $2,195,000 of cash and 9,044 shares of common stock. This payment in January 2010 settled the 4.50% Notes in full.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	NOTE 7: C
<SMALL>
	OMMITMENTS
</SMALL>
<SMALL>
	AND
</SMALL>
	C
<SMALL>
	ONTINGENCIES
</SMALL>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Operating Leases
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We lease facilities to support our business of discovering, developing and commercializing diagnostic tests in the fields of oncology, cardiology and women&#146;s health. On June&nbsp;1, 2010, we entered
	into a noncancelable operating lease for a new principal facility located in Austin, Texas. The original term was from June&nbsp;1, 2010 through May&nbsp;31, 2012, with an annual base rent of $57,000 and annual estimated common area charges, taxes
	and insurance of $37,000. This lease was amended on the same terms to May&nbsp;31, 2014.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Rental expense under operating
	leases for the years ended December&nbsp;31, 2012 and 2011 totaled $110,000 and $129,000, respectively.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	As of
	December&nbsp;31, 2012, including the extension of our Austin, TX facility operating lease in January 2013, future minimum rental payments under noncancelable operating leases were $94,000 and $39,000 for the years ending December&nbsp;31, 2013 and
	2014, respectively.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Noncancelable Collaboration Obligations and Other Commitments
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Under the terms of a research collaboration agreement with The Johns Hopkins University School of Medicine (&#147;JHU&#148;) directed at
	the discovery and validation of biomarkers in human subjects, including but not limited to clinical application of biomarkers in the understanding, diagnosis and management of human diseases, we were required to pay JHU $600,000, $618,000 and
	$637,000 for the years ending December&nbsp;31,&nbsp;2008, 2009 and 2010, respectively. In June 2010, the research collaboration agreement was amended by extending the term and reducing the payments to $300,000 for 2010, $400,000 for 2011, $400,000
	for 2012 and $100,000 for 2013. In conjunction with the amendment, JHU forgave the previously outstanding amounts owed of $623,000, which we recognize as a reduction to research and development expenses straight line over the term of the amended
	agreement. In January 2013, we further amended the collaboration agreement extending the term to March&nbsp;31, 2016 and requiring payments of $400,000 in 2013 and $100,000 in 2014. Collaboration expenses under the JHU collaboration were $251,000
	and $235,000 for the years ended December&nbsp;31, 2012 and 2011, respectively. Collaboration expenses under the JHU collaboration are included in research and development expenses. In addition, under the terms of the amended research collaboration
	agreement, we are required to pay the greater of 4% royalties on net sales of diagnostic tests using the assigned patents or annual minimum royalties of $57,500. As of December&nbsp;31, 2012 and 2011, we owed none and $4,000 related to research
	collaboration agreements with JHU, respectively.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Gain on Litigation Settlement
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On February&nbsp;9, 2012, we entered into a Settlement Agreement with Oppenheimer&nbsp;&amp; Co., Inc. (&#147;Oppenheimer&#148;) related
	to&nbsp;losses on our short and long-term&nbsp;investments in previous years. Under the terms of the Settlement Agreement, the total settlement before legal fees and costs was $1,000,000; $535,000 was paid in March 2012 ($379,000 net received by the
	Company) and $465,000 ($331,000 net received by the Company) was paid in August 2012. We recorded the net amounts as a component of non-operating income during the year ended December&nbsp;31, 2012.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-15
</FONT>
</P>
<A NAME="eolPage95"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Contingent Liabilities
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Molecular Analytical Systems, Inc. Litigation
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On July&nbsp;9, 2007,
	Molecular Analytical Systems (&#147;MAS&#148;) filed a lawsuit in the Superior Court of California for the County of Santa Clara (&#147;Superior Court&#148;) naming Vermillion and Bio-Rad Laboratories, Inc. (&#147;Bio-Rad&#148;) as defendants (the
	&#147;State Court lawsuit&#148;). In connection with the State Court lawsuit, MAS alleged that we breached our license agreement with MAS by transferring certain SELDI technology to Bio-Rad without obtaining MAS&#146;s consent. MAS listed the value
	of its claim as in excess of $5,000,000. Thereafter, the Superior Court ordered that the dispute be arbitrated before the Judicial Arbitration and Mediation Service (&#147;JAMS&#148;). MAS filed its demand for arbitration in 2010 and the arbitration
	hearing occurred in 2011.&nbsp;On&nbsp;February&nbsp;23, 2012, an interim arbitration award was issued by the Arbitrator. In the interim arbitration award, the Arbitrator denied MAS&#146;s claim for breach of the license agreement as well as several
	other of MAS&#146;s claims. The Arbitrator found that MAS was entitled to an accounting concerning our 2% royalty obligation to MAS either through February&nbsp;21, 2013 or until cumulative royalty payments reach $10 million, whichever comes first,
	and ordered that such royalties should be based on total GAAP revenues less revenues attributable to certain excluded entities, not just SELDI-related revenues.&nbsp;Subsequently, the parties agreed to resolve (i)&nbsp;any and all remaining royalty
	obligations owed to MAS from us and (ii)&nbsp;any and all claims for fees and costs that we had against MAS in return for Vermillion making a one-time payment to MAS of $35,000. We submitted to JAMS a mutual stipulation consistent with that
	agreement and the Arbitrator entered a final arbitration award incorporating that stipulation on May&nbsp;21, 2012. At our request, the Superior Court (i)&nbsp;confirmed the final arbitration award and (ii)&nbsp;entered the final arbitration award
	as the final judgment in this case on July&nbsp;26, 2012.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Bio-Rad Laboratories, Inc. Matters
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On November&nbsp;13, 2006, we completed the Instrument Business Sale to Bio-Rad. The &#147;Instrument Business Sale&#148; included the
	SELDI technology, ProteinChip arrays and accompanying software. Pursuant to the terms of the sales agreement, the total sales price was $20,000,000, of which $16,000,000 was paid by Bio-Rad to us at the closing of the transaction on
	November&nbsp;13, 2006. A total of $4,000,000 was held back from the sales proceeds contingent upon our meeting certain obligations, of which $2,000,000 was subsequently paid to us and $307,000 was paid to settle certain employee termination
	indemnifications in fiscal 2007. From the amounts held back and interest thereon, $1,830,000 was being held in escrow as of December&nbsp;31, 2011 to serve as security for us to fulfill certain obligations.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In August 2009, Bio-Rad also filed a proof of claim in the bankruptcy case for indemnification of the MAS lawsuit. Management has
	subsequently received a final arbitration ruling from JAMS and settled the MAS claim. At our request, the Superior Court (i)&nbsp;confirmed the final arbitration award and (ii)&nbsp;entered the final arbitration award as the final judgment in this
	case on July&nbsp;26, 2012. Thus, we believe that the possibility of any material loss from the indemnification of the MAS lawsuit is remote.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In connection with the Instrument Business Sale, we also entered into a manufacture and supply agreement with Bio-Rad on November&nbsp;13, 2006, whereby we agreed to purchase ProteinChip Systems and
	ProteinChip Arrays from Bio-Rad. In October 2009, Bio-Rad filed a proof of claim in our bankruptcy case based on certain contract claims and alleged breach of the manufacture and supply agreement for approximately $1,000,000.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In April 2012, we resolved the four contract claims made by Bio-Rad arising from the Instrument Business Sale. In exchange for a final
	settlement of these non-contingent claims, Bio-Rad received $700,000 from the escrow account established by the Company for the sale transaction, the Company was returned approximately $1,080,000 from the escrow account. The final $50,000 was
	returned to the Company in September 2012 after final resolution of the MAS lawsuit. We reversed $375,000 of general and administrative expense accrued in previous periods during the year ended December&nbsp;31, 2012 representing the accrued
	estimated liability in excess of the $700,000 settlement amount. We recognized the resulting gain on sale of instrument business of $1,830,000 from the release of the escrow account during the year ended December&nbsp;31, 2012.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-16
</FONT>
</P>
<A NAME="eolPage96"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Robert Goggin and Gy&ouml;rgy Bessenyei Litigation
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On May&nbsp;25, 2012, Gy&ouml;rgy B. Bessenyei and Robert S. Goggin, III, both stockholders of Vermillion, filed a verified complaint in
	the Delaware Court of Chancery (the &#147;Court&#148;) against Vermillion, each current member of our Board of Directors, and Gail S. Page. On June&nbsp;1, 2012, Mr.&nbsp;Bessenyei and Mr.&nbsp;Goggin filed an amended verified complaint that was
	substantially similar to the verified complaint. The amended verified complaint contains the following causes of action: breach of fiduciary duty under two standards, declaratory relief, preliminary injunctive relief, and permanent injunctive
	relief. The allegations in the amended verified complaint challenge the recent adoption by the Board of Directors of an amendment to our bylaws eliminating the board seat formerly held by Ms.&nbsp;Page. As previously disclosed by Vermillion, on
	May&nbsp;15, 2012, Ms.&nbsp;Page was terminated without cause as Vermillion&#146;s President and Chief Executive Officer, and, upon her termination, Ms.&nbsp;Page resigned her seat on the Board of Directors. For a variety of reasons, including an
	effort to streamline Vermillion&#146;s organization and extend its cash runway, the Board of Directors amended our bylaws to eliminate the vacant board seat, thereby reducing the size of the Board of Directors from seven to six members. This effort
	to streamline Vermillion&#146;s organization had begun in January 2012, when the Board of Directors amended the bylaws to eliminate an additional (eighth) seat on the Board of Directors. Mr.&nbsp;Bessenyei and Mr.&nbsp;Goggin claim that the Board of
	Directors&#146; decision to eliminate the seat on May&nbsp;15, 2012 was a breach of its fiduciary duties, alleging that the Board of Directors&#146; actions were intended to prevent Mr.&nbsp;Bessenyei&#146;s and Mr.&nbsp;Goggin&#146;s nominees from
	both being able to be elected to the Board of Directors, and to entrench the Board of Directors&#146; current members. Among other things, Mr.&nbsp;Bessenyei and Mr.&nbsp;Goggin sought to have the Court declare null and void the May&nbsp;15, 2012
	amendment to the bylaws, and award to Mr.&nbsp;Bessenyei and Mr.&nbsp;Goggin the costs and fees incurred by them in the action.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The parties negotiated a scheduling order, which was approved on June&nbsp;6, 2012, setting trial in this expedited action to start on
	July&nbsp;31, 2012. On June&nbsp;13, 2012, Vermillion and the other defendants filed an answer. The parties then engaged in extensive discovery, including document production, service of interrogatory responses, and the taking of depositions. On
	July&nbsp;26, 2012, Vermillion and the other defendants filed a motion to dismiss the case arguing that plaintiffs and their counsel provided improperly notarized documents verifying the complaint, amended complaint and discovery responses. On
	November&nbsp;16, 2012, the Court dismissed the lawsuit with prejudice. The plaintiffs filed a notice of appeal of that dismissal order on December&nbsp;10, 2012, and filed their opening appellate brief on February&nbsp;1, 2013. On February&nbsp;12,
	2013, the Delaware Supreme Court denied Vermillion and the other defendants&#146; motion to summarily affirm. Vermillion and the other defendants are in the process of preparing an appellate answering brief which will be filed by March&nbsp;4, 2013.
	No hearing date on the appeal has been set by the Delaware Supreme Court.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Gy&ouml;rgy Bessenyei Annual Shareholder Meeting Litigation
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On January&nbsp;9, 2013, Gy&ouml;rgy B. Bessenyei, a stockholder of Vermillion, filed a verified complaint in the
	Delaware Court of Chancery (the &#147;Court&#148;) against Vermillion, and each current member of our Board of Directors. The complaint contains a cause of action for violation of Section&nbsp;211 of the General Corporation Law of Delaware. The
	allegations in the complaint relate to the 2012 annual shareholder meeting which had not yet been held due to a scheduling order entered in the Goggin and Bessenyei litigation discussed above. The complaint seeks to have the Court compel Vermillion
	to hold its annual shareholder meeting and to award to Mr.&nbsp;Bessenyei the costs and fees incurred by him in the action. On January&nbsp;16, 2013, the parties held a scheduling conference with the Court. On January&nbsp;18, 2013, Vermillion filed
	its preliminary proxy setting the annual meeting date for March&nbsp;21, 2013. Thereafter, both parties submitted competing proposed orders related to the upcoming annual shareholder meeting. The Court has not yet signed either order.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In addition, from time to time, we are involved in legal proceedings and regulatory proceedings arising out of our operations. We
	establish reserves for specific liabilities in connection with legal actions that we deem to be probable and estimable. Other than as disclosed above, we are not currently a party to any proceeding, the adverse outcome of which would have a material
	adverse effect on our financial position or results of operations.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-17
</FONT>
</P>
<A NAME="eolPage97"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	NOTE 8: C
<SMALL>
	OMMON
</SMALL>
	S
<SMALL>
	TOCK
</SMALL>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	2010 Private Placement Sale
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On January&nbsp;7, 2010, in connection with the Second Amended Plan of Reorganization under Chapter 11 (&#147;Plan of Reorganization&#148;), we completed a private placement sale of 2,327,869 shares of
	our common stock to a group of new and existing investors for $43,050,000 in gross proceeds
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	2007 Private Placement Sale
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On August&nbsp;29, 2007 (the &#147;Closing Date&#148;), we completed a private placement sale of 2,451,309 shares of
	our common stock and warrants to purchase up to an additional 1,961,047 shares of our common stock with an exercise price of $9.25 per share and expiration date of August&nbsp;29, 2012, to a group of new and existing investors for $20,591,000 in
	gross proceeds (collectively referred to as the &#147;August&nbsp;29, 2007, Private Placement Sale&#148;). Existing investors included affiliates of the Company, who purchased 964,285 shares of our common stock and warrants to purchase up to an
	additional 771,428 shares of our common stock for $8,100,000. In connection with Quest Diagnostics&#146; participation in this transaction, we amended a warrant to purchase an additional 220,000 shares of our common stock that was originally issued
	to Quest Diagnostics on July&nbsp;22, 2005. Pursuant to the terms of the amendment, the exercise price for the purchase of our common stock was reduced from $35.00 per share to $25.00 per share and the expiration date of such warrant was extended
	from July&nbsp;22, 2010 to July&nbsp;22, 2011. The warrant expired unexercised in 2011. For services as placement agent, we paid Oppenheimer $1,200,000 and issued a warrant to purchase up to 92,100 shares of our common stock with an exercise price
	of $9.25 per share and expiration date of August&nbsp;29, 2012. The warrants expired unexercised in 2012. The warrants issued to the investors and Oppenheimer were valued at $7,194,000 and $581,000, respectively, based on the fair value as
	determined by the Black-Scholes model. The amended value of the warrant issued to Quest Diagnostics on July&nbsp;22, 2005, increased by $356,000, which is reflected in additional paid-in capital, from its original value of $2,200,000.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our outstanding warrants from the August 2007 offering were classified as liabilities in accordance with ASC 815, which required the
	warrants to be fair valued at each reporting period, with the changes in fair value recognized as interest and other expense in our consolidated statement of operations.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We had no warrants required to be classified as a liability at December&nbsp;31, 2012. At December&nbsp;31, 2011, we had warrants outstanding to purchase 195,012 shares of common stock which were required
	to be classified as a liability. The fair value of these warrants at December&nbsp;31, 2011 was de minimis and for the year ended December&nbsp;31, 2011, we recorded a gain of $378,000 in the consolidated statement of operations under ASC 815.
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_15"></A>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Warrants
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Warrants outstanding as of December&nbsp;31, 2012 and 2011 were as follows:
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="37%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ROWSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Exercise&nbsp;Price
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	per
	Share
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Number&nbsp;of&nbsp;Shares&nbsp;Outstanding&nbsp;under&nbsp;Warrant
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:47PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Issuance Date
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Expiration&nbsp;Date
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	December&nbsp;31, 2012
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	December&nbsp;31, 2011
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	August 29, 2007
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	August&nbsp;29,&nbsp;2012
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	9.25
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	*&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	195,012
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	November 1, 2011
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	October&nbsp;31,&nbsp;2013
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3.23
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	21,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	21,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	May 1, 2012
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	April 30, 2014
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3.18
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	21,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	November 1, 2012
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	October 31, 2014
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.93
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	21,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	63,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	216,012
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	*
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The exercise price of the warrants issued on August 29, 2007 was adjustable in accordance with the term of the warrants.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We periodically issue common stock warrants to a vendor in exchange for services. The warrants vest pro-rata on a monthly basis over a
	six month period and expire two years after issuance. The value of the warrants as determined by the Black-Sholes model was not significant and is classified as equity.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-18
</FONT>
</P>
<A NAME="eolPage98"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Debtor&#146;s Incentive Plan
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In connection with our voluntary petition for relief (our&nbsp;&#147;Bankruptcy Filing&#148;) under Chapter 11 of the United States
	Bankruptcy Code (&#147;Chapter&nbsp;11&#148;) in the United States Bankruptcy Court for the District of Delaware (the&nbsp;&#147;Bankruptcy Court&#148;), on April&nbsp;21, 2009, we filed the Debtor&#146;s Motion for Entry of an Order Approving the
	Debtor&#146;s Incentive Plan (the &#147;Debtor&#146;s Incentive Plan&#148;) and Authorizing Payments thereunder pursuant to &#167;&#167; 363(b) and 503(b) of the Bankruptcy Code (the &#147;Incentive Plan Motion&#148;) which sought to provide proper
	incentives to the directors and former directors (Gail Page, John Hamilton and James Burns, collectively, the &#147;Directors&#148;) to help achieve a successful sale or restructuring of the Company.&nbsp;At a hearing in June 2009, the Court entered
	an Order approving the Incentive Plan Motion (the &#147;Incentive Plan Order&#148;).&nbsp;The Debtor&#146;s Incentive Plan was only triggered upon the occurrence of a qualified transaction defined as the closing of any sale pursuant to section 363
	of the Bankruptcy Code or the effectiveness of a Reorganization Plan confirmed pursuant to section 1129 of the Bankruptcy Code. The Debtor&#146;s Incentive Plan payment was based upon a percentage of (A)&nbsp;the gross proceeds of Asset Sales, both
	prior to and after the Food and Drug Administration approval of the ovarian tumor triage test, and (B)&nbsp;the value of consideration&#151;cash, debt and equity&#151;distributed pursuant to a confirmed Reorganization Plan.&nbsp;In the end, the
	Incentive Plan Order provided that the Directors would receive: (i)&nbsp;zero, on Qualified Transaction Proceeds of 3,000,000 or less, (ii)&nbsp;6% on Qualified Transaction Proceeds of $3,000,001 to $10,000,000, and (iii)&nbsp;8% on Qualified
	Transaction Proceeds of greater than $10,000,000.&nbsp;While the Incentive Plan Order provided us with the authority to make distributions under the Debtor&#146;s Incentive Plan, we agreed as part of the Plan of Reorganization&nbsp;to seek final
	judicial approval of the amounts to be paid pursuant to the Debtor&#146;s Incentive Plan.&nbsp;In April 2010, our counsel, the Official Committee of the Equity Security Holders, and the Directors submitted a proposed settlement to the Bankruptcy
	Court and an order was issued by the Bankruptcy Court approving the Debtor&#146;s Incentive Plan. Under the Debtor&#146;s Incentive Plan, we were directed to distribute an aggregate of $5,000,000 in cash and 302,541 shares of restricted stock having
	a fair value of $6,626,000 in Debtor&#146;s Incentive Plan payments to the Directors. All such restricted stock vested with respect to 1/24th of the total distributed on each monthly anniversary of the vesting commencement date, June&nbsp;22, 2009.
	The total Debtor&#146;s Incentive Plan payments were allocated to Gail Page, James Burns and John Hamilton on a 60%-20%-20% basis, respectively. The contingency was accounted for upon the occurrence of the qualified transaction in January 2010 when
	the Bankruptcy Courts issued a confirmation order approving our Reorganization Plan. There were no Debtor&#146;s Incentive Plan expenses for the year ended December&nbsp;31, 2012. For the year ended December&nbsp;31, 2011, we incurred $1,657,000
	recorded in general and administrative expenses and we distributed 75,637 shares of common stock to the Directors under the Debtor&#146;s Incentive Plan.
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_16"></A>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	NOTE 9: A
<SMALL>
	CCUMULATED
</SMALL>
	O
<SMALL>
	THER
</SMALL>
	C
<SMALL>
	OMPREHENSIVE
</SMALL>
	L
<SMALL>
	OSS
</SMALL>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The components of accumulated other comprehensive loss as of December&nbsp;31, 2012 and 2011, were as follows:
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="71%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="11%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="11%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Year&nbsp;Ended&nbsp;December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:49PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	(In thousands)
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	&nbsp;&nbsp;&nbsp;&nbsp;2011&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Cumulative translation adjustment
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(153
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Accumulated other comprehensive loss
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(153
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-19
</FONT>
</P>
<A NAME="eolPage99"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_17"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	NOTE 10: L
<SMALL>
	OSS
</SMALL>
	P
<SMALL>
	ER
</SMALL>
	S
<SMALL>
	HARE
</SMALL>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The reconciliation of the numerators and denominators of basic and diluted loss per share for the years ended
	December&nbsp;31, 2012 and 2011 was as follows:
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="69%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:126PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	(In thousands, except per share data)
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Loss
<BR>
	(Numerator)
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Shares
<BR>
	(Denominator)
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Per&nbsp;Share
<BR>
	Amount
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Year ended December&nbsp;31, 2011:
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net loss&#151;basic
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(17,790
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	14,249,570
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(1.25
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted
	stock awards
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net loss&#151;diluted
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(17,790
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	14,249,570
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(1.25
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Year ended December&nbsp;31, 2012:
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net loss&#151;basic
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(7,146
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	15,010,868
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(0.48
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted
	stock awards
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net loss&#151;diluted
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(7,146
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	15,010,868
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(0.48
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Due to net losses for the years ended December&nbsp;31, 2012 and 2011, diluted loss per share is
	calculated using the weighted average number of common shares outstanding and excludes the effects of potential common stock shares that are antidilutive. The potential shares of common stock that have been excluded from the diluted loss per share
	calculation above for the years ended December&nbsp;31, 2012 and 2011 were as follows:
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_18"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="70%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Year Ended December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2012
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2011
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Stock options
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,092,374
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	930,060
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Stock warrants
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	63,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	216,012
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Restricted stock units
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8,334
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	114,748
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Potential common shares
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,163,708
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,260,820
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	NOTE 11: E
<SMALL>
	MPLOYEE
</SMALL>
	B
<SMALL>
	ENEFIT
</SMALL>
	P
<SMALL>
	LANS
</SMALL>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	2000 Stock Plan
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Under the Amended and Restated 2000 Stock Plan (the &#147;2000 Plan&#148;), options may be granted at prices not lower than 85% and 100% of the fair market value of the common stock for non-statutory and
	statutory stock options, respectively. Options generally vest monthly over a period of four years and unexercised options generally expire ten years from the date of grant. The authority of our Board of Directors to grant new stock options and
	awards under the 2000 Plan terminated in 2010. Options to purchase 8,333 and 21,833 shares of common stock were exercised during the years ended December&nbsp;31, 2012 and 2011, respectively. As of December&nbsp;31, 2012, options to purchase 336,656
	shares of common stock remained outstanding under the 2000 Plan. No additional shares of our common stock were reserved for future option grants under the 2000 Plan.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	2010 Stock Incentive Plan
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On February&nbsp;8, 2010, our Board of
	Directors approved the Vermillion, Inc. 2010 Stock Incentive Plan (the &#147;2010 Plan&#148;). The 2010 Plan is administered by the Compensation Committee of the Board of Directors. Our employees, directors, and consultants are eligible to receive
	awards under the 2010 Plan. The 2010 Plan permits the granting of a variety of awards, including stock options, share appreciation rights, restricted shares, restricted
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-20
</FONT>
</P>
<A NAME="eolPage100"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	share units, unrestricted shares, deferred share units, performance and cash-settled awards, and dividend equivalent rights. The 2010 Plan provides for issuance of up to 1,322,983 shares of
	common stock, par value $0.001 per share under the 2010 Plan, subject to adjustment as provided in the 2010 Plan. Unexercised options generally expire ten years from the date of grant. There were no 2010 Plan option exercises for the years ended
	December&nbsp;31, 2012 and 2011.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	During the year ended December&nbsp;31, 2011, we awarded 177,000 shares of restricted stock
	from the 2010 Plan having a fair value of $724,000 to our executive officers. All such restricted stock vests ratably on a quarterly basis over a three year period beginning on the vesting commencement in March 2011. We distributed 78,415 and 42,250
	of these shares of common stock to our officers during the years ended December&nbsp;31, 2012 and 2011, respectively.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In
	September 2011, our Board of Directors approved the Company making income tax gross-up payments to our now former Chief Executive Officer in connection with the distribution of the 85,000 shares of restricted stock granted on March&nbsp;18, 2011. A
	letter agreement to this effect was executed on October&nbsp;3, 2011. We expensed approximately $36,000 and $22,000 related to this letter agreement during the year ended December&nbsp;31, 2012 and 2011, respectively. All 85,000 common shares have
	been distributed as of December&nbsp;31, 2012.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	During the year ended December&nbsp;31, 2012, we issued 212,500 shares of
	restricted stock from the 2010 Plan having a fair value of $414,000 to the Board of Directors as payment for services rendered in 2012. During the year ended December&nbsp;31, 2011, we issued 97,295 shares of restricted stock from the 2010 Plan
	having a fair value of $373,000 to the Board of Directors as payment for services rendered in 2011.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The activity related to
	shares available for grant under the 2000 Plan and 2010 Plan for the years ended December&nbsp;31, 2012 and 2011 were as follows:
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_19"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="71%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2000
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Stock
<BR>
	Plan
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2010
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Stock
<BR>
	Option
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Plan
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Total
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Shares available at December&nbsp;31, 2010
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,013,983
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,013,983
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Options canceled
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	28,605
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	60,917
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	89,522
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Reduction in shares reserved
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(28,605
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(28,605
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Options granted
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(191,930
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(191,930
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Restricted stock units canceled
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	20,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	20,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Restricted stock units granted
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(274,295
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(274,295
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Shares available at December&nbsp;31, 2011
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	628,675
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	628,675
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Options canceled
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	251,058
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	136,595
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	387,653
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Reduction in shares reserved
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(251,058
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(251,058
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Options granted
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(558,300
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(558,300
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Restricted stock units canceled
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	28,001
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	28,001
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Restricted stock units granted
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(212,500
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(212,500
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Shares available at December&nbsp;31, 2012
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	22,471
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	22,471
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-21
</FONT>
</P>
<A NAME="eolPage101"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The stock option activity under the 2000 Plan and 2010 Plan for the years ended
	December&nbsp;31, 2012 and 2011 was as follows:
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_20"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="55%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Number of
<BR>
	Shares
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Weighted
<BR>
	Average
<BR>
	Exercise
<BR>
	Price
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Aggregate
<BR>
	Intrinsic
<BR>
	Value
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Weighted
<BR>
	Average
<BR>
	Remaining
<BR>
	Contractual
<BR>
	Term
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Options outstanding at December&nbsp;31, 2010
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	849,485
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	16.13
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,924
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5.81
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Granted
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	191,930
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2.40
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Exercised
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(21,833
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.55
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Canceled
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(89,522
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	23.04
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Options outstanding at December&nbsp;31, 2011
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	930,060
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12.97
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	16
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5.90
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Granted
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	558,300
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.54
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Exercised
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(8,333
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0.75
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Canceled
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(387,653
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	21.57
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Options outstanding at December&nbsp;31, 2012
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,092,374
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4.17
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	20
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	6.23
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Shares exercisable:
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	December&nbsp;31, 2012
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	606,215
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5.73
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3.85
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="5">
</TD>
<TD HEIGHT="5" COLSPAN="4">
</TD>
<TD HEIGHT="5" COLSPAN="4">
</TD>
<TD HEIGHT="5" COLSPAN="4">
</TD>
<TD HEIGHT="5" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Shares expected to vest:
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	December&nbsp;31, 2012
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	398,650
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2.23
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	9.20
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The range of exercise prices for options outstanding and exercisable at December&nbsp;31, 2012 are as follows:
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_21"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="21%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="11%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="11%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="11%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="11%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="11%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:48PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Exercise Price
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Options
<BR>
	Outstanding
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Weighted Average
<BR>
	Exercise Price
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Weighted Average
<BR>
	Remaining Life in
<BR>
	Years
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Options
<BR>
	Exercisable
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Weighted Average
<BR>
	Exercise Price
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$0.01&nbsp;&#150;&nbsp;$1.61
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	115,500
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.16
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	9.45
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	21,239
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0.95
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;1.62&nbsp;&#150;&nbsp;1.62
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	437,288
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.62
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	6.90
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	179,338
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.62
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;1.63&nbsp;&#150;&nbsp;2.04
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	202,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.98
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8.04
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	94,734
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2.00
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;2.05&nbsp;&#150;&nbsp;2.30
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	136,709
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2.30
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2.27
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	135,209
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2.30
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;2.31&nbsp;&#150;&nbsp;5.16
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	24,430
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4.38
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8.23
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10,795
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4.39
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;5.17&nbsp;&#150;&nbsp;10.20
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	49,049
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	9.20
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2.52
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	48,059
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	9.19
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.21&nbsp;&#150;&nbsp;14.70
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	71,349
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	13.35
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2.44
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	69,546
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	13.40
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	14.71&nbsp;&#150;&nbsp;86.40
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	56,049
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	26.67
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4.61
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	47,295
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	26.31
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$0.01 &#150;&nbsp;$86.40
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,092,374
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4.17
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	6.23
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	606,215
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5.73
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_22"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="54%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="19%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="19%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:45PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(in thousands)
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	Total&nbsp;Intrinsic&nbsp;Value
<BR>
	of
	Options
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	Exercised
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	Total&nbsp;Fair&nbsp;Value&nbsp;of
<BR>
	Vested Options
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Year ended December&nbsp;31, 2012
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	7
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	525
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Year ended December&nbsp;31, 2011
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	52
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,218
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-22
</FONT>
</P>
<A NAME="eolPage102"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_23"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Stock-Based Compensation
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Employee Stock-based Compensation Expense
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The assumptions used to
	calculate the fair value of options granted under the 2010 Plan that were incorporated in the Black-Scholes pricing model for the years ended December&nbsp;31, 2012 and 2011 were as follows:
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="71%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="13%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="12%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Year&nbsp;Ended&nbsp;December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	&nbsp;&nbsp;&nbsp;&nbsp;2011&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Dividend yield
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Volatility
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	78
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	77
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Risk-free interest rate
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.32
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.28
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Expected lives (years)
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	6.0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5.7
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Weighted average fair value
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.04
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.60
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The allocation of stock-based compensation expense by functional area for the years ended
	December&nbsp;31, 2012 and 2011 was as follows:
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_24"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="70%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="9%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="9%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Year&nbsp;Ended&nbsp;December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:48PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	(in thousands)
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	&nbsp;&nbsp;&nbsp;&nbsp;2011&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Research and development
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	112
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	683
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Sales and marketing
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	203
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	158
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	General and administrative
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	942
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2,442
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,257
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3,283
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have a 100.0% valuation allowance recorded against our deferred tax assets, and as a result ASC 718
	had no effect on income tax expense in the consolidated statement of operations or the consolidated statement of cash flows. As of December&nbsp;31, 2012, total unrecognized compensation cost related to nonvested stock option awards was $531,000 and
	the related weighted average period over which it is expected to be recognized was 1.77 years.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Non-employee Stock-based Compensation
	Expense
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Stock-based compensation expense related to stock options granted to non-employees is recognized as the stock
	options are earned. Certain former employees were converted into consultants to the Company whereby their existing stock options continued to vest, under the original terms of their stock option grants, as they provided consulting services to us.
	The values attributable to these options are amortized over the service period and the unvested portion of these options was remeasured at each vesting date. We believe that the fair value of the stock options is more reliably measurable than the
	fair value of the services received. The fair value of the stock options granted were revalued at each reporting date using the Black-Scholes valuation model as prescribed by ASC 505, &#147;Equity&#148;.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The stock-based compensation expense will fluctuate as the fair market value of the common stock fluctuates. In connection with stock
	options relating to non-employees, we recorded stock-based compensation allocated by functional area for the years ended December&nbsp;31, 2012 and 2011 as follows:
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_25"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="71%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="13%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="13%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Year&nbsp;Ended&nbsp;December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:48PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	(in thousands)
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	&nbsp;&nbsp;&nbsp;&nbsp;2011&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Research and development
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	15
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Sales and marketing
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	General and administrative
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	23
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	38
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	7
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-23
</FONT>
</P>
<A NAME="eolPage103"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	401(k)Plan
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our 401(k) Plan allows eligible employees to defer up to an annual limit of the lesser of 90.0% of eligible compensation or a maximum contribution amount subject to the Internal Revenue Service annual
	contribution limit. We are not required to make contributions under the 401(k) Plan. As of December&nbsp;31, 2012 and 2011, we have not contributed to the 401(k) Plan.
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_26"></A>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	NOTE 12: I
<SMALL>
	NCOME
</SMALL>
	T
<SMALL>
	AXES
</SMALL>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Domestic and foreign components of loss before income taxes for the years ended December&nbsp;31,&nbsp;2012 and 2011
	were as follows:
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="72%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Year&nbsp;Ended&nbsp;December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:48PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	(in thousands)
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	&nbsp;&nbsp;&nbsp;&nbsp;2011&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Domestic
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(7,052
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(17,696
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Foreign
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(94
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(94
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(7,146
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(17,790
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Based on the available objective evidence, management believes it is more likely than not that the net
	deferred tax assets will not be fully realizable. Accordingly, we have provided a full valuation allowance against our net deferred tax assets at December&nbsp;31,&nbsp;2012 and 2011. There was no income tax expense or benefit for the years ended
	December&nbsp;31, 2012 or 2011.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The components of deferred tax assets (liabilities) at December&nbsp;31, 2012 and 2011 were
	as follows:
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_27"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="72%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="9%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Year&nbsp;Ended&nbsp;December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:48PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	(in thousands)
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	&nbsp;&nbsp;&nbsp;&nbsp;2011&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Deferred tax assets:
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Depreciation and amortization
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8,955
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11,158
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Other
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,431
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,617
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net operating losses
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	46,918
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	42,443
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total deferred tax assets
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	57,304
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	55,218
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Valuation allowance
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(57,296
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(55,210
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net deferred tax assets
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Deferred tax liabilities:
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Other
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(8
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(8
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total deferred tax liabilities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(8
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(8
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net deferred tax asset (liabilitiy)
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-24
</FONT>
</P>
<A NAME="eolPage104"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The reconciliation of the statutory federal income tax rate to the Company&#146;s effective
	tax rate for the years ended December&nbsp;31, 2012 and 2011 was as follows:
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_28"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="71%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="13%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="12%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Year&nbsp;Ended&nbsp;December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2012
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2011
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Tax at federal statutory rate
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	34&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	34&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	State tax, net of federal benefit
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Valuation allowance
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(31
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(17
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Change in warrant valuation
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net operating loss and credit reduction due to section 382 limitations
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(35
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(11
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Permanent items
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	25
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(9
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Other
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Effective income tax rate
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;&nbsp;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	As of December&nbsp;31, 2012, we had a net operating loss of approximately $133,000,000 for federal and
	$108,000,000 for state tax purposes. If not utilized, these carryforwards will begin to expire beginning in 2017 for federal purposes. The state carryforwards began to expire in 2012. In 2012, approximately $2,100,000 of state net operating loss
	expired and approximately $1,800,000 will expire in 2013. As of December&nbsp;31, 2011, we had a net operating loss of approximately $114,000,000 for federal and $87,000,000 for state tax purposes.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our ability to use our net operating loss credit carryforwards may be restricted due to ownership change limitations occurring in the
	past or that could occur in the future, as required by Section&nbsp;382 of the Internal Revenue Code of 1986 (&#147;Section 382&#148;), as amended, as well as similar state provisions. These ownership changes may also limit the amount of net
	operating loss credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We
	believe that a Section&nbsp;382 ownership change occurred as a result of our follow-on public offering in February 2011. Any limitation may result in the expiration of a portion of the net operating loss credit carryforwards before utilization and
	any net operating loss credit carryforwards that expire prior to utilization as a result of such limitations will be removed from deferred tax assets with a corresponding reduction of our valuation allowance. Due to the existence of a valuation
	allowance, it is not expected that such limitations, if any, will have an impact on our results of operations or financial position.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	As of December&nbsp;31, 2011, we had $6,300,000 of net operating loss carryforwards from our Japan operations. We liquidated our Japanese subsidiary in December 2012. Accordingly, the deferred tax asset
	and related valuation allowance were written off.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We believe that it is more likely than not that the benefit from certain
	deferred tax assets will not be realized due to the history of our operating losses. In recognition of this risk, we have provided a valuation allowance on the deferred tax assets relating to these assets. The valuation allowance was $57,296,000 and
	$55,210,000 at December&nbsp;31, 2012 and 2011, respectively. The increase of $2,086,000 between 2012 and 2011 is primarily due to adjustments to the domestic deferred tax assets relating to net operating losses.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We file income tax returns in the U.S. and in various state jurisdictions with varying statutes of limitations. We have not been audited
	by the Internal Revenue Service or any state income or franchise tax agency. As of December&nbsp;31, 2012, our federal returns for the years ended 2009 through the current period and most state returns for the years ended 2008 through the current
	period are still open to examination. In addition, all of the net operating losses and research and development credits generated in years earlier than 2009 and 2008, respectively, are still subject to Internal Revenue Service audit. The federal and
	California tax returns for the year ended December&nbsp;31, 2011 reflect research and development carryforwards of $5,586,000 and $5,191,000,
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-25
</FONT>
</P>
<A NAME="eolPage105"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	respectively. We have recognized additional deferred tax assets for federal and California research and development credits of $69,000 and $51,000 for the year ended December&nbsp;31, 2012,
	respectively. As of December&nbsp;31, 2012, our gross unrecognized tax benefits are approximately $10,897,000 which are attributable to research and development credits. A reconciliation of the change in our unrecognized tax benefits is as follows:
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_29"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="63%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:48PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	(in thousands)
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Federal&nbsp;Tax
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	State&nbsp;Tax
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Total
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Balance at December&nbsp;31, 2010
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5,450
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5,089
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10,539
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Increase in tax position during 2011
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	136
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	102
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	238
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Balance at December&nbsp;31, 2011
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5,586
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5,191
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10,777
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Increase in tax postion during 2012
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	69
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	51
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	120
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Balance at December&nbsp;31, 2012
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5,655
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5,242
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10,897
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The increase for the year ended December&nbsp;31, 2012 relates to a tax position taken during the current
	year. The increase for the year ended December&nbsp;31, 2011 is related to tax positions taken during 2011 and prior years. If the $10.9 million of unrecognized income tax benefit is recognized, approximately $10.9&nbsp;million would impact the
	effective tax rate in the period in which each of the benefits is recognized.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We do not expect our unrecognized tax benefits
	to change significantly over the next 12&nbsp;months. We recognize interest and penalties relate to the unrecognized tax benefits within the interest expense line and other expense line, respectively, in the consolidated statement of operations and
	comprehensive loss. We have not recorded any interest or penalties as a result of uncertain tax positions as of December&nbsp;31, 2012 and 2011. Accrued interest and penalties would be included within the related liability in the consolidated
	balance sheet.
</FONT>
</P>
<P STYLE="MARGIN-TOP:18PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	NOTE 13: O
<SMALL>
	THER
</SMALL>
	R
<SMALL>
	ELATED
</SMALL>
	P
<SMALL>
	ARTY
</SMALL>
	T
<SMALL>
	RANSACTIONS
</SMALL>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Consulting Agreements
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On June&nbsp;17, 2011, we entered into a consulting agreement with Bruce A. Huebner, a member of our Board of Directors. Pursuant to the terms of the consulting agreement, Mr.&nbsp;Huebner provided
	consulting services regarding sales, marketing, business development and corporate strategy and was paid $200 per hour. For the year ended December&nbsp;31, 2012 and 2011, the total amount of consulting fee expense for Mr.&nbsp;Huebner was $5,000
	and $9,000, respectively. On November&nbsp;27, 2012, we announced the appointment of Mr.&nbsp;Huebner as Interim Chief Executive Officer. Mr.&nbsp;Huebner continues to serve on our Board of Directors.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On December&nbsp;3, 2012, we entered into a consulting agreement with our former President and Chief Executive Officer and director, Gail
	S. Page. Pursuant to the terms of the consulting agreement, Ms.&nbsp;Page will assist the Company as needed, including providing advice and recommendations with respect to the development and commercialization of the Company&#146;s existing and
	future diagnostic tests, and managing and developing relationships with existing and future collaborators and partners. She will provide a minimum of 48 and a maximum of 96 hours of consulting services per month. In consideration for such services,
	we will pay Ms.&nbsp;Page a monthly fee of $18,000, plus $250 for each hour of services provided in excess of the 48 hour minimum. The Consulting Agreement has an initial term of six months, after which it may be renewed for an additional six month
	term by mutual agreement of the Company and Ms.&nbsp;Page. For the year ended December&nbsp;31, 2012, the total amount of consulting fee expense to Ms.&nbsp;Page was $18,000. The consulting agreement has been terminated with an effective date of
	March&nbsp;15, 2013.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In November 2011, we entered into a consulting agreement with our former Senior Vice President and Chief
	Science Officer, Eric T. Fung, M.D., Ph.D. Pursuant to the terms of the consulting agreement, Dr.&nbsp;Fung served as our Chief Medical Officer and a member of our Scientific Advisory Board. Dr.&nbsp;Fung&#146;s consulting agreement and Scientific
	Advisory Board services were terminated in June 2012. For the year ended December&nbsp;31, 2012 and 2011, the total amount of consulting fee expense for Dr.&nbsp;Fung was $27,000 and $6,000, respectively. During 2012, Dr.&nbsp;Fung also continued to
	vest in restricted stock with a fair value of $11,000 until the termination of the consulting agreement.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-26
</FONT>
</P>
<A NAME="eolPage106"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On March&nbsp;1, 2012, we entered into a consulting agreement with our former Vice President
	of Strategy, who resigned effective February&nbsp;29, 2012. Pursuant to the terms of the consulting agreement, our former Vice President of Strategy provided consulting services. This consulting agreement was terminated in June 2012. For the year
	ended December&nbsp;31, 2012, the total amount of consulting fee expense to our former Vice President of Strategy was $23,000 and the fair value of continued vesting in restricted stock was $1,000 until the termination of the consulting agreement.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	F-27
</FONT>
</P>
<A NAME="eolPage107"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_NOTES_TO_FINANCIAL_STATEMENT>
<EFX_SIGNATURES>
<A NAME="FIS_SIGNATURES"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_TOC453081_25">
</A>
	SIGNATURES
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
	on its behalf by the undersigned, thereunto duly authorized.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">
<TR>
<TD WIDTH="46%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="5%">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="46%">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" COLSPAN="3">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Vermillion, Inc.
</B>
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Date: March 1, 2013
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/s/ Bruce A. Huebner
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Bruce A. Huebner
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Interim Chief Executive Officer
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(Principal Executive Officer)
</FONT>
</P>
</TD>
</TR>
<TR>
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Date: March 1, 2013
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/s/ Eric J. Schoen
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Eric J. Schoen
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Chief Accounting Officer
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following
	persons on behalf of the registrant and in the capacities and on the dates indicated.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">
<TR>
<TD WIDTH="44%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="34%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="18%">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Name
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Title
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Date
</B>
</FONT>
</P>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX;BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/s/ Bruce A. Huebner
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Bruce A. Huebner
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Interim Chief Executive Officer (Principal Executive Officer)
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	March 1, 2013
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX;BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/s/ Eric J. Schoen
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Eric J. Schoen
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Chief Accounting Officer (Principal Financial Officer)
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	March 1, 2013
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX;BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/s/ James S. Burns
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	James S. Burns
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Chairman of the Board of Directors
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	March 1, 2013
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX;BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/s/ John F. Hamilton
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	John F. Hamilton
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Director
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	March 1, 2013
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX;BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/s/ Peter S. Roddy
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Peter S. Roddy
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Director
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	March 1, 2013
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX;BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/s/ Carl Severinghaus
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Carl Severinghaus
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Director
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	March 1, 2013
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX;BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/s/ William C. Wallen, Ph.D.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	William C. Wallen, Ph.D.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Director
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	March 1, 2013
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1
</FONT>
</P>
<A NAME="eolPage108"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_SIGNATURES>
<EFX_EXHIBIT_INDEX>
<A NAME="FIS_EXHIBIT_INDEX"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D453081D10K_HTM_TOC453081_26">
</A>
	INDEX TO EXHIBITS
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_30"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="46%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="5%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="10%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="5%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="17%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="7%">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" COLSPAN="2" ROWSPAN="2" NOWRAP>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Exhibit
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX;BORDER-BOTTOM:1PX SOLID #000000;WIDTH:28PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Number
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX;BORDER-BOTTOM:1PX SOLID #000000;WIDTH:66PT" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Exhibit Description
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="7" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Incorporated by Reference
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Filed
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Herewith
</B>
</FONT>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Form
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	File No.
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Exhibit
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Filing Date
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2.1
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Findings of Fact, Conclusions of Law and Order Confirming Debtor&#146;s (Vermillion Inc.&#146;s) Second Amended Plan of Reorganization Under Chapter 11 of the Bankruptcy Code dated
	January&nbsp;7, 2010
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-31617
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	January&nbsp;12,&nbsp;2010
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3.1
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Fourth Amended and Restated Certificate of Incorporation of Vermillion, Inc. dated January&nbsp;22, 2010
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-31617
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	January&nbsp;25, 2010
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3.2
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Third Amended and Restated Bylaws of Vermillion, Inc., as amended effective May&nbsp;15, 2012
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#252;
</FONT>
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4.1
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Form of Vermillion, Inc.&#146;s (formerly Ciphergen Biosystems, Inc.) Common Stock Certificate
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	S-1/A
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	333-32812
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	August&nbsp;24, 2000
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4.2
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Preferred Shares Rights Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Continental Stock Transfer &amp; Trust Company dated
	March&nbsp;20,&nbsp;2002
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-A
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-31617
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4.2
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	March&nbsp;21, 2002
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4.3
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Amendment to Rights Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Wells Fargo Bank, N.A. dated July&nbsp;22, 2005
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-31617
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4.4
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	July&nbsp;28, 2005
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4.4
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Second Amendment to Rights Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Wells Fargo Bank, N.A. dated September&nbsp;30, 2005
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-31617
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4.5
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	October&nbsp;4, 2005
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4.5
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Third Amendment to Rights Agreement between Vermillion, Inc. and Wells Fargo Bank, N.A., dated September&nbsp;11, 2007
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-31617
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	September&nbsp;12,&nbsp;2007
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1993 Stock Option Plan #
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	S-1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	333-32812
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.3
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	March&nbsp;20, 2000
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.2
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Form of Stock Option Agreement #
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	S-1/A
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	333-32812
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.4
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	August&nbsp;24, 2000
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.3
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2000 Stock Plan and related form of Stock Option Agreement #
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	S-1/A
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	333-32812
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.5
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	August 4, 2000
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.4
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Amended and Restated 2000 Employee Stock Purchase Plan #
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-31617
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.6
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	November&nbsp;14, 2007
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.5
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Vermillion, Inc. 2010 Stock Incentive Plan&nbsp;#
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-31617
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	February&nbsp;12, 2010
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.6
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Ciphergen Biosystems, Inc. 401(k) Plan #
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-31617
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.7
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	March&nbsp;22, 2005
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.7
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Securities Purchase Agreement by and among Vermillion, Inc. and the purchasers party thereto dated August&nbsp;23, 2007
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	S-1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	333-146354
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.57
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	September&nbsp;27, 2007
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1
</FONT>
</P>
<A NAME="eolPage109"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_31"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="46%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="5%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="9%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="5%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="17%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="7%">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" COLSPAN="2" ROWSPAN="2" NOWRAP>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Exhibit
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX;BORDER-BOTTOM:1PX SOLID #000000;WIDTH:28PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Number
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX;BORDER-BOTTOM:1PX SOLID #000000;WIDTH:66PT" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Exhibit Description
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="7" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Incorporated by Reference
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Filed
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Herewith
</B>
</FONT>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Form
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	File No.
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Exhibit
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Filing Date
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.8
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Form of Warrant
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-31617
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.51
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	November&nbsp;14,&nbsp;2007
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.9
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Form of Securities Purchase Agreement between Vermillion, Inc. and the purchasers party thereto dated December&nbsp;24, 2009
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-31617
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	December&nbsp;29, 2009
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.10
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Employment Agreement between Sandra A. Gardiner and Vermillion, Inc. dated April&nbsp;9,&nbsp;2010&nbsp;#
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-31617
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	April 22, 2010
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.11
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Employment Agreement between Gail S. Page and Vermillion, Inc. dated September&nbsp;28, 2010 #
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-34810
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	September&nbsp;30,&nbsp;2010
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.12
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Employment Agreement between Eric T. Fung and Vermillion, Inc. dated September&nbsp;28, 2010 #
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-34810
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.2
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	September 30, 2010
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.13
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Form of Severance Agreement between key executive employees and Vermillion, Inc. #
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-31617
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	August&nbsp;29, 2008
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.14
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Form of Proprietary Information Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and certain of its employees #
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	S-1/A
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	333-32812
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.9
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	August&nbsp;24, 2000
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.15
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Consulting Agreement between Richard G. Taylor and Vermillion, Inc. dated August&nbsp;26,&nbsp;2008 #
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-31617
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	August&nbsp;29, 2008
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.16
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	MAS License Agreement with IllumeSys Pacific, Inc. dated April&nbsp;7, 1997
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	S-1/A
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	333-32812
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.23
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	August&nbsp;24, 2000
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.17
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	MAS License Agreement with Ciphergen Technologies, Inc. (formerly ISP Acquisition Corporation) dated April&nbsp;7,&nbsp;1997
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	S-1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	333-32812
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.24
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	August&nbsp;24, 2000
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.18
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Settlement Agreement and Mutual General Release by and among Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.), IllumeSys Pacific, Inc., Ciphergen Technologies, Inc., Molecular
	Analytical Systems, Inc., LumiCyte, Inc. and T. William Hutchens dated May&nbsp;28,&nbsp;2003 &#134;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-31617
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	99.2
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	June&nbsp;11, 2003
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.19
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Assignment Agreement by and among Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.), IllumeSys Pacific, Inc., Ciphergen Technologies, Inc., Molecular Analytical Systems, Inc.,
	LumiCyte, Inc. and T. William Hutchens dated May&nbsp;28,&nbsp;2003 &#134;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-31617
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	99.3
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	June&nbsp;11, 2003
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.20
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	License Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Molecular Analytical Systems, Inc. dated May&nbsp;28, 2003 &#134;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-31617
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	99.4
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	June&nbsp;11, 2003
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2
</FONT>
</P>
<A NAME="eolPage110"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_32"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="45%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="5%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="10%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="5%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="17%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="7%">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" COLSPAN="2" ROWSPAN="2" NOWRAP>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Exhibit
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX;BORDER-BOTTOM:1PX SOLID #000000;WIDTH:28PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Number
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX;BORDER-BOTTOM:1PX SOLID #000000;WIDTH:66PT" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Exhibit Description
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="7" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Incorporated by Reference
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Filed
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Herewith
</B>
</FONT>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Form
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	File No.
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Exhibit
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Filing Date
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.21
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Collaborative Research Agreement between University College London, UCL Biomedica plc and Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) dated
	September&nbsp;22,&nbsp;2005&nbsp;&#134;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-31617
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.54
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	March&nbsp;17,&nbsp;2006
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.22
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Distribution and Marketing Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Ciphergen Biosystems KK dated March&nbsp;24, 1999
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	S-1/A
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	333-32812
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.26
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	September&nbsp;22,&nbsp;2000
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.23
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Strategic Alliance Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Quest Diagnostics Incorporated dated July&nbsp;22, 2005
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-31617
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.44
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	July&nbsp;28, 2005
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.24
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Amendment to Strategic Alliance Agreement between Vermillion, Inc. and Quest Diagnostics Incorporated dated October&nbsp;7, 2009
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-31617
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.2
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	October&nbsp;21, 2009
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.25
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Amendment to Strategic Alliance Agreement between Vermillion, Inc. and Quest Diagnostics Incorporated dated November&nbsp;10, 2010
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-34810
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	November 12, 2010
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.26
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Amendment No. 5 to Strategic Alliance Agreement by and among Vermillion, Inc. and Quest Diagnostics Incorporated and Quest Diagnostics India Private Limited, dated
	April&nbsp;2,&nbsp;2011&#134;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	001-34810
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	May 10, 2011
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.27
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Stock Purchase Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Quest Diagnostics Incorporated dated July&nbsp;22,&nbsp;2005
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-31617
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.45
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	July&nbsp;28, 2005
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.28
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Warrant between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Quest Diagnostics Incorporated dated July&nbsp;22,&nbsp;2005
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-31617
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.46
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	July&nbsp;22, 2005
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.29
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Amendment to Warrant between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Quest Diagnostics Incorporated dated August&nbsp;29, 2007
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-31617
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.2
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	August&nbsp;29, 2007
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.30
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Letter Agreement between Vermillion, Inc. and Quest Diagnostics Incorporated dated&nbsp;August&nbsp;29,&nbsp;2007
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	S-1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	333-146354
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.38
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	September&nbsp;27, 2007
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.31
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Credit Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Quest Diagnostics Incorporated dated July&nbsp;22, 2005
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-31617
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.47
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	July&nbsp;28, 2005
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3
</FONT>
</P>
<A NAME="eolPage111"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_33"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="43%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="5%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="10%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="7%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="17%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="7%">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" COLSPAN="2" ROWSPAN="2" NOWRAP>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Exhibit
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX;BORDER-BOTTOM:1PX SOLID #000000;WIDTH:28PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Number
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX;BORDER-BOTTOM:1PX SOLID #000000;WIDTH:66PT" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Exhibit Description
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="7" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Incorporated by Reference
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Filed
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Herewith
</B>
</FONT>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Form
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	File No.
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Exhibit
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Filing Date
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.32
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Debtor-In-Possession Credit and Security Agreement between Vermillion, Inc. and Quest Diagnostics Incorporated dated October&nbsp;7, 2009
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-31617
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	October&nbsp;21, 2009
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.33
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Memorialization Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Quest Diagnostics Incorporated dated January&nbsp;12, 2006
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	S-1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	333-146354
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.40
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	September&nbsp;27,&nbsp;2007
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.34
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Patent Security Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Quest Diagnostics Incorporated dated July&nbsp;22, 2005
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-31617
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.48
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	July&nbsp;28, 2005
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.35
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Asset Purchase Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Bio-Rad Laboratories, Inc. dated August&nbsp;14, 2006
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	14a
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-31617
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Annex&nbsp;A
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	September&nbsp;12, 2006
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.36
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Amendment to Asset Purchase Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Bio-Rad Laboratories, Inc. dated November&nbsp;13,&nbsp;2006
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	S-1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	333-146354
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.47
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	September&nbsp;27, 2007
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.37
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Stock Purchase Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Bio-Rad Laboratories, Inc. dated November&nbsp;13,&nbsp;2006
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	S-1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	333-146354
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.48
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	September&nbsp;27, 2007
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.38
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Transition Services Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Bio-Rad Laboratories, Inc. dated November&nbsp;13,&nbsp;2006 &#134;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	S-1/A
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	333-146354
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.53
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	November&nbsp;27, 2007
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.39
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Amendment No.&nbsp;1 to Transition Services Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Bio-Rad Laboratories, Inc. dated
	May&nbsp;11,&nbsp;2007
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	S-1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	333-146354
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.50
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	September&nbsp;27, 2007
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.40
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Amendment No.&nbsp;2 to Transition Services Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Bio-Rad Laboratories, Inc. dated
	June&nbsp;15,&nbsp;2007
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	S-1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	333-146354
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.51
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	September&nbsp;27, 2007
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.41
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Manufacture and Supply Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Bio-Rad Laboratories, Inc. dated November&nbsp;13,&nbsp;2006 &#134;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	S-1/A
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	333-146354
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.56
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	November&nbsp;27, 2007
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4
</FONT>
</P>
<A NAME="eolPage112"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_34"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="45%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="6%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="10%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="5%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="17%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="7%">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" COLSPAN="2" ROWSPAN="2" NOWRAP>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Exhibit
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX;BORDER-BOTTOM:1PX SOLID #000000;WIDTH:28PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Number
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX;BORDER-BOTTOM:1PX SOLID #000000;WIDTH:66PT" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Exhibit Description
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="7" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Incorporated by Reference
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Filed
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Herewith
</B>
</FONT>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Form
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	File No.
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Exhibit
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Filing Date
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.42
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Amendment No.&nbsp;1 to Manufacture and Supply Agreement between Vermillion, Inc. and Bio-Rad Laboratories, Inc. dated August&nbsp;27, 2007
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	S-1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	333-146354
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.53
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	September&nbsp;27, 2007
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.43
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Cross License Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Bio-Rad Laboratories, Inc. dated November&nbsp;13,&nbsp;2006 &#134;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	S-1/A
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	333-146354
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.58
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	November&nbsp;27, 2007
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.44
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Sublicense Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Bio-Rad Laboratories, Inc. dated November&nbsp;13,&nbsp;2006
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	S-1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	333-146354
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.13
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	September&nbsp;27, 2007
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.45
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Letter Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Bio-Rad Laboratories, Inc. dated November&nbsp;13, 2006
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	S-1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	333-146354
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.55
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	September&nbsp;27,&nbsp;2007
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.46
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Sublease Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and Bio-Rad Laboratories, Inc. dated November&nbsp;13, 2006 &#134;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	S-1/A
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	333-146354
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.60
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	November&nbsp;27,&nbsp;2007
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.47
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Exclusive Distribution Agreement between Vermillion, Inc. and Pronto Diagnostics Ltd., dated August 1, 2011&#134;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	001-34810
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	August&nbsp;9,&nbsp;2011
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.48
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Consulting Agreement between Vermillion, Inc. and Bruce A. Huebner, dated June&nbsp;17,&nbsp;2011#
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	001-34810
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.2
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	August 9, 2011
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.49
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Consulting Agreement between Vermillion, Inc. and Eric T. Fung, dated November&nbsp;4,&nbsp;2011#
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	001-34810
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	November 9, 2011
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.50
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Asset Purchase Agreement between Vermillion, Inc. and Correlogic Systems, Inc., dated November 8, 2011
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	001-34810
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.50
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	March 27, 2012
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.51
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Employment Agreement between Eric J. Schoen and Vermillion, Inc. dated April&nbsp;4,&nbsp;2012 #
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	001-34810
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	April 10, 2012
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.52
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Employment Agreement between William Creech and Vermillion, Inc. dated April&nbsp;4,&nbsp;2012 #
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	001-34810
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.2
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	April 10, 2012
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.53
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Settlement Agreement and Release between Vermillion, Inc. and Oppenheimer &amp; Co., Inc. dated February&nbsp;9, 2012
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-K/A
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	001-34810
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.51
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	May 30, 2012
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.54
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Employment Agreement between Bruce A. Huebner and Vermillion, Inc. dated November 26, 2012 #
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	001-34810
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	November 28, 2012
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5
</FONT>
</P>
<A NAME="eolPage113"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="44%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="4%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="9%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="5%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="17%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="7%">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" COLSPAN="2" ROWSPAN="2" NOWRAP>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Exhibit
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX;BORDER-BOTTOM:1PX SOLID #000000;WIDTH:28PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Number
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX;BORDER-BOTTOM:1PX SOLID #000000;WIDTH:66PT" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Exhibit Description
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="7" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Incorporated by Reference
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Filed
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Herewith
</B>
</FONT>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Form
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	File No.
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Exhibit
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Filing Date
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.55
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Consulting Agreement between Gail S. Page and Vermillion, Inc. dated December&nbsp;3,&nbsp;2012&nbsp;#
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	001-34810
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.2
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	November&nbsp;28,&nbsp;2012
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.56
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Separation Agreement and Release between Gail Page and Vermillion, Inc. dated December 7, 2012 #
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	001-34810
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	December 11, 2012
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	14.1
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Code of Ethics
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	001-34810
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	14.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	December 7, 2010
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	21.0
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Subsidiaries of Registrant
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#252;
</FONT>
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	23.1
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Consent of BDO USA, LLP, Independent Registered Public Accounting Firm
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#252;
</FONT>
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	23.2
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting&nbsp;Firm
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#252;
</FONT>
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	31.1
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#252;
</FONT>
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	31.2
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Certification of the Chief Accounting Officer Pursuant to Section 302 of the Sarbanes-Oxley Act&nbsp;of&nbsp;2002
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#252;
</FONT>
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	32.0
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Certification of the Chief Executive Officer and Chief Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
	Act&nbsp;of&nbsp;2002
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(1)
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	101.INS
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	XBRL Instance Document
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(1)
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	101.SCH
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	XBRL Taxonomy Extension Schema Document
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(1)
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	101.CAL
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	XBRL Taxonomy Extension Calculation Linkbase Document
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(1)
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	101.DEF
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	XBRL Taxonomy Extension Definition Linkbase Document
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	101.LAB
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	XBRL Taxonomy Extension Label Linkbase Document
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(1)
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	101.PRE
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	XBRL Taxonomy Extension Presentation Linkbase Document
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(1)
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Attached as Exhibit&nbsp;101 to this report are documents formatted in XBRL (Extensible Business Reporting Language).
	Users of this data are advised that, pursuant to Rule&nbsp;406T of Regulation&nbsp;S-T, the interactive data file is deemed not filed or part of a registration statement or prospectus for purposes of Sections&nbsp;11 or 12 of the Securities Act of
	1933, as amended, is deemed not filed for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended, and is otherwise not subject to liability under these sections.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	6
</FONT>
</P>
<A NAME="eolPage114"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D453081D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(1)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Furnished herewith
</FONT>
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	#
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Management contracts or compensatory plan or arrangement.
</FONT>
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#134;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Confidential treatment has been granted with respect to certain provisions of this agreement. Omitted portions have been filed separately with the SEC.
</FONT>
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#134;&#134;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Certain portions of this exhibit have been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to such omitted portions.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	7
</FONT>
</P>
</EFX_EXHIBIT_INDEX>
</EFX_FORM>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage115"></A>
<A NAME="D453081DEX32_HTM"></A>
<EFX_EXHIBIT_3>
<A NAME="FIS_EXHIBIT_3"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Exhibit 3.2
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE:120PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:120PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<EFX_BY-LAWS>
<A NAME="FIS_BY-LAWS"></A>
<P STYLE="MARGIN-TOP:42PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="3">
<B>
	THIRD AMENDED AND RESTATED BYLAWS
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="3">
<B>
	OF
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="3">
<B>
	VERMILLION, INC.
</B>
</FONT>
</P>
<A NAME="eolPage116"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	TABLE OF CONTENTS
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="8%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD WIDTH="84%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
	&nbsp;
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="RIGHT" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
<U>
	Page
</U>
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" COLSPAN="3">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_1">
	ARTICLE I&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CORPORATE OFFICES
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_2">
	REGISTERED OFFICE
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_3">
	OTHER OFFICES
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" COLSPAN="3">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_4">
	ARTICLE II&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MEETINGS OF STOCKHOLDERS
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_5">
	PLACE OF MEETINGS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_6">
	ANNUAL MEETING
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_7">
	SPECIAL MEETING
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_8">
	NOTICE OF STOCKHOLDERS&#146; MEETINGS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_9">
	MANNER OF GIVING NOTICE; AFFIDAVIT OF NOTICE
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.6
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_10">
	QUORUM
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.7
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_11">
	ADJOURNED MEETING; NOTICE
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.8
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_12">
	VOTING
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.9
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_13">
	WAIVER OF NOTICE
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.10
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_14">
	RECORD DATE FOR STOCKHOLDER NOTICE; VOTING; GIVING CONSENTS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.11
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_15">
	PROXIES
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.12
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_16">
	LIST OF STOCKHOLDERS ENTITLED TO VOTE
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.13
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_17">
	ADVANCE NOTICE PROVISIONS FOR STOCKHOLDER PROPOSALS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.14
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_18">
	ADVANCE NOTICE PROVISIONS FOR STOCKHOLDER NOMINATIONS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	6
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" COLSPAN="3">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_19">
	ARTICLE III&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DIRECTORS
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_20">
	POWERS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_21">
	NUMBER OF DIRECTORS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_22">
	ELECTION, QUALIFICATION AND TERM OF OFFICE OF DIRECTORS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_23">
	RESIGNATION AND VACANCIES
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	9
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.5
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_24">
	PLACE OF MEETINGS; MEETINGS BY TELEPHONE
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	9
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.6
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_25">
	FIRST MEETINGS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	9
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.7
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_26">
	REGULAR MEETINGS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.8
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_27">
	SPECIAL MEETINGS; NOTICE
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.9
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_28">
	QUORUM
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.10
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_29">
	WAIVER OF NOTICE
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.11
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_30">
	ADJOURNED MEETING; NOTICE
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.12
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_31">
	BOARD ACTION BY WRITTEN CONSENT WITHOUT A MEETING
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.13
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_32">
	FEES AND COMPENSATION OF DIRECTORS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.14
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_33">
	APPROVAL OF LOANS TO OFFICERS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.15
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_34">
	REMOVAL OF DIRECTORS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" COLSPAN="3">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_35">
	ARTICLE IV&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;COMMITTEES
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_36">
	COMMITTEES OF DIRECTORS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_37">
	COMMITTEE MINUTES
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_38">
	MEETINGS AND ACTION OF COMMITTEES
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" COLSPAN="3">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_39">
	ARTICLE V&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;OFFICERS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_40">
	OFFICERS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_41">
	ELECTION OF OFFICERS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_42">
	SUBORDINATE OFFICERS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_43">
	REMOVAL AND RESIGNATION OF OFFICERS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.5
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_44">
	VACANCIES IN OFFICES
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	-i-
</FONT>
</P>
<A NAME="eolPage117"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	TABLE OF CONTENTS
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(continued)
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="8%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD WIDTH="84%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
	&nbsp;
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="RIGHT" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
<U>
	Page
</U>
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.6
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_45">
	CHAIRMAN OF THE BOARD
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.7
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_46">
	PRESIDENT
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	13
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.8
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_47">
	VICE PRESIDENT
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	13
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.9
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_48">
	SECRETARY
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	13
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.10
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_49">
	TREASURER
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	13
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.11
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_50">
	ASSISTANT SECRETARY
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	13
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.12
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_51">
	ASSISTANT TREASURER
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	14
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.13
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_52">
	AUTHORITY AND DUTIES OF OFFICERS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	14
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" COLSPAN="3">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_53">
	ARTICLE VI&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;INDEMNITY
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	14
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_54">
	INDEMNIFICATION OF DIRECTORS AND OFFICERS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	14
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_55">
	INDEMNIFICATION OF OTHERS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	14
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_56">
	INSURANCE
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	14
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" COLSPAN="3">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_57">
	ARTICLE VII&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RECORDS AND REPORTS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	15
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_58">
	MAINTENANCE AND INSPECTION OF RECORDS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	15
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_59">
	INSPECTION BY DIRECTORS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	15
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_60">
	ANNUAL STATEMENT TO STOCKHOLDERS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	15
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.4
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_61">
	REPRESENTATION OF SHARES OF OTHER CORPORATIONS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	15
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" COLSPAN="3">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_62">
	ARTICLE VIII&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;GENERAL MATTERS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	16
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.1
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_63">
	CHECKS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	16
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.2
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_64">
	EXECUTION OF CORPORATE CONTRACTS AND INSTRUMENTS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	16
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.3
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_65">
	STOCK CERTIFICATES; PARTLY PAID SHARES
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	16
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.4
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_66">
	SPECIAL DESIGNATION ON CERTIFICATES
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	16
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.5
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_67">
	LOST CERTIFICATES
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	17
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.6
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_68">
	CONSTRUCTION; DEFINITIONS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	17
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.7
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_69">
	DIVIDENDS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	17
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.8
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_70">
	FISCAL YEAR
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	17
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.9
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_71">
	SEAL
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	17
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.10
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_72">
	TRANSFER OF STOCK
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	17
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.11
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_73">
	STOCK TRANSFER AGREEMENTS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	17
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.12
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_74">
	REGISTERED STOCKHOLDERS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	17
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" COLSPAN="3">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_75">
	ARTICLE IX&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AMENDMENTS
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	18
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" COLSPAN="3">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_76">
	ARTICLE X&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DISSOLUTION
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	18
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" COLSPAN="3">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_77">
	ARTICLE XI&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CUSTODIAN
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	18
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.1
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_78">
	APPOINTMENT OF A CUSTODIAN IN CERTAIN CASES
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	18
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.2
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D453081DEX32_HTM_EX453081_79">
	DUTIES OF CUSTODIAN
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	19
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	-ii-
</FONT>
</P>
<A NAME="eolPage118"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	THIRD AMENDED AND RESTATED BYLAWS
</U>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	OF
</U>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	VERMILLION, INC.
</U>
</FONT>
</P>
<P STYLE="MARGIN-TOP:24PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ARTICLE I
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
<A NAME="D453081DEX32_HTM_EX453081_1">
</A>
	CORPORATE OFFICES
</U>
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.1
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
<A NAME="D453081DEX32_HTM_EX453081_2">
</A>
	REGISTERED OFFICE
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The registered office of the corporation shall be in the City of Wilmington, County of New Castle, State of Delaware. The name of the registered agent of the corporation at such location is Corporation
	Trust Company.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.2
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
<A NAME="D453081DEX32_HTM_EX453081_3">
</A>
	OTHER OFFICES
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The board of directors may at any time establish other offices at any place or places where the corporation is qualified to do business.
</FONT>
</P>
<P STYLE="MARGIN-TOP:24PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_4">
</A>
	ARTICLE II
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	MEETINGS OF STOCKHOLDERS
</U>
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2.1
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
<A NAME="D453081DEX32_HTM_EX453081_5">
</A>
	PLACE OF MEETINGS
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Meetings of stockholders shall be held at any place, within or outside the State of Delaware, designated by the board of directors. In the absence of any such designation, stockholders&#146; meetings
	shall be held at the registered office of the corporation.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2.2
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
<A NAME="D453081DEX32_HTM_EX453081_6">
</A>
	ANNUAL MEETING
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The annual meeting of stockholders shall be held each year on a date and at a time designated by the board of directors. In the absence of such designation, the annual meeting of stockholders shall be
	held on the Second Tuesday of May in each year at 10:00&nbsp;a.m. However, if such day falls on a legal holiday, then the meeting shall be held at the same time and place on the next succeeding full business day. At the meeting, directors shall be
	elected and any other proper business may be transacted.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2.3
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
<A NAME="D453081DEX32_HTM_EX453081_7">
</A>
	SPECIAL MEETING
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	A special meeting of the stockholders may be called, at any time for any purpose or purposes, by the board of directors.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2.4
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
<A NAME="D453081DEX32_HTM_EX453081_8">
</A>
	NOTICE OF STOCKHOLDERS&#146; MEETINGS
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	All notices of meetings with stockholders shall be in writing and shall be sent or otherwise given in accordance with Section&nbsp;2.5 of these bylaws not less than ten&nbsp;(10) nor more than sixty
	(60)&nbsp;days before the date of the meeting to each stockholder entitled to vote at such meeting. The notice shall specify the place, date, and hour of the meeting, and, in the case of a special meeting, the purpose or purposes for which the
	meeting is called.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2.5
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
<A NAME="D453081DEX32_HTM_EX453081_9">
</A>
	MANNER OF GIVING NOTICE; AFFIDAVIT OF NOTICE
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Written notice of any meeting of stockholders, if mailed, is given when deposited in the United States mail, postage prepaid, directed to the stockholder at his address as it appears on the records of the
	corporation. An affidavit of the secretary or an assistant secretary or of the transfer agent of the corporation that the notice has been given shall, in the absence of fraud, be prima facie evidence of the facts stated therein.
</FONT>
</P>
<A NAME="eolPage119"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2.6
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
<A NAME="D453081DEX32_HTM_EX453081_10">
</A>
	QUORUM
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The holders of a majority of the stock issued and outstanding and entitled to vote thereat, present in person or represented by proxy, shall constitute a quorum at all meetings of the stockholders for the
	transaction of business except as otherwise provided by statute or by the certificate of incorporation. If, however, such quorum is not present or represented at any meeting of the stockholders, then the stockholders entitled to vote thereat,
	present in person or represented by proxy, shall have power to adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum is present or represented. At such adjourned meeting at which a quorum is
	present or represented, any business may be transacted that might have been transacted at the meeting as originally noticed.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2.7
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
<A NAME="D453081DEX32_HTM_EX453081_11">
</A>
	ADJOURNED MEETING; NOTICE
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	When a meeting is adjourned to another time or place, unless these bylaws otherwise require, notice need not be given of the adjourned meeting if the time and place thereof are announced at the meeting at
	which the adjournment is taken. At the adjourned meeting the corporation may transact any business that might have been transacted at the original meeting. If the adjournment is for more than thirty (30)&nbsp;days, or if after the adjournment a new
	record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2.8
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
<A NAME="D453081DEX32_HTM_EX453081_12">
</A>
	VOTING
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The stockholders entitled to vote at any meeting of stockholders shall be determined in accordance with the provisions of Section&nbsp;2.11 of these bylaws, subject to the provisions of Sections&nbsp;217
	and 218 of the General Corporation Law of Delaware (relating to voting rights of fiduciaries, pledgors and joint owners of stock and to voting trusts and other voting agreements).
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Except as may be otherwise provided in the Certificate of Incorporation, each stockholder shall be entitled to one vote for each share of
	capital stock held by such stockholder.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2.9
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
<A NAME="D453081DEX32_HTM_EX453081_13">
</A>
	WAIVER OF NOTICE
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Whenever notice is required to be given under any provision of the General Corporation Law of Delaware or of the certificate of incorporation or these bylaws, a written waiver thereof, signed by the
	person entitled to notice, whether before or after the time stated therein, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for
	the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special
	meeting of the stockholders need be specified in any written waiver of notice unless so required by the certificate of incorporation or these bylaws.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2.10
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
<U>
<A NAME="D453081DEX32_HTM_EX453081_14">
</A>
	RECORD DATE FOR STOCKHOLDER NOTICE; VOTING; GIVING CONSENTS
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In order that the corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any
	adjournment thereof, or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful
	action, the board of directors may fix, in advance, a record date, which shall not be more than sixty&nbsp;(60) nor less than ten (10)&nbsp;days before the date of such meeting, nor more than sixty (60)&nbsp;days prior to any other action.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	If the board of directors does not so fix a record date:
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(a)&nbsp;&nbsp;&nbsp;&nbsp;The record date for determining stockholders entitled to notice of or to vote at a meeting of
	stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	-2-
</FONT>
</P>
<A NAME="eolPage120"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(b)&nbsp;&nbsp;&nbsp;&nbsp;The record date for determining stockholders
	entitled to express consent to corporate action in writing without a meeting when no prior action by the board of directors is necessary, shall be the day on which the first written consent is expressed.
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(c)&nbsp;&nbsp;&nbsp;&nbsp;The record date for determining stockholders for any other purpose shall be at the close of
	business on the day on which the board of directors adopts the resolution relating thereto.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	A determination of stockholders
	of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the board of directors may fix a new record date for the adjourned meeting.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_15">
</A>
	2.11
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
<U>
	PROXIES
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Each
	stockholder entitled to vote at a meeting of stockholders or to express consent or dissent to corporate action may authorize another person or persons to act for him by a written proxy, signed by the stockholder and filed with the secretary of the
	corporation, but no such proxy shall be voted or acted upon after three (3)&nbsp;years from its date, unless the proxy provides for a longer period. A proxy shall be deemed signed if the stockholder&#146;s name is placed on the proxy (whether by
	manual signature, typewriting, telegraphic transmission or otherwise) by the stockholder or the stockholder&#146;s attorney-in-fact. The revocability of a proxy that states on its face that it is irrevocable shall be governed by the provisions of
	Section&nbsp;212(e) of the General Corporation Law of Delaware.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_16">
</A>
	2.12
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
<U>
	LIST OF STOCKHOLDERS ENTITLED TO VOTE
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The officer who has charge of the stock ledger of a corporation shall prepare and make, at least ten (10)&nbsp;days before every meeting of stockholders, a complete list of the stockholders entitled to
	vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose
	germane to the meeting, during ordinary business hours, for a period of at least ten (10)&nbsp;days prior to the meeting, either at a place within the city where the meeting is to be held, which place shall be specified in the notice of the meeting,
	or, if not so specified, at the place where the meeting is to be held. The list shall also be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any stockholder who is present.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_17">
</A>
	2.13
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
<U>
	ADVANCE NOTICE PROVISIONS FOR STOCKHOLDER PROPOSALS
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(a)&nbsp;&nbsp;&nbsp;&nbsp;At an annual meeting or at a special meeting of the stockholders, only such business shall be
	conducted as shall have been properly brought before such meeting. To be properly brought before a meeting, business must be (i)&nbsp;brought before the meeting by the corporation and specified in the notice of meeting (or any supplement thereto)
	given by or at the direction of the board of directors or any committee thereof, (ii)&nbsp;brought before the meeting by or at the direction of the board of directors or any committee thereof, or (iii)&nbsp;otherwise properly brought before the
	meeting by a stockholder who (A)&nbsp;was a stockholder of record (and, with respect to any beneficial owner, if different from such stockholder of record, on whose behalf such business is proposed, only if such beneficial owner was the beneficial
	owner of shares of the corporation) both at the time of giving the notice provided for in this Section&nbsp;2.13 and at the time of the meeting, (B)&nbsp;is entitled to vote at the meeting, and (C)&nbsp;has complied with this Section&nbsp;2.13 as to
	such business. Except for proposals properly made in accordance with Rule&nbsp;14a-8 (or any successor thereto) under the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (as so amended and inclusive of such
	rules and regulations, the &#147;
<I>
	Exchange Act
</I>
	&#148;), and included in the notice of meeting given by or at the direction of the board of directors, the foregoing clause (iii)&nbsp;shall be the exclusive means for a stockholder to propose
	business to be brought before a meeting of the stockholders. Stockholders seeking to nominate a person or persons for election to the board of directors must comply with Section&nbsp;2.14, and this Section&nbsp;2.13 shall not be applicable to
	nominations except as expressly provided in Section&nbsp;2.14.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	-3-
</FONT>
</P>
<A NAME="eolPage121"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(b)&nbsp;&nbsp;&nbsp;&nbsp;Without qualification, for business to be
	properly brought before a meeting by a stockholder, the stockholder must (i)&nbsp;provide Timely Notice (as defined below) thereof in writing and in proper form (as provided for in Section&nbsp;2.13(c)) to the secretary of the corporation and
	(ii)&nbsp;provide any updates or supplements to such notice at the times and in the forms required by this Section&nbsp;2.13. To be timely, a stockholder&#146;s notice must be delivered to, or mailed and received at, the principal executive offices
	of the corporation either, as applicable (such notice within the following time periods, &#147;
<I>
	Timely Notice
</I>
	&#148;):
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:8%; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(1)&nbsp;&nbsp;&nbsp;&nbsp;for an annual meeting, not earlier than the one hundred twentieth (120th)&nbsp;day nor later than the ninetieth (90th)&nbsp;day prior to the one-year anniversary of the
	preceding year&#146;s annual meeting; provided, however, that if the date of the annual meeting is more than thirty&nbsp;(30) days before or more than sixty&nbsp;(60) days after such anniversary date, notice by the stockholder to be timely must be
	so delivered, or mailed and received, on or before the later of (x)&nbsp;the ninetieth (90th)&nbsp;day prior to such annual meeting or (y)&nbsp;the tenth (10th)&nbsp;day following the date on which Public Disclosure (as defined below) of the date of
	such annual meeting was first made, or
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:8%; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(2)&nbsp;&nbsp;&nbsp;&nbsp;for a special meeting, not earlier than the
	one hundred twentieth (120th)&nbsp;day nor later than the ninetieth (90th)&nbsp;day prior to such special meeting or, if later, the tenth (10th)&nbsp;day following the date on which Public Disclosure of the date of such special meeting was first
	made.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In no event shall any adjournment or postponement of an annual meeting or of a special meeting or the announcement
	thereof commence a new time period (or extend any time period) for the giving of Timely Notice as described above.
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(c)&nbsp;&nbsp;&nbsp;&nbsp;To be in proper form for purposes of this Section&nbsp;2.13, a stockholder&#146;s notice to the secretary shall set forth:
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:8%; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(i)&nbsp;&nbsp;&nbsp;&nbsp;As to each Proposing Person (as defined below), (A)&nbsp;the name and address of such Proposing
	Person (including, if applicable, the name and address that appear on the corporation&#146;s books and records) and (B)&nbsp;the class or series and number of shares of the corporation that are, directly or indirectly, owned of record or
	beneficially owned (within the meaning of Rule&nbsp;13d-3 under the Exchange Act) by such Proposing Person, except that such Proposing Person shall in all events be deemed to beneficially own any shares of any class or series of the corporation as
	to which such Proposing Person has a right to acquire beneficial ownership at any time in the future (the disclosures to be made pursuant to the foregoing clauses (A)&nbsp;and (B)&nbsp;are referred to as &#147;
<I>
	Stockholder Information
</I>
	&#148;);
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:8%; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(ii)&nbsp;&nbsp;&nbsp;&nbsp;As to each Proposing Person, (A)&nbsp;any derivative, swap or other transaction or
	series of transactions engaged in, directly or indirectly, by such Proposing Person, the purpose or effect of which is to give such Proposing Person economic risk similar to ownership of shares of any class or series of the corporation, including
	due to the fact that the value of such derivative, swap or other transaction or series of transactions is determined by reference to the price, value or volatility of any shares of any class or series of the corporation, or which derivative, swap or
	other transaction or series of transactions provides, directly or indirectly, the opportunity to profit from any increase in the price or value of shares of any class or series of the corporation (any such derivative, swap or other transaction or
	series of transactions as described in this clause (A)&nbsp;is referred to as a &#147;
<I>
	Synthetic Equity Interest
</I>
	&#148;), all of which Synthetic Equity Interests shall be disclosed without regard to whether (x)&nbsp;any such Synthetic Equity
	Interest conveys any voting rights in shares of any class or series of the corporation to such Proposing Person, (y)&nbsp;any such Synthetic Equity Interest is required to be, or is capable of being, settled through delivery of shares of any class
	or series of the corporation or (z)&nbsp;such Proposing Person may have entered into other transactions that hedge or mitigate the economic effect of such Synthetic Equity Interest, (B)&nbsp;any proxy (other than a revocable proxy or consent given
	in response to a solicitation made pursuant to, and in accordance with, Section&nbsp;14(a)&nbsp;of the Exchange Act by way of a solicitation statement filed on Schedule 14A), agreement, arrangement, understanding or relationship pursuant to which
	such Proposing Person has or shares a right to vote any shares of any class or series of the corporation, (C)&nbsp;any agreement, arrangement, understanding or relationship, including any
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	-4-
</FONT>
</P>
<A NAME="eolPage122"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:8%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	repurchase or similar stock borrowing agreement or arrangement, engaged in, directly or indirectly, by such Proposing Person, the purpose or effect of which is to mitigate loss to, reduce the
	economic risk (of ownership or otherwise) of shares of any class or series of the corporation by, manage the risk of share price changes for, or increase or decrease the voting power of, such Proposing Person with respect to the shares of any class
	or series of the corporation, or which provides, directly or indirectly, the opportunity to profit from any decrease in the price or value of the shares of any class or series of the corporation (any such agreement, arrangement, understanding or
	relationship as described in this clause (C)&nbsp;is referred to as a &#147;
<I>
	Short Interest
</I>
	&#148;), (D)&nbsp;any rights to dividends on the shares of any class or series of the corporation owned beneficially by such Proposing Person that are
	separated or separable from the underlying shares of the corporation, (E)&nbsp;any performance related fees (other than an asset based fee) that such Proposing Person is entitled to based on any increase or decrease in the price or value of shares
	of any class or series of the corporation, or any Synthetic Equity Interests or Short Interests, if any, and (F)&nbsp;any other information relating to such Proposing Person that would be required to be disclosed in a proxy statement or other filing
	required to be made in connection with solicitations of proxies or consents by such Proposing Person in support of the business proposed to be brought before the meeting pursuant to Section&nbsp;14(a) of the Exchange Act (the disclosures to be made
	pursuant to the foregoing clauses (A)&nbsp;through (F)&nbsp;are referred to as &#147;
<I>
	Disclosable Interests
</I>
	&#148;); provided, however, that Disclosable Interests shall not include any such disclosures with respect to the ordinary course
	business activities of any broker, dealer, commercial bank, trust company or other nominee who is a Proposing Person solely as a result of being the stockholder directed to prepare and submit the notice required by these bylaws on behalf of a
	beneficial owner; and
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:8%; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(iii)&nbsp;&nbsp;&nbsp;&nbsp;As to each item of business that the stockholder proposes
	to bring before the meeting, (A)&nbsp;a reasonably brief description of the business desired to be brought before the meeting, the reasons for conducting such business at the meeting and any material interest in such business of each Proposing
	Person, (B)&nbsp;the text of the proposal or business (including the text of any resolutions proposed for consideration), and (C)&nbsp;a reasonably detailed description of all agreements, arrangements understandings and relationships
	(x)&nbsp;between or among any of the Proposing Persons or (y)&nbsp;between or among any Proposing Person and any other person, including the name of such other person, in connection with the proposal of such business by such stockholder.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	For purposes of this Section&nbsp;2.13, the term &#147;
<I>
	Proposing Person
</I>
	&#148; shall mean (i)&nbsp;the stockholder providing the
	notice of business proposed to be brought before a meeting, (ii)&nbsp;the beneficial owner or beneficial owners, if different from any Proposing Person pursuant to the foregoing clause (i), on whose behalf the notice of the business proposed to be
	brought before the meeting is made, (iii)&nbsp;any affiliate or associate (each within the meaning of Rule&nbsp;12b-2 under the Exchange Act for purposes of these bylaws) of any Proposing Person pursuant to the foregoing clauses (i)&nbsp;or (ii),
	and (iv)&nbsp;any other person with whom any Proposing Person pursuant to the foregoing clauses (i), (ii)&nbsp;or (iii)&nbsp;is Acting in Concert (as defined below).
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	A person shall be deemed to be &#147;
<I>
	Acting in Concert
</I>
	&#148; with another person for purposes of these bylaws if such person knowingly acts (whether or not pursuant to an express agreement,
	arrangement or understanding) in concert with, or towards a common goal relating to the management, governance or control of the corporation in parallel with, such other person where (A)&nbsp;each person is conscious of the other person&#146;s
	conduct or intent and this awareness is an element in their decision-making processes and (B)&nbsp;at least one additional factor suggests that such persons intend to act in concert or in parallel, which such additional factors may include, without
	limitation, exchanging information (whether publicly or privately), attending meetings, conducting discussions, or making or soliciting invitations to act in concert or in parallel; provided, however, that a person shall not be deemed to be Acting
	in Concert with any other person solely as a result of the solicitation or receipt of revocable proxies or consents from such other person in response to a solicitation made pursuant to, and in accordance with, Section&nbsp;14(a) of the Exchange Act
	by way of a proxy or consent solicitation statement filed on Schedule&nbsp;14A. A person Acting in Concert with another person shall be deemed to be Acting in Concert with any third party who is also Acting in Concert with such other person.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	-5-
</FONT>
</P>
<A NAME="eolPage123"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(d)&nbsp;&nbsp;&nbsp;&nbsp;A stockholder providing notice of business
	proposed to be brought before a meeting shall further update and supplement such notice, if necessary, so that the information provided or required to be provided in such notice pursuant to this Section&nbsp;2.13 shall be true and correct as of the
	record date for the meeting and as of the date that is ten&nbsp;(10) business days prior to the meeting or any adjournment or postponement thereof, and such update and supplement shall be delivered to, or mailed and received by, the secretary at the
	principal executive offices of the corporation not later than five&nbsp;(5)&nbsp;business days after the record date for the meeting in the case of the update and supplement required to be made as of the record date, and not later than
	eight&nbsp;(8)&nbsp;business days, if practicable (or, if not practicable, on the first practicable date) prior to the date for the meeting or any adjournment or postponement thereof, in the case of the update and supplement required to be made as
	of ten&nbsp;(10)&nbsp;business days prior to the meeting or any adjournment or postponement thereof.
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(e)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything in these bylaws to the contrary, no business shall be conducted at a
	meeting except in accordance with this Section&nbsp;2.13. The board of directors, chairman of the board, presiding officer of the meeting or president shall, if the facts warrant, determine that the business was not properly brought before the
	meeting in accordance with this Section&nbsp;2.13, and if he or she should so determine, he or she shall so declare to the meeting and any such business not properly brought before the meeting shall not be transacted.
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(f)&nbsp;&nbsp;&nbsp;&nbsp;This Section&nbsp;2.13 is expressly intended to apply to any business proposed to be brought
	before a meeting of stockholders regardless of whether (i)&nbsp;such proposal is made pursuant to Rule&nbsp;14a-8 under the Exchange Act (or any successor thereto) or (ii)&nbsp;such business is already the subject of any notice to the stockholders
	or Public Disclosure from the board of directors. In addition to the requirements of this Section&nbsp;2.13 with respect to any business proposed to be brought before a meeting, each Proposing Person shall comply with all applicable requirements of
	the Exchange Act with respect to any such business; provided, however, that references in these bylaws to the Exchange Act, or the rules and regulations promulgated thereunder are not intended to and shall not limit the requirements of these bylaws
	applicable to nominations or proposals or any other business to be considered pursuant to these bylaws regardless of the stockholder&#146;s intent to utilize Rule 14a-8 under the Exchange Act (or any successor thereto). Nothing in this
	Section&nbsp;2.13 shall be deemed to affect the rights of stockholders to request inclusion of proposals in the corporation&#146;s proxy statement pursuant to Rule&nbsp;14a-8 under the Exchange Act (or any successor thereto).
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(g)&nbsp;&nbsp;&nbsp;&nbsp;For purposes of these bylaws, &#147;
<I>
	Public Disclosure
</I>
	&#148; shall mean disclosure in a
	press release reported by a national news service or in a document publicly filed by the corporation with the Securities and Exchange Commission pursuant to Sections 13, 14 or 15(d)&nbsp;of the Exchange Act.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_18">
</A>
	2.14 &nbsp;&nbsp;
<U>
	ADVANCE NOTICE PROVISIONS FOR STOCKHOLDER NOMINATIONS
</U>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(a)&nbsp;&nbsp;&nbsp;&nbsp;Nominations of any person for election to the board of directors at an annual meeting or at a
	special meeting may be made at such meeting only (i)&nbsp;by or at the direction of the board of directors, including by any committee or persons appointed by the board of directors, or (ii)&nbsp;by a stockholder who (A)&nbsp;was a stockholder of
	record (and, with respect to any beneficial owner, if different from such stockholder of record, on whose behalf such nomination is proposed to be made, only if such beneficial owner was the beneficial owner of shares of the corporation) both at the
	time of giving the notice provided for in this Section&nbsp;2.14 and at the time of the meeting, (B)&nbsp;is entitled to vote at the meeting, and (C)&nbsp;has complied with this Section&nbsp;2.14 as to such nomination. The foregoing clause
	(ii)&nbsp;shall be the exclusive means for a stockholder to make any nomination of a person or persons for election to the board of directors at an annual meeting or at a special meeting.
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(b)&nbsp;&nbsp;&nbsp;&nbsp;Without qualification, for a stockholder to make any nomination of a person or persons for
	election to the board of directors at an annual meeting or at a special meeting, the stockholder must (i)&nbsp;provide Timely Notice (as defined in Section&nbsp;2.13) thereof in writing and in proper form (as set forth in Section&nbsp;2.14(c)) to
	the secretary of the corporation at the principal executive offices of the corporation, and (ii)&nbsp;provide any updates or supplements to such notice at the times and in the forms required by this
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	-6-
</FONT>
</P>
<A NAME="eolPage124"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Section&nbsp;2.14. In no event shall any adjournment or postponement of an annual meeting or of a special meeting or the announcement thereof commence a new time period (or extend any time
	period) for the giving of a stockholder&#146;s notice as described in this Section&nbsp;2.14(b).
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(c)&nbsp;&nbsp;&nbsp;&nbsp;To be in proper form for purposes of this Section&nbsp;2.14, a stockholder&#146;s notice to the
	secretary shall set forth:
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:8%; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(i)&nbsp;&nbsp;&nbsp;&nbsp;As to each Nominating Person (as defined below), the
	Stockholder Information (as defined in Section&nbsp;2.13(c)(i), except that for purposes of this Section&nbsp;2.14 the term &#147;Nominating Person&#148; shall be substituted for the term &#147;Proposing Person&#148; in all places it appears in
	Section&nbsp;2.13(c)(i));
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:8%; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(ii)&nbsp;&nbsp;&nbsp;&nbsp;As to each Nominating Person, any Disclosable Interests
	(as defined in Section&nbsp;2.13(c)(ii), except that for purposes of this Section&nbsp;2.14 the term &#147;Nominating Person&#148; shall be substituted for the term &#147;Proposing Person&#148; in all places it appears in Section&nbsp;2.13(c)(ii)
	and the disclosure in clause&nbsp;(F) of Section&nbsp;2.13(c)(ii) shall be made with respect to the election of directors at the meeting);
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:8%; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(iii)&nbsp;&nbsp;&nbsp;&nbsp;As to each person whom a Nominating Person proposes to nominate for election as a director, (A)&nbsp;all information with respect to such proposed nominee that would be
	required to be set forth in a stockholder&#146;s notice pursuant to this Section&nbsp;2.14 if such proposed nominee were a Nominating Person, (B)&nbsp;all information relating to such proposed nominee that would be required to be disclosed in a
	proxy statement or other filings required to be made in connection with solicitations of proxies for election of directors in a contested election pursuant to Section&nbsp;14(a) under the Exchange Act (including but not limited to such proposed
	nominee&#146;s written consent to being named in the proxy statement as a nominee and to serving as a director if elected), and (C)&nbsp;a description of all direct and indirect compensation and other material monetary agreements, arrangements and
	understandings during the past three years, and any other material relationships, between or among any Nominating Person, on the one hand, and each proposed nominee, such proposed nominee&#146;s respective affiliates and associates, and any other
	persons with whom such proposed nominee (or any of such proposed nominee&#146;s respective affiliates or associates) is Acting in Concert, on the other hand, including, without limitation, all information that would be required to be disclosed
	pursuant to Item&nbsp;404 under Regulation S-K if such Nominating Person were the &#147;registrant&#148; for purposes of such rule and the proposed nominee were a director or executive officer of such registrant; and
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:8%; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(iv)&nbsp;&nbsp;&nbsp;&nbsp;If required by the corporation, as to any proposed nominee, such other information (A)&nbsp;as
	may reasonably be required by the corporation to determine the eligibility of such proposed nominee to serve as an independent director of the corporation or (B)&nbsp;that could be material to a reasonable stockholder&#146;s understanding of the
	independence or lack of independence of such proposed nominee.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	For purposes of this Section&nbsp;2.14, the term
	&#147;
<I>
	Nominating Person
</I>
	&#148; shall mean (i)&nbsp;the stockholder providing the notice of the nomination proposed to be made at the meeting, (ii)&nbsp;the beneficial owner or beneficial owners, if different from any Nominating Person pursuant
	to the foregoing clause (i), on whose behalf the notice of the nomination proposed to be made at the meeting is made, (iii)&nbsp;any affiliate or associate of any Nominating Person pursuant to the foregoing clauses (i)&nbsp;or (ii), and
	(iv)&nbsp;any other person with whom any Nominating Person pursuant to the foregoing clauses (i), (ii), or (iii)&nbsp;is Acting in Concert.
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(d)&nbsp;&nbsp;&nbsp;&nbsp;A stockholder providing notice of any nomination proposed to be made at a meeting shall further update and supplement such notice, if necessary, so that the information provided
	or required to be provided in such notice pursuant to this Section&nbsp;2.14 shall be true and correct as of the record date for the meeting and as of the date that is ten (10)&nbsp;business days prior to the meeting or any adjournment or
	postponement thereof, and such update and supplement shall be delivered to, or mailed and received by, the secretary at the principal executive offices of the corporation not later than five&nbsp;(5)&nbsp;business days after the record date for the
	meeting in the case of the update and supplement required to be made as of the record date, and not later than eight&nbsp;(8)&nbsp;business days, if practicable (or, if not practicable, on the first practicable date) prior to the date for the
	meeting or any adjournment or postponement thereof, in the case of the update and supplement required to be made as of ten&nbsp;(10)&nbsp;business days prior to the meeting or any adjournment or postponement thereof.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	-7-
</FONT>
</P>
<A NAME="eolPage125"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(e)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything in these bylaws to the
	contrary, no person shall be eligible for election as a director of the corporation unless nominated in accordance with this Section&nbsp;2.14. The board of directors, chairman of the board, presiding officer of the meeting or president shall, if
	the facts warrant, determine that a nomination was not properly made in accordance with this Section&nbsp;2.14, and if he or she should so determine, he or she shall so declare such determination to the meeting and any such nomination not properly
	made shall be disregarded.
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(f)&nbsp;&nbsp;&nbsp;&nbsp;This Section&nbsp;2.14 is expressly intended to apply to
	any nomination proposed to be made at an annual or special meeting of stockholders regardless of whether the election of directors is already the subject of any notice to the stockholders or Public Disclosure from the board of directors. In addition
	to the requirements of this Section&nbsp;2.14 with respect to any nomination proposed to be made at a meeting, each Nominating Person shall comply with all applicable requirements of the Exchange Act with respect to any such nominations; provided,
	however, that references in these bylaws to the Exchange Act, or the rules and regulations promulgated thereunder are not intended to and shall not limit the requirements of these bylaws applicable to nominations or proposals or any other business
	to be considered pursuant to these bylaws regardless of the stockholder&#146;s intent to utilize Rule 14a-8 under the Exchange Act (or any successor thereto). Nothing in this Section&nbsp;2.14 shall be deemed to affect the rights of stockholders to
	request inclusion of proposals in the corporation&#146;s proxy statement pursuant to Rule 14a-8 under the Exchange Act (or any successor thereto).
</FONT>
</P>
<P STYLE="MARGIN-TOP:24PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ARTICLE III
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
<A NAME="D453081DEX32_HTM_EX453081_19">
</A>
	DIRECTORS
</U>
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_20">
</A>
	3.1
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	POWERS
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Subject to the
	provisions of the General Corporation Law of Delaware and any limitations in the certificate of incorporation or these bylaws relating to action required to be approved by the stockholders or by the outstanding shares, the business and affairs of
	the corporation shall be managed and all corporate powers shall be exercised by or under the direction of the board of directors.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_21">
</A>
	3.2
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	NUMBER OF DIRECTORS
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The
	board of directors shall consist of six (6)&nbsp;members. The number of directors may be changed by an amendment to this bylaw, duly adopted by the board of directors or by the stockholders, or by a duly adopted amendment to the certificate of
	incorporation. Upon the closing of the first sale of the corporation&#146;s common stock pursuant to a firmly underwritten registered public offering (the &#147;
<I>
	IPO
</I>
	&#148;), the directors shall be divided into three classes, with the term of
	office of the first class, which class shall initially consist of two directors, to expire at the first annual meeting of stockholders held after the IPO; the term of office of the second class, which shall initially consist of three directors, to
	expire at the second annual meeting of stockholders held after the IPO; the term of office of the third class, which class shall initially consist of three directors, to expire at the third annual meeting of stockholders held after the IPO; and
	thereafter for each such term to expire at each third succeeding annual meeting of stockholders held after such election.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	No
	reduction of the authorized number of directors shall have the effect of removing any director before that director&#146;s term of office expires.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_22">
</A>
	3.3
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	ELECTION, QUALIFICATION AND TERM OF OFFICE OF DIRECTORS
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Except as provided in Section&nbsp;3.4 of these bylaws, directors shall be elected at each annual meeting of stockholders to hold office until the next annual meeting. Directors need not be stockholders
	unless so required by the certificate of incorporation or these bylaws, wherein other qualifications for directors may be prescribed. Each director, including a director elected to fill a vacancy, shall hold office until his successor is elected and
	qualified or until his earlier resignation or removal.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Elections of directors need not be by written ballot.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	-8-
</FONT>
</P>
<A NAME="eolPage126"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_23">
</A>
	3.4
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	RESIGNATION AND VACANCIES
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Any director may resign at any time upon written notice to the corporation. When one or more directors so resigns and the resignation is
	effective at a future date, a majority of the directors then in office, including those who have so resigned, shall have power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become
	effective, and each director so chosen shall hold office as provided in this section in the filling of other vacancies.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Unless otherwise provided in the certificate of incorporation or these bylaws:
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(a) Vacancies and newly created directorships resulting from any increase in the authorized number of directors elected by
	all of the stockholders having the right to vote as a single class may be filled by a majority of the directors then in office, although less than a quorum, or by a sole remaining director.
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(b) Whenever the holders of any class or classes of stock or series thereof are entitled to elect one or more directors by
	the provisions of the certificate of incorporation, vacancies and newly created directorships of such class or classes or series may be filled by a majority of the directors elected by such class or classes or series thereof then in office, or by a
	sole remaining director so elected.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	If at any time, by reason of death or resignation or other cause, the corporation should
	have no directors in office, then any officer or any stockholder or an executor, administrator, trustee or guardian of a stockholder, or other fiduciary entrusted with like responsibility for the person or estate of a stockholder, may call a special
	meeting of stockholders in accordance with the provisions of the certificate of incorporation or these bylaws, or may apply to the Court of Chancery for a decree summarily ordering an election as provided in Section&nbsp;211 of the General
	Corporation Law of Delaware.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	If, at the time of filling any vacancy or any newly created directorship, the directors then in
	office constitute less than a majority of the whole board (as constituted immediately prior to any such increase), then the Court of Chancery may, upon application of any stockholder or stockholders holding at least ten (10)&nbsp;percent of the
	total number of the shares at the time outstanding having the right to vote for such directors, summarily order an election to be held to fill any such vacancies or newly created directorships, or to replace the directors chosen by the directors
	then in office as aforesaid, which election shall be governed by the provisions of Section&nbsp;211 of the General Corporation Law of Delaware as far as applicable.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_24">
</A>
	3.5
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	PLACE OF MEETINGS; MEETINGS BY TELEPHONE
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The board of directors of the corporation may hold meetings, both regular and special, either within or outside the State of Delaware.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Unless otherwise restricted by the certificate of incorporation or these bylaws, members of the board of directors, or any committee
	designated by the board of directors, may participate in a meeting of the board of directors, or any committee, by means of conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear
	each other, and such participation in a meeting shall constitute presence in person at the meeting.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_25">
</A>
	3.6
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	FIRST MEETINGS
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The first
	meeting of each newly elected board of directors shall be held at such time and place as shall be fixed by the vote of the stockholders at the annual meeting and no notice of such meeting need be given to the newly elected directors in order legally
	to constitute the meeting, provided a quorum shall be present. In the event of the failure of the stockholders to fix the time or place of such first meeting of the newly elected board of directors, or in the event such meeting is not held at the
	time and place so fixed by the stockholders, the meeting may be held at such time and place as shall be specified in a notice given as hereinafter provided for special meetings of the board of directors, or as shall be specified in a written waiver
	signed by all of the directors.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	-9-
</FONT>
</P>
<A NAME="eolPage127"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3.7
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
<A NAME="D453081DEX32_HTM_EX453081_26">
</A>
	REGULAR MEETINGS
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Regular meetings of the board of directors may be held without notice at such time and at such place as shall from time to time be determined by the board.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_27">
</A>
	3.8
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	SPECIAL MEETINGS; NOTICE
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Special meetings of the board may be called by the president on 48 hours&#146; notice to each director, either personally or by mail,
	telegram, telex, or telephone; special meetings shall be called by the president or secretary in like manner and on like notice on the written request of two (2)&nbsp;directors unless the board consists of only one (1)&nbsp;director, in which case
	special meetings shall be called by the president or secretary in like manner and on like notice on the written request of the sole director.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_28">
</A>
	3.9
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	QUORUM
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	At all meetings
	of the board of directors, a majority of the authorized number of directors shall constitute a quorum for the transaction of business and the act of a majority of the directors present at any meeting at which there is a quorum shall be the act of
	the board of directors, except as may be otherwise specifically provided by statute or by the certificate of incorporation. If a quorum is not present at any meeting of the board of directors, then the directors present thereat may adjourn the
	meeting from time to time, without notice other than announcement at the meeting, until a quorum is present.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_29">
</A>
	3.10
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
<U>
	WAIVER OF NOTICE
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Whenever notice is required to be given under any provision of the General Corporation Law of Delaware or of the certificate of incorporation or these bylaws, a written waiver thereof, signed by the
	person entitled to notice, whether before or after the time stated therein, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for
	the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special
	meeting of the directors, or members of a committee of directors, need be specified in any written waiver of notice unless so required by the certificate of incorporation or these bylaws.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_30">
</A>
	3.11
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
<U>
	ADJOURNED MEETING; NOTICE
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	If a quorum is not present at any meeting of the board of directors, then the directors present thereat may adjourn the meeting from time to time, without notice other than announcement at the meeting,
	until a quorum is present.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_31">
</A>
	3.12
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
<U>
	BOARD ACTION BY WRITTEN CONSENT WITHOUT A MEETING
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Unless otherwise restricted by the certificate of incorporation or these bylaws, any action required or permitted to be taken at any meeting of the board of directors, or of any committee thereof, may be
	taken without a meeting if all members of the board or committee, as the case may be, consent thereto in writing and the writing or writings are filed with the minutes of proceedings of the board or committee.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_32">
</A>
	3.13
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
<U>
	FEES AND COMPENSATION OF DIRECTORS
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Unless otherwise restricted by the certificate of incorporation or these bylaws, the board of directors shall have the authority to fix the compensation of directors.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_33">
</A>
	3.14
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
<U>
	APPROVAL OF LOANS TO OFFICERS
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The corporation may lend money to, or guarantee any obligation of, or otherwise assist any officer or other employee of the corporation or of its subsidiary, including any officer or employee who is a
	director of the
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	-10-
</FONT>
</P>
<A NAME="eolPage128"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	corporation or its subsidiary, whenever, in the judgment of the directors, such loan, guaranty or assistance may reasonably be expected to benefit the corporation. The loan, guaranty or other
	assistance may be with or without interest and may be unsecured, or secured in such manner as the board of directors shall approve, including, without limitation, a pledge of shares of stock of the corporation. Nothing contained in this
	section&nbsp;shall be deemed to deny, limit or restrict the powers of guaranty or warranty of the corporation at common law or under any statute.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_34">
</A>
	3.15
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
<U>
	REMOVAL OF DIRECTORS
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Unless otherwise restricted by statute, by the certificate of incorporation or by these bylaws, any director or the entire board of directors may be removed, with or without cause, by the holders of a
	majority of the shares then entitled to vote at an election of directors.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	No reduction of the authorized number of directors
	shall have the effect of removing any director prior to the expiration of such director&#146;s term of office.
</FONT>
</P>
<P STYLE="MARGIN-TOP:24PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ARTICLE IV
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
<A NAME="D453081DEX32_HTM_EX453081_35">
</A>
	COMMITTEES
</U>
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_36">
</A>
	4.1
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	COMMITTEES OF DIRECTORS
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The board of directors may, by resolution passed by a majority of the whole board, designate one or more committees, with each committee
	to consist of one or more of the directors of the corporation. The board may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or
	disqualification of a member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not he or they constitute a quorum, may unanimously appoint another member of the board of directors to
	act at the meeting in the place of any such absent or disqualified member. Any such committee, to the extent provided in the resolution of the board of directors or in the bylaws of the corporation, shall have and may exercise all the powers and
	authority of the board of directors in the management of the business and affairs of the corporation, and may authorize the seal of the corporation to be affixed to all papers that may require it; but no such committee shall have the power or
	authority to (i)&nbsp;amend the certificate of incorporation (except that a committee may, to the extent authorized in the resolution or resolutions providing for the issuance of shares of stock adopted by the board of directors as provided in
	Section&nbsp;151(a) of the General Corporation Law of Delaware, fix any of the preferences or rights of such shares relating to dividends, redemption, dissolution, any distribution of assets of the corporation or the conversion into, or the exchange
	of such shares for, shares of any other class or classes or any other series of the same or any other class or classes of stock of the corporation), (ii)&nbsp;adopt an agreement of merger or consolidation under Sections 251 or 252 of the General
	Corporation Law of Delaware, (iii)&nbsp;recommend to the stockholders the sale, lease or exchange of all or substantially all of the corporation&#146;s property and assets, (iv)&nbsp;recommend to the stockholders a dissolution of the corporation or
	a revocation of a dissolution, or (v)&nbsp;amend the bylaws of the corporation; and, unless the board resolution establishing the committee, the bylaws or the certificate of incorporation expressly so provide, no such committee shall have the power
	or authority to declare a dividend, to authorize the issuance of stock, or to adopt a certificate of ownership and merger pursuant to Section&nbsp;253 of the General Corporation Law of Delaware.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_37">
</A>
	4.2
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	COMMITTEE MINUTES
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Each
	committee shall keep regular minutes of its meetings and report the same to the board of directors when required.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_38">
</A>
	4.3
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	MEETINGS AND ACTION OF COMMITTEES
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Meetings and actions of committees shall be governed by, and held and taken in accordance with, the provisions of Article&nbsp;III of these bylaws, Section&nbsp;3.5 (place of meetings and meetings by
	telephone), Section&nbsp;3.7
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	-11-
</FONT>
</P>
<A NAME="eolPage129"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(regular meetings), Section&nbsp;3.8 (special meetings and notice), Section&nbsp;3.9 (quorum), Section&nbsp;3.10 (waiver of notice), Section&nbsp;3.11 (adjournment and notice of adjournment), and
	Section&nbsp;3.12 (action without a meeting), with such changes in the context of those bylaws as are necessary to substitute the committee and its members for the board of directors and its members; provided, however, that the time of regular
	meetings of committees may also be called by resolution of the board of directors and that notice of special meetings of committees shall also be given to all alternate members, who shall have the right to attend all meetings of the committee. The
	board of directors may adopt rules for the government of any committee not inconsistent with the provisions of these bylaws.
</FONT>
</P>
<P STYLE="MARGIN-TOP:24PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ARTICLE V
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_39">
</A>
<U>
	OFFICERS
</U>
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_40">
</A>
	5.1
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	OFFICERS
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The officers of
	the corporation shall be a president, one or more vice presidents, a secretary, and a treasurer. The corporation may also have, at the discretion of the board of directors, a chairman of the board, one or more assistant vice presidents, assistant
	secretaries, assistant treasurers, and any such other officers as may be appointed in accordance with the provisions of Section&nbsp;5.3 of these bylaws. Any number of offices may be held by the same person.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_41">
</A>
	5.2
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	ELECTION OF OFFICERS
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The
	officers of the corporation, except such officers as may be appointed in accordance with the provisions of Sections 5.3 or 5.5 of these bylaws, shall be chosen by the board of directors, subject to the rights, if any, of an officer under any
	contract of employment.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_42">
</A>
	5.3
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	SUBORDINATE OFFICERS
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The
	board of directors may appoint, or empower the president to appoint, such other officers and agents as the business of the corporation may require, each of whom shall hold office for such period, have such authority, and perform such duties as are
	provided in these bylaws or as the board of directors may from time to time determine.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_43">
</A>
	5.4
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	REMOVAL AND RESIGNATION OF OFFICERS
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Subject to the rights, if any, of an officer under any contract of employment, any officer may be removed, either with or without cause, by an affirmative vote of the majority of the board of directors at
	any regular or special meeting of the board or, except in the case of an officer chosen by the board of directors, by any officer upon whom such power of removal may be conferred by the board of directors.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Any officer may resign at any time by giving written notice to the corporation. Any resignation shall take effect at the date of the
	receipt of that notice or at any later time specified in that notice; and, unless otherwise specified in that notice, the acceptance of the resignation shall not be necessary to make it effective. Any resignation is without prejudice to the rights,
	if any, of the corporation under any contract to which the officer is a party.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_44">
</A>
	5.5
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	VACANCIES IN OFFICES
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Any
	vacancy occurring in any office of the corporation shall be filled by the board of directors.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_45">
</A>
	5.6
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	CHAIRMAN OF THE BOARD
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The chairman of the board, if such an officer be elected, shall, if present, preside at meetings of the board of directors and exercise
	and perform such other powers and duties as may from time to time be assigned to him by the board of directors or as may be prescribed by these bylaws. If there is no president, then the chairman of the board shall also be the chief executive
	officer of the corporation and shall have the powers and duties prescribed in Section&nbsp;5.7 of these bylaws.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	-12-
</FONT>
</P>
<A NAME="eolPage130"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_46">
</A>
	5.7
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	PRESIDENT
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Subject to
	such supervisory powers, if any, as may be given by the board of directors to the chairman of the board, if there be such an officer, the president shall be the chief executive officer of the corporation and shall, subject to the control of the
	board of directors, have general supervision, direction, and control of the business and the officers of the corporation. He shall preside at all meetings of the stockholders and, in the absence or nonexistence of a chairman of the board, at all
	meetings of the board of directors. He shall have the general powers and duties of management usually vested in the office of president of a corporation and shall have such other powers and duties as may be prescribed by the board of directors or
	these bylaws.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_47">
</A>
	5.8
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	VICE PRESIDENT
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In the
	absence or disability of the president, the vice presidents, if any, in order of their rank as fixed by the board of directors or, if not ranked, a vice president designated by the board of directors, shall perform all the duties of the president
	and when so acting shall have all the powers of, and be subject to all the restrictions upon, the president. The vice presidents shall have such other powers and perform such other duties as from time to time may be prescribed for them respectively
	by the board of directors, these bylaws, the president or the chairman of the board.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_48">
</A>
	5.9
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	SECRETARY
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The secretary
	shall keep or cause to be kept, at the principal executive office of the corporation or such other place as the board of directors may direct, a book of minutes of all meetings and actions of directors, committees of directors, and stockholders. The
	minutes shall show the time and place of each meeting, whether regular or special (and, if special, how authorized and the notice given), the names of those present at directors&#146; meetings or committee meetings, the number of shares present or
	represented at stockholders&#146; meetings, and the proceedings thereof.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The secretary shall keep, or cause to be kept, at
	the principal executive office of the corporation or at the office of the corporation&#146;s transfer agent or registrar, as determined by resolution of the board of directors, a share register, or a duplicate share register, showing the names of
	all stockholders and their addresses, the number and classes of shares held by each, the number and date of certificates evidencing such shares, and the number and date of cancellation of every certificate surrendered for cancellation.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The secretary shall give, or cause to be given, notice of all meetings of the stockholders and of the board of directors required to be
	given by law or by these bylaws. He shall keep the seal of the corporation, if one be adopted, in safe custody and shall have such other powers and perform such other duties as may be prescribed by the board of directors or by these bylaws.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_49">
</A>
	5.10
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
<U>
	TREASURER
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The treasurer shall keep and maintain, or cause to be kept and maintained, adequate and correct books and records of accounts of the
	properties and business transactions of the corporation, including accounts of its assets, liabilities, receipts, disbursements, gains, losses, capital, retained earnings, and shares. The books of account shall at all reasonable times be open to
	inspection, by any director.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The treasurer shall deposit all money and other valuables in the name and to the credit of the
	corporation with such depositaries as may be designated by the board of directors. He shall disburse the funds of the corporation as may be ordered by the board of directors, shall render to the president and directors, whenever they request it, an
	account of all of his transactions as treasurer and of the financial condition of the corporation, and shall have such other powers and perform such other duties as may be prescribed by the board of directors or these bylaws.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_50">
</A>
	5.11
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
<U>
	ASSISTANT SECRETARY
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The assistant secretary, or, if there is more than one, the assistant secretaries in the order determined by the stockholders or board of directors (or if there be no such determination, then in the order
	of their election) shall,
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	-13-
</FONT>
</P>
<A NAME="eolPage131"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	in the absence of the secretary or in the event of his or her inability or refusal to act, perform the duties and exercise the powers of the secretary and shall perform such other duties and have
	such other powers as the board of directors or the stockholders may from time to time prescribe.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_51">
</A>
	5.12
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
<U>
	ASSISTANT TREASURER
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The assistant treasurer, or, if there is more than one, the assistant treasurers, in the order determined by the stockholders or board of directors (or if there be no such determination, then in the order
	of their election), shall, in the absence of the treasurer or in the event of his or her inability or refusal to act, perform the duties and exercise the powers of the treasurer and shall perform such other duties and have such other powers as the
	board of directors or the stockholders may from time to time prescribe.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_52">
</A>
	5.13
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
<U>
	AUTHORITY AND DUTIES OF OFFICERS
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In addition to the foregoing authority and duties, all officers of the corporation shall respectively have such authority and perform such duties in the management of the business of the corporation as
	may be designated from time to time by the board of directors or the stockholders.
</FONT>
</P>
<P STYLE="MARGIN-TOP:24PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ARTICLE VI
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
<A NAME="D453081DEX32_HTM_EX453081_53">
</A>
	INDEMNITY
</U>
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_54">
</A>
	6.1
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	INDEMNIFICATION OF DIRECTORS AND OFFICERS
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The corporation shall, to the maximum extent and in the manner permitted by the General Corporation Law of Delaware, indemnify each of its directors and officers against expenses (including
	attorneys&#146; fees), judgments, fines, settlements, and other amounts actually and reasonably incurred in connection with any proceeding, arising by reason of the fact that such person is or was an agent of the corporation. For purposes of this
	Section&nbsp;6.1, a &#147;director&#148; or &#147;officer&#148; of the corporation includes any person (i)&nbsp;who is or was a director or officer of the corporation, (ii)&nbsp;who is or was serving at the request of the corporation as a director
	or officer of another corporation, partnership, joint venture, trust or other enterprise, or (iii)&nbsp;who was a director or officer of a corporation which was a predecessor corporation of the corporation or of another enterprise at the request of
	such predecessor corporation.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_55">
</A>
	6.2
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	INDEMNIFICATION OF OTHERS
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The corporation shall have the power, to the extent and in the manner permitted by the General Corporation Law of Delaware, to indemnify
	each of its employees and agents (other than directors and officers) against expenses (including attorneys&#146; fees), judgments, fines, settlements, and other amounts actually and reasonably incurred in connection with any proceeding, arising by
	reason of the fact that such person is or was an agent of the corporation. For purposes of this Section&nbsp;6.2, an &#147;employee&#148; or &#147;agent&#148; of the corporation (other than a director or officer) includes any person (i)&nbsp;who is
	or was an employee or agent of the corporation, (ii)&nbsp;who is or was serving at the request of the corporation as an employee or agent of another corporation, partnership, joint venture, trust or other enterprise, or (iii)&nbsp;who was an
	employee or agent of a corporation which was a predecessor corporation of the corporation or of another enterprise at the request of such predecessor corporation.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_56">
</A>
	6.3
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	INSURANCE
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The
	corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of
	another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against him and incurred by him in any such capacity, or arising out of his status as such, whether or not the corporation would have the power
	to indemnify him against such liability under the provisions of the General Corporation Law of Delaware.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	-14-
</FONT>
</P>
<A NAME="eolPage132"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ARTICLE VII
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_57">
</A>
<U>
	RECORDS AND REPORTS
</U>
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_58">
</A>
	7.1
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	MAINTENANCE AND INSPECTION OF RECORDS
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The corporation shall, either at its principal executive office or at such place or places as designated by the board of directors, keep a record of its stockholders listing their names and addresses and
	the number and class of shares held by each stockholder, a copy of these bylaws as amended to date, accounting books, and other records.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Any stockholder of record, in person or by attorney or other agent, shall, upon written demand under oath stating the purpose thereof, have the right during the usual hours for business to inspect for any
	proper purpose the corporation&#146;s stock ledger, a list of its stockholders, and its other books and records and to make copies or extracts therefrom. A proper purpose shall mean a purpose reasonably related to such person&#146;s interest as a
	stockholder. In every instance where an attorney or other agent is the person who seeks the right to inspection, the demand under oath shall be accompanied by a power of attorney or such other writing that authorizes the attorney or other agent to
	so act on behalf of the stockholder. The demand under oath shall be directed to the corporation at its registered office in Delaware or at its principal place of business.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The officer who has charge of the stock ledger of a corporation shall prepare and make, at least ten (10)&nbsp;days before every meeting of stockholders, a complete list of the stockholders entitled to
	vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose
	germane to the meeting, during ordinary business hours, for a period of at least ten (10)&nbsp;days prior to the meeting, either at a place within the city where the meeting is to be held, which place shall be specified in the notice of the meeting,
	or, if not so specified, at the place where the meeting is to be held. The list shall also be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any stockholder who is present.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_59">
</A>
	7.2
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	INSPECTION BY DIRECTORS
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Any director shall have the right to examine the corporation&#146;s stock ledger, a list of its stockholders, and its other books and
	records for a purpose reasonably related to his position as a director. The Court of Chancery is hereby vested with the exclusive jurisdiction to determine whether a director is entitled to the inspection sought. The Court may summarily order the
	corporation to permit the director to inspect any and all books and records, the stock ledger, and the stock list and to make copies or extracts therefrom. The Court may, in its discretion, prescribe any limitations or conditions with reference to
	the inspection, or award such other and further relief as the Court may deem just and proper.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_60">
</A>
	7.3
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	ANNUAL STATEMENT TO STOCKHOLDERS
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The board of directors shall present at each annual meeting, and at any special meeting of the stockholders when called for by vote of the stockholders, a full and clear statement of the business and
	condition of the corporation.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_61">
</A>
	7.4
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	REPRESENTATION OF SHARES OF OTHER CORPORATIONS
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The chairman of the board, the president, any vice president, the treasurer, the secretary or assistant secretary of this corporation, or any other person authorized by the board of directors or the
	president or a vice president, is authorized to vote, represent, and exercise on behalf of this corporation all rights incident to any and all shares of any other corporation or corporations standing in the name of this corporation. The authority
	granted herein may be exercised either by such person directly or by any other person authorized to do so by proxy or power of attorney duly executed by such person having the authority.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	-15-
</FONT>
</P>
<A NAME="eolPage133"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ARTICLE VIII
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_62">
</A>
<U>
	GENERAL MATTERS
</U>
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_63">
</A>
	8.1
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	CHECKS
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	From time to
	time, the board of directors shall determine by resolution which person or persons may sign or endorse all checks, drafts, other orders for payment of money, notes or other evidences of indebtedness that are issued in the name of or payable to the
	corporation, and only the persons so authorized shall sign or endorse those instruments.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_64">
</A>
	8.2
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	EXECUTION OF CORPORATE CONTRACTS AND INSTRUMENTS
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The board of directors, except as otherwise provided in these bylaws, may authorize any officer or officers, or agent or agents, to enter into any contract or execute any instrument in the name of and on
	behalf of the corporation; such authority may be general or confined to specific instances. Unless so authorized or ratified by the board of directors or within the agency power of an officer, no officer, agent or employee shall have any power or
	authority to bind the corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose or for any amount.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_65">
</A>
	8.3
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	STOCK CERTIFICATES; PARTLY PAID SHARES
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The shares of a corporation shall be represented by certificates, provided that the board of directors of the corporation may provide by resolution or resolutions that some or all of any or all classes or
	series of its stock shall be uncertificated shares. Any such resolution shall not apply to shares represented by a certificate until such certificate is surrendered to the corporation. Notwithstanding the adoption of such a resolution by the board
	of directors, every holder of stock represented by certificates and upon request every holder of uncertificated shares shall be entitled to have a certificate signed by, or in the name of the corporation by the chairman or vice-chairman of the board
	of directors, or the president or vice-president, and by the treasurer or an assistant treasurer, or the secretary or an assistant secretary of such corporation representing the number of shares registered in certificate form. Any or all of the
	signatures on the certificate may be a facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate has ceased to be such officer, transfer agent or registrar before such
	certificate is issued, it may be issued by the corporation with the same effect as if he were such officer, transfer agent or registrar at the date of issue.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The corporation may issue the whole or any part of its shares as partly paid and subject to call for the remainder of the consideration to be paid therefor. Upon the face or back of each stock certificate
	issued to represent any such partly paid shares, upon the books and records of the corporation in the case of uncertificated partly paid shares, the total amount of the consideration to be paid therefor and the amount paid thereon shall be stated.
	Upon the declaration of any dividend on fully paid shares, the corporation shall declare a dividend upon partly paid shares of the same class, but only upon the basis of the percentage of the consideration actually paid thereon.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_66">
</A>
	8.4
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	SPECIAL DESIGNATION ON CERTIFICATES
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	If the corporation is authorized to issue more than one class of stock or more than one series of any class, then the powers, the designations, the preferences, and the relative, participating, optional
	or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights shall be set forth in full or summarized on the face or back of the certificate that the
	corporation shall issue to represent such class or series of stock; provided, however, that, except as otherwise provided in Section&nbsp;202 of the General Corporation Law of Delaware, in lieu of the foregoing requirements there may be set forth on
	the face or back of the certificate that the corporation shall issue to represent such class or series of stock a statement that the corporation will furnish without charge to each stockholder who so requests the powers, the designations, the
	preferences, and the relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	-16-
</FONT>
</P>
<A NAME="eolPage134"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_67">
</A>
	8.5
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	LOST CERTIFICATES
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Except
	as provided in this Section&nbsp;8.5, no new certificates for shares shall be issued to replace a previously issued certificate unless the latter is surrendered to the corporation and cancelled at the same time. The corporation may issue a new
	certificate of stock or uncertificated shares in the place of any certificate theretofore issued by it, alleged to have been lost, stolen or destroyed, and the corporation may require the owner of the lost, stolen or destroyed certificate, or his
	legal representative, to give the corporation a bond sufficient to indemnify it against any claim that may be made against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate or
	uncertificated shares.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_68">
</A>
	8.6
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	CONSTRUCTION; DEFINITIONS
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Unless the context requires otherwise, the general provisions, rules of construction, and definitions in the Delaware General Corporation
	Law shall govern the construction of these bylaws. Without limiting the generality of this provision, the singular number includes the plural, the plural number includes the singular, and the term &#147;person&#148; includes both a natural person
	and a legally created entity, such as but not limited to a corporation.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_69">
</A>
	8.7
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	DIVIDENDS
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The directors
	of the corporation, subject to any restrictions contained in the certificate of incorporation, may declare and pay dividends upon the shares of its capital stock pursuant to the General Corporation Law of Delaware. Dividends may be paid in cash, in
	property, or in shares of the corporation&#146;s capital stock.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The directors of the corporation may set apart out of any of
	the funds of the corporation available for dividends a reserve or reserves for any proper purpose and may abolish any such reserve. Such purposes shall include but not be limited to equalizing dividends, repairing or maintaining any property of the
	corporation, and meeting contingencies.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_70">
</A>
	8.8
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	FISCAL YEAR
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The fiscal
	year of the corporation shall be fixed by resolution of the board of directors and may be changed by the board of directors.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_71">
</A>
	8.9
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	SEAL
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The seal of the
	corporation shall be such as from time to time may be approved by the board of directors.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_72">
</A>
	8.10
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
<U>
	TRANSFER OF STOCK
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Upon surrender to the corporation or the transfer agent of the corporation of a certificate for shares duly endorsed or accompanied by proper evidence of succession, assignation or authority to transfer,
	it shall be the duty of the corporation to issue a new certificate to the person entitled thereto, cancel the old certificate, and record the transaction in its books.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_73">
</A>
	8.11
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
<U>
	STOCK TRANSFER AGREEMENTS
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The corporation shall have power to enter into and perform any agreement with any number of stockholders of any one or more classes of stock of the corporation to restrict the transfer of shares of stock
	of the corporation of any one or more classes owned by such stockholders in any manner not prohibited by the General Corporation Law of Delaware.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_74">
</A>
	8.12
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
<U>
	REGISTERED STOCKHOLDERS
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The corporation shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends and to vote as such owner, shall be entitled to hold
	liable for calls and
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	-17-
</FONT>
</P>
<A NAME="eolPage135"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	assessments the person registered on its books as the owner of shares, and shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of
	another person, whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of Delaware.
</FONT>
</P>
<P STYLE="MARGIN-TOP:24PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ARTICLE IX
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_75">
</A>
<U>
	AMENDMENTS
</U>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The original or other bylaws of the corporation may be adopted, amended or repealed by the stockholders entitled to vote; provided,
	however, that the corporation may, in its certificate of incorporation, confer the power to adopt, amend or repeal bylaws upon the directors. The fact that such power has been so conferred upon the directors shall not divest the stockholders of the
	power, nor limit their power to adopt, amend or repeal bylaws.
</FONT>
</P>
<P STYLE="MARGIN-TOP:24PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ARTICLE X
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_76">
</A>
<U>
	DISSOLUTION
</U>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	If it should be deemed advisable in the judgment of the board of directors of the corporation that the corporation should be dissolved, the board, after the adoption of a resolution to that effect by a
	majority of the whole board at any meeting called for that purpose, shall cause notice to be mailed to each stockholder entitled to vote thereon of the adoption of the resolution and of a meeting of stockholders to take action upon the resolution.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	At the meeting a vote shall be taken for and against the proposed dissolution. If a majority of the outstanding stock of the
	corporation, entitled to vote thereon votes for the proposed dissolution, then a certificate stating that the dissolution has been authorized in accordance with the provisions of Section&nbsp;275 of the General Corporation Law of Delaware and
	setting forth the names and residences of the directors and officers shall be executed, acknowledged, and filed and shall become effective in accordance with Section&nbsp;103 of the General Corporation Law of Delaware. Upon such certificate&#146;s
	becoming effective in accordance with Section&nbsp;103 of the General Corporation Law of Delaware, the corporation shall be dissolved.
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Whenever all the stockholders entitled to vote on a dissolution consent in writing, either in person or by duly authorized attorney, to a dissolution, no meeting of directors or stockholders shall be
	necessary. The consent shall be filed and shall become effective in accordance with Section&nbsp;103 of the General Corporation Law of Delaware. Upon such consent&#146;s becoming effective in accordance with Section&nbsp;103 of the General
	Corporation Law of Delaware, the corporation shall be dissolved. If the consent is signed by an attorney, then the original power of attorney or a photocopy thereof shall be attached to and filed with the consent. The consent filed with the
	Secretary of State shall have attached to it the affidavit of the secretary or some other officer of the corporation stating that the consent has been signed by or on behalf of all the stockholders entitled to vote on a dissolution; in addition,
	there shall be attached to the consent a certification by the secretary or some other officer of the corporation setting forth the names and residences of the directors and officers of the corporation.
</FONT>
</P>
<P STYLE="MARGIN-TOP:24PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ARTICLE XI
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_77">
</A>
<U>
	CUSTODIAN
</U>
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_78">
</A>
	11.1
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
<U>
	APPOINTMENT OF A CUSTODIAN IN CERTAIN CASES
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Court of Chancery, upon application of any stockholder, may appoint one or more persons to be custodians and, if the corporation is insolvent, to be receivers, of and for the corporation when:
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(a)&nbsp;&nbsp;&nbsp;&nbsp;at any meeting held for the election of directors the stockholders are so divided
	that they have failed to elect successors to directors whose terms have expired or would have expired upon qualification of their successors; or
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	-18-
</FONT>
</P>
<A NAME="eolPage136"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(b)&nbsp;&nbsp;&nbsp;&nbsp;the business of the corporation is suffering or
	is threatened with irreparable injury because the directors are so divided respecting the management of the affairs of the corporation that the required vote for action by the board of directors cannot be obtained and the stockholders are unable to
	terminate this division; or
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(c)&nbsp;&nbsp;&nbsp;&nbsp;the corporation has abandoned its business and has
	failed within a reasonable time to take steps to dissolve, liquidate or distribute its assets.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A NAME="D453081DEX32_HTM_EX453081_79">
</A>
	11.2
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;
<U>
	DUTIES OF CUSTODIAN
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The custodian shall have all the powers and title of a receiver appointed under Section&nbsp;291 of the General Corporation Law of Delaware, but the authority of the custodian shall be to continue the
	business of the corporation and not to liquidate its affairs and distribute its assets, except when the Court of Chancery otherwise orders and except in cases arising under Sections 226(a)(3) or 352(a)(2) of the General Corporation Law of Delaware.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	-19-
</FONT>
</P>
</EFX_BY-LAWS>
</EFX_EXHIBIT_3>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage137"></A>
<A NAME="D453081DEX210_HTM"></A>
<EFX_EXHIBIT_21>
<A NAME="FIS_EXHIBIT_21"></A>
<EFX_SUBSIDIARIES>
<A NAME="FIS_SUBSIDIARIES"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Exhibit 21.0
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Vermillion, Inc. Subsidiaries
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	December&nbsp;31, 2012
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="51%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="47%">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Subsidiary
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	State/Country of
	Incorporation/Formation
</B>
</FONT>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	IllumeSys Pacific, Inc.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	California
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Ciphergen Technologies, Inc.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	California
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Ciphergen Biosystems International, Inc.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Delaware
</FONT>
</TD>
</TR>
</TABLE>
</EFX_SUBSIDIARIES>
</EFX_EXHIBIT_21>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage138"></A>
<A NAME="D453081DEX231_HTM"></A>
<EFX_EXHIBIT_23>
<A NAME="FIS_EXHIBIT_23"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Exhibit 23.1
</B>
</FONT>
</P>
<EFX_EXPERTS_CONSENT>
<A NAME="FIS_EXPERTS_CONSENT"></A>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	Consent of Independent Registered Public Accounting Firm
</U>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Vermillion, Inc
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Austin, Texas
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We hereby consent to the
	incorporation by reference in the Registration Statement on Form S-8 (No. 333-167204) of Vermillion, Inc of our report dated March 1, 2013, relating to the consolidated financial statements which appear in this Form 10-K.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">
<TR>
<TD WIDTH="100%">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/s/ BDO USA, LLP
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Austin, Texas
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="13">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	March 1, 2013
</FONT>
</TD>
</TR>
</TABLE>
</EFX_EXPERTS_CONSENT>
</EFX_EXHIBIT_23>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage139"></A>
<A NAME="D453081DEX232_HTM"></A>
<EFX_EXHIBIT_23>
<A NAME="FIS_EXHIBIT_23_2"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Exhibit 23.2
</B>
</FONT>
</P>
<EFX_EXPERTS_CONSENT>
<A NAME="FIS_EXPERTS_CONSENT_2"></A>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Consent of Independent Registered Public Accounting Firm
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We hereby consent to the
	incorporation by reference in the Registration Statement on Form S-8 (No. 333-167204) of Vermillion, Inc. of our report dated March&nbsp;26, 2012 relating to the consolidated financial statements, which appears in this Form 10-K.
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">
<TR>
<TD WIDTH="100%">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/s/ PricewaterhouseCoopers LLP
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Austin, Texas
</FONT>
</TD>
</TR>
<TR>
<TD HEIGHT="8">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	March 1, 2013
</FONT>
</TD>
</TR>
</TABLE>
</EFX_EXPERTS_CONSENT>
</EFX_EXHIBIT_23>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage140"></A>
<A NAME="D453081DEX311_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Exhibit 31.1
</B>
</FONT>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION"></A>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Certification of the Chief Executive Officer Pursuant to Section&nbsp;302 of
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	the Sarbanes-Oxley Act Of 2002
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	I, Bruce A. Huebner, certify that:
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	I have reviewed this annual report on Form 10-K of Vermillion, Inc.;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2.
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
	light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3.
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
	condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4.
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures [as defined in Exchange Act
	Rules 13a-15(e) and 15d-15(e)] and internal control over financial reporting [as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)] for the registrant and have:
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(a)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
	information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(b)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
	reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(c)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
	disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(d)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal
	quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5.
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
	registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions):
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(a)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
	affect the registrant&#146;s ability to record, process, summarize and report financial information; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(b)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial
	reporting.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">
<TR>
<TD WIDTH="47%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="5%">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD WIDTH="46%">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Date: March 1, 2013
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/s/ Bruce A. Huebner
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Bruce A. Huebner
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Interim Chief
	Executive Officer
</FONT>
</P>
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage141"></A>
<A NAME="D453081DEX312_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31_2"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	EXHIBIT 31.2
</B>
</FONT>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_2"></A>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Certification of the Chief Accounting Officer Pursuant to Section&nbsp;302 of
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	the Sarbanes-Oxley Act Of 2002
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	I, Eric J. Schoen, certify that:
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	I have reviewed this annual report on Form 10-K of Vermillion, Inc.;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2.
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
	light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3.
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
	condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4.
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures [as defined in Exchange Act
	Rules 13a-15(e) and 15d-15(e)] and internal control over financial reporting [as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)] for the registrant and have:
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(a)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
	information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(b)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
	reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(c)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
	disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(d)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal
	quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5.
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
	registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions):
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(a)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
	affect the registrant&#146;s ability to record, process, summarize and report financial information; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(b)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial
	reporting.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">
<TR>
<TD WIDTH="47%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="5%">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD WIDTH="46%">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Date: March 1, 2013
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/s/ Eric J. Schoen
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Eric J. Schoen
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Chief
	Accounting Officer
</FONT>
</P>
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage142"></A>
<A NAME="D453081DEX320_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Exhibit 32.0
</B>
</FONT>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_3"></A>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Certification of the Chief Executive Officer and Chief Accounting Officer
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Pursuant to 18 U.S.C. Section&nbsp;1350,
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	as Adopted Pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	with Respect to the Annual Report on Form 10-K
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	for the Year Ended December&nbsp;31, 2012
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Pursuant to Section&nbsp;906 of the
	Sarbanes-Oxley Act of 2002 (subsections (a)&nbsp;and (b)&nbsp;of section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of Vermillion, Inc., a Delaware corporation (the &#147;Company&#148;), does hereby certify,
	to the best of such officer&#146;s knowledge, that:
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company&#146;s annual report on Form 10-K for the year ended December&nbsp;31, 2012, (the &#147;Form 10-K&#148;) fully complies with the requirements of
	Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;); and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2.
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">
<TR>
<TD WIDTH="47%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="5%">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD WIDTH="46%">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Date: March 1, 2013
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/s/ Bruce A. Huebner
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Bruce A. Huebner
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Interim Chief
	Executive Officer
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(Principal Executive Officer)
</FONT>
</P>
</TD>
</TR>
<TR>
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Date: March 1, 2013
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/s/ Eric J. Schoen
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Eric J. Schoen
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Chief
	Accounting Officer
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The certification set forth above is being furnished as an Exhibit solely pursuant to Section&nbsp;906 of the
	Sarbanes-Oxley Act of 2002 and is not being filed as part of the Form 10-K or as a separate disclosure document of the Company or the certifying officers.
</FONT>
</P>
</EFX_CERTIFICATION>
</EFX_EXHIBIT_32>

<!-- FOOTER LOGO -->
</BODY>
</HTML>
